ID BMR1A_HUMAN Reviewed; 532 AA. AC P36894; A8K6U9; Q8NEN8; DT 01-JUN-1994, integrated into UniProtKB/Swiss-Prot. DT 15-MAR-2005, sequence version 2. DT 28-JAN-2026, entry version 257. DE RecName: Full=Bone morphogenetic protein receptor type-1A; DE Short=BMP type-1A receptor; DE Short=BMPR-1A; DE EC=2.7.11.30; DE AltName: Full=Activin receptor-like kinase 3; DE Short=ALK-3; DE AltName: Full=Serine/threonine-protein kinase receptor R5; DE Short=SKR5; DE AltName: CD_antigen=CD292; DE Flags: Precursor; GN Name=BMPR1A; Synonyms=ACVRLK3, ALK3; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT THR-2. RC TISSUE=Placenta; RX PubMed=8397373; RA ten Dijke P., Ichijo H., Franzen P., Schulz P., Saras J., Toyoshima H., RA Heldin C.-H., Miyazono K.; RT "Activin receptor-like kinases: a novel subclass of cell-surface receptors RT with predicted serine/threonine kinase activity."; RL Oncogene 8:2879-2887(1993). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT THR-2. RC TISSUE=Placenta; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP INTERACTION WITH BMP4. RX PubMed=8006002; DOI=10.1016/s0021-9258(17)32506-1; RA ten Dijke P., Yamashita H., Sampath T.K., Reddi A.H., Estevez M., RA Riddle D.L., Ichijo H., Heldin C.H., Miyazono K.; RT "Identification of type I receptors for osteogenic protein-1 and bone RT morphogenetic protein-4."; RL J. Biol. Chem. 269:16985-16988(1994). RN [5] RP INTERACTION WITH TGFBR3, AND SUBCELLULAR LOCATION. RX PubMed=19726563; DOI=10.1091/mbc.e09-07-0539; RA Lee N.Y., Kirkbride K.C., Sheu R.D., Blobe G.C.; RT "The transforming growth factor-beta type III receptor mediates distinct RT subcellular trafficking and downstream signaling of activin-like kinase RT (ALK)3 and ALK6 receptors."; RL Mol. Biol. Cell 20:4362-4370(2009). RN [6] RP INTERACTION WITH TSC22D1. RX PubMed=21791611; DOI=10.1128/mcb.05448-11; RA Yan X., Zhang J., Pan L., Wang P., Xue H., Zhang L., Gao X., Zhao X., RA Ning Y., Chen Y.G.; RT "TSC-22 promotes transforming growth factor beta-mediated cardiac RT myofibroblast differentiation by antagonizing Smad7 activity."; RL Mol. Cell. Biol. 31:3700-3709(2011). RN [7] RP INTERACTION WITH BMP2, AND MUTAGENESIS OF 107-ASP--GLN-109. RX PubMed=22799562; DOI=10.1021/bi300942x; RA Mahlawat P., Ilangovan U., Biswas T., Sun L.Z., Hinck A.P.; RT "Structure of the Alk1 extracellular domain and characterization of its RT bone morphogenetic protein (BMP) binding properties."; RL Biochemistry 51:6328-6341(2012). RN [8] RP INTERACTION WITH GDF5. RX PubMed=24098149; DOI=10.1371/journal.pgen.1003846; RA Degenkolbe E., Konig J., Zimmer J., Walther M., Reissner C., Nickel J., RA Ploger F., Raspopovic J., Sharpe J., Dathe K., Hecht J.T., Mundlos S., RA Doelken S.C., Seemann P.; RT "A GDF5 point mutation strikes twice--causing BDA1 and SYNS2."; RL PLoS Genet. 9:E1003846-E1003846(2013). RN [9] RP INTERACTION WITH BMP2 AND BMP6. RX PubMed=31800957; DOI=10.1182/blood.2019002620; RA Wang C.Y., Xu Y., Traeger L., Dogan D.Y., Xiao X., Steinbicker A.U., RA Babitt J.L.; RT "Erythroferrone lowers hepcidin by sequestering BMP2/6 heterodimer from RT binding to the BMP type I receptor ALK3."; RL Blood 135:453-456(2020). RN [10] RP INTERACTION WITH SCUBE3. RX PubMed=33308444; DOI=10.1016/j.ajhg.2020.11.015; RG Genomics England Research Consortium; RA Lin Y.C., Niceta M., Muto V., Vona B., Pagnamenta A.T., Maroofian R., RA Beetz C., van Duyvenvoorde H., Dentici M.L., Lauffer P., Vallian S., RA Ciolfi A., Pizzi S., Bauer P., Gruening N.M., Bellacchio E., RA Del Fattore A., Petrini S., Shaheen R., Tiosano D., Halloun R., RA Pode-Shakked B., Albayrak H.M., Isik E., Wit J.M., Dittrich M., RA Freire B.L., Bertola D.R., Jorge A.A.L., Barel O., Sabir A.H., RA Al Tenaiji A.M.J., Taji S.M., Al-Sannaa N., Al-Abdulwahed H., Digilio M.C., RA Irving M., Anikster Y., Bhavani G.S.L., Girisha K.M., Haaf T., Taylor J.C., RA Dallapiccola B., Alkuraya F.S., Yang R.B., Tartaglia M.; RT "SCUBE3 loss-of-function causes a recognizable recessive developmental RT disorder due to defective bone morphogenetic protein signaling."; RL Am. J. Hum. Genet. 108:115-133(2021). RN [11] RP X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 55-143 IN COMPLEX WITH BMP2, RP DISULFIDE BOND, AND INTERACTION WITH BMP2. RX PubMed=10881198; DOI=10.1038/75903; RA Kirsch T., Sebald W., Dreyer M.K.; RT "Crystal structure of the BMP-2-BRIA ectodomain complex."; RL Nat. Struct. Biol. 7:492-496(2000). RN [12] {ECO:0007744|PDB:1REW} RP X-RAY CRYSTALLOGRAPHY (1.86 ANGSTROMS) OF 24-152, AND INTERACTION WITH RP BMP2. RX PubMed=15064755; DOI=10.1038/nsmb756; RA Keller S., Nickel J., Zhang J.L., Sebald W., Mueller T.D.; RT "Molecular recognition of BMP-2 and BMP receptor IA."; RL Nat. Struct. Mol. Biol. 11:481-488(2004). RN [13] {ECO:0007744|PDB:2H62, ECO:0007744|PDB:2H64} RP X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 24-152, AND INTERACTION WITH RP BMP2. RX PubMed=17295905; DOI=10.1186/1472-6807-7-6; RA Weber D., Kotzsch A., Nickel J., Harth S., Seher A., Mueller U., Sebald W., RA Mueller T.D.; RT "A silent H-bond can be mutationally activated for high-affinity RT interaction of BMP-2 and activin type IIB receptor."; RL BMC Struct. Biol. 7:6-6(2007). RN [14] RP DISEASE. RX PubMed=11381269; DOI=10.1038/88919; RA Howe J.R., Bair J.L., Sayed M.G., Anderson M.E., Mitros F.A., RA Petersen G.M., Velculescu V.E., Traverso G., Vogelstein B.; RT "Germline mutations of the gene encoding bone morphogenetic protein RT receptor 1A in juvenile polyposis."; RL Nat. Genet. 28:184-187(2001). RN [15] RP STRUCTURE BY NMR OF 51-152, DISULFIDE BONDS, AND INTERACTION WITH BMP2. RX PubMed=18937504; DOI=10.1021/bi801059j; RA Klages J., Kotzsch A., Coles M., Sebald W., Nickel J., Muller T., RA Kessler H.; RT "The solution structure of BMPR-IA reveals a local disorder-to-order RT transition upon BMP-2 binding."; RL Biochemistry 47:11930-11939(2008). RN [16] RP VARIANTS JPS ARG-124; ASP-338 AND TYR-376. RX PubMed=11536076; DOI=10.1086/323703; RA Zhou X.-P., Woodford-Richens K., Lehtonen R., Kurose K., Aldred M., RA Hampel H., Launonen V., Virta S., Pilarski R., Salovaara R., Bodmer W.F., RA Conrad B.A., Dunlop M., Hodgson S.V., Iwama T., Jaervinen H., RA Kellokumpu I., Kim J.C., Leggett B., Markie D., Mecklin J.-P., Neale K., RA Phillips R., Piris J., Rozen P., Houlston R.S., Aaltonen L.A., RA Tomlinson I.P.M., Eng C.; RT "Germline mutations in BMPR1A/ALK3 cause a subset of cases of juvenile RT polyposis syndrome and of Cowden and Bannayan-Riley-Ruvalcaba syndromes."; RL Am. J. Hum. Genet. 69:704-711(2001). RN [17] RP VARIANTS JPS ASP-62; TYR-82 AND CYS-443. RX PubMed=12417513; DOI=10.1007/bf02557528; RA Sayed M.G., Ahmed A.F., Ringold J.R., Anderson M.E., Bair J.L., RA Mitros F.A., Lynch H.T., Tinley S.T., Petersen G.M., Giardiello F.M., RA Vogelstein B., Howe J.R.; RT "Germline SMAD4 or BMPR1A mutations and phenotype of juvenile polyposis."; RL Ann. Surg. Oncol. 9:901-906(2002). RN [18] RP VARIANT JPS ARG-130. RX PubMed=12136244; DOI=10.1007/s00439-002-0748-9; RA Friedl W., Uhlhaas S., Schulmann K., Stolte M., Loff S., Back W., RA Mangold E., Stern M., Knaebel H.P., Sutter C., Weber R.G., Pistorius S., RA Burger B., Propping P.; RT "Juvenile polyposis: massive gastric polyposis is more common in MADH4 RT mutation carriers than in BMPR1A mutation carriers."; RL Hum. Genet. 111:108-111(2002). RN [19] RP VARIANT JPS THR-470. RX PubMed=12630959; DOI=10.1034/j.1399-0004.2003.00008.x; RA Kim I.J., Park J.H., Kang H.C., Kim K.H., Kim J.H., Ku J.L., Kang S.B., RA Park S.Y., Lee J.S., Park J.G.; RT "Identification of a novel BMPR1A germline mutation in a Korean juvenile RT polyposis patient without SMAD4 mutation."; RL Clin. Genet. 63:126-130(2003). RN [20] RP INVOLVEMENT IN JUVENILE POLYPOSIS OF INFANCY. RX PubMed=16685657; DOI=10.1086/504301; RA Delnatte C., Sanlaville D., Mougenot J.-F., Vermeesch J.-R., Houdayer C., RA Blois M.-C., Genevieve D., Goulet O., Fryns J.-P., Jaubert F., Vekemans M., RA Lyonnet S., Romana S., Eng C., Stoppa-Lyonnet D.; RT "Contiguous gene deletion within chromosome arm 10q is associated with RT juvenile polyposis of infancy, reflecting cooperation between the BMPR1A RT and PTEN tumor-suppressor genes."; RL Am. J. Hum. Genet. 78:1066-1074(2006). RN [21] RP INVOLVEMENT IN HMPS2. RX PubMed=16525031; DOI=10.1136/jmg.2005.034827; RA Cao X., Eu K.W., Kumarasinghe M.P., Li H.H., Loi C., Cheah P.Y.; RT "Mapping of hereditary mixed polyposis syndrome (HMPS) to chromosome 10q23 RT by genomewide high-density single nucleotide polymorphism (SNP) scan and RT identification of BMPR1A loss of function."; RL J. Med. Genet. 43:E13-E13(2006). RN [22] RP VARIANTS [LARGE SCALE ANALYSIS] THR-2; TYR-58; CYS-443; MET-450 AND RP GLN-486. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [23] RP VARIANT THR-460. RX PubMed=25860647; DOI=10.1007/s10689-015-9803-2; RA Hansen M.F., Johansen J., Bjoernevoll I., Sylvander A.E., Steinsbekk K.S., RA Saetrom P., Sandvik A.K., Drabloes F., Sjursen W.; RT "A novel POLE mutation associated with cancers of colon, pancreas, ovaries RT and small intestine."; RL Fam. Cancer 14:437-448(2015). CC -!- FUNCTION: On ligand binding, forms a receptor complex consisting of two CC type II and two type I transmembrane serine/threonine kinases. Type II CC receptors phosphorylate and activate type I receptors which CC autophosphorylate, then bind and activate SMAD transcriptional CC regulators. Receptor for BMP2, BMP4, GDF5 and GDF6. Positively CC regulates chondrocyte differentiation through GDF5 interaction. CC Mediates induction of adipogenesis by GDF6. May promote the expression CC of HAMP, potentially via its interaction with BMP2 (By similarity). CC {ECO:0000250|UniProtKB:P36895}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[receptor-protein] + ATP = O-phospho-L-threonyl- CC [receptor-protein] + ADP + H(+); Xref=Rhea:RHEA:44880, Rhea:RHEA- CC COMP:11024, Rhea:RHEA-COMP:11025, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, CC ChEBI:CHEBI:456216; EC=2.7.11.30; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[receptor-protein] + ATP = O-phospho-L-seryl- CC [receptor-protein] + ADP + H(+); Xref=Rhea:RHEA:18673, Rhea:RHEA- CC COMP:11022, Rhea:RHEA-COMP:11023, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, ChEBI:CHEBI:83421, CC ChEBI:CHEBI:456216; EC=2.7.11.30; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250}; CC Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250}; CC -!- SUBUNIT: Interacts with low affinity with GDF5; positively regulates CC chondrocyte differentiation (PubMed:24098149). Interacts with BMP4 CC (PubMed:8006002). Interacts with SCUBE3 (PubMed:33308444). Interacts CC with TSC22D1/TSC-22 (PubMed:21791611). Interacts with BMP2; the CC interaction may induce HAMP expression (PubMed:10881198, CC PubMed:15064755, PubMed:17295905, PubMed:18937504, PubMed:31800957). CC Interacts with BMP6 (PubMed:31800957). Interacts with heterodimers CC composed of BMP2 and BMP6 in vitro; the interaction may induce HAMP CC expression (PubMed:31800957). Interacts with TGFBR3 (PubMed:19726563). CC {ECO:0000269|PubMed:10881198, ECO:0000269|PubMed:15064755, CC ECO:0000269|PubMed:17295905, ECO:0000269|PubMed:18937504, CC ECO:0000269|PubMed:19726563, ECO:0000269|PubMed:21791611, CC ECO:0000269|PubMed:24098149, ECO:0000269|PubMed:31800957, CC ECO:0000269|PubMed:33308444, ECO:0000269|PubMed:8006002}. CC -!- INTERACTION: CC P36894; P12643: BMP2; NbExp=17; IntAct=EBI-1029237, EBI-1029262; CC P36894; P12644: BMP4; NbExp=2; IntAct=EBI-1029237, EBI-1998134; CC P36894; P43026: GDF5; NbExp=4; IntAct=EBI-1029237, EBI-8571476; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:19726563}; CC Single-pass type I membrane protein {ECO:0000255}. Cell surface CC {ECO:0000250|UniProtKB:P36895}. CC -!- TISSUE SPECIFICITY: Highly expressed in skeletal muscle. CC -!- PTM: Glycosylated. {ECO:0000250|UniProtKB:P36895}. CC -!- DISEASE: Juvenile polyposis syndrome (JPS) [MIM:174900]: Autosomal CC dominant gastrointestinal hamartomatous polyposis syndrome in which CC patients are at risk for developing gastrointestinal cancers. The CC lesions are typified by a smooth histological appearance, predominant CC stroma, cystic spaces and lack of a smooth muscle core. Multiple CC juvenile polyps usually occur in a number of Mendelian disorders. CC Sometimes, these polyps occur without associated features as in JPS; CC here, polyps tend to occur in the large bowel and are associated with CC an increased risk of colon and other gastrointestinal cancers. CC {ECO:0000269|PubMed:11536076, ECO:0000269|PubMed:12136244, CC ECO:0000269|PubMed:12417513, ECO:0000269|PubMed:12630959}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Polyposis syndrome, mixed hereditary 2 (HMPS2) [MIM:610069]: A CC disease is characterized by atypical juvenile polyps, colonic adenomas, CC and colorectal carcinomas. {ECO:0000269|PubMed:16525031}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and CC PTEN is a cause of chromosome 10q23 deletion syndrome, which shows CC overlapping features of the following three disorders: Bannayan-Zonana CC syndrome, Cowden disease and juvenile polyposis syndrome. CC {ECO:0000269|PubMed:11381269, ECO:0000269|PubMed:16525031}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr CC protein kinase family. TGFB receptor subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; Z22535; CAA80257.1; -; mRNA. DR EMBL; AK291764; BAF84453.1; -; mRNA. DR EMBL; BC028383; AAH28383.1; -; mRNA. DR CCDS; CCDS7378.1; -. DR PIR; I37163; I37163. DR RefSeq; NP_001393490.1; NM_001406561.1. DR RefSeq; NP_001393491.1; NM_001406562.1. DR RefSeq; NP_001393492.1; NM_001406563.1. DR RefSeq; NP_001393493.1; NM_001406564.1. DR RefSeq; NP_001393494.1; NM_001406565.1. DR RefSeq; NP_001393495.1; NM_001406566.1. DR RefSeq; NP_001393496.1; NM_001406567.1. DR RefSeq; NP_001393497.1; NM_001406568.1. DR RefSeq; NP_001393498.1; NM_001406569.1. DR RefSeq; NP_001393499.1; NM_001406570.1. DR RefSeq; NP_001393500.1; NM_001406571.1. DR RefSeq; NP_001393501.1; NM_001406572.1. DR RefSeq; NP_001393502.1; NM_001406573.1. DR RefSeq; NP_001393503.1; NM_001406574.1. DR RefSeq; NP_001393504.1; NM_001406575.1. DR RefSeq; NP_001393505.1; NM_001406576.1. DR RefSeq; NP_001393506.1; NM_001406577.1. DR RefSeq; NP_001393507.1; NM_001406578.1. DR RefSeq; NP_001393508.1; NM_001406579.1. DR RefSeq; NP_001393509.1; NM_001406580.1. DR RefSeq; NP_001393510.1; NM_001406581.1. DR RefSeq; NP_001393511.1; NM_001406582.1. DR RefSeq; NP_004320.2; NM_004329.2. DR RefSeq; XP_047281636.1; XM_047425680.1. DR RefSeq; XP_054222620.1; XM_054366645.1. DR PDB; 1ES7; X-ray; 2.90 A; B/D=55-143. DR PDB; 1REW; X-ray; 1.86 A; C/D=24-152. DR PDB; 2GOO; X-ray; 2.20 A; B/E=24-152. DR PDB; 2H62; X-ray; 1.85 A; C=24-152. DR PDB; 2H64; X-ray; 1.92 A; B=24-152. DR PDB; 2K3G; NMR; -; A=51-152. DR PDB; 2QJ9; X-ray; 2.44 A; C/D=24-152. DR PDB; 2QJA; X-ray; 2.60 A; C/D=24-152. DR PDB; 2QJB; X-ray; 2.50 A; C/D=24-152. DR PDB; 3NH7; X-ray; 2.70 A; A/B/C/D=24-152. DR PDB; 3QB4; X-ray; 2.28 A; B/D=24-152. DR PDBsum; 1ES7; -. DR PDBsum; 1REW; -. DR PDBsum; 2GOO; -. DR PDBsum; 2H62; -. DR PDBsum; 2H64; -. DR PDBsum; 2K3G; -. DR PDBsum; 2QJ9; -. DR PDBsum; 2QJA; -. DR PDBsum; 2QJB; -. DR PDBsum; 3NH7; -. DR PDBsum; 3QB4; -. DR AlphaFoldDB; P36894; -. DR BMRB; P36894; -. DR SMR; P36894; -. DR BioGRID; 107125; 266. DR CORUM; P36894; -. DR DIP; DIP-5793N; -. DR FunCoup; P36894; 1712. DR IntAct; P36894; 128. DR MINT; P36894; -. DR STRING; 9606.ENSP00000361107; -. DR BindingDB; P36894; -. DR ChEMBL; CHEMBL5275; -. DR DrugBank; DB11639; Dibotermin alfa. DR DrugCentral; P36894; -. DR GuidetoPHARMACOLOGY; 1786; -. DR GlyCosmos; P36894; 1 site, No reported glycans. DR GlyGen; P36894; 2 sites. DR iPTMnet; P36894; -. DR PhosphoSitePlus; P36894; -. DR SwissPalm; P36894; -. DR BioMuta; BMPR1A; -. DR DMDM; 61252444; -. DR jPOST; P36894; -. DR MassIVE; P36894; -. DR PaxDb; 9606-ENSP00000361107; -. DR PeptideAtlas; P36894; -. DR ProteomicsDB; 55228; -. DR ABCD; P36894; 1 sequenced antibody. DR Antibodypedia; 4524; 791 antibodies from 39 providers. DR DNASU; 657; -. DR Ensembl; ENST00000372037.8; ENSP00000361107.2; ENSG00000107779.17. DR Ensembl; ENST00000480152.3; ENSP00000483569.2; ENSG00000107779.17. DR Ensembl; ENST00000635816.2; ENSP00000489707.1; ENSG00000107779.17. DR Ensembl; ENST00000636056.2; ENSP00000490273.1; ENSG00000107779.17. DR Ensembl; ENST00000638429.1; ENSP00000492290.1; ENSG00000107779.17. DR Ensembl; ENST00000713672.1; ENSP00000518974.1; ENSG00000107779.17. DR Ensembl; ENST00000713675.1; ENSP00000518977.1; ENSG00000107779.17. DR GeneID; 657; -. DR KEGG; hsa:657; -. DR MANE-Select; ENST00000372037.8; ENSP00000361107.2; NM_004329.3; NP_004320.2. DR UCSC; uc001kdy.4; human. DR AGR; HGNC:1076; -. DR ClinPGx; PA25386; -. DR CTD; 657; -. DR DisGeNET; 657; -. DR GeneCards; BMPR1A; -. DR GeneReviews; BMPR1A; -. DR HGNC; HGNC:1076; BMPR1A. DR HPA; ENSG00000107779; Low tissue specificity. DR MalaCards; BMPR1A; -. DR MIM; 174900; phenotype. DR MIM; 601299; gene. DR MIM; 610069; phenotype. DR MIM; 612242; phenotype. DR OpenTargets; ENSG00000107779; -. DR Orphanet; 440437; Familial colorectal cancer Type X. DR Orphanet; 329971; Generalized juvenile polyposis/juvenile polyposis coli. DR Orphanet; 157794; Hereditary mixed polyposis syndrome. DR Orphanet; 79076; Juvenile polyposis of infancy. DR VEuPathDB; HostDB:ENSG00000107779; -. DR eggNOG; KOG2052; Eukaryota. DR GeneTree; ENSGT00940000156225; -. DR HOGENOM; CLU_000288_8_1_1; -. DR InParanoid; P36894; -. DR OMA; GSCPNNV; -. DR OrthoDB; 69842at2759; -. DR PAN-GO; P36894; 8 GO annotations based on evolutionary models. DR PhylomeDB; P36894; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; P36894; -. DR Reactome; R-HSA-201451; Signaling by BMP. DR SignaLink; P36894; -. DR SIGNOR; P36894; -. DR Agora; ENSG00000107779; -. DR BioGRID-ORCS; 657; 88 hits in 1193 CRISPR screens. DR ChiTaRS; BMPR1A; human. DR EvolutionaryTrace; P36894; -. DR GeneWiki; BMPR1A; -. DR GenomeRNAi; 657; -. DR Pharos; P36894; Tchem. DR PRO; PR:P36894; -. DR Proteomes; UP000005640; Chromosome 10. DR RNAct; P36894; protein. DR Bgee; ENSG00000107779; Expressed in secondary oocyte and 211 other cell types or tissues. DR ExpressionAtlas; P36894; baseline and differential. DR GO; GO:0030425; C:dendrite; IEA:Ensembl. DR GO; GO:0009897; C:external side of plasma membrane; IDA:BHF-UCL. DR GO; GO:1990712; C:HFE-transferrin receptor complex; IC:BHF-UCL. DR GO; GO:0016020; C:membrane; TAS:ProtInc. DR GO; GO:0043025; C:neuronal cell body; IEA:Ensembl. DR GO; GO:0005886; C:plasma membrane; IDA:BHF-UCL. DR GO; GO:0043235; C:receptor complex; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IDA:HGNC-UCL. DR GO; GO:0036122; F:BMP binding; IPI:BHF-UCL. DR GO; GO:0098821; F:BMP receptor activity; IDA:ARUK-UCL. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0042803; F:protein homodimerization activity; IDA:BHF-UCL. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:HGNC-UCL. DR GO; GO:0046332; F:SMAD binding; IDA:HGNC-UCL. DR GO; GO:0005025; F:transforming growth factor beta receptor activity, type I; IDA:UniProt. DR GO; GO:0004675; F:transmembrane receptor protein serine/threonine kinase activity; TAS:Reactome. DR GO; GO:0001525; P:angiogenesis; IMP:BHF-UCL. DR GO; GO:1990262; P:anti-Mullerian hormone receptor signaling pathway; IDA:UniProt. DR GO; GO:0060928; P:atrioventricular node cell development; ISS:BHF-UCL. DR GO; GO:0003171; P:atrioventricular valve development; ISS:BHF-UCL. DR GO; GO:0030509; P:BMP signaling pathway; IDA:HGNC-UCL. DR GO; GO:0003161; P:cardiac conduction system development; ISS:BHF-UCL. DR GO; GO:0003215; P:cardiac right ventricle morphogenesis; ISS:BHF-UCL. DR GO; GO:0030154; P:cell differentiation; IBA:GO_Central. DR GO; GO:0071773; P:cellular response to BMP stimulus; IMP:BHF-UCL. DR GO; GO:0071363; P:cellular response to growth factor stimulus; IBA:GO_Central. DR GO; GO:0021953; P:central nervous system neuron differentiation; IEA:Ensembl. DR GO; GO:0002062; P:chondrocyte differentiation; IEA:Ensembl. DR GO; GO:0048589; P:developmental growth; IEA:Ensembl. DR GO; GO:0035912; P:dorsal aorta morphogenesis; ISS:BHF-UCL. DR GO; GO:0009950; P:dorsal/ventral axis specification; IEA:Ensembl. DR GO; GO:0009953; P:dorsal/ventral pattern formation; IBA:GO_Central. DR GO; GO:0007398; P:ectoderm development; IEA:Ensembl. DR GO; GO:0042733; P:embryonic digit morphogenesis; IEA:Ensembl. DR GO; GO:0048568; P:embryonic organ development; ISS:BHF-UCL. DR GO; GO:0003272; P:endocardial cushion formation; ISS:BHF-UCL. DR GO; GO:0003203; P:endocardial cushion morphogenesis; ISS:BHF-UCL. DR GO; GO:0050673; P:epithelial cell proliferation; IEA:Ensembl. DR GO; GO:1905285; P:fibrous ring of heart morphogenesis; ISS:BHF-UCL. DR GO; GO:0060914; P:heart formation; IEA:Ensembl. DR GO; GO:0035137; P:hindlimb morphogenesis; IEA:Ensembl. DR GO; GO:0006955; P:immune response; IMP:BHF-UCL. DR GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl. DR GO; GO:0048368; P:lateral mesoderm development; IEA:Ensembl. DR GO; GO:0030324; P:lung development; IEA:Ensembl. DR GO; GO:0000165; P:MAPK cascade; IEA:Ensembl. DR GO; GO:0048382; P:mesendoderm development; IEA:Ensembl. DR GO; GO:0001707; P:mesoderm formation; IEA:Ensembl. DR GO; GO:0003183; P:mitral valve morphogenesis; ISS:BHF-UCL. DR GO; GO:0001880; P:Mullerian duct regression; IEA:Ensembl. DR GO; GO:0010629; P:negative regulation of gene expression; ISS:BHF-UCL. DR GO; GO:0051148; P:negative regulation of muscle cell differentiation; IEA:Ensembl. DR GO; GO:0050768; P:negative regulation of neurogenesis; IEA:Ensembl. DR GO; GO:0014912; P:negative regulation of smooth muscle cell migration; IMP:BHF-UCL. DR GO; GO:0014032; P:neural crest cell development; IEA:Ensembl. DR GO; GO:0021998; P:neural plate mediolateral regionalization; IEA:Ensembl. DR GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IEA:Ensembl. DR GO; GO:0001649; P:osteoblast differentiation; IEA:Ensembl. DR GO; GO:0003151; P:outflow tract morphogenesis; ISS:BHF-UCL. DR GO; GO:0003148; P:outflow tract septum morphogenesis; ISS:BHF-UCL. DR GO; GO:0048352; P:paraxial mesoderm structural organization; IEA:Ensembl. DR GO; GO:0061626; P:pharyngeal arch artery morphogenesis; ISS:BHF-UCL. DR GO; GO:0021983; P:pituitary gland development; IEA:Ensembl. DR GO; GO:0030501; P:positive regulation of bone mineralization; IMP:BHF-UCL. DR GO; GO:0060045; P:positive regulation of cardiac muscle cell proliferation; ISS:BHF-UCL. DR GO; GO:1904414; P:positive regulation of cardiac ventricle development; ISS:BHF-UCL. DR GO; GO:1900006; P:positive regulation of dendrite development; TAS:UniProt. DR GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IEA:Ensembl. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL. DR GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; IEA:Ensembl. DR GO; GO:1902895; P:positive regulation of miRNA transcription; IEA:Ensembl. DR GO; GO:0045669; P:positive regulation of osteoblast differentiation; IMP:BHF-UCL. DR GO; GO:0060391; P:positive regulation of SMAD protein signal transduction; IDA:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:BHF-UCL. DR GO; GO:0032915; P:positive regulation of transforming growth factor beta2 production; ISS:BHF-UCL. DR GO; GO:1904707; P:positive regulation of vascular associated smooth muscle cell proliferation; IMP:BHF-UCL. DR GO; GO:0006606; P:protein import into nucleus; IEA:Ensembl. DR GO; GO:0060043; P:regulation of cardiac muscle cell proliferation; ISS:BHF-UCL. DR GO; GO:2000772; P:regulation of cellular senescence; IEA:Ensembl. DR GO; GO:0048378; P:regulation of lateral mesodermal cell fate specification; IEA:Ensembl. DR GO; GO:0060021; P:roof of mouth development; IEA:Ensembl. DR GO; GO:0035019; P:somatic stem cell population maintenance; IEA:Ensembl. DR GO; GO:0001756; P:somitogenesis; IEA:Ensembl. DR GO; GO:0048863; P:stem cell differentiation; ISS:UniProt. DR GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IMP:FlyBase. DR GO; GO:0003186; P:tricuspid valve morphogenesis; ISS:BHF-UCL. DR GO; GO:0003223; P:ventricular compact myocardium morphogenesis; ISS:BHF-UCL. DR GO; GO:0060412; P:ventricular septum morphogenesis; ISS:BHF-UCL. DR GO; GO:0003222; P:ventricular trabecula myocardium morphogenesis; ISS:BHF-UCL. DR CDD; cd14220; STKc_BMPR1a; 1. DR CDD; cd23612; TFP_LU_ECD_BMPR1A; 1. DR DisProt; DP01990; -. DR FunFam; 1.10.510.10:FF:000018; Receptor protein serine/threonine kinase; 1. DR FunFam; 2.10.60.10:FF:000001; Receptor protein serine/threonine kinase; 1. DR FunFam; 3.30.200.20:FF:000055; Receptor protein serine/threonine kinase; 1. DR Gene3D; 2.10.60.10; CD59; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR000472; Activin_recp. DR InterPro; IPR003605; GS_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR045860; Snake_toxin-like_sf. DR InterPro; IPR000333; TGFB_receptor. DR PANTHER; PTHR23255:SF50; BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1A; 1. DR PANTHER; PTHR23255; TRANSFORMING GROWTH FACTOR-BETA RECEPTOR TYPE I AND II; 1. DR Pfam; PF01064; Activin_recp; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF08515; TGF_beta_GS; 1. DR SMART; SM00467; GS; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF57302; Snake toxin-like; 1. DR PROSITE; PS51256; GS; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; ATP-binding; Cell membrane; Disease variant; Disulfide bond; KW Glycoprotein; Kinase; Magnesium; Manganese; Membrane; Metal-binding; KW Nucleotide-binding; Proteomics identification; Receptor; KW Reference proteome; Serine/threonine-protein kinase; Signal; Transferase; KW Transmembrane; Transmembrane helix. FT SIGNAL 1..23 FT /evidence="ECO:0000255" FT CHAIN 24..532 FT /note="Bone morphogenetic protein receptor type-1A" FT /id="PRO_0000024410" FT TOPO_DOM 24..152 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 153..176 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 177..532 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 204..233 FT /note="GS" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00585" FT DOMAIN 234..525 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 107..109 FT /note="Mediates specificity for BMP ligand" FT /evidence="ECO:0000269|PubMed:22799562" FT ACT_SITE 362 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 240..248 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 261 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT CARBOHYD 73 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 61..82 FT /evidence="ECO:0000269|PubMed:10881198, FT ECO:0000269|PubMed:18937504" FT DISULFID 63..67 FT /evidence="ECO:0000269|PubMed:10881198, FT ECO:0000269|PubMed:18937504" FT DISULFID 76..100 FT /evidence="ECO:0000269|PubMed:10881198, FT ECO:0000269|PubMed:18937504" FT DISULFID 110..124 FT /evidence="ECO:0000269|PubMed:10881198, FT ECO:0000269|PubMed:18937504" FT DISULFID 125..130 FT /evidence="ECO:0000269|PubMed:10881198, FT ECO:0000269|PubMed:18937504" FT VARIANT 2 FT /note="P -> T (in dbSNP:rs11528010)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:8397373" FT /id="VAR_041397" FT VARIANT 58 FT /note="F -> Y (in a renal clear cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041398" FT VARIANT 62 FT /note="Y -> D (in JPS)" FT /evidence="ECO:0000269|PubMed:12417513" FT /id="VAR_022828" FT VARIANT 82 FT /note="C -> Y (in JPS)" FT /evidence="ECO:0000269|PubMed:12417513" FT /id="VAR_022829" FT VARIANT 124 FT /note="C -> R (in JPS; dbSNP:rs199476087)" FT /evidence="ECO:0000269|PubMed:11536076" FT /id="VAR_015533" FT VARIANT 130 FT /note="C -> R (in JPS; dbSNP:rs1131691168)" FT /evidence="ECO:0000269|PubMed:12136244" FT /id="VAR_022830" FT VARIANT 338 FT /note="A -> D (in JPS; dbSNP:rs199476086)" FT /evidence="ECO:0000269|PubMed:11536076" FT /id="VAR_015534" FT VARIANT 376 FT /note="C -> Y (in JPS; dbSNP:rs199476088)" FT /evidence="ECO:0000269|PubMed:11536076" FT /id="VAR_015535" FT VARIANT 443 FT /note="R -> C (in JPS; dbSNP:rs35619497)" FT /evidence="ECO:0000269|PubMed:12417513, FT ECO:0000269|PubMed:17344846" FT /id="VAR_022831" FT VARIANT 450 FT /note="V -> M (in dbSNP:rs55932635)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041399" FT VARIANT 460 FT /note="M -> T (found in a patient with tubular adenoma and FT rectal neuroendocrine tumor; uncertain significance; FT dbSNP:rs758309022)" FT /evidence="ECO:0000269|PubMed:25860647" FT /id="VAR_077353" FT VARIANT 470 FT /note="M -> T (in JPS; dbSNP:rs199476089)" FT /evidence="ECO:0000269|PubMed:12630959" FT /id="VAR_022832" FT VARIANT 486 FT /note="R -> Q (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs752802257)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041400" FT MUTAGEN 107..109 FT /note="DFQ->REL: Affinity for BMP2 decreased by over 200- FT fold." FT /evidence="ECO:0000269|PubMed:22799562" FT STRAND 59..62 FT /evidence="ECO:0007829|PDB:2H62" FT STRAND 64..66 FT /evidence="ECO:0007829|PDB:2H62" FT STRAND 75..88 FT /evidence="ECO:0007829|PDB:2H62" FT STRAND 90..92 FT /evidence="ECO:0007829|PDB:2H62" FT STRAND 94..101 FT /evidence="ECO:0007829|PDB:2H62" FT HELIX 106..111 FT /evidence="ECO:0007829|PDB:2H62" FT STRAND 116..118 FT /evidence="ECO:0007829|PDB:2QJA" FT STRAND 120..125 FT /evidence="ECO:0007829|PDB:2H62" FT HELIX 130..133 FT /evidence="ECO:0007829|PDB:2H62" SQ SEQUENCE 532 AA; 60198 MW; 00CE2DDDA3A44170 CRC64; MPQLYIYIRL LGAYLFIISR VQGQNLDSML HGTGMKSDSD QKKSENGVTL APEDTLPFLK CYCSGHCPDD AINNTCITNG HCFAIIEEDD QGETTLASGC MKYEGSDFQC KDSPKAQLRR TIECCRTNLC NQYLQPTLPP VVIGPFFDGS IRWLVLLISM AVCIIAMIIF SSCFCYKHYC KSISSRRRYN RDLEQDEAFI PVGESLKDLI DQSQSSGSGS GLPLLVQRTI AKQIQMVRQV GKGRYGEVWM GKWRGEKVAV KVFFTTEEAS WFRETEIYQT VLMRHENILG FIAADIKGTG SWTQLYLITD YHENGSLYDF LKCATLDTRA LLKLAYSAAC GLCHLHTEIY GTQGKPAIAH RDLKSKNILI KKNGSCCIAD LGLAVKFNSD TNEVDVPLNT RVGTKRYMAP EVLDESLNKN HFQPYIMADI YSFGLIIWEM ARRCITGGIV EEYQLPYYNM VPSDPSYEDM REVVCVKRLR PIVSNRWNSD ECLRAVLKLM SECWAHNPAS RLTALRIKKT LAKMVESQDV KI // ID BRAF_HUMAN Reviewed; 766 AA. AC P15056; A4D1T4; B6HY61; B6HY62; B6HY63; B6HY64; B6HY65; B6HY66; Q13878; AC Q3MIN6; Q9UDP8; Q9Y6T3; DT 01-NOV-1990, integrated into UniProtKB/Swiss-Prot. DT 19-JUL-2004, sequence version 4. DT 28-JAN-2026, entry version 267. DE RecName: Full=Serine/threonine-protein kinase B-raf {ECO:0000305}; DE EC=2.7.11.1 {ECO:0000269|PubMed:21441910, ECO:0000269|PubMed:29433126}; DE AltName: Full=Proto-oncogene B-Raf; DE AltName: Full=p94; DE AltName: Full=v-Raf murine sarcoma viral oncogene homolog B1; GN Name=BRAF {ECO:0000312|HGNC:HGNC:1097}; Synonyms=BRAF1, RAFB1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE, FUNCTION, AND RP PHOSPHORYLATION AT THR-373. RC TISSUE=Testis; RX PubMed=1508179; DOI=10.1128/mcb.12.9.3733-3742.1992; RA Stephens R.M., Sithanandam G., Copeland T.D., Kaplan D.R., Rapp U.R., RA Morrison D.K.; RT "95-kilodalton B-Raf serine/threonine kinase: identification of the protein RT and its major autophosphorylation site."; RL Mol. Cell. Biol. 12:3733-3742(1992). RN [2] RP SEQUENCE REVISION TO 31-33. RA Albert S., Wixler L., Rapp U.R.; RL Submitted (JAN-2004) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NIEHS SNPs program; RL Submitted (MAR-2008) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12690205; DOI=10.1126/science.1083423; RA Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K., RA Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R., RA Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A., RA Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D., RA Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S., RA Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R., RA Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N., RA Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E., RA Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R., RA Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T., RA Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W., RA Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A., RA Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X., RA Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E., RA Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H., RA Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J., RA Adams M.D., Tsui L.-C.; RT "Human chromosome 7: DNA sequence and biology."; RL Science 300:767-772(2003). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12853948; DOI=10.1038/nature01782; RA Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H., RA Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K., RA Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A., RA Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H., RA Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A., RA Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P., RA Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M., RA Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S., RA Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., RA Strowmatt C., Latreille P., Miller N., Johnson D., Murray J., RA Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., RA Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., RA Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E., RA Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E., RA Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A., RA Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A., RA Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R., RA McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H., RA Wilson R.K.; RT "The DNA sequence of human chromosome 7."; RL Nature 424:157-164(2003). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Liver; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-200. RC TISSUE=Placenta; RX PubMed=1630826; RA Eychene A., Barnier J.V., Apiou F., Dutrillaux B., Calothy G.; RT "Chromosomal assignment of two human B-raf(Rmil) proto-oncogene loci: B- RT raf-1 encoding the p94Braf/Rmil and B-raf-2, a processed pseudogene."; RL Oncogene 7:1657-1660(1992). RN [8] RP PROTEIN SEQUENCE OF 2-51; 56-95; 151-158; 189-199; 253-260; 294-354; RP 361-424; 444-507; 510-522; 559-570; 579-626; 663-680; 692-698; 702-719; RP 727-735 AND 753-766, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT RP ALA-2, PHOSPHORYLATION AT SER-365; THR-396; SER-399; THR-401 AND SER-729, RP AND IDENTIFICATION BY MASS SPECTROMETRY. RC TISSUE=Colon carcinoma, and Hepatoma; RA Bienvenut W.V., Boldt K., von Kriegsheim A.F., Zebisch A., Kolch W.; RL Submitted (DEC-2008) to UniProtKB. RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 117-766. RC TISSUE=Testis; RX PubMed=2284096; RA Sithanandam G., Kolch W., Duh F.-M., Rapp U.R.; RT "Complete coding sequence of a human B-raf cDNA and detection of B-raf RT protein kinase with isozyme specific antibodies."; RL Oncogene 5:1775-1780(1990). RN [10] RP NUCLEOTIDE SEQUENCE [MRNA] OF 381-766, DISEASE, AND CHROMOSOMAL RP REARRANGEMENT. RC TISSUE=Brain; RX PubMed=18974108; DOI=10.1158/0008-5472.can-08-2097; RA Jones D.T.W., Kocialkowski S., Liu L., Pearson D.M., Backlund L.M., RA Ichimura K., Collins V.P.; RT "Tandem duplication producing a novel oncogenic BRAF fusion gene defines RT the majority of pilocytic astrocytomas."; RL Cancer Res. 68:8673-8677(2008). RN [11] RP NUCLEOTIDE SEQUENCE [MRNA] OF 439-766. RX PubMed=3043188; DOI=10.1128/mcb.8.6.2651-2654.1988; RA Ikawa S., Fukui M., Ueyama Y., Tamaoki N., Yamamoto T., Toyoshima K.; RT "B-raf, a new member of the raf family, is activated by DNA RT rearrangement."; RL Mol. Cell. Biol. 8:2651-2654(1988). RN [12] RP PHOSPHORYLATION AT SER-365 BY SGK1. RX PubMed=11410590; DOI=10.1074/jbc.m102808200; RA Zhang B.H., Tang E.D., Zhu T., Greenberg M.E., Vojtek A.B., Guan K.L.; RT "Serum- and glucocorticoid-inducible kinase SGK phosphorylates and RT negatively regulates B-Raf."; RL J. Biol. Chem. 276:31620-31626(2001). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-401, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=16964243; DOI=10.1038/nbt1240; RA Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; RT "A probability-based approach for high-throughput protein phosphorylation RT analysis and site localization."; RL Nat. Biotechnol. 24:1285-1292(2006). RN [14] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-401; SER-446; SER-447 AND RP SER-729, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [16] RP SUBUNIT, INTERACTION WITH DGKH, SUBCELLULAR LOCATION, AND PHOSPHORYLATION RP AT THR-753 BY MAPK1. RX PubMed=19710016; DOI=10.1074/jbc.m109.043604; RA Yasuda S., Kai M., Imai S., Takeishi K., Taketomi A., Toyota M., Kanoh H., RA Sakane F.; RT "Diacylglycerol kinase eta augments C-Raf activity and B-Raf/C-Raf RT heterodimerization."; RL J. Biol. Chem. 284:29559-29570(2009). RN [17] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [18] RP INTERACTION WITH AKAP13; MAP2K1 AND KSR1. RX PubMed=21102438; DOI=10.1038/ncb2130; RA Smith F.D., Langeberg L.K., Cellurale C., Pawson T., Morrison D.K., RA Davis R.J., Scott J.D.; RT "AKAP-Lbc enhances cyclic AMP control of the ERK1/2 cascade."; RL Nat. Cell Biol. 12:1242-1249(2010). RN [19] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [20] RP INTERACTION WITH KSR2, SUBUNIT, CATALYTIC ACTIVITY, FUNCTION, AND RP MUTAGENESIS OF LYS-483. RX PubMed=21441910; DOI=10.1038/nature09860; RA Brennan D.F., Dar A.C., Hertz N.T., Chao W.C., Burlingame A.L., RA Shokat K.M., Barford D.; RT "A Raf-induced allosteric transition of KSR stimulates phosphorylation of RT MEK."; RL Nature 472:366-369(2011). RN [21] RP INTERACTION WITH PRMT5, METHYLATION AT ARG-671, CHARACTERIZATION OF VARIANT RP CRC GLU-600, AND MUTAGENESIS OF ARG-671. RX PubMed=21917714; DOI=10.1126/scisignal.2001936; RA Andreu-Perez P., Esteve-Puig R., de Torre-Minguela C., Lopez-Fauqued M., RA Bech-Serra J.J., Tenbaum S., Garcia-Trevijano E.R., Canals F., Merlino G., RA Avila M.A., Recio J.A.; RT "Protein arginine methyltransferase 5 regulates ERK1/2 signal transduction RT amplitude and cell fate through CRAF."; RL Sci. Signal. 4:RA58-RA58(2011). RN [22] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-729, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [23] RP UBIQUITINATION BY RNF149. RX PubMed=22628551; DOI=10.1074/jbc.m111.319822; RA Hong S.W., Jin D.H., Shin J.S., Moon J.H., Na Y.S., Jung K.A., Kim S.M., RA Kim J.C., Kim K.P., Hong Y.S., Lee J.L., Choi E.K., Lee J.S., Kim T.W.; RT "Ring finger protein 149 is an E3 ubiquitin ligase active on wild-type v- RT Raf murine sarcoma viral oncogene homolog B1 (BRAF)."; RL J. Biol. Chem. 287:24017-24025(2012). RN [24] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-151; SER-365; THR-401; RP SER-446 AND SER-729, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [25] RP UBIQUITINATION AT LYS-578, AND MUTAGENESIS OF LYS-578. RX PubMed=23907581; DOI=10.1038/srep02344; RA An L., Jia W., Yu Y., Zou N., Liang L., Zhao Y., Fan Y., Cheng J., Shi Z., RA Xu G., Li G., Yang J., Zhang H.; RT "Lys63-linked polyubiquitination of BRAF at lysine 578 is required for RT BRAF-mediated signaling."; RL Sci. Rep. 3:2344-2344(2013). RN [26] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-151, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [27] RP INTERACTION WITH FNIP1 AND FNIP2. RX PubMed=27353360; DOI=10.1038/ncomms12037; RA Woodford M.R., Dunn D.M., Blanden A.R., Capriotti D., Loiselle D., RA Prodromou C., Panaretou B., Hughes P.F., Smith A., Ackerman W., RA Haystead T.A., Loh S.N., Bourboulia D., Schmidt L.S., Marston Linehan W., RA Bratslavsky G., Mollapour M.; RT "The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance RT drug binding."; RL Nat. Commun. 7:12037-12037(2016). RN [28] RP INTERACTION WITH YWHAZ. RX PubMed=31024343; DOI=10.3389/fphys.2019.00388; RA Popov I.K., Hiatt S.M., Whalen S., Keren B., Ruivenkamp C., RA van Haeringen A., Chen M.J., Cooper G.M., Korf B.R., Chang C.; RT "A YWHAZ variant associated with cardiofaciocutaneous syndrome activates RT the RAF-ERK pathway."; RL Front. Physiol. 10:388-388(2019). RN [29] RP FUNCTION, AND SUBUNIT. RX PubMed=36402789; DOI=10.1038/s41467-022-34907-0; RA McGrail K., Granado-Martinez P., Esteve-Puig R., Garcia-Ortega S., Ding Y., RA Sanchez-Redondo S., Ferrer B., Hernandez-Losa J., Canals F., Manzano A., RA Navarro-Sabate A., Bartrons R., Yanes O., Perez-Alea M., Munoz-Couselo E., RA Garcia-Patos V., Recio J.A.; RT "BRAF activation by metabolic stress promotes glycolysis sensitizing RT NRASQ61-mutated melanomas to targeted therapy."; RL Nat. Commun. 13:7113-7113(2022). RN [30] RP DEPHOSPHORYLATION AT SER-365 BY SMP COMPLEX. RX PubMed=35768504; DOI=10.1038/s41586-022-04838-3; RA Liau N.P.D., Johnson M.C., Izadi S., Gerosa L., Hammel M., Bruning J.M., RA Wendorff T.J., Phung W., Hymowitz S.G., Sudhamsu J.; RT "Structural basis for SHOC2 modulation of RAS signalling."; RL Nature 609:400-407(2022). RN [31] RP DEPHOSPHORYLATION AT SER-365 BY SMP COMPLEX. RX PubMed=35830882; DOI=10.1038/s41586-022-05086-1; RA Hauseman Z.J., Fodor M., Dhembi A., Viscomi J., Egli D., Bleu M., Katz S., RA Park E., Jang D.M., Porter K.A., Meili F., Guo H., Kerr G., Molle S., RA Velez-Vega C., Beyer K.S., Galli G.G., Maira S.M., Stams T., Clark K., RA Eck M.J., Tordella L., Thoma C.R., King D.A.; RT "Structure of the MRAS-SHOC2-PP1C phosphatase complex."; RL Nature 609:416-423(2022). RN [32] RP X-RAY CRYSTALLOGRAPHY (2.57 ANGSTROMS) OF 444-719 IN COMPLEX WITH RP INHIBITOR. RX PubMed=18287029; DOI=10.1073/pnas.0711741105; RA Tsai J., Lee J.T., Wang W., Zhang J., Cho H., Mamo S., Bremer R., RA Gillette S., Kong J., Haass N.K., Sproesser K., Li L., Smalley K.S., RA Fong D., Zhu Y.L., Marimuthu A., Nguyen H., Lam B., Liu J., Cheung I., RA Rice J., Suzuki Y., Luu C., Settachatgul C., Shellooe R., Cantwell J., RA Kim S.H., Schlessinger J., Zhang K.Y., West B.L., Powell B., Habets G., RA Zhang C., Ibrahim P.N., Hirth P., Artis D.R., Herlyn M., Bollag G.; RT "Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent RT antimelanoma activity."; RL Proc. Natl. Acad. Sci. U.S.A. 105:3041-3046(2008). RN [33] {ECO:0007744|PDB:5VR3, ECO:0007744|PDB:5VYK} RP X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 36-110, FUNCTION, CATALYTIC RP ACTIVITY, ACTIVITY REGULATION, INTERACTION WITH KSR1; KSR2; MAP2K1 AND RP MAP2K2, AND MUTAGENESIS OF MET-53; LYS-88; ARG-509 AND ILE-666. RX PubMed=29433126; DOI=10.1038/nature25478; RA Lavoie H., Sahmi M., Maisonneuve P., Marullo S.A., Thevakumaran N., Jin T., RA Kurinov I., Sicheri F., Therrien M.; RT "MEK drives BRAF activation through allosteric control of KSR proteins."; RL Nature 554:549-553(2018). RN [34] RP VARIANTS LNCR VAL-466 AND ARG-597. RX PubMed=12460919; RA Naoki K., Chen T.-H., Richards W.G., Sugarbaker D.J., Meyerson M.; RT "Missense mutations of the BRAF gene in human lung adenocarcinoma."; RL Cancer Res. 62:7001-7003(2002). RN [35] RP VARIANTS CANCER GLU-464; VAL-464; ALA-466; GLU-466; VAL-466; ALA-469; RP GLU-469; LYS-586; LEU-595; ARG-596; ARG-597; VAL-597; GLU-600 AND ASP-600, RP AND CHARACTERIZATION OF VARIANTS CANCER VAL-464; ALA-469; VAL-597 AND RP GLU-600. RX PubMed=12068308; DOI=10.1038/nature00766; RA Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., RA Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., RA Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., RA Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., RA Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., RA Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., RA Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W.C., RA Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., RA Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.; RT "Mutations of the BRAF gene in human cancer."; RL Nature 417:949-954(2002). RN [36] RP VARIANTS CRC ILE-462; SER-463; GLU-464; GLU-600 AND GLU-601. RX PubMed=12198537; DOI=10.1038/418934a; RA Rajagopalan H., Bardelli A., Lengauer C., Kinzler K.W., Vogelstein B., RA Velculescu V.E.; RT "Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status."; RL Nature 418:934-934(2002). RN [37] RP VARIANTS NHL ALA-469; ARG-469 AND GLY-594. RX PubMed=14612909; DOI=10.1038/sj.bjc.6601371; RA Lee J.W., Yoo N.J., Soung Ark W.S., Kim S.Y., Lee J.H., Park J.Y., RA Cho Y.G., Kim C.J., Ko Y.H., Kim S.H., Nam S.W., Lee J.Y., Lee S.H.; RT "BRAF mutations in non-Hodgkin's lymphoma."; RL Br. J. Cancer 89:1958-1960(2003). RN [38] RP CHARACTERIZATION OF VARIANT MELANOMA GLU-600. RX PubMed=14500344; RA Hingorani S.R., Jacobetz M.A., Robertson G.P., Herlyn M., Tuveson D.A.; RT "Suppression of BRAF(V599E) in human melanoma abrogates transformation."; RL Cancer Res. 63:5198-5202(2003). RN [39] RP VARIANTS CFC1 PRO-246; ARG-257; GLU-469; PHE-485; GLU-499; LYS-501; GLY-501 RP AND ASP-581. RX PubMed=16474404; DOI=10.1038/ng1749; RA Niihori T., Aoki Y., Narumi Y., Neri G., Cave H., Verloes A., Okamoto N., RA Hennekam R.C.M., Gillessen-Kaesbach G., Wieczorek D., Kavamura M.I., RA Kurosawa K., Ohashi H., Wilson L., Heron D., Bonneau D., Corona G., RA Kaname T., Naritomi K., Baumann C., Matsumoto N., Kato K., Kure S., RA Matsubara Y.; RT "Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome."; RL Nat. Genet. 38:294-296(2006). RN [40] RP VARIANT [LARGE SCALE ANALYSIS] GLU-600. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [41] RP VARIANTS CFC1 ARG-257; ALA-467; SER-468; GLU-469; PHE-485; GLU-499; RP LYS-501; GLY-501; ASP-581; LEU-595 AND VAL-596. RX PubMed=16439621; DOI=10.1126/science.1124642; RA Rodriguez-Viciana P., Tetsu O., Tidyman W.E., Estep A.L., Conger B.A., RA Cruz M.S., McCormick F., Rauen K.A.; RT "Germline mutations in genes within the MAPK pathway cause cardio-facio- RT cutaneous syndrome."; RL Science 311:1287-1290(2006). RN [42] RP VARIANTS [LARGE SCALE ANALYSIS] SER-301; ALA-469; VAL-469; SER-581; RP ARG-596; ARG-597; VAL-597 AND GLU-600. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [43] RP VARIANTS CFC1 PRO-241; PRO-244; PRO-246; ARG-257; LYS-262; SER-468; RP GLU-469; GLU-499; ASN-499; ASP-580; ASP-581 AND LEU-595. RX PubMed=18042262; DOI=10.1111/j.1399-0004.2007.00931.x; RA Schulz A.L., Albrecht B., Arici C., van der Burgt I., Buske A., RA Gillessen-Kaesbach G., Heller R., Horn D., Hubner C.A., Korenke G.C., RA Konig R., Kress W., Kruger G., Meinecke P., Mucke J., Plecko B., RA Rossier E., Schinzel A., Schulze A., Seemanova E., Seidel H., Spranger S., RA Tuysuz B., Uhrig S., Wieczorek D., Kutsche K., Zenker M.; RT "Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous RT and Costello syndrome."; RL Clin. Genet. 73:62-70(2008). RN [44] RP VARIANT LPRD3 PRO-241, VARIANTS NS7 ARG-241; MET-241; CYS-531 AND VAL-597, RP AND VARIANTS CFC1 PHE-245; PRO-246; ARG-257; LYS-275; GLU-469; PHE-485; RP ASN-499; LYS-501; PRO-525; LEU-595; ARG-599; GLN-601; GLU-638 AND ARG-709. RX PubMed=19206169; DOI=10.1002/humu.20955; RA Sarkozy A., Carta C., Moretti S., Zampino G., Digilio M.C., Pantaleoni F., RA Scioletti A.P., Esposito G., Cordeddu V., Lepri F., Petrangeli V., RA Dentici M.L., Mancini G.M., Selicorni A., Rossi C., Mazzanti L., Marino B., RA Ferrero G.B., Silengo M.C., Memo L., Stanzial F., Faravelli F., Stuppia L., RA Puxeddu E., Gelb B.D., Dallapiccola B., Tartaglia M.; RT "Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous RT syndromes: molecular diversity and associated phenotypic spectrum."; RL Hum. Mutat. 30:695-702(2009). RN [45] RP VARIANT CRC GLU-600. RX PubMed=23263490; DOI=10.1038/ng.2503; RG CORGI Consortium; RG WGS500 Consortium; RA Palles C., Cazier J.B., Howarth K.M., Domingo E., Jones A.M., Broderick P., RA Kemp Z., Spain S.L., Guarino Almeida E., Salguero I., Sherborne A., RA Chubb D., Carvajal-Carmona L.G., Ma Y., Kaur K., Dobbins S., Barclay E., RA Gorman M., Martin L., Kovac M.B., Humphray S., Lucassen A., Holmes C.C., RA Bentley D., Donnelly P., Taylor J., Petridis C., Roylance R., Sawyer E.J., RA Kerr D.J., Clark S., Grimes J., Kearsey S.E., Thomas H.J., McVean G., RA Houlston R.S., Tomlinson I.; RT "Germline mutations affecting the proofreading domains of POLE and POLD1 RT predispose to colorectal adenomas and carcinomas."; RL Nat. Genet. 45:136-144(2013). RN [46] RP VARIANT CRC GLU-600. RX PubMed=24455489; DOI=10.3389/fonc.2013.00333; RA D'mello S.A., Flanagan J.U., Green T.N., Leung E.Y., Askarian-Amiri M.E., RA Joseph W.R., McCrystal M.R., Isaacs R.J., Shaw J.H., Furneaux C.E., RA During M.J., Finlay G.J., Baguley B.C., Kalev-Zylinska M.L.; RT "Evidence that GRIN2A mutations in melanoma correlate with decreased RT survival."; RL Front. Oncol. 3:333-333(2014). CC -!- FUNCTION: Protein kinase involved in the transduction of mitogenic CC signals from the cell membrane to the nucleus (Probable). CC Phosphorylates MAP2K1, and thereby activates the MAP kinase signal CC transduction pathway (PubMed:21441910, PubMed:29433126). Phosphorylates CC PFKFB2 (PubMed:36402789). May play a role in the postsynaptic responses CC of hippocampal neurons (PubMed:1508179). {ECO:0000269|PubMed:1508179, CC ECO:0000269|PubMed:21441910, ECO:0000269|PubMed:29433126, CC ECO:0000269|PubMed:36402789, ECO:0000305}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:21441910, ECO:0000269|PubMed:29433126}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:21441910}; CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250}; CC Note=Binds 2 Zn(2+) ions per subunit. {ECO:0000250}; CC -!- ACTIVITY REGULATION: In quiescent cells, maintained in an inactive CC state via an intramolecular interaction between the protein kinase and CC N-terminal domains. Following mitogen-mediated cell activation, binds CC via its RGB domain to active HRAS (GTP-bound) which releases the CC inhibitory intramolecular interaction between the two domains. This CC allows the MAP2K1-mediated dimerization of KSR1 or KSR2, and BRAF which CC activates BRAF. {ECO:0000269|PubMed:29433126}. CC -!- SUBUNIT: Monomer (PubMed:19710016). Homodimer (PubMed:19710016, CC PubMed:36402789). Heterodimerizes with RAF1, and the heterodimer CC possesses a highly increased kinase activity compared to the respective CC homodimers or monomers (PubMed:19710016). Heterodimerization is CC mitogen-regulated and enhanced by 14-3-3 proteins. MAPK1/ERK2 CC activation can induce a negative feedback that promotes the CC dissociation of the heterodimer by phosphorylating BRAF at Thr-753. CC Heterodimerizes (via N-terminus) with KSR1 (via N-terminus) or KSR2 CC (via N-terminus) in a MAP2K1-dependent manner (PubMed:29433126). CC Interacts with MAP2K1 and MAP2K2 (PubMed:29433126). Found in a complex CC with at least BRAF, HRAS, MAP2K1, MAPK3 and RGS14. Interacts with RIT1. CC Interacts (via N-terminus) with RGS14 (via RBD domains); the CC interaction mediates the formation of a ternary complex with RAF1, a CC ternary complex inhibited by GNAI1 (By similarity). Interacts with DGKH CC (PubMed:19710016). Interacts with PRMT5 (PubMed:21917714). Interacts CC with KSR2 (PubMed:21441910). Interacts with AKAP13, MAP2K1 and KSR1. CC Identified in a complex with AKAP13, MAP2K1 and KSR1 (PubMed:21102438). CC Interacts with FNIP1 and FNIP2 (PubMed:27353360). {ECO:0000250, CC ECO:0000269|PubMed:18287029, ECO:0000269|PubMed:19710016, CC ECO:0000269|PubMed:21102438, ECO:0000269|PubMed:21441910, CC ECO:0000269|PubMed:21917714, ECO:0000269|PubMed:27353360, CC ECO:0000269|PubMed:29433126, ECO:0000269|PubMed:36402789}. CC -!- INTERACTION: CC P15056; P21399: ACO1; NbExp=4; IntAct=EBI-365980, EBI-2847111; CC P15056; P31749: AKT1; NbExp=4; IntAct=EBI-365980, EBI-296087; CC P15056; P10398: ARAF; NbExp=9; IntAct=EBI-365980, EBI-365961; CC P15056; P49407: ARRB1; NbExp=4; IntAct=EBI-365980, EBI-743313; CC P15056; O14965: AURKA; NbExp=5; IntAct=EBI-365980, EBI-448680; CC P15056; P25311: AZGP1; NbExp=3; IntAct=EBI-365980, EBI-2513837; CC P15056; Q92560: BAP1; NbExp=4; IntAct=EBI-365980, EBI-1791447; CC P15056; Q07817: BCL2L1; NbExp=7; IntAct=EBI-365980, EBI-78035; CC P15056; Q92843: BCL2L2; NbExp=4; IntAct=EBI-365980, EBI-707714; CC P15056; P15056: BRAF; NbExp=14; IntAct=EBI-365980, EBI-365980; CC P15056; P40259: CD79B; NbExp=3; IntAct=EBI-365980, EBI-2873732; CC P15056; Q6P1J9: CDC73; NbExp=4; IntAct=EBI-365980, EBI-930143; CC P15056; P42772: CDKN2B; NbExp=4; IntAct=EBI-365980, EBI-711280; CC P15056; P61024: CKS1B; NbExp=4; IntAct=EBI-365980, EBI-456371; CC P15056; P35221: CTNNA1; NbExp=4; IntAct=EBI-365980, EBI-701918; CC P15056; Q13618: CUL3; NbExp=2; IntAct=EBI-365980, EBI-456129; CC P15056; Q16254: E2F4; NbExp=4; IntAct=EBI-365980, EBI-448943; CC P15056; Q9GZV4: EIF5A2; NbExp=4; IntAct=EBI-365980, EBI-748028; CC P15056; Q7Z589: EMSY; NbExp=4; IntAct=EBI-365980, EBI-6598631; CC P15056; P18074: ERCC2; NbExp=3; IntAct=EBI-365980, EBI-6380590; CC P15056; P28715: ERCC5; NbExp=3; IntAct=EBI-365980, EBI-765885; CC P15056; O43524: FOXO3; NbExp=5; IntAct=EBI-365980, EBI-1644164; CC P15056; Q8WXI9: GATAD2B; NbExp=3; IntAct=EBI-365980, EBI-923440; CC P15056; P17174: GOT1; NbExp=5; IntAct=EBI-365980, EBI-727329; CC P15056; P49840: GSK3A; NbExp=6; IntAct=EBI-365980, EBI-1044067; CC P15056; O95714: HERC2; NbExp=2; IntAct=EBI-365980, EBI-1058922; CC P15056; P01112: HRAS; NbExp=9; IntAct=EBI-365980, EBI-350145; CC P15056; P08238: HSP90AB1; NbExp=5; IntAct=EBI-365980, EBI-352572; CC P15056; O75874: IDH1; NbExp=4; IntAct=EBI-365980, EBI-715695; CC P15056; O14920: IKBKB; NbExp=5; IntAct=EBI-365980, EBI-81266; CC P15056; P46940: IQGAP1; NbExp=4; IntAct=EBI-365980, EBI-297509; CC P15056; P27987: ITPKB; NbExp=4; IntAct=EBI-365980, EBI-751388; CC P15056; Q14145: KEAP1; NbExp=16; IntAct=EBI-365980, EBI-751001; CC P15056; Q02750: MAP2K1; NbExp=65; IntAct=EBI-365980, EBI-492564; CC P15056; P36507: MAP2K2; NbExp=13; IntAct=EBI-365980, EBI-1056930; CC P15056; Q13233: MAP3K1; NbExp=2; IntAct=EBI-365980, EBI-49776; CC P15056; Q15759: MAPK11; NbExp=4; IntAct=EBI-365980, EBI-298304; CC P15056; Q16659: MAPK6; NbExp=3; IntAct=EBI-365980, EBI-1384105; CC P15056; Q13164: MAPK7; NbExp=5; IntAct=EBI-365980, EBI-1213983; CC P15056; Q9NX70: MED29; NbExp=4; IntAct=EBI-365980, EBI-394656; CC P15056; O00255: MEN1; NbExp=4; IntAct=EBI-365980, EBI-592789; CC P15056; P07196: NEFL; NbExp=4; IntAct=EBI-365980, EBI-475646; CC P15056; P01111: NRAS; NbExp=8; IntAct=EBI-365980, EBI-721993; CC P15056; Q9BRP1: PDCD2L; NbExp=6; IntAct=EBI-365980, EBI-2372173; CC P15056; P48736: PIK3CG; NbExp=4; IntAct=EBI-365980, EBI-1030384; CC P15056; P27986: PIK3R1; NbExp=3; IntAct=EBI-365980, EBI-79464; CC P15056; P16885: PLCG2; NbExp=4; IntAct=EBI-365980, EBI-617403; CC P15056; Q07864: POLE; NbExp=6; IntAct=EBI-365980, EBI-348526; CC P15056; O15297: PPM1D; NbExp=4; IntAct=EBI-365980, EBI-1551512; CC P15056; Q02156: PRKCE; NbExp=3; IntAct=EBI-365980, EBI-706254; CC P15056; P57735: RAB25; NbExp=4; IntAct=EBI-365980, EBI-1050500; CC P15056; P04049: RAF1; NbExp=73; IntAct=EBI-365980, EBI-365996; CC P15056; Q12967: RALGDS; NbExp=4; IntAct=EBI-365980, EBI-365861; CC P15056; P61224: RAP1B; NbExp=4; IntAct=EBI-365980, EBI-358143; CC P15056; Q15349: RPS6KA2; NbExp=2; IntAct=EBI-365980, EBI-1384149; CC P15056; Q8N122: RPTOR; NbExp=4; IntAct=EBI-365980, EBI-1567928; CC P15056; Q8IYM1: SEPTIN12; NbExp=4; IntAct=EBI-365980, EBI-2585067; CC P15056; P31947: SFN; NbExp=6; IntAct=EBI-365980, EBI-476295; CC P15056; Q9UMX1: SUFU; NbExp=4; IntAct=EBI-365980, EBI-740595; CC P15056; P04637: TP53; NbExp=4; IntAct=EBI-365980, EBI-366083; CC P15056; Q13114: TRAF3; NbExp=2; IntAct=EBI-365980, EBI-357631; CC P15056; P40337: VHL; NbExp=7; IntAct=EBI-365980, EBI-301246; CC P15056; P31946: YWHAB; NbExp=14; IntAct=EBI-365980, EBI-359815; CC P15056; P62258: YWHAE; NbExp=11; IntAct=EBI-365980, EBI-356498; CC P15056; P61981: YWHAG; NbExp=12; IntAct=EBI-365980, EBI-359832; CC P15056; P27348: YWHAQ; NbExp=12; IntAct=EBI-365980, EBI-359854; CC P15056; P63104: YWHAZ; NbExp=15; IntAct=EBI-365980, EBI-347088; CC P15056; Q61097: Ksr1; Xeno; NbExp=3; IntAct=EBI-365980, EBI-1536336; CC P15056; P29678: MAP2K1; Xeno; NbExp=2; IntAct=EBI-365980, EBI-1631983; CC P15056; Q99N57: Raf1; Xeno; NbExp=3; IntAct=EBI-365980, EBI-397757; CC P15056; Q8CGE9: Rgs12; Xeno; NbExp=2; IntAct=EBI-365980, EBI-7340552; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250}. Cytoplasm CC {ECO:0000269|PubMed:19710016}. Cell membrane CC {ECO:0000269|PubMed:19710016}. Note=Colocalizes with RGS14 and RAF1 in CC both the cytoplasm and membranes. {ECO:0000250}. CC -!- TISSUE SPECIFICITY: Brain and testis. CC -!- PTM: Phosphorylation at Ser-365 by SGK1 inhibits its activity (Ref.8, CC PubMed:11410590). Phosphorylation at Thr-753 by MAPK1 CC (PubMed:19710016). Dephosphorylation of Ser-365 by the SHOC2-MRAS-PP1c CC (SMP) complex consisting of SHOC2, GTP-bound M-Ras/MRAS and the CC catalytic subunit of protein phosphatase 1 (PPP1CA, PPP1CB or PPP1CC); CC this relieves inactivation and stimulates kinase activity CC (PubMed:35768504, PubMed:35830882). {ECO:0000269|PubMed:11410590, CC ECO:0000269|PubMed:19710016, ECO:0000269|PubMed:35768504, CC ECO:0000269|PubMed:35830882, ECO:0000269|Ref.8}. CC -!- PTM: Methylation at Arg-671 decreases stability and kinase activity. CC {ECO:0000269|PubMed:21917714}. CC -!- PTM: Ubiquitinated by RNF149; which leads to proteasomal degradation. CC Polyubiquitinated at Lys-578 in response to EGF. CC {ECO:0000269|PubMed:22628551, ECO:0000269|PubMed:23907581}. CC -!- DISEASE: Note=Defects in BRAF are found in a wide range of cancers. CC {ECO:0000269|PubMed:18974108}. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:12198537, CC ECO:0000269|PubMed:21917714, ECO:0000269|PubMed:23263490, CC ECO:0000269|PubMed:24455489}. Note=The disease may be caused by CC variants affecting the gene represented in this entry. CC -!- DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting CC tissues of the lung. The most common form of lung cancer is non-small CC cell lung cancer (NSCLC) that can be divided into 3 major histologic CC subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung CC cancer. NSCLC is often diagnosed at an advanced stage and has a poor CC prognosis. {ECO:0000269|PubMed:12460919}. Note=The gene represented in CC this entry is involved in disease pathogenesis. CC -!- DISEASE: Familial non-Hodgkin lymphoma (NHL) [MIM:605027]: Cancer that CC starts in cells of the lymph system, which is part of the body's immune CC system. NHLs can occur at any age and are often marked by enlarged CC lymph nodes, fever and weight loss. {ECO:0000269|PubMed:14612909}. CC Note=The gene represented in this entry is involved in disease CC pathogenesis. CC -!- DISEASE: Cardiofaciocutaneous syndrome 1 (CFC1) [MIM:115150]: A CC multiple congenital anomaly disorder characterized by a distinctive CC facial appearance, heart defects and intellectual disability. Heart CC defects include pulmonic stenosis, atrial septal defects and CC hypertrophic cardiomyopathy. Some affected individuals present with CC ectodermal abnormalities such as sparse, friable hair, hyperkeratotic CC skin lesions and a generalized ichthyosis-like condition. Typical CC facial features are similar to Noonan syndrome. They include high CC forehead with bitemporal constriction, hypoplastic supraorbital ridges, CC downslanting palpebral fissures, a depressed nasal bridge, and CC posteriorly angulated ears with prominent helices. CC {ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:16474404, CC ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:19206169}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Noonan syndrome 7 (NS7) [MIM:613706]: A form of Noonan CC syndrome, a disease characterized by short stature, facial dysmorphic CC features such as hypertelorism, a downward eyeslant and low-set CC posteriorly rotated ears, and a high incidence of congenital heart CC defects and hypertrophic cardiomyopathy. Other features can include a CC short neck with webbing or redundancy of skin, deafness, motor delay, CC variable intellectual deficits, multiple skeletal defects, CC cryptorchidism, and bleeding diathesis. Individuals with Noonan CC syndrome are at risk of juvenile myelomonocytic leukemia, a CC myeloproliferative disorder characterized by excessive production of CC myelomonocytic cells. {ECO:0000269|PubMed:19206169}. Note=The disease CC is caused by variants affecting the gene represented in this entry. CC -!- DISEASE: LEOPARD syndrome 3 (LPRD3) [MIM:613707]: A disorder CC characterized by lentigines, electrocardiographic conduction CC abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities CC of genitalia, retardation of growth, and sensorineural deafness. CC {ECO:0000269|PubMed:19206169}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Note=A chromosomal aberration involving BRAF is found in CC pilocytic astrocytomas. A tandem duplication of 2 Mb at 7q34 leads to CC the expression of a KIAA1549-BRAF fusion protein with a constitutive CC kinase activity and inducing cell transformation. CC {ECO:0000269|PubMed:18974108}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr CC protein kinase family. RAF subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAD43193.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC Sequence=CAQ43111.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAQ43112.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAQ43113.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAQ43114.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAQ43115.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAQ43116.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/828/BRAF"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M95712; AAA35609.2; -; mRNA. DR EMBL; AC006344; AAD43193.1; ALT_SEQ; Genomic_DNA. DR EMBL; EU600171; ACD11489.1; -; Genomic_DNA. DR EMBL; AC006347; AAD15551.1; -; Genomic_DNA. DR EMBL; CH236950; EAL24023.1; -; Genomic_DNA. DR EMBL; BC101757; AAI01758.1; -; mRNA. DR EMBL; BC112079; AAI12080.1; -; mRNA. DR EMBL; X65187; CAA46301.1; -; Genomic_DNA. DR EMBL; M21001; AAA96495.1; -; mRNA. DR EMBL; AM989472; CAQ43111.1; ALT_INIT; mRNA. DR EMBL; AM989473; CAQ43112.1; ALT_INIT; mRNA. DR EMBL; AM989474; CAQ43113.1; ALT_INIT; mRNA. DR EMBL; AM989475; CAQ43114.1; ALT_INIT; mRNA. DR EMBL; AM989476; CAQ43115.1; ALT_INIT; mRNA. DR EMBL; AM989477; CAQ43116.1; ALT_INIT; mRNA. DR CCDS; CCDS5863.1; -. DR PIR; A57977; TVHUBF. DR RefSeq; NP_004324.2; NM_004333.4. DR PDB; 1UWH; X-ray; 2.95 A; A/B=448-723. DR PDB; 1UWJ; X-ray; 3.50 A; A/B=448-723. DR PDB; 2FB8; X-ray; 2.90 A; A/B=445-723. DR PDB; 2L05; NMR; -; A=149-232. DR PDB; 3C4C; X-ray; 2.57 A; A/B=444-721. DR PDB; 3D4Q; X-ray; 2.80 A; A/B=433-726. DR PDB; 3IDP; X-ray; 2.70 A; A/B=434-727. DR PDB; 3II5; X-ray; 2.79 A; A/B=432-726. DR PDB; 3NY5; X-ray; 1.99 A; A/B/C/D=153-237. DR PDB; 3OG7; X-ray; 2.45 A; A/B=448-720. DR PDB; 3PPJ; X-ray; 3.70 A; A/B=432-726. DR PDB; 3PPK; X-ray; 3.00 A; A/B=432-726. DR PDB; 3PRF; X-ray; 2.90 A; A/B=432-726. DR PDB; 3PRI; X-ray; 3.50 A; A/B=432-726. DR PDB; 3PSB; X-ray; 3.40 A; A/B=433-726. DR PDB; 3PSD; X-ray; 3.60 A; A/B=433-726. DR PDB; 3Q4C; X-ray; 3.20 A; A/B=432-726. DR PDB; 3Q96; X-ray; 3.10 A; A/B=446-727. DR PDB; 3SKC; X-ray; 3.20 A; A/B=432-726. DR PDB; 3TV4; X-ray; 3.40 A; A/B=432-726. DR PDB; 3TV6; X-ray; 3.30 A; A/B=432-726. DR PDB; 4CQE; X-ray; 2.30 A; A/B=448-723. DR PDB; 4DBN; X-ray; 3.15 A; A/B=445-726. DR PDB; 4E26; X-ray; 2.55 A; A/B=432-726. DR PDB; 4E4X; X-ray; 3.60 A; A/B=432-726. DR PDB; 4EHE; X-ray; 3.30 A; A/B=432-726. DR PDB; 4EHG; X-ray; 3.50 A; A/B=432-726. DR PDB; 4FC0; X-ray; 2.95 A; A/B=445-726. DR PDB; 4FK3; X-ray; 2.65 A; A/B=444-723. DR PDB; 4G9C; X-ray; 3.50 A; A/B=432-726. DR PDB; 4G9R; X-ray; 3.20 A; A/B=432-726. DR PDB; 4H58; X-ray; 3.10 A; A/B/C=448-722. DR PDB; 4JVG; X-ray; 3.09 A; A/B/C/D=444-723. DR PDB; 4KSP; X-ray; 2.93 A; A/B=445-726. DR PDB; 4KSQ; X-ray; 3.30 A; A/B=445-726. DR PDB; 4MBJ; X-ray; 3.60 A; A/B=432-723. DR PDB; 4MNE; X-ray; 2.85 A; B/C/F/G=432-726. DR PDB; 4MNF; X-ray; 2.80 A; A/B=432-736. DR PDB; 4PP7; X-ray; 3.40 A; A/B=432-726. DR PDB; 4R5Y; X-ray; 3.50 A; A/B=444-723. DR PDB; 4RZV; X-ray; 2.99 A; A/B=443-723. DR PDB; 4RZW; X-ray; 3.49 A; A/B=443-723. DR PDB; 4WO5; X-ray; 2.83 A; A/B=444-723. DR PDB; 4XV1; X-ray; 2.47 A; A/B=444-705. DR PDB; 4XV2; X-ray; 2.50 A; A/B=444-705. DR PDB; 4XV3; X-ray; 2.80 A; A/B=444-705. DR PDB; 4XV9; X-ray; 2.00 A; A=442-705. DR PDB; 4YHT; X-ray; 3.05 A; A/B=449-720. DR PDB; 5C9C; X-ray; 2.70 A; A/B=432-726. DR PDB; 5CSW; X-ray; 2.66 A; A/B=442-721. DR PDB; 5CSX; X-ray; 2.51 A; A=442-721. DR PDB; 5CT7; X-ray; 3.17 A; A/B=445-723. DR PDB; 5FD2; X-ray; 2.89 A; A/B=433-726. DR PDB; 5HI2; X-ray; 2.51 A; A=444-737. DR PDB; 5HID; X-ray; 2.50 A; A/B=444-737. DR PDB; 5HIE; X-ray; 3.00 A; A/B/C/D=432-726. DR PDB; 5ITA; X-ray; 1.95 A; A/B=448-723. DR PDB; 5J17; NMR; -; A=151-232. DR PDB; 5J18; NMR; -; A=151-232. DR PDB; 5J2R; NMR; -; A=151-232. DR PDB; 5JRQ; X-ray; 2.29 A; A/B=448-723. DR PDB; 5JSM; X-ray; 2.19 A; A/B/C/D=448-723. DR PDB; 5JT2; X-ray; 2.70 A; A/B/C/D=448-723. DR PDB; 5VAL; X-ray; 2.26 A; A/B=445-723. DR PDB; 5VAM; X-ray; 2.10 A; A/B=445-723. DR PDB; 5VR3; X-ray; 2.10 A; A=36-114. DR PDB; 5VYK; X-ray; 1.75 A; A/C=36-110. DR PDB; 6B8U; X-ray; 2.68 A; A/B=445-723. DR PDB; 6CAD; X-ray; 2.55 A; A/B=444-723. DR PDB; 6N0P; X-ray; 2.37 A; A/B=449-721. DR PDB; 6N0Q; X-ray; 2.04 A; A/B=445-723. DR PDB; 6NSQ; X-ray; 3.05 A; A/B=444-723. DR PDB; 6NYB; EM; 4.10 A; A=1-766. DR PDB; 6P3D; X-ray; 2.11 A; A=448-721. DR PDB; 6P7G; X-ray; 2.65 A; A/B/C/D=448-723. DR PDB; 6PP9; X-ray; 2.59 A; A=445-723. DR PDB; 6Q0J; EM; 4.90 A; A/B=1-766. DR PDB; 6Q0K; EM; 6.80 A; A/B=1-766. DR PDB; 6Q0T; EM; 5.70 A; A/B=1-766. DR PDB; 6U2G; X-ray; 2.89 A; B=432-726. DR PDB; 6U2H; X-ray; 2.50 A; C/D=447-735. DR PDB; 6UAN; EM; 3.90 A; B/C=1-766. DR PDB; 6UUO; X-ray; 3.29 A; A/B=444-723. DR PDB; 6V2U; X-ray; 3.78 A; A/B=445-723. DR PDB; 6V2W; X-ray; 3.12 A; A=445-723. DR PDB; 6V34; X-ray; 3.15 A; A/B=448-721. DR PDB; 6XAG; X-ray; 3.30 A; C/D=447-735. DR PDB; 6XFP; X-ray; 2.00 A; A=442-721. DR PDB; 6XLO; X-ray; 2.49 A; A/B=442-721. DR PDB; 7K0V; X-ray; 1.93 A; A/B/C/D=444-723. DR PDB; 7M0T; X-ray; 3.19 A; A=445-723. DR PDB; 7M0U; X-ray; 3.09 A; A=445-723. DR PDB; 7M0V; X-ray; 3.16 A; A=445-723. DR PDB; 7M0W; X-ray; 3.09 A; A=445-723. DR PDB; 7M0X; X-ray; 2.47 A; A=445-723. DR PDB; 7M0Y; X-ray; 3.45 A; A=445-723. DR PDB; 7M0Z; X-ray; 3.12 A; A=445-723. DR PDB; 7MFD; EM; 3.66 A; A=1-766. DR PDB; 7MFE; EM; 4.07 A; A=1-766. DR PDB; 7MFF; EM; 3.89 A; A/B=1-766. DR PDB; 7P3V; X-ray; 2.37 A; A/B=448-719. DR PDB; 7SHV; X-ray; 2.88 A; A/B=432-726. DR PDB; 7ZR0; EM; 3.40 A; K=1-766. DR PDB; 7ZR5; EM; 3.90 A; K=1-766. DR PDB; 7ZR6; EM; 4.20 A; K=1-766. DR PDB; 8C7X; X-ray; 1.65 A; A/B=444-721. DR PDB; 8C7Y; X-ray; 1.65 A; A/B=444-721. DR PDB; 8DGS; EM; 4.30 A; A=1-766. DR PDB; 8DGT; EM; 3.90 A; A=1-766. DR PDB; 8F7O; X-ray; 3.54 A; A/B=441-723. DR PDB; 8F7P; X-ray; 2.74 A; A/B=441-723. DR PDB; 8QQG; X-ray; 2.98 A; A/B/C=448-722. DR PDB; 8VSO; X-ray; 1.50 A; P=361-369. DR PDB; 8VYO; EM; 3.74 A; A=1-766. DR PDB; 8VYP; EM; 3.29 A; C=1-766. DR PDB; 8VYQ; EM; 4.43 A; C=360-734. DR PDB; 8VYR; EM; 4.32 A; A=1-766. DR PDB; 8VYS; EM; 3.06 A; A=1-766. DR PDB; 8VYU; EM; 4.07 A; A=1-766. DR PDB; 8VYV; EM; 5.86 A; C=1-766. DR PDB; 8VYW; EM; 4.76 A; C=360-734. DR PDB; 9AXX; X-ray; 2.07 A; B/D=445-723. DR PDB; 9AXY; X-ray; 3.60 A; A=445-723. DR PDB; 9BFB; X-ray; 1.92 A; A=445-723. DR PDB; 9BP8; X-ray; 1.73 A; A=445-723. DR PDB; 9EW6; X-ray; 1.65 A; P=361-369. DR PDB; 9F35; X-ray; 2.30 A; B=360-370. DR PDBsum; 1UWH; -. DR PDBsum; 1UWJ; -. DR PDBsum; 2FB8; -. DR PDBsum; 2L05; -. DR PDBsum; 3C4C; -. DR PDBsum; 3D4Q; -. DR PDBsum; 3IDP; -. DR PDBsum; 3II5; -. DR PDBsum; 3NY5; -. DR PDBsum; 3OG7; -. DR PDBsum; 3PPJ; -. DR PDBsum; 3PPK; -. DR PDBsum; 3PRF; -. DR PDBsum; 3PRI; -. DR PDBsum; 3PSB; -. DR PDBsum; 3PSD; -. DR PDBsum; 3Q4C; -. DR PDBsum; 3Q96; -. DR PDBsum; 3SKC; -. DR PDBsum; 3TV4; -. DR PDBsum; 3TV6; -. DR PDBsum; 4CQE; -. DR PDBsum; 4DBN; -. DR PDBsum; 4E26; -. DR PDBsum; 4E4X; -. DR PDBsum; 4EHE; -. DR PDBsum; 4EHG; -. DR PDBsum; 4FC0; -. DR PDBsum; 4FK3; -. DR PDBsum; 4G9C; -. DR PDBsum; 4G9R; -. DR PDBsum; 4H58; -. DR PDBsum; 4JVG; -. DR PDBsum; 4KSP; -. DR PDBsum; 4KSQ; -. DR PDBsum; 4MBJ; -. DR PDBsum; 4MNE; -. DR PDBsum; 4MNF; -. DR PDBsum; 4PP7; -. DR PDBsum; 4R5Y; -. DR PDBsum; 4RZV; -. DR PDBsum; 4RZW; -. DR PDBsum; 4WO5; -. DR PDBsum; 4XV1; -. DR PDBsum; 4XV2; -. DR PDBsum; 4XV3; -. DR PDBsum; 4XV9; -. DR PDBsum; 4YHT; -. DR PDBsum; 5C9C; -. DR PDBsum; 5CSW; -. DR PDBsum; 5CSX; -. DR PDBsum; 5CT7; -. DR PDBsum; 5FD2; -. DR PDBsum; 5HI2; -. DR PDBsum; 5HID; -. DR PDBsum; 5HIE; -. DR PDBsum; 5ITA; -. DR PDBsum; 5J17; -. DR PDBsum; 5J18; -. DR PDBsum; 5J2R; -. DR PDBsum; 5JRQ; -. DR PDBsum; 5JSM; -. DR PDBsum; 5JT2; -. DR PDBsum; 5VAL; -. DR PDBsum; 5VAM; -. DR PDBsum; 5VR3; -. DR PDBsum; 5VYK; -. DR PDBsum; 6B8U; -. DR PDBsum; 6CAD; -. DR PDBsum; 6N0P; -. DR PDBsum; 6N0Q; -. DR PDBsum; 6NSQ; -. DR PDBsum; 6NYB; -. DR PDBsum; 6P3D; -. DR PDBsum; 6P7G; -. DR PDBsum; 6PP9; -. DR PDBsum; 6Q0J; -. DR PDBsum; 6Q0K; -. DR PDBsum; 6Q0T; -. DR PDBsum; 6U2G; -. DR PDBsum; 6U2H; -. DR PDBsum; 6UAN; -. DR PDBsum; 6UUO; -. DR PDBsum; 6V2U; -. DR PDBsum; 6V2W; -. DR PDBsum; 6V34; -. DR PDBsum; 6XAG; -. DR PDBsum; 6XFP; -. DR PDBsum; 6XLO; -. DR PDBsum; 7K0V; -. DR PDBsum; 7M0T; -. DR PDBsum; 7M0U; -. DR PDBsum; 7M0V; -. DR PDBsum; 7M0W; -. DR PDBsum; 7M0X; -. DR PDBsum; 7M0Y; -. DR PDBsum; 7M0Z; -. DR PDBsum; 7MFD; -. DR PDBsum; 7MFE; -. DR PDBsum; 7MFF; -. DR PDBsum; 7P3V; -. DR PDBsum; 7SHV; -. DR PDBsum; 7ZR0; -. DR PDBsum; 7ZR5; -. DR PDBsum; 7ZR6; -. DR PDBsum; 8C7X; -. DR PDBsum; 8C7Y; -. DR PDBsum; 8DGS; -. DR PDBsum; 8DGT; -. DR PDBsum; 8F7O; -. DR PDBsum; 8F7P; -. DR PDBsum; 8QQG; -. DR PDBsum; 8VSO; -. DR PDBsum; 8VYO; -. DR PDBsum; 8VYP; -. DR PDBsum; 8VYQ; -. DR PDBsum; 8VYR; -. DR PDBsum; 8VYS; -. DR PDBsum; 8VYU; -. DR PDBsum; 8VYV; -. DR PDBsum; 8VYW; -. DR PDBsum; 9AXX; -. DR PDBsum; 9AXY; -. DR PDBsum; 9BFB; -. DR PDBsum; 9BP8; -. DR PDBsum; 9EW6; -. DR PDBsum; 9F35; -. DR AlphaFoldDB; P15056; -. DR BMRB; P15056; -. DR EMDB; EMD-0541; -. DR EMDB; EMD-14875; -. DR EMDB; EMD-14883; -. DR EMDB; EMD-14884; -. DR EMDB; EMD-20550; -. DR EMDB; EMD-20551; -. DR EMDB; EMD-20552; -. DR EMDB; EMD-20708; -. DR EMDB; EMD-23813; -. DR EMDB; EMD-23814; -. DR EMDB; EMD-23815; -. DR EMDB; EMD-27428; -. DR EMDB; EMD-27429; -. DR EMDB; EMD-43673; -. DR EMDB; EMD-43674; -. DR EMDB; EMD-43675; -. DR EMDB; EMD-43676; -. DR EMDB; EMD-43677; -. DR EMDB; EMD-43678; -. DR EMDB; EMD-43679; -. DR EMDB; EMD-43680; -. DR SMR; P15056; -. DR BioGRID; 107141; 185. DR CORUM; P15056; -. DR DIP; DIP-1045N; -. DR FunCoup; P15056; 5390. DR IntAct; P15056; 446. DR MINT; P15056; -. DR STRING; 9606.ENSP00000419060; -. DR BindingDB; P15056; -. DR ChEMBL; CHEMBL5145; -. DR DrugBank; DB08553; (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime. DR DrugBank; DB15068; Agerafenib. DR DrugBank; DB15254; Avutometinib. DR DrugBank; DB12854; BMS-908662. DR DrugBank; DB08912; Dabrafenib. DR DrugBank; DB11718; Encorafenib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB14773; Lifirafenib. DR DrugBank; DB07000; N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide. DR DrugBank; DB06999; PLX-4720. DR DrugBank; DB16038; PLX8394. DR DrugBank; DB05984; RAF-265. DR DrugBank; DB08896; Regorafenib. DR DrugBank; DB14840; Ripretinib. DR DrugBank; DB00398; Sorafenib. DR DrugBank; DB15266; Tovorafenib. DR DrugBank; DB08881; Vemurafenib. DR DrugBank; DB05190; XL281. DR DrugCentral; P15056; -. DR GuidetoPHARMACOLOGY; 1943; -. DR TCDB; 8.A.23.1.48; the basigin (basigin) family. DR GlyGen; P15056; 1 site. DR iPTMnet; P15056; -. DR PhosphoSitePlus; P15056; -. DR SwissPalm; P15056; -. DR BioMuta; BRAF; -. DR DMDM; 50403720; -. DR CPTAC; CPTAC-3112; -. DR CPTAC; CPTAC-3113; -. DR CPTAC; CPTAC-5771; -. DR CPTAC; CPTAC-5817; -. DR CPTAC; CPTAC-5818; -. DR CPTAC; CPTAC-5819; -. DR CPTAC; CPTAC-5820; -. DR CPTAC; CPTAC-5821; -. DR CPTAC; CPTAC-5822; -. DR CPTAC; non-CPTAC-5352; -. DR CPTAC; non-CPTAC-5353; -. DR CPTAC; non-CPTAC-5354; -. DR CPTAC; non-CPTAC-5355; -. DR CPTAC; non-CPTAC-5356; -. DR CPTAC; non-CPTAC-5357; -. DR CPTAC; non-CPTAC-5727; -. DR CPTAC; non-CPTAC-5728; -. DR CPTAC; non-CPTAC-5729; -. DR jPOST; P15056; -. DR MassIVE; P15056; -. DR PaxDb; 9606-ENSP00000288602; -. DR PeptideAtlas; P15056; -. DR ProteomicsDB; 53102; -. DR Pumba; P15056; -. DR Antibodypedia; 751; 2321 antibodies from 54 providers. DR CPTC; P15056; 7 antibodies. DR DNASU; 673; -. DR Ensembl; ENST00000646891.2; ENSP00000493543.1; ENSG00000157764.15. DR GeneID; 673; -. DR KEGG; hsa:673; -. DR MANE-Select; ENST00000646891.2; ENSP00000493543.1; NM_004333.6; NP_004324.2. DR UCSC; uc003vwc.5; human. DR AGR; HGNC:1097; -. DR CIViC; 673; 6 clinical assertions and 454 evidence items across 166 molecular profiles. DR ClinPGx; PA25408; -. DR CTD; 673; -. DR DisGeNET; 673; -. DR GeneCards; BRAF; -. DR GeneReviews; BRAF; -. DR HGNC; HGNC:1097; BRAF. DR HPA; ENSG00000157764; Low tissue specificity. DR MalaCards; BRAF; -. DR MIM; 114500; phenotype. DR MIM; 115150; phenotype. DR MIM; 164757; gene. DR MIM; 211980; phenotype. DR MIM; 605027; phenotype. DR MIM; 613706; phenotype. DR MIM; 613707; phenotype. DR OpenTargets; ENSG00000157764; -. DR Orphanet; 1340; Cardiofaciocutaneous syndrome. DR Orphanet; 58017; Classic hairy cell leukemia. DR Orphanet; 54595; Craniopharyngioma. DR Orphanet; 96253; Cushing disease. DR Orphanet; 146; Differentiated thyroid carcinoma. DR Orphanet; 389; Langerhans cell histiocytosis. DR Orphanet; 626; Large/giant congenital melanocytic nevus. DR Orphanet; 648; Noonan syndrome. DR Orphanet; 500; Noonan syndrome with multiple lentigines. DR Orphanet; 251615; Pilomyxoid astrocytoma. DR Orphanet; 840; Syringocystadenoma papilliferum. DR VEuPathDB; HostDB:ENSG00000157764; -. DR eggNOG; KOG0193; Eukaryota. DR GeneTree; ENSGT00940000156154; -. DR HOGENOM; CLU_023684_1_0_1; -. DR InParanoid; P15056; -. DR OrthoDB; 774951at2759; -. DR PAN-GO; P15056; 3 GO annotations based on evolutionary models. DR PhylomeDB; P15056; -. DR BRENDA; 2.7.10.2; 2681. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; P15056; -. DR Reactome; R-HSA-1295596; Spry regulation of FGF signaling. DR Reactome; R-HSA-170968; Frs2-mediated activation. DR Reactome; R-HSA-170984; ARMS-mediated activation. DR Reactome; R-HSA-187706; Signalling to p38 via RIT and RIN. DR Reactome; R-HSA-5673000; RAF activation. DR Reactome; R-HSA-5674135; MAP2K and MAPK activation. DR Reactome; R-HSA-5674499; Negative feedback regulation of MAPK pathway. DR Reactome; R-HSA-5675221; Negative regulation of MAPK pathway. DR Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants. DR Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants. DR Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions. DR Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF. DR Reactome; R-HSA-9649948; Signaling downstream of RAS mutants. DR Reactome; R-HSA-9656223; Signaling by RAF1 mutants. DR Reactome; R-HSA-9726840; SHOC2 M1731 mutant abolishes MRAS complex function. DR Reactome; R-HSA-9726842; Gain-of-function MRAS complexes activate RAF signaling. DR SignaLink; P15056; -. DR SIGNOR; P15056; -. DR Agora; ENSG00000157764; -. DR BioGRID-ORCS; 673; 88 hits in 1213 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; D57F7ABA; Synthetic Condensate 000274. DR ChiTaRS; BRAF; human. DR EvolutionaryTrace; P15056; -. DR GeneWiki; BRAF_(gene); -. DR GenomeRNAi; 673; -. DR Pharos; P15056; Tclin. DR PRO; PR:P15056; -. DR Proteomes; UP000005640; Chromosome 7. DR RNAct; P15056; protein. DR Bgee; ENSG00000157764; Expressed in buccal mucosa cell and 183 other cell types or tissues. DR ExpressionAtlas; P15056; baseline and differential. DR GO; GO:0044297; C:cell body; IEA:Ensembl. DR GO; GO:0034451; C:centriolar satellite; IDA:HPA. DR GO; GO:0036064; C:ciliary basal body; IDA:HPA. DR GO; GO:0005929; C:cilium; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0005739; C:mitochondrion; IBA:GO_Central. DR GO; GO:0043005; C:neuron projection; IEA:Ensembl. DR GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell. DR GO; GO:0005886; C:plasma membrane; IBA:GO_Central. DR GO; GO:0098794; C:postsynapse; IEA:GOC. DR GO; GO:0098793; C:presynapse; IEA:GOC. DR GO; GO:0097229; C:sperm end piece; IDA:HPA. DR GO; GO:0097225; C:sperm midpiece; IDA:HPA. DR GO; GO:0097228; C:sperm principal piece; IDA:HPA. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005509; F:calcium ion binding; IDA:BHF-UCL. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0004708; F:MAP kinase kinase activity; IMP:UniProtKB. DR GO; GO:0004709; F:MAP kinase kinase kinase activity; IBA:GO_Central. DR GO; GO:0004672; F:protein kinase activity; IDA:BHF-UCL. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0097110; F:scaffold protein binding; IPI:BHF-UCL. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0009887; P:animal organ morphogenesis; TAS:ProtInc. DR GO; GO:0043369; P:CD4-positive or CD8-positive, alpha-beta T cell lineage commitment; IEA:Ensembl. DR GO; GO:0043367; P:CD4-positive, alpha-beta T cell differentiation; IEA:Ensembl. DR GO; GO:0071277; P:cellular response to calcium ion; IDA:BHF-UCL. DR GO; GO:0071466; P:cellular response to xenobiotic stimulus; IEA:Ensembl. DR GO; GO:0072577; P:endothelial cell apoptotic process; IEA:Ensembl. DR GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IDA:BHF-UCL. DR GO; GO:0070371; P:ERK1 and ERK2 cascade; IBA:GO_Central. DR GO; GO:0090150; P:establishment of protein localization to membrane; IDA:CACAO. DR GO; GO:0060324; P:face development; IEA:Ensembl. DR GO; GO:0060323; P:head morphogenesis; IEA:Ensembl. DR GO; GO:0060291; P:long-term synaptic potentiation; IEA:Ensembl. DR GO; GO:0000165; P:MAPK cascade; IDA:UniProtKB. DR GO; GO:0002318; P:myeloid progenitor cell differentiation; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; IEA:Ensembl. DR GO; GO:0010764; P:negative regulation of fibroblast migration; IEA:Ensembl. DR GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:2000301; P:negative regulation of synaptic vesicle exocytosis; IEA:Ensembl. DR GO; GO:0048680; P:positive regulation of axon regeneration; IEA:Ensembl. DR GO; GO:0050772; P:positive regulation of axonogenesis; IEA:Ensembl. DR GO; GO:0010828; P:positive regulation of D-glucose transmembrane transport; IDA:CACAO. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:BHF-UCL. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL. DR GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:UniProtKB. DR GO; GO:0051496; P:positive regulation of stress fiber assembly; IEA:Ensembl. DR GO; GO:1900026; P:positive regulation of substrate adhesion-dependent cell spreading; IEA:Ensembl. DR GO; GO:0099170; P:postsynaptic modulation of chemical synaptic transmission; IEA:Ensembl. DR GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc. DR GO; GO:0042127; P:regulation of cell population proliferation; IEA:Ensembl. DR GO; GO:0045580; P:regulation of T cell differentiation; IEA:Ensembl. DR GO; GO:0035019; P:somatic stem cell population maintenance; IEA:Ensembl. DR GO; GO:0043149; P:stress fiber assembly; IEA:Ensembl. DR GO; GO:0034446; P:substrate adhesion-dependent cell spreading; IEA:Ensembl. DR GO; GO:0016079; P:synaptic vesicle exocytosis; IEA:Ensembl. DR GO; GO:0033077; P:T cell differentiation in thymus; IEA:Ensembl. DR GO; GO:0050852; P:T cell receptor signaling pathway; IEA:Ensembl. DR GO; GO:0048538; P:thymus development; IEA:Ensembl. DR GO; GO:0030878; P:thyroid gland development; IEA:Ensembl. DR GO; GO:0008542; P:visual learning; IEA:Ensembl. DR CDD; cd20871; C1_B-Raf; 1. DR CDD; cd17134; RBD_BRAF; 1. DR CDD; cd14062; STKc_Raf; 1. DR DisProt; DP03825; -. DR FunFam; 3.10.20.90:FF:000015; B-Raf proto-oncogene serine/threonine-protein kinase; 1. DR FunFam; 3.30.200.20:FF:000024; B-Raf proto-oncogene serine/threonine-protein kinase; 1. DR FunFam; 3.30.60.20:FF:000004; B-Raf proto-oncogene serine/threonine-protein kinase; 1. DR FunFam; 1.10.510.10:FF:000036; RAF proto-oncogene serine/threonine-protein kinase; 1. DR Gene3D; 3.30.60.20; -; 1. DR Gene3D; 3.10.20.90; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR046349; C1-like_sf. DR InterPro; IPR020454; DAG/PE-bd. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR002219; PKC_DAG/PE. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR003116; RBD_dom. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR051681; Ser/Thr_Kinases-Pseudokinases. DR InterPro; IPR029071; Ubiquitin-like_domsf. DR PANTHER; PTHR44329; SERINE/THREONINE-PROTEIN KINASE TNNI3K-RELATED; 1. DR PANTHER; PTHR44329:SF240; SERINE_THREONINE-PROTEIN KINASE B-RAF; 1. DR Pfam; PF00130; C1_1; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF02196; RBD; 1. DR PRINTS; PR00008; DAGPEDOMAIN. DR SMART; SM00109; C1; 1. DR SMART; SM00455; RBD; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF57889; Cysteine-rich domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF54236; Ubiquitin-like; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS50898; RBD; 1. DR PROSITE; PS00479; ZF_DAG_PE_1; 1. DR PROSITE; PS50081; ZF_DAG_PE_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Allosteric enzyme; ATP-binding; Cardiomyopathy; KW Cell membrane; Chromosomal rearrangement; Cytoplasm; Deafness; KW Direct protein sequencing; Disease variant; Ectodermal dysplasia; KW Intellectual disability; Isopeptide bond; Kinase; Membrane; Metal-binding; KW Methylation; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Proto-oncogene; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Ubl conjugation; Zinc; KW Zinc-finger. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000269|Ref.8" FT CHAIN 2..766 FT /note="Serine/threonine-protein kinase B-raf" FT /id="PRO_0000085665" FT DOMAIN 155..227 FT /note="RBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00262" FT DOMAIN 457..717 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT ZN_FING 234..280 FT /note="Phorbol-ester/DAG-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT REGION 1..38 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 308..454 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1..13 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 314..341 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 348..363 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 423..447 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 576 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 235 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 248 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 251 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 261 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 264 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 269 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 272 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT /evidence="ECO:0000250" FT BINDING 280 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT /evidence="ECO:0000250" FT BINDING 463..471 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 483 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 380..381 FT /note="Breakpoint for translocation to form KIAA1549-BRAF FT fusion protein" FT SITE 438..439 FT /note="Breakpoint for translocation to form KIAA1549-BRAF FT fusion protein" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0000269|Ref.8" FT MOD_RES 151 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 333 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P28028" FT MOD_RES 365 FT /note="Phosphoserine; by SGK1" FT /evidence="ECO:0000269|PubMed:11410590, ECO:0000269|Ref.8, FT ECO:0007744|PubMed:23186163" FT MOD_RES 373 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:1508179" FT MOD_RES 396 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|Ref.8" FT MOD_RES 399 FT /note="Phosphoserine" FT /evidence="ECO:0000269|Ref.8" FT MOD_RES 401 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|Ref.8, ECO:0007744|PubMed:16964243, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163" FT MOD_RES 446 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 447 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 671 FT /note="Omega-N-methylarginine; by PRMT5" FT /evidence="ECO:0000269|PubMed:21917714" FT MOD_RES 729 FT /note="Phosphoserine" FT /evidence="ECO:0000269|Ref.8, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 750 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P28028" FT MOD_RES 753 FT /note="Phosphothreonine; by MAPK1" FT /evidence="ECO:0000269|PubMed:19710016" FT CROSSLNK 578 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:23907581" FT VARIANT 241 FT /note="T -> M (in NS7; dbSNP:rs387906660)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058620" FT VARIANT 241 FT /note="T -> P (in CFC1 and LPRD3; dbSNP:rs387906661)" FT /evidence="ECO:0000269|PubMed:18042262, FT ECO:0000269|PubMed:19206169" FT /id="VAR_058621" FT VARIANT 241 FT /note="T -> R (in NS7; dbSNP:rs387906660)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058622" FT VARIANT 244 FT /note="T -> P (in CFC1; dbSNP:rs397507465)" FT /evidence="ECO:0000269|PubMed:18042262" FT /id="VAR_065171" FT VARIANT 245 FT /note="L -> F (in CFC1; dbSNP:rs397507466)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058623" FT VARIANT 246 FT /note="A -> P (in CFC1; dbSNP:rs180177034)" FT /evidence="ECO:0000269|PubMed:16474404, FT ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:19206169" FT /id="VAR_026113" FT VARIANT 257 FT /note="Q -> R (in CFC1; dbSNP:rs180177035)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:18042262, FT ECO:0000269|PubMed:19206169" FT /id="VAR_026114" FT VARIANT 262 FT /note="Q -> K (in CFC1; dbSNP:rs397507470)" FT /evidence="ECO:0000269|PubMed:18042262" FT /id="VAR_065172" FT VARIANT 275 FT /note="E -> K (in CFC1; dbSNP:rs2129044284)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058624" FT VARIANT 301 FT /note="P -> S (in dbSNP:rs34776339)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040391" FT VARIANT 462 FT /note="R -> I (in CRC; dbSNP:rs180177032)" FT /evidence="ECO:0000269|PubMed:12198537" FT /id="VAR_018613" FT VARIANT 463 FT /note="I -> S (in CRC; dbSNP:rs180177033)" FT /evidence="ECO:0000269|PubMed:12198537" FT /id="VAR_018614" FT VARIANT 464 FT /note="G -> E (in CRC; dbSNP:rs121913348)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:12198537" FT /id="VAR_018615" FT VARIANT 464 FT /note="G -> V (in a colorectal cancer cell line; elevated FT kinase activity; efficiently induces cell transformation; FT dbSNP:rs121913348)" FT /evidence="ECO:0000269|PubMed:12068308" FT /id="VAR_018616" FT VARIANT 466 FT /note="G -> A (in melanoma; dbSNP:rs121913351)" FT /evidence="ECO:0000269|PubMed:12068308" FT /id="VAR_018617" FT VARIANT 466 FT /note="G -> E (in melanoma; dbSNP:rs121913351)" FT /evidence="ECO:0000269|PubMed:12068308" FT /id="VAR_018618" FT VARIANT 466 FT /note="G -> V (in LNCR; dbSNP:rs121913351)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:12460919" FT /id="VAR_018512" FT VARIANT 467 FT /note="S -> A (in CFC1; dbSNP:rs869025606)" FT /evidence="ECO:0000269|PubMed:16439621" FT /id="VAR_035096" FT VARIANT 468 FT /note="F -> S (in CFC1; dbSNP:rs397507473)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:18042262" FT /id="VAR_035097" FT VARIANT 469 FT /note="G -> A (in NHL; also in a lung adenocarcinoma FT sample; somatic mutation; elevated kinase activity; FT efficiently induces cell transformation; FT dbSNP:rs121913355)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:14612909, ECO:0000269|PubMed:17344846" FT /id="VAR_018620" FT VARIANT 469 FT /note="G -> E (in CFC1 and colon cancer; FT dbSNP:rs121913355)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:16474404, FT ECO:0000269|PubMed:18042262, ECO:0000269|PubMed:19206169" FT /id="VAR_018621" FT VARIANT 469 FT /note="G -> R (in NHL; dbSNP:rs121913357)" FT /evidence="ECO:0000269|PubMed:14612909" FT /id="VAR_018622" FT VARIANT 469 FT /note="G -> V (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs121913355)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040392" FT VARIANT 485 FT /note="L -> F (in CFC1; dbSNP:rs180177036)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:19206169" FT /id="VAR_026115" FT VARIANT 499 FT /note="K -> E (in CFC1; dbSNP:rs180177037)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:18042262" FT /id="VAR_026116" FT VARIANT 499 FT /note="K -> N (in CFC1; dbSNP:rs397507476)" FT /evidence="ECO:0000269|PubMed:18042262, FT ECO:0000269|PubMed:19206169" FT /id="VAR_058625" FT VARIANT 501 FT /note="E -> G (in CFC1; dbSNP:rs180177039)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404" FT /id="VAR_026117" FT VARIANT 501 FT /note="E -> K (in CFC1; dbSNP:rs180177038)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:19206169" FT /id="VAR_026118" FT VARIANT 525 FT /note="L -> P (in CFC1; dbSNP:rs869025340)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058626" FT VARIANT 531 FT /note="W -> C (in NS7; dbSNP:rs606231228)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058627" FT VARIANT 580 FT /note="N -> D (in CFC1; dbSNP:rs2128999571)" FT /evidence="ECO:0000269|PubMed:18042262" FT /id="VAR_065173" FT VARIANT 581 FT /note="N -> D (in CFC1; dbSNP:rs180177040)" FT /evidence="ECO:0000269|PubMed:16439621, FT ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:18042262" FT /id="VAR_026119" FT VARIANT 581 FT /note="N -> S (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs121913370)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040393" FT VARIANT 586 FT /note="E -> K (in ovarian cancer; dbSNP:rs121913340)" FT /evidence="ECO:0000269|PubMed:12068308" FT /id="VAR_018623" FT VARIANT 594 FT /note="D -> G (in NHL; dbSNP:rs121913338)" FT /evidence="ECO:0000269|PubMed:14612909" FT /id="VAR_018624" FT VARIANT 595 FT /note="F -> L (in CFC1; also found in colon cancer; FT dbSNP:rs121913341)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:16439621, ECO:0000269|PubMed:18042262, FT ECO:0000269|PubMed:19206169" FT /id="VAR_018625" FT VARIANT 596 FT /note="G -> R (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs121913361)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:17344846" FT /id="VAR_018626" FT VARIANT 596 FT /note="G -> V (in CFC1; dbSNP:rs397507483)" FT /evidence="ECO:0000269|PubMed:16439621" FT /id="VAR_035098" FT VARIANT 597 FT /note="L -> R (in LNCR; also found in an ovarian serous FT carcinoma sample; somatic mutation; dbSNP:rs121913366)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:12460919, ECO:0000269|PubMed:17344846" FT /id="VAR_018513" FT VARIANT 597 FT /note="L -> V (in NS7; also in a lung adenocarcinoma FT sample; somatic mutation; elevated kinase activity; FT efficiently induces cell transformation; FT dbSNP:rs121913369)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:19206169" FT /id="VAR_018627" FT VARIANT 599 FT /note="T -> R (in CFC1; dbSNP:rs121913375)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058628" FT VARIANT 600 FT /note="V -> D (in a melanoma cell line; requires 2 FT nucleotide substitutions; dbSNP:rs121913377)" FT /evidence="ECO:0000269|PubMed:12068308" FT /id="VAR_018628" FT VARIANT 600 FT /note="V -> E (in CRC; also found in sarcoma, metastatic FT melanoma, ovarian serous carcinoma, pilocytic astrocytoma; FT somatic mutation; most common mutation; constitutive and FT elevated kinase activity; efficiently induces cell FT transformation; suppression of mutation in melanoma causes FT growth arrest and promotes apoptosis; loss of regulation by FT PMRT5; dbSNP:rs113488022)" FT /evidence="ECO:0000269|PubMed:12068308, FT ECO:0000269|PubMed:12198537, ECO:0000269|PubMed:14500344, FT ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:21917714, ECO:0000269|PubMed:23263490, FT ECO:0000269|PubMed:24455489" FT /id="VAR_018629" FT VARIANT 601 FT /note="K -> E (in CRC; dbSNP:rs121913364)" FT /evidence="ECO:0000269|PubMed:12198537" FT /id="VAR_018630" FT VARIANT 601 FT /note="K -> Q (in CFC1; dbSNP:rs121913364)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058629" FT VARIANT 638 FT /note="D -> E (in CFC1; dbSNP:rs180177042)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058630" FT VARIANT 709 FT /note="Q -> R (in CFC1; dbSNP:rs397507486)" FT /evidence="ECO:0000269|PubMed:19206169" FT /id="VAR_058631" FT MUTAGEN 53 FT /note="M->D: Reduces interaction with KSR1 and MAP2K1 and FT thus phosphorylation of MAP2K1." FT /evidence="ECO:0000269|PubMed:29433126" FT MUTAGEN 88 FT /note="K->E: Reduces interaction with KSR1 and MAP2K1 and FT thus phosphorylation of MAP2K1." FT /evidence="ECO:0000269|PubMed:29433126" FT MUTAGEN 483 FT /note="K->S: Reduces kinase activity with MAP2K1." FT /evidence="ECO:0000269|PubMed:21441910" FT MUTAGEN 509 FT /note="R->H: Loss of MAP2K1-mediated-BRAF-KSR1 FT dimerization." FT /evidence="ECO:0000269|PubMed:29433126" FT MUTAGEN 578 FT /note="K->R: Blocks EGF-induced ubiquitination and ERK FT activation." FT /evidence="ECO:0000269|PubMed:23907581" FT MUTAGEN 666 FT /note="I->R: No effect on MAP2K1-mediated-BRAF-KSR1 FT dimerization, however loss of BRAF-mediated phosphorylation FT of MAP2K1." FT /evidence="ECO:0000269|PubMed:29433126" FT MUTAGEN 671 FT /note="R->K: Increased kinase activity and stability in FT response to EGF treatment." FT /evidence="ECO:0000269|PubMed:21917714" FT CONFLICT 766 FT /note="H -> D (in Ref. 11; AAA96495)" FT /evidence="ECO:0000305" FT HELIX 43..68 FT /evidence="ECO:0007829|PDB:5VYK" FT HELIX 76..103 FT /evidence="ECO:0007829|PDB:5VYK" FT STRAND 156..161 FT /evidence="ECO:0007829|PDB:3NY5" FT TURN 162..164 FT /evidence="ECO:0007829|PDB:3NY5" FT STRAND 165..170 FT /evidence="ECO:0007829|PDB:3NY5" FT HELIX 177..186 FT /evidence="ECO:0007829|PDB:3NY5" FT TURN 187..189 FT /evidence="ECO:0007829|PDB:3NY5" FT HELIX 192..194 FT /evidence="ECO:0007829|PDB:3NY5" FT STRAND 195..199 FT /evidence="ECO:0007829|PDB:3NY5" FT STRAND 206..208 FT /evidence="ECO:0007829|PDB:3NY5" FT HELIX 214..217 FT /evidence="ECO:0007829|PDB:3NY5" FT STRAND 221..226 FT /evidence="ECO:0007829|PDB:3NY5" FT HELIX 448..450 FT /evidence="ECO:0007829|PDB:6P3D" FT HELIX 454..456 FT /evidence="ECO:0007829|PDB:5JRQ" FT STRAND 458..466 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 469..484 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 487..489 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 492..505 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 516..520 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 522..524 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 526..530 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 534..536 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 537..542 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 543..545 FT /evidence="ECO:0007829|PDB:6P3D" FT HELIX 550..569 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 579..581 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 582..585 FT /evidence="ECO:0007829|PDB:8C7X" FT TURN 586..588 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 589..592 FT /evidence="ECO:0007829|PDB:8C7X" FT TURN 598..600 FT /evidence="ECO:0007829|PDB:6XFP" FT TURN 602..605 FT /evidence="ECO:0007829|PDB:4RZV" FT HELIX 609..612 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 614..619 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 622..626 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 629..631 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 635..651 FT /evidence="ECO:0007829|PDB:8C7X" FT TURN 655..658 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 662..671 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 678..680 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 683..685 FT /evidence="ECO:0007829|PDB:5JRQ" FT HELIX 687..696 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 701..703 FT /evidence="ECO:0007829|PDB:8C7X" FT HELIX 707..721 FT /evidence="ECO:0007829|PDB:8C7X" FT STRAND 723..726 FT /evidence="ECO:0007829|PDB:6U2H" SQ SEQUENCE 766 AA; 84437 MW; 0798C2AAB487E813 CRC64; MAALSGGGGG GAEPGQALFN GDMEPEAGAG AGAAASSAAD PAIPEEVWNI KQMIKLTQEH IEALLDKFGG EHNPPSIYLE AYEEYTSKLD ALQQREQQLL ESLGNGTDFS VSSSASMDTV TSSSSSSLSV LPSSLSVFQN PTDVARSNPK SPQKPIVRVF LPNKQRTVVP ARCGVTVRDS LKKALMMRGL IPECCAVYRI QDGEKKPIGW DTDISWLTGE ELHVEVLENV PLTTHNFVRK TFFTLAFCDF CRKLLFQGFR CQTCGYKFHQ RCSTEVPLMC VNYDQLDLLF VSKFFEHHPI PQEEASLAET ALTSGSSPSA PASDSIGPQI LTSPSPSKSI PIPQPFRPAD EDHRNQFGQR DRSSSAPNVH INTIEPVNID DLIRDQGFRG DGGSTTGLSA TPPASLPGSL TNVKALQKSP GPQRERKSSS SSEDRNRMKT LGRRDSSDDW EIPDGQITVG QRIGSGSFGT VYKGKWHGDV AVKMLNVTAP TPQQLQAFKN EVGVLRKTRH VNILLFMGYS TKPQLAIVTQ WCEGSSLYHH LHIIETKFEM IKLIDIARQT AQGMDYLHAK SIIHRDLKSN NIFLHEDLTV KIGDFGLATV KSRWSGSHQF EQLSGSILWM APEVIRMQDK NPYSFQSDVY AFGIVLYELM TGQLPYSNIN NRDQIIFMVG RGYLSPDLSK VRSNCPKAMK RLMAECLKKK RDERPLFPQI LASIELLARS LPKIHRSASE PSLNRAGFQT EDFSLYACAS PKTPIQAGGY GAFPVH // ID NF1_HUMAN Reviewed; 2839 AA. AC P21359; O00662; Q14284; Q14930; Q14931; Q9UMK3; DT 01-MAY-1991, integrated into UniProtKB/Swiss-Prot. DT 01-JUN-1994, sequence version 2. DT 28-JAN-2026, entry version 262. DE RecName: Full=Neurofibromin; DE AltName: Full=Neurofibromatosis-related protein NF-1; DE Contains: DE RecName: Full=Neurofibromin truncated; GN Name=NF1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS I AND II). RX PubMed=1457041; DOI=10.1089/dna.1992.11.727; RA Bernards A., Haase V.H., Murthy A.E., Menon A., Hannigan G.E., RA Gusella J.F.; RT "Complete human NF1 cDNA sequence: two alternatively spliced mRNAs and RT absence of expression in a neuroblastoma line."; RL DNA Cell Biol. 11:727-734(1992). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM I). RX PubMed=2134734; DOI=10.1126/science.2134734; RA Wallace M.R., Marchuk D.A., Andersen L.B., Letcher R., Odeh H.M., RA Saulino A.M., Fountain J.W., Brereton A., Nicholson J., Mitchell A.L., RA Brownstein B.H., Collins F.S.; RT "Type 1 neurofibromatosis gene: identification of a large transcript RT disrupted in three NF1 patients."; RL Science 249:181-186(1990). RN [3] RP ERRATUM OF PUBMED:2134734. RX PubMed=2125369; RA Wallace M.R., Marchuk D.A., Andersen L.B., Letcher R., Odeh H.M., RA Saulino A.M., Fountain J.W., Brereton A., Nicholson J., Mitchell A.L., RA Brownstein B.H., Collins F.S.; RL Science 250:1749-1749(1990). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM I). RX PubMed=1783401; DOI=10.1016/0888-7543(91)90017-9; RA Marchuk D.A., Saulino A.M., Tavakkol R., Swaroop M., Wallace M.R., RA Andersen L.B., Mitchell A.L., Gutmann D.H., Boguski M.S., Collins F.S.; RT "cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of RT the NF1 gene product."; RL Genomics 11:931-940(1991). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND ALTERNATIVE SPLICING. RC TISSUE=Placenta; RX PubMed=1339276; DOI=10.1016/0006-291x(92)91294-z; RA Suzuki H., Takahashi K., Kubota Y., Shibahara S.; RT "Molecular cloning of a cDNA coding for neurofibromatosis type 1 protein RT isoform lacking the domain related to ras GTPase-activating protein."; RL Biochem. Biophys. Res. Commun. 187:984-990(1992). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5). RC TISSUE=Kidney; RX PubMed=7570581; DOI=10.1620/tjem.175.225; RA Suzuki H., Takahashi K., Shibahara S.; RT "Evidence for the presence of two amino-terminal isoforms of neurofibromin, RT a gene product responsible for neurofibromatosis type 1."; RL Tohoku J. Exp. Med. 175:225-233(1995). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS CYS-80; LEU-678; HIS-1422 RP AND LEU-2511. RG NIEHS SNPs program; RL Submitted (NOV-2004) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 335-2839 (ISOFORM I), AND RP VARIANT NF1 PRO-1953. RX PubMed=2114220; DOI=10.1016/0092-8674(90)90253-b; RA Cawthon R.M., Weiss R., Xu G., Viskochil D., Culver M., Stevens J., RA Robertson M., Dunn D., Gesteland R., O'Connell P., White R.; RT "A major segment of the neurofibromatosis type 1 gene: cDNA sequence, RT genomic structure, and point mutations."; RL Cell 62:193-201(1990). RN [11] RP NUCLEOTIDE SEQUENCE [MRNA] OF 335-2839 (ISOFORMS I AND 6). RX PubMed=2116237; DOI=10.1016/0092-8674(90)90024-9; RA Xu G., O'Connell P., Viskochil D., Cawthon R.M., Robertson M., Culver M., RA Dunn D., Stevens J., Gesteland R., White R., Weiss R.; RT "The neurofibromatosis type 1 gene encodes a protein related to GAP."; RL Cell 62:599-608(1990). RN [12] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 707-782. RX PubMed=9002664; DOI=10.1093/hmg/6.1.9; RA Regnier V., Meddeb M., Lecointre G., Richard F., Duverger A., Nguyen V.C., RA Dutrillaux B., Bernheim A., Danglot G.; RT "Emergence and scattering of multiple neurofibromatosis (NF1)-related RT sequences during hominoid evolution suggest a process of pericentromeric RT interchromosomal transposition."; RL Hum. Mol. Genet. 6:9-16(1997). RN [13] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 751-1611 (ISOFORMS I AND II). RX PubMed=7774960; DOI=10.1016/0888-7543(95)80104-t; RA Li Y., O'Connell P., Breidenbach H.H., Cawthon R.M., Stevens J., Xu G., RA Neil S., Robertson M., White R., Viskochil D.; RT "Genomic organization of the neurofibromatosis 1 gene (NF1)."; RL Genomics 25:9-18(1995). RN [14] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1090-1598 (ISOFORM 4). RX PubMed=2121370; DOI=10.1016/0092-8674(90)90150-d; RA Martin G.A., Viskochil D., Bollag G., McCabe P.C., Crosier W.J., RA Haubruck H., Conroy L., Clark R., O'Connell P., Cawthon R.M., Innis M., RA McCormick F.; RT "The GAP-related domain of the neurofibromatosis type 1 gene product RT interacts with ras p21."; RL Cell 63:843-849(1990). RN [15] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1168-1566 (ISOFORMS I AND II). RX PubMed=1923522; RA Nishi T., Lee P.S., Oka K., Levin V.A., Tanase S., Morino Y., Saya H.; RT "Differential expression of two types of the neurofibromatosis type 1 (NF1) RT gene transcripts related to neuronal differentiation."; RL Oncogene 6:1555-1559(1991). RN [16] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1371-1391 (ISOFORM II), FUNCTION, AND TISSUE RP SPECIFICITY. RX PubMed=8417346; DOI=10.1128/mcb.13.1.487-495.1993; RA Andersen L.B., Ballester R., Marchuk D.A., Chang E., Gutmann D.H., RA Saulino A.M., Camonis J., Wigler M., Collins F.S.; RT "A conserved alternative splice in the von Recklinghausen neurofibromatosis RT (NF1) gene produces two neurofibromin isoforms, both of which have GTPase- RT activating protein activity."; RL Mol. Cell. Biol. 13:487-495(1993). RN [17] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1371-1391 (ISOFORM II). RX PubMed=1662505; DOI=10.1016/0006-291x(91)92029-j; RA Suzuki Y., Suzuki H., Kayama T., Yoshimoto T., Shibahara S.; RT "Brain tumors predominantly express the neurofibromatosis type 1 gene RT transcripts containing the 63 base insert in the region coding for GTPase RT activating protein-related domain."; RL Biochem. Biophys. Res. Commun. 181:955-961(1991). RN [18] RP FUNCTION. RX PubMed=2121371; DOI=10.1016/0092-8674(90)90151-4; RA Ballester R., Marchuk D.A., Boguski M.S., Saulino A.M., Letcher R., RA Wigler M., Collins F.S.; RT "The NF1 locus encodes a protein functionally related to mammalian GAP and RT yeast IRA proteins."; RL Cell 63:851-859(1990). RN [19] RP RNA EDITING. RX PubMed=8602361; DOI=10.1093/nar/24.3.478; RA Skuse G.R., Cappione A.J., Sowden M., Metheny L.J., Smith H.C.; RT "The neurofibromatosis type I messenger RNA undergoes base-modification RNA RT editing."; RL Nucleic Acids Res. 24:478-485(1996). RN [20] RP RNA EDITING. RX PubMed=11727199; DOI=10.1086/337952; RA Mukhopadhyay D., Anant S., Lee R.M., Kennedy S., Viskochil D., RA Davidson N.O.; RT "C-->U editing of neurofibromatosis 1 mRNA occurs in tumors that express RT both the type II transcript and apobec-1, the catalytic subunit of the RT apolipoprotein B mRNA-editing enzyme."; RL Am. J. Hum. Genet. 70:38-50(2002). RN [21] RP REVIEW ON VARIANTS. RX PubMed=7981724; DOI=10.1002/humu.1380040202; RA Upadhyaya M., Shaw D.J., Harper P.S.; RT "Molecular basis of neurofibromatosis type 1 (NF1): mutation analysis and RT polymorphisms in the NF1 gene."; RL Hum. Mutat. 4:83-101(1994). RN [22] RP REVIEW ON VARIANTS. RX PubMed=8825042; DOI=10.1136/jmg.33.1.2; RA Shen M.H., Harper P.S., Upadhyaya M.; RT "Molecular genetics of neurofibromatosis type 1 (NF1)."; RL J. Med. Genet. 33:2-17(1996). RN [23] RP SUBCELLULAR LOCATION, AND NUCLEAR LOCALIZATION SIGNAL. RX PubMed=14988005; DOI=10.1016/s0014-5793(04)00078-x; RA Vandenbroucke I., Van Oostveldt P., Coene E., De Paepe A., Messiaen L.; RT "Neurofibromin is actively transported to the nucleus."; RL FEBS Lett. 560:98-102(2004). RN [24] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [25] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [26] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-864; SER-2188; SER-2515; RP SER-2521 AND SER-2543, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [27] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [28] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-864; SER-876 AND SER-2515, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [30] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-864 AND SER-2817, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [31] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [32] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2543 AND SER-2817, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [33] RP INTERACTION WITH HTR6. RX PubMed=23027611; DOI=10.1002/emmm.201201410; RA Meffre J., Chaumont-Dubel S., Mannoury la Cour C., Loiseau F., Watson D.J., RA Dekeyne A., Seveno M., Rivet J.M., Gaven F., Deleris P., Herve D., RA Fone K.C., Bockaert J., Millan M.J., Marin P.; RT "5-HT(6) receptor recruitment of mTOR as a mechanism for perturbed RT cognition in schizophrenia."; RL EMBO Mol. Med. 4:1043-1056(2012). RN [34] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-864; SER-876; SER-2188; RP SER-2515; SER-2521; SER-2523; SER-2543; THR-2565; SER-2597 AND SER-2802, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [35] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2543 AND SER-2817, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [36] RP INTERACTION WITH SPRED2, AND SUBCELLULAR LOCATION. RX PubMed=34626534; DOI=10.1016/j.ajhg.2021.09.007; RA Motta M., Fasano G., Gredy S., Brinkmann J., Bonnard A.A., RA Simsek-Kiper P.O., Gulec E.Y., Essaddam L., Utine G.E., RA Guarnetti Prandi I., Venditti M., Pantaleoni F., Radio F.C., Ciolfi A., RA Petrini S., Consoli F., Vignal C., Hepbasli D., Ullrich M., de Boer E., RA Vissers L.E.L.M., Gritli S., Rossi C., De Luca A., Ben Becher S., RA Gelb B.D., Dallapiccola B., Lauri A., Chillemi G., Schuh K., Cave H., RA Zenker M., Tartaglia M.; RT "SPRED2 loss-of-function causes a recessive Noonan syndrome-like RT phenotype."; RL Am. J. Hum. Genet. 108:2112-2129(2021). RN [37] RP X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 1198-1551. RX PubMed=9687500; DOI=10.1093/emboj/17.15.4313; RA Scheffzek K., Ahmadian M.R., Wiesmuller L., Kabsch W., Stege P., RA Schmitz F., Wittinghofer A.; RT "Structural analysis of the GAP-related domain from neurofibromin and its RT implications."; RL EMBO J. 17:4313-4327(1998). RN [38] RP X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 1581-1837, LIPID-BINDING, DOMAIN, RP AND MUTAGENESIS OF LYS-1691; ARG-1695; ARG-1769 AND LYS-1771. RX PubMed=16397625; DOI=10.1038/sj.embor.7400602; RA D'Angelo I., Welti S., Bonneau F., Scheffzek K.; RT "A novel bipartite phospholipid-binding module in the neurofibromatosis RT type 1 protein."; RL EMBO Rep. 7:174-179(2006). RN [39] RP X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 1566-1837 IN COMPLEX WITH RP PHOSPHOLIPID, LIPID-BINDING, AND DOMAIN. RX PubMed=17187824; DOI=10.1016/j.jmb.2006.11.055; RA Welti S., Fraterman S., D'Angelo I., Wilm M., Scheffzek K.; RT "The sec14 homology module of neurofibromin binds cellular RT glycerophospholipids: mass spectrometry and structure of a lipid complex."; RL J. Mol. Biol. 366:551-562(2007). RN [40] RP X-RAY CRYSTALLOGRAPHY (2.19 ANGSTROMS) OF 1581-1837 OF VARIANT NF1 VAL-1605 RP AND MUTANT LYS-1771 DEL IN COMPLEX WITH LIPID, CHARACTERIZATION OF VARIANT RP NF1 VAL-1605, MUTAGENESIS OF LYS-1771, LIPID-BINDING, AND DOMAIN. RX PubMed=21089070; DOI=10.1002/humu.21405; RA Welti S., Kuhn S., D'Angelo I., Brugger B., Kaufmann D., Scheffzek K.; RT "Structural and biochemical consequences of NF1 associated nontruncating RT mutations in the Sec14-PH module of neurofibromin."; RL Hum. Mutat. 32:191-197(2011). RN [41] RP VARIANT GLU-1444. RX PubMed=1568247; DOI=10.1016/0092-8674(92)90408-5; RA Li Y., Bollag G., Clark R., Stevens J., Conroy L., Fults D., Ward K., RA Friedman E., Samowitz W., Robertson M., Bradley P., McCormick F., White R., RA Cawthon R.M.; RT "Somatic mutations in the neurofibromatosis 1 gene in human tumors."; RL Cell 69:275-281(1992). RN [42] RP VARIANTS NF1 MET-2164 AND ASN-2192. RX PubMed=1302608; DOI=10.1093/hmg/1.9.735; RA Upadhyaya M., Shen M.H., Cherryson A., Farnham J., Maynard J., Huson S.M., RA Harper P.S.; RT "Analysis of mutations at the neurofibromatosis 1 (NF1) locus."; RL Hum. Mol. Genet. 1:735-740(1992). RN [43] RP VARIANT GLY-HIS-GLU-GLN-GLN-LYS-LEU-PRO-ALA-ALA-THR-LEU-ALA-LEU-1733 INS. RX PubMed=8317503; RA Tassabehji M., Strachan T., Sharland M., Colley A., Donnai D., Harris R., RA Thakker N.; RT "Tandem duplication within a neurofibromatosis type 1 (NF1) gene exon in a RT family with features of Watson syndrome and Noonan syndrome."; RL Am. J. Hum. Genet. 53:90-95(1993). RN [44] RP VARIANT MET-991 DEL. RX PubMed=7904209; DOI=10.1093/hmg/2.11.1861; RA Shen M.H., Harper P.S., Upadhyaya M.; RT "Neurofibromatosis type 1 (NF1): the search for mutations by PCR- RT heteroduplex analysis on Hydrolink gels."; RL Hum. Mol. Genet. 2:1861-1864(1993). RN [45] RP VARIANTS NF1 ASP-1166 AND ARG-1440. RX PubMed=7981679; DOI=10.1093/hmg/3.7.1109; RA Purandare S.M., Lanyon W.G., Connor J.M.; RT "Characterisation of inherited and sporadic mutations in neurofibromatosis RT type-1."; RL Hum. Mol. Genet. 3:1109-1115(1994). RN [46] RP VARIANT NF1 2387-ASN-PHE-2388 DEL. RX PubMed=8081387; DOI=10.1002/humu.1380030404; RA Abernathy C.R., Colman S.D., Kousseff B.G., Wallace M.R.; RT "Two NF1 mutations: frameshift in the GAP-related domain, and loss of two RT codons toward the 3' end of the gene."; RL Hum. Mutat. 3:347-352(1994). RN [47] RP VARIANT NF1 ALA-2631. RX PubMed=8544190; DOI=10.1136/jmg.32.9.706; RA Upadhyaya M., Maynard J., Osborn M.J., Huson S.M., Ponder M., RA Ponder B.A.J., Harper P.S.; RT "Characterisation of germline mutations in the neurofibromatosis type 1 RT (NF1) gene."; RL J. Med. Genet. 32:706-710(1995). RN [48] RP VARIANT NF1 ARG-629. RX PubMed=8834249; DOI=10.1007/bf02267073; RA Gasparini P., D'Agruma L., de Cillis G.P., Balestrazzi P., Mingarelli R., RA Zelante L.; RT "Scanning the first part of the neurofibromatosis type 1 gene by RNA-SSCP: RT identification of three novel mutations and of two new polymorphisms."; RL Hum. Genet. 97:492-495(1996). RN [49] RP VARIANT NF1 ARG-1035. RX PubMed=8807336; RX DOI=10.1002/(sici)1098-1004(1996)8:1<51::aid-humu7>3.0.co;2-s; RA Wu R., Legius E., Robberecht W., Dumoulin M., Cassiman J.-J., Fryns J.-P.; RT "Neurofibromatosis type I gene mutation in a patient with features of RT LEOPARD syndrome."; RL Hum. Mutat. 8:51-56(1996). RN [50] RP VARIANTS NF1 SER-1412; GLN-1440; GLU-1444 AND GLY-1489. RX PubMed=9003501; DOI=10.1007/s004390050317; RA Upadhyaya M., Osborn M.J., Maynard J., Kim M.R., Tamanoi F., Cooper D.N.; RT "Mutational and functional analysis of the neurofibromatosis type 1 (NF1) RT gene."; RL Hum. Genet. 99:88-92(1997). RN [51] RP VARIANTS NF1 ARG-844 AND PRO-898. RX PubMed=9150739; DOI=10.1007/s004390050427; RA Maynard J., Krawczak M., Upadhyaya M.; RT "Characterization and significance of nine novel mutations in exon 16 of RT the neurofibromatosis type 1 (NF1) gene."; RL Hum. Genet. 99:674-676(1997). RN [52] RP VARIANT NF1 ARG-1952. RX PubMed=9101300; RX DOI=10.1002/(sici)1098-1004(1997)9:4<366::aid-humu12>3.0.co;2-0; RA Hudson J., Wu C.L., Tassabehji M., Summers E.M., Simon S., Super M., RA Donnai D., Thakker N.; RT "Novel and recurrent mutations in the neurofibromatosis type 1 (NF1) RT gene."; RL Hum. Mutat. 9:366-367(1997). RN [53] RP VARIANTS NF1 GLY-338 AND TRP-1611. RX PubMed=9298829; RX DOI=10.1002/(sici)1098-1004(1997)10:3<248::aid-humu14>3.0.co;2-#; RA Upadhyaya M., Maynard J., Osborn M.J., Harper P.S.; RT "Six novel mutations in the neurofibromatosis type 1 (NF1) gene."; RL Hum. Mutat. 10:248-250(1997). RN [54] RP VARIANT NF1 PRO-1276. RX PubMed=9668168; DOI=10.1093/hmg/7.8.1261; RA Klose A., Ahmadian M.R., Schuelke M., Scheffzek K., Hoffmeyer S., RA Gewies A., Schmitz F., Kaufmann D., Peters H., Wittinghofer A., RA Nuernberg P.; RT "Selective disactivation of neurofibromin GAP activity in neurofibromatosis RT type 1 (NF1)."; RL Hum. Mol. Genet. 7:1261-1268(1998). RN [55] RP VARIANTS NF1 HIS-765 AND GLY-1204. RX PubMed=10336779; RX DOI=10.1002/(sici)1098-1004(1998)11:5<411::aid-humu11>3.0.co;2-2; RA Krkljus S., Abernathy C.R., Johnson J.S., Williams C.A., Driscoll D.J., RA Zori R., Stalker H.J., Rasmussen S.A., Collins F.S., Kousseff B.G., RA Baumbach L., Wallace M.R.; RT "Analysis of CpG C-to-T mutations in neurofibromatosis type 1."; RL Hum. Mutat. 11:411-411(1998). RN [56] RP VARIANT NF1 PRO-508. RX PubMed=11258625; DOI=10.1097/00125817-199909000-00002; RA Messiaen L.M., Callens T., Roux K.J., Mortier G.R., De Paepe A., RA Abramowicz M., Pericak-Vance M.A., Vance J.M., Wallace M.R.; RT "Exon 10b of the NF1 gene represents a mutational hotspot and harbors a RT recurrent missense mutation Y489C associated with aberrant splicing."; RL Genet. Med. 1:248-253(1999). RN [57] RP VARIANT NF1 PRO-1446. RX PubMed=10220149; RX DOI=10.1002/(sici)1098-1004(1999)13:4<337::aid-humu12>3.0.co;2-f; RA Peters H., Hess D., Fahsold R., Schuelke M.; RT "A novel mutation L1425P in the GAP-region of the NF1 gene detected by RT temperature gradient gel electrophoresis (TGGE)."; RL Hum. Mutat. 13:337-337(1999). RN [58] RP VARIANTS NF1 PRO-216; PRO-357; CYS-491; PRO-549; THR-581; ARG-583; PHE-665; RP PRO-695; PRO-763; SER-777; LYS-780; PRO-781; PRO-847; SER-1156; PRO-1250; RP GLN-1276; PRO-1276; PRO-1446; VAL-1605 AND ILE-2507, AND VARIANT GLU-176. RX PubMed=10712197; DOI=10.1086/302809; RA Fahsold R., Hoffmeyer S., Mischung C., Gille C., Ehlers C., RA Kuecuekceylan N., Abdel-Nour M., Gewies A., Peters H., Kaufmann D., RA Buske A., Tinschert S., Nuernberg P.; RT "Minor lesion mutational spectrum of the entire NF1 gene does not explain RT its high mutability but points to a functional domain upstream of the GAP- RT related domain."; RL Am. J. Hum. Genet. 66:790-818(2000). RN [59] RP VARIANTS NF1 SER-117; TRP-1204; PRO-1446 AND 2387-ASN-PHE-2388 DEL. RX PubMed=10607834; DOI=10.1093/hmg/9.2.237; RA Ars E., Serra E., Garcia J., Kruyer H., Gaona A., Lazaro C., Estivill X.; RT "Mutations affecting mRNA splicing are the most common molecular defects in RT patients with neurofibromatosis type 1."; RL Hum. Mol. Genet. 9:237-247(2000). RN [60] RP ERRATUM OF PUBMED:10607834. RA Ars E., Serra E., Garcia J., Kruyer H., Gaona A., Lazaro C., Estivill X.; RL Hum. Mol. Genet. 9:659-659(2000). RN [61] RP VARIANT NF1 PHE-844. RX PubMed=10980545; RX DOI=10.1002/1098-1004(200009)16:3<274::aid-humu21>3.3.co;2-6; RA Boulandet E.G., Pantel J., Cazeneuve C., Van Gijn M., Vidaud D., Lemay S., RA Martin J., Zeller J., Revuz J., Goossens M., Amselem S., Wolkenstein P.; RT "NF1 gene analysis focused on CpG-rich exons in a cohort of 93 patients RT with neurofibromatosis type 1."; RL Hum. Mutat. 16:274-275(2000). RN [62] RP VARIANT SPINAL FSNF PRO-2088. RX PubMed=11704931; DOI=10.1086/324648; RA Kaufmann D., Mueller R., Bartelt B., Wolf M., Kunzi-Rapp K., Hanemann C.O., RA Fahsold R., Hein C., Vogel W., Assum G.; RT "Spinal neurofibromatosis without cafe-au-lait macules in two families with RT null mutations of the NF1 gene."; RL Am. J. Hum. Genet. 69:1395-1400(2001). RN [63] RP VARIANTS NF1 LYS-780; CYS-784; PRO-1147; CYS-1193; ARG-1444; SER-1785; RP ASN-2012 AND LYS-2357. RX PubMed=11735023; DOI=10.1007/s004390100594; RA Han S.S., Cooper D.N., Upadhyaya M.N.; RT "Evaluation of denaturing high performance liquid chromatography (DHPLC) RT for the mutational analysis of the neurofibromatosis type 1 (NF1) gene."; RL Hum. Genet. 109:487-497(2001). RN [64] RP VARIANTS NF1 PHE-82; ARG-784 AND GLU-1444. RX PubMed=11857752; DOI=10.1002/humu.9018; RA Kluwe L., Friedrich R.E., Korf B., Fahsold R., Mautner V.-F.; RT "NF1 mutations in neurofibromatosis 1 patients with plexiform RT neurofibromas."; RL Hum. Mutat. 19:309-309(2002). RN [65] RP VARIANT NFNS GLU-1459 DEL. RX PubMed=12707950; DOI=10.1002/ajmg.a.20023; RA Baralle D., Mattocks C., Kalidas K., Elmslie F., Whittaker J., Lees M., RA Ragge N., Patton M.A., Winter R.M., ffrench-Constant C.; RT "Different mutations in the NF1 gene are associated with neurofibromatosis- RT Noonan syndrome (NFNS)."; RL Am. J. Med. Genet. A 119:1-8(2003). RN [66] RP VARIANTS NF1 TYR-93; VAL-604; ARG-844 AND PRO-898, AND VARIANTS ASP-74; RP GLU-176; ARG-712 AND GLN-1276. RX PubMed=12522551; DOI=10.1007/s00439-002-0858-4; RA Wang Q., Montmain G., Ruano E., Upadhyaya M., Dudley S., Liskay R.M., RA Thibodeau S.N., Puisieux A.; RT "Neurofibromatosis type 1 gene as a mutational target in a mismatch repair- RT deficient cell type."; RL Hum. Genet. 112:117-123(2003). RN [67] RP VARIANTS NF1 LYS-780; PRO-847; GLU-848 AND ARG-968; ASN-1444; LEU-1953 DEL RP AND ARG-2001. RX PubMed=12552569; DOI=10.1002/humu.9111; RA De Luca A., Buccino A., Gianni D., Mangino M., Giustini S., Richetta A., RA Divona L., Calvieri S., Mingarelli R., Dallapiccola B.; RT "NF1 gene analysis based on DHPLC."; RL Hum. Mutat. 21:171-172(2003). RN [68] RP VARIANTS NF1 ARG-578; PRO-920 AND ALA-2221. RX PubMed=12746402; DOI=10.1136/jmg.40.5.368; RA Kluwe L., Tatagiba M., Fuensterer C., Mautner V.F.; RT "NF1 mutations and clinical spectrum in patients with spinal RT neurofibromas."; RL J. Med. Genet. 40:368-371(2003). RN [69] RP VARIANT NF1 VAL-186, AND CHARACTERIZATION OF VARIANT NF1 VAL-186. RX PubMed=15523642; DOI=10.1002/humu.20103; RA Zatkova A., Messiaen L., Vandenbroucke I., Wieser R., Fonatsch C., RA Krainer A.R., Wimmer K.; RT "Disruption of exonic splicing enhancer elements is the principal cause of RT exon skipping associated with seven nonsense or missense alleles of NF1."; RL Hum. Mutat. 24:491-501(2004). RN [70] RP VARIANTS NF1 ASN-157; ARG-629; SER-777; LYS-780; ARG-784; PRO-847; GLU-848; RP ARG-968; ASN-1444; LEU-1953 DEL AND ARG-2001, AND VARIANT GLU-176. RX PubMed=15146469; DOI=10.1002/humu.9245; RA De Luca A., Schirinzi A., Buccino A., Bottillo I., Sinibaldi L., RA Torrente I., Ciavarella A., Dottorini T., Porciello R., Giustini S., RA Calvieri S., Dallapiccola B.; RT "Novel and recurrent mutations in the NF1 gene in Italian patients with RT neurofibromatosis type 1."; RL Hum. Mutat. 23:629-629(2004). RN [71] RP VARIANTS NF1 ARG-31; PRO-145; ARG-324; VAL-337; CYS-489; PRO-532; ARG-574; RP ARG-629; PHE-665; PHE-844; PRO-844; MET-991 DEL; VAL-1073; ARG-1196; RP GLY-1276; GLN-1276; GLU-1430; GLU-1459 DEL AND GLY-1489, AND VARIANTS RP GLU-176 AND CYS-873. RX PubMed=15060124; DOI=10.1136/jmg.2003.011890; RA Mattocks C., Baralle D., Tarpey P., ffrench-Constant C., Bobrow M., RA Whittaker J.; RT "Automated comparative sequence analysis identifies mutations in 89% of NF1 RT patients and confirms a mutation cluster in exons 11-17 distinct from the RT GAP related domain."; RL J. Med. Genet. 41:E48-E48(2004). RN [72] RP VARIANT NF1 PRO-1243. RX PubMed=15520408; DOI=10.1136/jmg.2004.021683; RA Ferner R.E., Hughes R.A.C., Hall S.M., Upadhyaya M., Johnson M.R.; RT "Neurofibromatous neuropathy in neurofibromatosis 1 (NF1)."; RL J. Med. Genet. 41:837-841(2004). RN [73] RP VARIANT NF1 ARG-844. RX PubMed=15948193; DOI=10.1002/ajmg.a.30813; RA Bertola D.R., Pereira A.C., Passetti F., de Oliveira P.S.L., Messiaen L., RA Gelb B.D., Kim C.A., Krieger J.E.; RT "Neurofibromatosis-Noonan syndrome: molecular evidence of the concurrence RT of both disorders in a patient."; RL Am. J. Med. Genet. A 136:242-245(2005). RN [74] RP VARIANTS NFNS ARG-194; GLU-1444; THR-1451; LEU-1453 AND GLU-1459 DEL. RX PubMed=16380919; DOI=10.1086/498454; RA De Luca A., Bottillo I., Sarkozy A., Carta C., Neri C., Bellacchio E., RA Schirinzi A., Conti E., Zampino G., Battaglia A., Majore S., Rinaldi M.M., RA Carella M., Marino B., Pizzuti A., Digilio M.C., Tartaglia M., RA Dallapiccola B.; RT "NF1 gene mutations represent the major molecular event underlying RT neurofibromatosis-Noonan syndrome."; RL Am. J. Hum. Genet. 77:1092-1101(2005). RN [75] RP VARIANTS [LARGE SCALE ANALYSIS] ILE-1187; LEU-1951 AND ARG-2745. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [76] RP VARIANT NF1 MET-991 DEL. RX PubMed=17160901; DOI=10.1086/510781; RA Upadhyaya M., Huson S.M., Davies M., Thomas N., Chuzhanova N., RA Giovannini S., Evans D.G., Howard E., Kerr B., Griffiths S., Consoli C., RA Side L., Adams D., Pierpont M., Hachen R., Barnicoat A., Li H., Wallace P., RA Van Biervliet J.P., Stevenson D., Viskochil D., Baralle D., Haan E., RA Riccardi V., Turnpenny P., Lazaro C., Messiaen L.; RT "An absence of cutaneous neurofibromas associated with a 3-bp inframe RT deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a RT clinically significant NF1 genotype-phenotype correlation."; RL Am. J. Hum. Genet. 80:140-151(2007). RN [77] RP VARIANT NFNS PHE-1411. RX PubMed=19845691; DOI=10.1111/j.1399-0004.2009.01233.x; RA Nystrom A.M., Ekvall S., Allanson J., Edeby C., Elinder M., Holmstrom G., RA Bondeson M.L., Anneren G.; RT "Noonan syndrome and neurofibromatosis type I in a family with a novel RT mutation in NF1."; RL Clin. Genet. 76:524-534(2009). RN [78] RP VARIANT NF1 THR-160. RX PubMed=21838856; DOI=10.1186/1897-4287-9-6; RA Ponti G., Losi L., Martorana D., Priola M., Boni E., Pollio A., Neri T.M., RA Seidenari S.; RT "Clinico-pathological and biomolecular findings in Italian patients with RT multiple cutaneous neurofibromas."; RL Hered. Cancer Clin. Pract. 9:6-6(2011). RN [79] RP VARIANTS GLU-176; THR-330; ASP-393; LEU-393; PRO-519; THR-776 AND PHE-1484. RX PubMed=22108604; DOI=10.1038/ejhg.2011.207; RA Thomas L., Spurlock G., Eudall C., Thomas N.S., Mort M., Hamby S.E., RA Chuzhanova N., Brems H., Legius E., Cooper D.N., Upadhyaya M.; RT "Exploring the somatic NF1 mutational spectrum associated with NF1 RT cutaneous neurofibromas."; RL Eur. J. Hum. Genet. 20:411-419(2012). RN [80] RP VARIANTS NF1 TRP-93; ARG-1048; ARG-1189; ARG-1661 (ISOFORM I) AND THR-1918 RP (ISOFORM I). RX PubMed=23758643; DOI=10.1111/ahg.12026; RA Nemethova M., Bolcekova A., Ilencikova D., Durovcikova D., Hlinkova K., RA Hlavata A., Kovacs L., Kadasi L., Zatkova A.; RT "Thirty-nine novel neurofibromatosis 1 (NF1) gene mutations identified in RT Slovak patients."; RL Ann. Hum. Genet. 77:364-379(2013). RN [81] RP VARIANT NF1 PRO-2125. RX PubMed=24413922; DOI=10.1007/s00381-013-2352-9; RA Ben-Salem S., Al-Shamsi A.M., Ali B.R., Al-Gazali L.; RT "The mutational spectrum of the NF1 gene in neurofibromatosis type I RT patients from UAE."; RL Childs Nerv. Syst. 30:1183-1189(2014). CC -!- FUNCTION: Stimulates the GTPase activity of Ras. NF1 shows greater CC affinity for Ras GAP, but lower specific activity. May be a regulator CC of Ras activity. {ECO:0000269|PubMed:2121371, CC ECO:0000269|PubMed:8417346}. CC -!- SUBUNIT: Interacts with HTR6 (PubMed:23027611). Interacts with SPRED2 CC (PubMed:34626534). {ECO:0000269|PubMed:23027611, CC ECO:0000269|PubMed:34626534}. CC -!- INTERACTION: CC P21359; P05067: APP; NbExp=3; IntAct=EBI-1172917, EBI-77613; CC P21359; P01112: HRAS; NbExp=3; IntAct=EBI-1172917, EBI-350145; CC P21359; P34741: SDC2; NbExp=4; IntAct=EBI-1172917, EBI-1172957; CC P21359; Q7Z699: SPRED1; NbExp=6; IntAct=EBI-1172917, EBI-5235340; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:14988005}. Nucleus, CC nucleolus {ECO:0000269|PubMed:14988005}. Cell membrane CC {ECO:0000269|PubMed:34626534}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=6; CC Comment=Experimental confirmation may be lacking for some isoforms.; CC Name=II {ECO:0000303|PubMed:1923522}; CC IsoId=P21359-1; Sequence=Displayed; CC Name=I {ECO:0000303|PubMed:1923522}; CC IsoId=P21359-2; Sequence=VSP_001628; CC Name=3; CC IsoId=P21359-3; Sequence=VSP_001629, VSP_001630; CC Name=4; CC IsoId=P21359-4; Sequence=VSP_001631, VSP_001632; CC Name=5; CC IsoId=P21359-5; Sequence=VSP_043467, VSP_043468; CC Name=6; CC IsoId=P21359-6; Sequence=VSP_001628, VSP_053587; CC -!- TISSUE SPECIFICITY: Detected in brain, peripheral nerve, lung, colon CC and muscle. {ECO:0000269|PubMed:8417346}. CC -!- DOMAIN: Binds phospholipids via its C-terminal CRAL-TRIO domain. Binds CC primarily glycerophospholipids with monounsaturated C18:1 and/or C16:1 CC fatty acid moieties and a phosphatidylethanolamine or CC phosphatidylcholine headgroup. Has lesser affinity for lipids CC containing phosphatidylserine and phosphatidylinositol. CC {ECO:0000269|PubMed:16397625, ECO:0000269|PubMed:17187824, CC ECO:0000269|PubMed:21089070}. CC -!- PTM: Ubiquitinated by RNF7/RBX2, leading to its degradation. CC {ECO:0000250|UniProtKB:Q04690}. CC -!- RNA EDITING: Modified_positions=1306 {ECO:0000269|PubMed:11727199, CC ECO:0000269|PubMed:8602361}; Note=The stop codon (UGA) at position 1306 CC is created by RNA editing. Various levels of RNA editing occurs in CC peripheral nerve-sheath tumor samples (PNSTs) from patients with NF1. CC Preferentially observed in transcripts containing exon 23A.; CC -!- DISEASE: Neurofibromatosis 1 (NF1) [MIM:162200]: A disease CC characterized by patches of skin pigmentation (cafe-au-lait spots), CC Lisch nodules of the iris, tumors in the peripheral nervous system and CC fibromatous skin tumors. Individuals with the disorder have increased CC susceptibility to the development of benign and malignant tumors. CC {ECO:0000269|PubMed:10220149, ECO:0000269|PubMed:10336779, CC ECO:0000269|PubMed:10607834, ECO:0000269|PubMed:10712197, CC ECO:0000269|PubMed:10980545, ECO:0000269|PubMed:11258625, CC ECO:0000269|PubMed:11735023, ECO:0000269|PubMed:11857752, CC ECO:0000269|PubMed:12522551, ECO:0000269|PubMed:12552569, CC ECO:0000269|PubMed:12746402, ECO:0000269|PubMed:1302608, CC ECO:0000269|PubMed:15060124, ECO:0000269|PubMed:15146469, CC ECO:0000269|PubMed:15520408, ECO:0000269|PubMed:15523642, CC ECO:0000269|PubMed:15948193, ECO:0000269|PubMed:17160901, CC ECO:0000269|PubMed:21089070, ECO:0000269|PubMed:2114220, CC ECO:0000269|PubMed:21838856, ECO:0000269|PubMed:23758643, CC ECO:0000269|PubMed:24413922, ECO:0000269|PubMed:7981679, CC ECO:0000269|PubMed:8081387, ECO:0000269|PubMed:8544190, CC ECO:0000269|PubMed:8807336, ECO:0000269|PubMed:8834249, CC ECO:0000269|PubMed:9003501, ECO:0000269|PubMed:9101300, CC ECO:0000269|PubMed:9150739, ECO:0000269|PubMed:9298829, CC ECO:0000269|PubMed:9668168}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Leukemia, juvenile myelomonocytic (JMML) [MIM:607785]: An CC aggressive pediatric myelodysplastic syndrome/myeloproliferative CC disorder characterized by malignant transformation in the hematopoietic CC stem cell compartment with proliferation of differentiated progeny. CC Patients have splenomegaly, enlarged lymph nodes, rashes, and CC hemorrhages. Note=The disease is caused by variants affecting the gene CC represented in this entry. CC -!- DISEASE: Watson syndrome (WTSN) [MIM:193520]: A syndrome characterized CC by the presence of pulmonary stenosis, cafe-au-lait spots, and CC intellectual disability. It is considered as an atypical form of CC neurofibromatosis. Note=The disease is caused by variants affecting the CC gene represented in this entry. CC -!- DISEASE: Familial spinal neurofibromatosis (FSNF) [MIM:162210]: CC Considered to be an alternative form of neurofibromatosis, showing CC multiple spinal tumors. {ECO:0000269|PubMed:11704931}. Note=The disease CC is caused by variants affecting the gene represented in this entry. CC -!- DISEASE: Neurofibromatosis-Noonan syndrome (NFNS) [MIM:601321]: CC Characterized by manifestations of both NF1 and Noonan syndrome (NS). CC NS is a disorder characterized by dysmorphic facial features, short CC stature, hypertelorism, cardiac anomalies, deafness, motor delay, and a CC bleeding diathesis. {ECO:0000269|PubMed:12707950, CC ECO:0000269|PubMed:16380919, ECO:0000269|PubMed:19845691}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. Note=The gene represented in this entry may be CC involved in disease pathogenesis. CC -!- CAUTION: Was originally thought to be associated with LEOPARD (LS), an CC autosomal dominant syndrome. {ECO:0000305|PubMed:8807336}. CC -!- SEQUENCE CAUTION: CC Sequence=AAA59923.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/134/NF1"; CC -!- WEB RESOURCE: Name=Mendelian genes neurofibromin 1 (NF1); Note=Leiden CC Open Variation Database (LOVD); CC URL="https://databases.lovd.nl/shared/genes/NF1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M89914; AAA59925.1; -; mRNA. DR EMBL; M82814; AAA59924.1; -; mRNA. DR EMBL; M60496; AAA59928.1; -; mRNA. DR EMBL; D12625; BAA02150.1; -; mRNA. DR EMBL; M38106; AAA74897.1; -; mRNA. DR EMBL; M38107; AAB59558.1; -; mRNA. DR EMBL; D42072; BAA07669.1; -; mRNA. DR EMBL; AY796305; AAV50004.1; -; Genomic_DNA. DR EMBL; AC004222; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC079915; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC134669; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC135724; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC138207; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC139072; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471147; EAW80272.1; -; Genomic_DNA. DR EMBL; CH471147; EAW80275.1; -; Genomic_DNA. DR EMBL; AH000834; AAA18483.1; -; Genomic_DNA. DR EMBL; Y07853; CAA69179.1; -; Genomic_DNA. DR EMBL; U17690; AAB48380.1; -; Genomic_DNA. DR EMBL; U17680; AAB48380.1; JOINED; Genomic_DNA. DR EMBL; U17681; AAB48380.1; JOINED; Genomic_DNA. DR EMBL; U17682; AAB48380.1; JOINED; Genomic_DNA. DR EMBL; U17683; AAB48380.1; JOINED; Genomic_DNA. DR EMBL; U17684; AAB48380.1; JOINED; Genomic_DNA. DR EMBL; U17685; AAB48380.1; JOINED; Genomic_DNA. DR EMBL; U17686; AAB48380.1; JOINED; Genomic_DNA. DR EMBL; U17687; AAB48380.1; JOINED; Genomic_DNA. DR EMBL; U17688; AAB48380.1; JOINED; Genomic_DNA. DR EMBL; U17689; AAB48380.1; JOINED; Genomic_DNA. DR EMBL; U17690; AAB48379.1; -; Genomic_DNA. DR EMBL; U17680; AAB48379.1; JOINED; Genomic_DNA. DR EMBL; U17681; AAB48379.1; JOINED; Genomic_DNA. DR EMBL; U17682; AAB48379.1; JOINED; Genomic_DNA. DR EMBL; U17683; AAB48379.1; JOINED; Genomic_DNA. DR EMBL; U17684; AAB48379.1; JOINED; Genomic_DNA. DR EMBL; U17685; AAB48379.1; JOINED; Genomic_DNA. DR EMBL; U17687; AAB48379.1; JOINED; Genomic_DNA. DR EMBL; U17688; AAB48379.1; JOINED; Genomic_DNA. DR EMBL; U17689; AAB48379.1; JOINED; Genomic_DNA. DR EMBL; U17656; AAB48373.1; -; Genomic_DNA. DR EMBL; U17659; AAB48374.1; -; Genomic_DNA. DR EMBL; U17662; AAB48375.1; -; Genomic_DNA. DR EMBL; U17668; AAB48376.1; -; Genomic_DNA. DR EMBL; U17667; AAB48376.1; JOINED; Genomic_DNA. DR EMBL; U17673; AAB48377.1; -; Genomic_DNA. DR EMBL; U17677; AAB48378.1; -; Genomic_DNA. DR EMBL; U17676; AAB48378.1; JOINED; Genomic_DNA. DR EMBL; M60915; AAA59921.1; -; mRNA. DR EMBL; M60915; AAA59922.1; -; mRNA. DR EMBL; M61213; AAA59923.1; ALT_INIT; mRNA. DR EMBL; S51751; AAB24636.1; -; mRNA. DR EMBL; D10490; BAA01371.1; -; mRNA. DR CCDS; CCDS11264.1; -. [P21359-2] DR CCDS; CCDS42292.1; -. [P21359-1] DR CCDS; CCDS45645.1; -. [P21359-5] DR PIR; B55282; B55282. DR PIR; I78852; I78852. DR RefSeq; NP_000258.1; NM_000267.4. [P21359-2] DR RefSeq; NP_001035957.1; NM_001042492.3. [P21359-1] DR RefSeq; NP_001121619.1; NM_001128147.3. [P21359-5] DR PDB; 1NF1; X-ray; 2.50 A; A=1198-1551. DR PDB; 2D4Q; X-ray; 2.30 A; A/B=1581-1837. DR PDB; 2E2X; X-ray; 2.50 A; A/B=1566-1837. DR PDB; 3P7Z; X-ray; 2.65 A; A/B=1566-1837. DR PDB; 3PEG; X-ray; 2.52 A; A=1566-1837. DR PDB; 3PG7; X-ray; 2.19 A; A/B=1581-1837. DR PDB; 6OB2; X-ray; 2.85 A; B/D=1209-1484. DR PDB; 6OB3; X-ray; 2.10 A; B/D=1209-1484. DR PDB; 6V65; X-ray; 2.76 A; B=1203-1551. DR PDB; 6V6F; X-ray; 2.54 A; B=1203-1551. DR PDB; 7MOC; EM; 4.56 A; A/B=2-2839. DR PDB; 7MP5; EM; 5.60 A; A/B=2-2839. DR PDB; 7MP6; EM; 6.25 A; A/B=2-2839. DR PDB; 7PGP; EM; 3.10 A; F/N=1-2839. DR PDB; 7PGQ; EM; 3.50 A; F/N=1-2839. DR PDB; 7PGR; EM; 4.00 A; F/N=1-2839. DR PDB; 7PGS; EM; 3.40 A; F/N=1-2839. DR PDB; 7PGT; EM; 4.80 A; F/N=1-2839. DR PDB; 7PGU; EM; 3.30 A; F/N=1-2839. DR PDB; 7R03; EM; 3.60 A; A/B=1-2839. DR PDB; 7R04; EM; 3.70 A; A/B=1-2839. DR PDB; 8E20; EM; 3.60 A; A/B=1-2839. DR PDB; 8EDL; EM; 3.70 A; A=1-2839. DR PDB; 8EDM; EM; 3.60 A; A/B=1-2839. DR PDB; 8EDN; EM; 3.80 A; A=1-2839. DR PDB; 8EDO; EM; 3.40 A; A/B=1039-2302. DR PDBsum; 1NF1; -. DR PDBsum; 2D4Q; -. DR PDBsum; 2E2X; -. DR PDBsum; 3P7Z; -. DR PDBsum; 3PEG; -. DR PDBsum; 3PG7; -. DR PDBsum; 6OB2; -. DR PDBsum; 6OB3; -. DR PDBsum; 6V65; -. DR PDBsum; 6V6F; -. DR PDBsum; 7MOC; -. DR PDBsum; 7MP5; -. DR PDBsum; 7MP6; -. DR PDBsum; 7PGP; -. DR PDBsum; 7PGQ; -. DR PDBsum; 7PGR; -. DR PDBsum; 7PGS; -. DR PDBsum; 7PGT; -. DR PDBsum; 7PGU; -. DR PDBsum; 7R03; -. DR PDBsum; 7R04; -. DR PDBsum; 8E20; -. DR PDBsum; 8EDL; -. DR PDBsum; 8EDM; -. DR PDBsum; 8EDN; -. DR PDBsum; 8EDO; -. DR EMDB; EMD-13391; -. DR EMDB; EMD-13392; -. DR EMDB; EMD-13393; -. DR EMDB; EMD-13394; -. DR EMDB; EMD-13395; -. DR EMDB; EMD-13396; -. DR EMDB; EMD-14218; -. DR EMDB; EMD-14219; -. DR EMDB; EMD-23924; -. DR EMDB; EMD-23929; -. DR EMDB; EMD-23930; -. DR EMDB; EMD-27826; -. DR EMDB; EMD-28035; -. DR EMDB; EMD-28036; -. DR EMDB; EMD-28037; -. DR EMDB; EMD-28038; -. DR SMR; P21359; -. DR BioGRID; 110836; 239. DR CORUM; P21359; -. DR FunCoup; P21359; 3476. DR IntAct; P21359; 149. DR MINT; P21359; -. DR STRING; 9606.ENSP00000351015; -. DR GlyGen; P21359; 5 sites, 1 O-linked glycan (3 sites). DR iPTMnet; P21359; -. DR PhosphoSitePlus; P21359; -. DR SwissPalm; P21359; -. DR BioMuta; NF1; -. DR DMDM; 548350; -. DR CPTAC; CPTAC-1622; -. DR jPOST; P21359; -. DR MassIVE; P21359; -. DR PaxDb; 9606-ENSP00000351015; -. DR PeptideAtlas; P21359; -. DR ProteomicsDB; 53861; -. [P21359-1] DR ProteomicsDB; 53862; -. [P21359-2] DR ProteomicsDB; 53863; -. [P21359-3] DR ProteomicsDB; 53864; -. [P21359-4] DR ProteomicsDB; 53865; -. [P21359-5] DR Pumba; P21359; -. DR Antibodypedia; 3471; 481 antibodies from 39 providers. DR CPTC; P21359; 3 antibodies. DR DNASU; 4763; -. DR Ensembl; ENST00000356175.7; ENSP00000348498.3; ENSG00000196712.20. [P21359-2] DR Ensembl; ENST00000358273.9; ENSP00000351015.4; ENSG00000196712.20. [P21359-1] DR Ensembl; ENST00000431387.8; ENSP00000412921.4; ENSG00000196712.20. [P21359-5] DR Ensembl; ENST00000487476.5; ENSP00000491589.1; ENSG00000196712.20. [P21359-3] DR GeneID; 4763; -. DR KEGG; hsa:4763; -. DR MANE-Select; ENST00000358273.9; ENSP00000351015.4; NM_001042492.3; NP_001035957.1. DR UCSC; uc002hgf.3; human. [P21359-1] DR AGR; HGNC:7765; -. DR CIViC; 4763; 58 evidence items across 51 molecular profiles. DR ClinPGx; PA31572; -. DR CTD; 4763; -. DR DisGeNET; 4763; -. DR GeneCards; NF1; -. DR GeneReviews; NF1; -. DR HGNC; HGNC:7765; NF1. DR HPA; ENSG00000196712; Low tissue specificity. DR MalaCards; NF1; -. DR MIM; 114500; phenotype. DR MIM; 162200; phenotype. DR MIM; 162210; phenotype. DR MIM; 193520; phenotype. DR MIM; 601321; phenotype. DR MIM; 607785; phenotype. DR MIM; 613113; gene. DR OpenTargets; ENSG00000196712; -. DR Orphanet; 97685; 17q11 microdeletion syndrome. DR Orphanet; 139474; 17q11.2 microduplication syndrome. DR Orphanet; 99756; Alveolar rhabdomyosarcoma. DR Orphanet; 99757; Embryonal rhabdomyosarcoma. DR Orphanet; 29072; Hereditary pheochromocytoma-paraganglioma. DR Orphanet; 86834; Juvenile myelomonocytic leukemia. DR Orphanet; 363700; Neurofibromatosis type 1 due to NF1 mutation or intragenic deletion. DR Orphanet; 638; Neurofibromatosis-Noonan syndrome. DR Orphanet; 293199; Pleomorphic rhabdomyosarcoma. DR VEuPathDB; HostDB:ENSG00000196712; -. DR eggNOG; KOG1826; Eukaryota. DR GeneTree; ENSGT00550000074797; -. DR HOGENOM; CLU_036305_0_0_1; -. DR InParanoid; P21359; -. DR OMA; TKEPYMF; -. DR OrthoDB; 28245at2759; -. DR PAN-GO; P21359; 0 GO annotations based on evolutionary models. DR PhylomeDB; P21359; -. DR PathwayCommons; P21359; -. DR Reactome; R-HSA-5658442; Regulation of RAS by GAPs. DR Reactome; R-HSA-6802953; RAS signaling downstream of NF1 loss-of-function variants. DR SignaLink; P21359; -. DR SIGNOR; P21359; -. DR Agora; ENSG00000196712; -. DR BioGRID-ORCS; 4763; 62 hits in 1192 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; NF1; human. DR EvolutionaryTrace; P21359; -. DR GeneWiki; Neurofibromin_1; -. DR GenomeRNAi; 4763; -. DR Pharos; P21359; Tbio. DR PRO; PR:P21359; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; P21359; protein. DR Bgee; ENSG00000196712; Expressed in colonic epithelium and 202 other cell types or tissues. DR ExpressionAtlas; P21359; baseline and differential. DR GO; GO:0030424; C:axon; IDA:HGNC-UCL. DR GO; GO:0005737; C:cytoplasm; ISS:HGNC-UCL. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0030425; C:dendrite; IDA:HGNC-UCL. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0005730; C:nucleolus; IEA:UniProtKB-SubCell. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; ISS:HGNC-UCL. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0098793; C:presynapse; IEA:GOC. DR GO; GO:0005096; F:GTPase activator activity; IDA:UniProtKB. DR GO; GO:0031210; F:phosphatidylcholine binding; IDA:UniProtKB. DR GO; GO:0008429; F:phosphatidylethanolamine binding; IDA:UniProtKB. DR GO; GO:0030036; P:actin cytoskeleton organization; ISS:HGNC-UCL. DR GO; GO:0030325; P:adrenal gland development; ISS:HGNC-UCL. DR GO; GO:0021764; P:amygdala development; IEA:Ensembl. DR GO; GO:0001525; P:angiogenesis; IEA:Ensembl. DR GO; GO:0048844; P:artery morphogenesis; ISS:HGNC-UCL. DR GO; GO:0007420; P:brain development; ISS:HGNC-UCL. DR GO; GO:0048593; P:camera-type eye morphogenesis; ISS:HGNC-UCL. DR GO; GO:0007154; P:cell communication; ISS:HGNC-UCL. DR GO; GO:0034605; P:cellular response to heat; IEA:Ensembl. DR GO; GO:0021987; P:cerebral cortex development; ISS:HGNC-UCL. DR GO; GO:0050890; P:cognition; IMP:HGNC-UCL. DR GO; GO:0030199; P:collagen fibril organization; ISS:HGNC-UCL. DR GO; GO:0001935; P:endothelial cell proliferation; IEA:Ensembl. DR GO; GO:0030198; P:extracellular matrix organization; ISS:HGNC-UCL. DR GO; GO:0097192; P:extrinsic apoptotic signaling pathway in absence of ligand; IEA:Ensembl. DR GO; GO:0008625; P:extrinsic apoptotic signaling pathway via death domain receptors; IEA:Ensembl. DR GO; GO:0048144; P:fibroblast proliferation; IEA:Ensembl. DR GO; GO:0021897; P:forebrain astrocyte development; ISS:HGNC-UCL. DR GO; GO:0048853; P:forebrain morphogenesis; ISS:HGNC-UCL. DR GO; GO:0061534; P:gamma-aminobutyric acid secretion, neurotransmission; IEA:Ensembl. DR GO; GO:0061535; P:glutamate secretion, neurotransmission; IEA:Ensembl. DR GO; GO:0048820; P:hair follicle maturation; IEA:Ensembl. DR GO; GO:0007507; P:heart development; ISS:HGNC-UCL. DR GO; GO:0001889; P:liver development; ISS:HGNC-UCL. DR GO; GO:0060291; P:long-term synaptic potentiation; IEA:Ensembl. DR GO; GO:0000165; P:MAPK cascade; ISS:HGNC-UCL. DR GO; GO:0033024; P:mast cell apoptotic process; IEA:Ensembl. DR GO; GO:0070662; P:mast cell proliferation; IEA:Ensembl. DR GO; GO:0001656; P:metanephros development; ISS:HGNC-UCL. DR GO; GO:0022011; P:myelination in peripheral nervous system; ISS:HGNC-UCL. DR GO; GO:0097529; P:myeloid leukocyte migration; IEA:Ensembl. DR GO; GO:0016525; P:negative regulation of angiogenesis; IEA:Ensembl. DR GO; GO:0048712; P:negative regulation of astrocyte differentiation; IEA:Ensembl. DR GO; GO:0030336; P:negative regulation of cell migration; IMP:MGI. DR GO; GO:0001953; P:negative regulation of cell-matrix adhesion; IEA:Ensembl. DR GO; GO:0001937; P:negative regulation of endothelial cell proliferation; IMP:MGI. DR GO; GO:0048147; P:negative regulation of fibroblast proliferation; ISS:UniProtKB. DR GO; GO:0002686; P:negative regulation of leukocyte migration; IEA:Ensembl. DR GO; GO:0043409; P:negative regulation of MAPK cascade; IMP:MGI. DR GO; GO:0070667; P:negative regulation of mast cell proliferation; IEA:Ensembl. DR GO; GO:0007406; P:negative regulation of neuroblast proliferation; ISS:HGNC-UCL. DR GO; GO:0046929; P:negative regulation of neurotransmitter secretion; IEA:Ensembl. DR GO; GO:0048715; P:negative regulation of oligodendrocyte differentiation; ISS:HGNC-UCL. DR GO; GO:0045671; P:negative regulation of osteoclast differentiation; IEA:Ensembl. DR GO; GO:0042308; P:negative regulation of protein import into nucleus; IEA:Ensembl. DR GO; GO:0035021; P:negative regulation of Rac protein signal transduction; IEA:Ensembl. DR GO; GO:0046580; P:negative regulation of Ras protein signal transduction; IEA:Ensembl. DR GO; GO:1900148; P:negative regulation of Schwann cell migration; IEA:Ensembl. DR GO; GO:0010626; P:negative regulation of Schwann cell proliferation; IEA:Ensembl. DR GO; GO:2000647; P:negative regulation of stem cell proliferation; IEA:Ensembl. DR GO; GO:1904753; P:negative regulation of vascular associated smooth muscle cell migration; IEA:Ensembl. DR GO; GO:0021915; P:neural tube development; IEA:Ensembl. DR GO; GO:0007405; P:neuroblast proliferation; IEA:Ensembl. DR GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl. DR GO; GO:0098597; P:observational learning; IEA:Ensembl. DR GO; GO:0048709; P:oligodendrocyte differentiation; IEA:Ensembl. DR GO; GO:0001649; P:osteoblast differentiation; ISS:HGNC-UCL. DR GO; GO:0030316; P:osteoclast differentiation; IEA:Ensembl. DR GO; GO:0007422; P:peripheral nervous system development; ISS:HGNC-UCL. DR GO; GO:0043491; P:phosphatidylinositol 3-kinase/protein kinase B signal transduction; ISS:HGNC-UCL. DR GO; GO:0043473; P:pigmentation; ISS:HGNC-UCL. DR GO; GO:0043065; P:positive regulation of apoptotic process; ISS:HGNC-UCL. DR GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IEA:Ensembl. DR GO; GO:2001241; P:positive regulation of extrinsic apoptotic signaling pathway in absence of ligand; IEA:Ensembl. DR GO; GO:0043547; P:positive regulation of GTPase activity; IDA:UniProtKB. DR GO; GO:0033027; P:positive regulation of mast cell apoptotic process; IEA:Ensembl. DR GO; GO:0043525; P:positive regulation of neuron apoptotic process; ISS:HGNC-UCL. DR GO; GO:1904707; P:positive regulation of vascular associated smooth muscle cell proliferation; IEA:Ensembl. DR GO; GO:0006606; P:protein import into nucleus; IEA:Ensembl. DR GO; GO:0016601; P:Rac protein signal transduction; IEA:Ensembl. DR GO; GO:0007265; P:Ras protein signal transduction; ISS:HGNC-UCL. DR GO; GO:0045765; P:regulation of angiogenesis; IMP:HGNC-UCL. DR GO; GO:0043535; P:regulation of blood vessel endothelial cell migration; IMP:HGNC-UCL. DR GO; GO:0045124; P:regulation of bone resorption; ISS:HGNC-UCL. DR GO; GO:0001952; P:regulation of cell-matrix adhesion; ISS:HGNC-UCL. DR GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; IEA:Ensembl. DR GO; GO:0010468; P:regulation of gene expression; IEA:Ensembl. DR GO; GO:0045685; P:regulation of glial cell differentiation; ISS:HGNC-UCL. DR GO; GO:1902531; P:regulation of intracellular signal transduction; IBA:GO_Central. DR GO; GO:0048169; P:regulation of long-term neuronal synaptic plasticity; IEA:Ensembl. DR GO; GO:1900271; P:regulation of long-term synaptic potentiation; IEA:Ensembl. DR GO; GO:0099175; P:regulation of postsynapse organization; IEA:Ensembl. DR GO; GO:0032228; P:regulation of synaptic transmission, GABAergic; IEA:Ensembl. DR GO; GO:0001666; P:response to hypoxia; ISS:HGNC-UCL. DR GO; GO:0014044; P:Schwann cell development; ISS:HGNC-UCL. DR GO; GO:0036135; P:Schwann cell migration; IEA:Ensembl. DR GO; GO:0014010; P:Schwann cell proliferation; IEA:Ensembl. DR GO; GO:0007519; P:skeletal muscle tissue development; IEA:Ensembl. DR GO; GO:0048745; P:smooth muscle tissue development; ISS:HGNC-UCL. DR GO; GO:0021510; P:spinal cord development; ISS:HGNC-UCL. DR GO; GO:0072089; P:stem cell proliferation; IEA:Ensembl. DR GO; GO:0048485; P:sympathetic nervous system development; ISS:HGNC-UCL. DR GO; GO:1904738; P:vascular associated smooth muscle cell migration; IEA:Ensembl. DR GO; GO:1990874; P:vascular associated smooth muscle cell proliferation; IEA:Ensembl. DR GO; GO:0008542; P:visual learning; ISS:HGNC-UCL. DR GO; GO:0042060; P:wound healing; ISS:HGNC-UCL. DR CDD; cd13313; PH_NF1; 1. DR CDD; cd05130; RasGAP_Neurofibromin; 1. DR CDD; cd00170; SEC14; 1. DR FunFam; 2.30.29.30:FF:000070; Neurofibromin 1; 1. DR FunFam; 3.40.525.10:FF:000004; Neurofibromin 1; 1. DR FunFam; 1.10.506.10:FF:000015; Neurofibromin isoform 1; 1. DR FunFam; 1.10.506.10:FF:000023; Neurofibromin isoform 1; 1. DR Gene3D; 3.40.525.10; CRAL-TRIO lipid binding domain; 1. DR Gene3D; 1.10.506.10; GTPase Activation - p120gap, domain 1; 2. DR Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR001251; CRAL-TRIO_dom. DR InterPro; IPR036865; CRAL-TRIO_dom_sf. DR InterPro; IPR011993; PH-like_dom_sf. DR InterPro; IPR054071; PH_NF1. DR InterPro; IPR039360; Ras_GTPase. DR InterPro; IPR023152; RasGAP_CS. DR InterPro; IPR001936; RasGAP_dom. DR InterPro; IPR008936; Rho_GTPase_activation_prot. DR PANTHER; PTHR10194:SF142; NEUROFIBROMIN; 1. DR PANTHER; PTHR10194; RAS GTPASE-ACTIVATING PROTEINS; 1. DR Pfam; PF13716; CRAL_TRIO_2; 1. DR Pfam; PF21877; PH_NF1; 1. DR Pfam; PF00616; RasGAP; 1. DR SMART; SM00323; RasGAP; 1. DR SMART; SM00516; SEC14; 1. DR SUPFAM; SSF48371; ARM repeat; 1. DR SUPFAM; SSF48350; GTPase activation domain, GAP; 1. DR PROSITE; PS50191; CRAL_TRIO; 1. DR PROSITE; PS00509; RAS_GTPASE_ACTIV_1; 1. DR PROSITE; PS50018; RAS_GTPASE_ACTIV_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Cell membrane; KW Disease variant; GTPase activation; Lipid-binding; Membrane; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; RNA editing; KW Tumor suppressor; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000250|UniProtKB:P97526" FT CHAIN 2..2839 FT /note="Neurofibromin" FT /id="PRO_0000010773" FT CHAIN 2..1305 FT /note="Neurofibromin truncated" FT /id="PRO_0000010774" FT DOMAIN 1251..1482 FT /note="Ras-GAP" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00167" FT DOMAIN 1580..1738 FT /note="CRAL-TRIO" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00056" FT REGION 1580..1837 FT /note="Lipid binding" FT REGION 2787..2839 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 2555..2571 FT /note="Bipartite nuclear localization signal" FT COMPBIAS 2801..2827 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT SITE 1276 FT /note="Arginine finger; crucial for GTP hydrolysis by FT stabilizing the transition state" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00167" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0000250|UniProtKB:P97526" FT MOD_RES 864 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163" FT MOD_RES 876 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2188 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2467 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q04690" FT MOD_RES 2514 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q04690" FT MOD_RES 2515 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163" FT MOD_RES 2521 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2523 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 2543 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 2565 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 2597 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 2802 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 2817 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:24275569" FT VAR_SEQ 548..551 FT /note="ALLV -> VRGK (in isoform 3)" FT /evidence="ECO:0000303|PubMed:1339276" FT /id="VSP_001629" FT VAR_SEQ 552..2839 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:1339276" FT /id="VSP_001630" FT VAR_SEQ 574..593 FT /note="SSQMLFYICKKLTSHQMLSS -> RYMYFYFLNSTFKFYFVFLS (in FT isoform 5)" FT /evidence="ECO:0000303|PubMed:7570581" FT /id="VSP_043467" FT VAR_SEQ 594..2839 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:7570581" FT /id="VSP_043468" FT VAR_SEQ 1371..1391 FT /note="Missing (in isoform I and isoform 6)" FT /evidence="ECO:0000303|PubMed:1457041, FT ECO:0000303|PubMed:1783401, ECO:0000303|PubMed:1923522, FT ECO:0000303|PubMed:2114220, ECO:0000303|PubMed:2116237, FT ECO:0000303|PubMed:2134734" FT /id="VSP_001628" FT VAR_SEQ 1591..1598 FT /note="SIFYQAGT -> TPPPEPET (in isoform 4)" FT /evidence="ECO:0000303|PubMed:2121370" FT /id="VSP_001631" FT VAR_SEQ 1599..2839 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:2121370" FT /id="VSP_001632" FT VAR_SEQ 2792 FT /note="P -> PASLPCSNSAVFMQLFPHQ (in isoform 6)" FT /evidence="ECO:0000303|PubMed:2116237" FT /id="VSP_053587" FT VARIANT 31 FT /note="H -> R (in NF1; dbSNP:rs199474725)" FT /evidence="ECO:0000269|PubMed:15060124" FT /id="VAR_032459" FT VARIANT 74 FT /note="A -> D (in mismatch repair deficient cancer cells; FT dbSNP:rs199474726)" FT /evidence="ECO:0000269|PubMed:12522551" FT /id="VAR_017550" FT VARIANT 80 FT /note="Y -> C (in dbSNP:rs4795581)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_022254" FT VARIANT 80 FT /note="Y -> S (in dbSNP:rs4795581)" FT /id="VAR_049135" FT VARIANT 82 FT /note="S -> F (in NF1; dbSNP:rs199474729)" FT /evidence="ECO:0000269|PubMed:11857752" FT /id="VAR_021730" FT VARIANT 93 FT /note="C -> W (in NF1; dbSNP:rs1597629882)" FT /evidence="ECO:0000269|PubMed:23758643" FT /id="VAR_071668" FT VARIANT 93 FT /note="C -> Y (in NF1; dbSNP:rs199474728)" FT /evidence="ECO:0000269|PubMed:12522551" FT /id="VAR_017551" FT VARIANT 117 FT /note="I -> S (in NF1; dbSNP:rs199474731)" FT /evidence="ECO:0000269|PubMed:10607834" FT /id="VAR_010989" FT VARIANT 145 FT /note="L -> P (in NF1; dbSNP:rs199474734)" FT /evidence="ECO:0000269|PubMed:15060124" FT /id="VAR_032460" FT VARIANT 157 FT /note="I -> N (in NF1; dbSNP:rs199474744)" FT /evidence="ECO:0000269|PubMed:15146469" FT /id="VAR_021731" FT VARIANT 160 FT /note="R -> T (in NF1; dbSNP:rs199474752)" FT /evidence="ECO:0000269|PubMed:21838856" FT /id="VAR_065888" FT VARIANT 176 FT /note="D -> E (found in mismatch repair deficient cancer FT cells; also found in a cutaneous neurofibroma from a FT patient with neurofibromatosis; somatic mutation; FT dbSNP:rs112306990)" FT /evidence="ECO:0000269|PubMed:10712197, FT ECO:0000269|PubMed:12522551, ECO:0000269|PubMed:15060124, FT ECO:0000269|PubMed:15146469, ECO:0000269|PubMed:22108604" FT /id="VAR_017552" FT VARIANT 186 FT /note="D -> V (in NF1; reduced splicing enhancement; FT dbSNP:rs1567820771)" FT /evidence="ECO:0000269|PubMed:15523642" FT /id="VAR_032461" FT VARIANT 194 FT /note="L -> R (in NFNS; dbSNP:rs199474753)" FT /evidence="ECO:0000269|PubMed:16380919" FT /id="VAR_032462" FT VARIANT 216 FT /note="L -> P (in NF1; dbSNP:rs199474756)" FT /evidence="ECO:0000269|PubMed:10712197" FT /id="VAR_021732" FT VARIANT 324 FT /note="C -> R (in NF1; dbSNP:rs199474735)" FT /evidence="ECO:0000269|PubMed:15060124" FT /id="VAR_032463" FT VARIANT 330 FT /note="A -> T (in a cutaneous neurofibroma from a patient FT with neurofibromatosis; somatic mutation; FT dbSNP:rs199474767)" FT /evidence="ECO:0000269|PubMed:22108604" FT /id="VAR_067201" FT VARIANT 337 FT /note="E -> V (in NF1; dbSNP:rs199474736)" FT /evidence="ECO:0000269|PubMed:15060124" FT /id="VAR_032464" FT VARIANT 338 FT /note="D -> G (in NF1; dbSNP:rs199474773)" FT /evidence="ECO:0000269|PubMed:9298829" FT /id="VAR_010990" FT VARIANT 357 FT /note="L -> P (in NF1; dbSNP:rs137854563)" FT /evidence="ECO:0000269|PubMed:10712197" FT /id="VAR_021733" FT VARIANT 393 FT /note="H -> D (in a cutaneous neurofibroma from a patient FT with neurofibromatosis; somatic mutation; FT dbSNP:rs199474768)" FT /evidence="ECO:0000269|PubMed:22108604" FT /id="VAR_067202" FT VARIANT 393 FT /note="H -> L (in a cutaneous neurofibroma from a patient FT with neurofibromatosis; somatic mutation; FT dbSNP:rs199474769)" FT /evidence="ECO:0000269|PubMed:22108604" FT /id="VAR_067203" FT VARIANT 489 FT /note="Y -> C (in NF1; dbSNP:rs137854557)" FT /evidence="ECO:0000269|PubMed:15060124" FT /id="VAR_032465" FT VARIANT 491 FT /note="Y -> C (in NF1; dbSNP:rs199474757)" FT /evidence="ECO:0000269|PubMed:10712197" FT /id="VAR_021734" FT VARIANT 508 FT /note="L -> P (in NF1; dbSNP:rs137854558)" FT /evidence="ECO:0000269|PubMed:11258625" FT /id="VAR_010991" FT VARIANT 519 FT /note="Q -> P (in a cutaneous neurofibroma from a patient FT with neurofibromatosis; somatic mutation; FT dbSNP:rs199474770)" FT /evidence="ECO:0000269|PubMed:22108604" FT /id="VAR_067204" FT VARIANT 532 FT /note="L -> P (in NF1; dbSNP:rs199474737)" FT /evidence="ECO:0000269|PubMed:15060124" FT /id="VAR_032466" FT VARIANT 549 FT /note="L -> P (in NF1; dbSNP:rs199474758)" FT /evidence="ECO:0000269|PubMed:10712197" FT /id="VAR_021735" FT VARIANT 574 FT /note="S -> R (in NF1; dbSNP:rs2144015494 and FT dbSNP:rs2066929440)" FT /evidence="ECO:0000269|PubMed:15060124" FT /id="VAR_032467" FT VARIANT 578 FT /note="L -> R (in NF1; dbSNP:rs199474774)" FT /evidence="ECO:0000269|PubMed:12746402" FT /id="VAR_021736" FT VARIANT 581 FT /note="I -> T (in NF1; dbSNP:rs199474759)" FT /evidence="ECO:0000269|PubMed:10712197" FT /id="VAR_021737" FT VARIANT 583 FT /note="K -> R (in NF1; dbSNP:rs199474760)" FT /evidence="ECO:0000269|PubMed:10712197" FT /id="VAR_021738" FT VARIANT 604 FT /note="L -> V (in NF1; dbSNP:rs142712751)" FT /evidence="ECO:0000269|PubMed:12522551" FT /id="VAR_017553" FT VARIANT 629 FT /note="G -> R (in NF1; affects splicing by creating a novel FT splice acceptor site; dbSNP:rs199474738)" FT /evidence="ECO:0000269|PubMed:15060124, FT ECO:0000269|PubMed:15146469, ECO:0000269|PubMed:8834249" FT /id="VAR_002653" FT VARIANT 665 FT /note="S -> F (in NF1; uncertain significance; FT dbSNP:rs145891889)" FT /evidence="ECO:0000269|PubMed:10712197, FT ECO:0000269|PubMed:15060124" FT /id="VAR_021739" FT VARIANT 678 FT /note="P -> L (in dbSNP:rs17881753)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_022255" FT VARIANT 695 FT /note="L -> P (in NF1; dbSNP:rs199474761)" FT /evidence="ECO:0000269|PubMed:10712197" FT /id="VAR_021740" FT VARIANT 712 FT /note="H -> R (in mismatch repair deficient cancer cells; FT dbSNP:rs199474727)" FT /evidence="ECO:0000269|PubMed:12522551" FT /id="VAR_017554" FT VARIANT 763 FT /note="L -> P (in NF1; dbSNP:rs199474762)" FT /evidence="ECO:0000269|PubMed:10712197" FT /id="VAR_021741" FT VARIANT 765 FT /note="R -> H (in NF1; uncertain significance; FT dbSNP:rs199474777)" FT /evidence="ECO:0000269|PubMed:10336779" FT /id="VAR_021742" FT VARIANT 776 FT /note="A -> T (in a cutaneous neurofibroma from a patient FT with neurofibromatosis; somatic mutation; FT dbSNP:rs199474771)" FT /evidence="ECO:0000269|PubMed:22108604" FT /id="VAR_067205" FT VARIANT 777 FT /note="W -> S (in NF1; dbSNP:rs199474745)" FT /evidence="ECO:0000269|PubMed:10712197, FT ECO:0000269|PubMed:15146469" FT /id="VAR_021743" FT VARIANT 780 FT /note="T -> K (in NF1; dbSNP:rs199474746)" FT /evidence="ECO:0000269|PubMed:10712197, FT ECO:0000269|PubMed:11735023, ECO:0000269|PubMed:12552569, FT ECO:0000269|PubMed:15146469" FT /id="VAR_021744" FT VARIANT 781 FT /note="H -> P (in NF1; dbSNP:rs199474763)" FT /evidence="ECO:0000269|PubMed:10712197" FT /id="VAR_021745" FT VARIANT 784 FT /note="W -> C (in NF1; dbSNP:rs199474778)" FT /evidence="ECO:0000269|PubMed:11735023" FT /id="VAR_021746" FT VARIANT 784 FT /note="W -> R (in NF1; dbSNP:rs199474730)" FT /evidence="ECO:0000269|PubMed:11857752, FT ECO:0000269|PubMed:15146469" FT /id="VAR_021747" FT VARIANT 844 FT /note="L -> F (in NF1; dbSNP:rs199474785)" FT /evidence="ECO:0000269|PubMed:10980545, FT ECO:0000269|PubMed:15060124" FT /id="VAR_010992" FT VARIANT 844 FT /note="L -> P (in NF1; dbSNP:rs137854566)" FT /evidence="ECO:0000269|PubMed:15060124" FT /id="VAR_032468" FT VARIANT 844 FT /note="L -> R (in NF1; sporadic; dbSNP:rs137854566)" FT /evidence="ECO:0000269|PubMed:12522551, FT ECO:0000269|PubMed:15948193, ECO:0000269|PubMed:9150739" FT /id="VAR_002654" FT VARIANT 847 FT /note="L -> P (in NF1; dbSNP:rs199474747)" FT /evidence="ECO:0000269|PubMed:10712197, FT ECO:0000269|PubMed:12552569, ECO:0000269|PubMed:15146469" FT /id="VAR_021748" FT VARIANT 848 FT /note="G -> E (in NF1; dbSNP:rs199474748)" FT /evidence="ECO:0000269|PubMed:12552569, FT ECO:0000269|PubMed:15146469" FT /id="VAR_021749" FT VARIANT 873 FT /note="R -> C (in dbSNP:rs199474739)" FT /evidence="ECO:0000269|PubMed:15060124" FT /id="VAR_032469" FT VARIANT 898 FT /note="L -> P (in NF1; sporadic; dbSNP:rs199474786)" FT /evidence="ECO:0000269|PubMed:12522551, FT ECO:0000269|PubMed:9150739" FT /id="VAR_002655" FT VARIANT 920 FT /note="L -> P (in NF1; patient with cafe-au-lait spots; may FT be a distinct form of NF1; dbSNP:rs199474775)" FT /evidence="ECO:0000269|PubMed:12746402" FT /id="VAR_021750" FT VARIANT 968 FT /note="M -> R (in NF1; dbSNP:rs199474749)" FT /evidence="ECO:0000269|PubMed:12552569, FT ECO:0000269|PubMed:15146469" FT /id="VAR_021751" FT VARIANT 991 FT /note="Missing (in NF1; most patients carrying the mutation FT do not manifest cutaneous neurofibromas)" FT /evidence="ECO:0000269|PubMed:15060124, FT ECO:0000269|PubMed:17160901, ECO:0000269|PubMed:7904209" FT /id="VAR_002656" FT VARIANT 1035 FT /note="M -> R (in NF1; dbSNP:rs137854553)" FT /evidence="ECO:0000269|PubMed:8807336" FT /id="VAR_002657" FT VARIANT 1048 FT /note="W -> R (in NF1; dbSNP:rs1555614634)" FT /evidence="ECO:0000269|PubMed:23758643" FT /id="VAR_071669" FT VARIANT 1073 FT /note="M -> V (in NF1; dbSNP:rs199474740)" FT /evidence="ECO:0000269|PubMed:15060124" FT /id="VAR_032470" FT VARIANT 1147 FT /note="L -> P (in NF1; dbSNP:rs199474779)" FT /evidence="ECO:0000269|PubMed:11735023" FT /id="VAR_021752" FT VARIANT 1156 FT /note="N -> S (in NF1; dbSNP:rs199474764)" FT /evidence="ECO:0000269|PubMed:10712197" FT /id="VAR_021753" FT VARIANT 1166 FT /note="G -> D (in NF1; dbSNP:rs199474787)" FT /evidence="ECO:0000269|PubMed:7981679" FT /id="VAR_010993" FT VARIANT 1187 FT /note="L -> I (in a colorectal cancer sample; somatic FT mutation; dbSNP:rs2067142260)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035543" FT VARIANT 1189 FT /note="Q -> R (in NF1; dbSNP:rs752039618)" FT /evidence="ECO:0000269|PubMed:23758643" FT /id="VAR_071670" FT VARIANT 1193 FT /note="F -> C (in NF1; dbSNP:rs199474780)" FT /evidence="ECO:0000269|PubMed:11735023" FT /id="VAR_021754" FT VARIANT 1196 FT /note="L -> R (in NF1; dbSNP:rs199474741)" FT /evidence="ECO:0000269|PubMed:15060124" FT /id="VAR_032471" FT VARIANT 1204 FT /note="R -> G (in NF1; dbSNP:rs199474732)" FT /evidence="ECO:0000269|PubMed:10336779" FT /id="VAR_021755" FT VARIANT 1204 FT /note="R -> W (in NF1; dbSNP:rs199474732)" FT /evidence="ECO:0000269|PubMed:10607834" FT /id="VAR_010994" FT VARIANT 1243 FT /note="L -> P (in NF1; with neurofibromatous neuropathy; FT dbSNP:rs137854564)" FT /evidence="ECO:0000269|PubMed:15520408" FT /id="VAR_032472" FT VARIANT 1250 FT /note="R -> P (in NF1; dbSNP:rs199474765)" FT /evidence="ECO:0000269|PubMed:10712197" FT /id="VAR_021756" FT VARIANT 1276 FT /note="R -> G (in NF1; dbSNP:rs199474742)" FT /evidence="ECO:0000269|PubMed:15060124" FT /id="VAR_032473" FT VARIANT 1276 FT /note="R -> P (in NF1; complete loss of GAP activity; FT dbSNP:rs137854556)" FT /evidence="ECO:0000269|PubMed:10712197, FT ECO:0000269|PubMed:9668168" FT /id="VAR_010995" FT VARIANT 1276 FT /note="R -> Q (in NF1 and mismatch repair deficient cancer FT cells; dbSNP:rs137854556)" FT /evidence="ECO:0000269|PubMed:10712197, FT ECO:0000269|PubMed:12522551, ECO:0000269|PubMed:15060124" FT /id="VAR_017555" FT VARIANT 1411 FT /note="L -> F (in NFNS; dbSNP:rs199474789)" FT /evidence="ECO:0000269|PubMed:19845691" FT /id="VAR_065236" FT VARIANT 1412 FT /note="R -> S (in NF1; significant reduction of GAP FT activity; dbSNP:rs137854554)" FT /evidence="ECO:0000269|PubMed:9003501" FT /id="VAR_010996" FT VARIANT 1422 FT /note="Y -> H (in dbSNP:rs17884349)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_022256" FT VARIANT 1430 FT /note="K -> E (in NF1)" FT /evidence="ECO:0000269|PubMed:15060124" FT /id="VAR_032474" FT VARIANT 1440 FT /note="K -> Q (in NF1; dbSNP:rs199474790)" FT /evidence="ECO:0000269|PubMed:9003501" FT /id="VAR_010997" FT VARIANT 1440 FT /note="K -> R (in NF1; dbSNP:rs199474788)" FT /evidence="ECO:0000269|PubMed:7981679" FT /id="VAR_002658" FT VARIANT 1444 FT /note="K -> E (in NF1 and NFNS; significant reduction of FT intrinsic GAP activity; dbSNP:rs137854550)" FT /evidence="ECO:0000269|PubMed:11857752, FT ECO:0000269|PubMed:1568247, ECO:0000269|PubMed:16380919, FT ECO:0000269|PubMed:9003501" FT /id="VAR_002659" FT VARIANT 1444 FT /note="K -> N (in NF1; dbSNP:rs199474750)" FT /evidence="ECO:0000269|PubMed:12552569, FT ECO:0000269|PubMed:15146469" FT /id="VAR_021757" FT VARIANT 1444 FT /note="K -> R (in NF1; dbSNP:rs199474781)" FT /evidence="ECO:0000269|PubMed:11735023" FT /id="VAR_021758" FT VARIANT 1446 FT /note="L -> P (in NF1; dbSNP:rs199474733)" FT /evidence="ECO:0000269|PubMed:10220149, FT ECO:0000269|PubMed:10607834, ECO:0000269|PubMed:10712197" FT /id="VAR_008129" FT VARIANT 1451 FT /note="N -> T (in NFNS; dbSNP:rs199474754)" FT /evidence="ECO:0000269|PubMed:16380919" FT /id="VAR_032475" FT VARIANT 1453 FT /note="V -> L (in NFNS; dbSNP:rs199474755)" FT /evidence="ECO:0000269|PubMed:16380919" FT /id="VAR_032476" FT VARIANT 1459 FT /note="Missing (in NFNS; dbSNP:rs267606607)" FT /evidence="ECO:0000269|PubMed:12707950, FT ECO:0000269|PubMed:15060124, ECO:0000269|PubMed:16380919" FT /id="VAR_032477" FT VARIANT 1484 FT /note="S -> F (in a cutaneous neurofibroma from a patient FT with neurofibromatosis; somatic mutation; FT dbSNP:rs199474772)" FT /evidence="ECO:0000269|PubMed:22108604" FT /id="VAR_067206" FT VARIANT 1489 FT /note="S -> G (in NF1; dbSNP:rs199474743)" FT /evidence="ECO:0000269|PubMed:15060124, FT ECO:0000269|PubMed:9003501" FT /id="VAR_010998" FT VARIANT 1605 FT /note="I -> V (in NF1; reduces protein stability; FT dbSNP:rs199474766)" FT /evidence="ECO:0000269|PubMed:10712197, FT ECO:0000269|PubMed:21089070" FT /id="VAR_021759" FT VARIANT 1611 FT /note="R -> W (in NF1; dbSNP:rs1060500316)" FT /evidence="ECO:0000269|PubMed:9298829" FT /id="VAR_002660" FT VARIANT 1733 FT /note="L -> LGHEQQKLPAATLAL (in NF1)" FT /evidence="ECO:0000269|PubMed:8317503" FT /id="VAR_002661" FT VARIANT 1785 FT /note="A -> S (in NF1; dbSNP:rs199474782)" FT /evidence="ECO:0000269|PubMed:11735023" FT /id="VAR_021760" FT VARIANT 1951 FT /note="P -> L (in a colorectal cancer sample; somatic FT mutation; dbSNP:rs2151550343)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035544" FT VARIANT 1952 FT /note="W -> R (in NF1; dbSNP:rs199474791)" FT /evidence="ECO:0000269|PubMed:9101300" FT /id="VAR_002662" FT VARIANT 1953 FT /note="L -> P (in NF1; dbSNP:rs199474792)" FT /evidence="ECO:0000269|PubMed:2114220" FT /id="VAR_002663" FT VARIANT 1953 FT /note="Missing (in NF1)" FT /evidence="ECO:0000269|PubMed:12552569, FT ECO:0000269|PubMed:15146469" FT /id="VAR_021761" FT VARIANT 2001 FT /note="G -> R (in NF1; dbSNP:rs199474751)" FT /evidence="ECO:0000269|PubMed:12552569, FT ECO:0000269|PubMed:15146469" FT /id="VAR_021762" FT VARIANT 2012 FT /note="D -> N (in NF1; dbSNP:rs199474783)" FT /evidence="ECO:0000269|PubMed:11735023" FT /id="VAR_021763" FT VARIANT 2088 FT /note="L -> P (in FSNF; no cafe-au-lait macules; null FT mutation; 50% reduction of protein level; FT dbSNP:rs137854561)" FT /evidence="ECO:0000269|PubMed:11704931" FT /id="VAR_017669" FT VARIANT 2125 FT /note="L -> P (in NF1; dbSNP:rs1597843129)" FT /evidence="ECO:0000269|PubMed:24413922" FT /id="VAR_071671" FT VARIANT 2164 FT /note="L -> M (in NF1; dbSNP:rs137854551)" FT /evidence="ECO:0000269|PubMed:1302608" FT /id="VAR_002664" FT VARIANT 2192 FT /note="Y -> N (in NF1; dbSNP:rs267606598)" FT /evidence="ECO:0000269|PubMed:1302608" FT /id="VAR_002665" FT VARIANT 2221 FT /note="P -> A (in NF1; dbSNP:rs199474776)" FT /evidence="ECO:0000269|PubMed:12746402" FT /id="VAR_021764" FT VARIANT 2357 FT /note="E -> K (in NF1; dbSNP:rs199474784)" FT /evidence="ECO:0000269|PubMed:11735023" FT /id="VAR_021765" FT VARIANT 2387..2388 FT /note="Missing (in NF1)" FT /evidence="ECO:0000269|PubMed:10607834, FT ECO:0000269|PubMed:8081387" FT /id="VAR_002666" FT VARIANT 2507 FT /note="T -> I (in NF1; dbSNP:rs149055633)" FT /evidence="ECO:0000269|PubMed:10712197" FT /id="VAR_021766" FT VARIANT 2511 FT /note="V -> L (in dbSNP:rs2230850)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_022257" FT VARIANT 2631 FT /note="T -> A (in NF1; dbSNP:rs199474793)" FT /evidence="ECO:0000269|PubMed:8544190" FT /id="VAR_002667" FT VARIANT 2745 FT /note="G -> R (in a breast cancer sample; somatic mutation; FT dbSNP:rs2151587866)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035545" FT MUTAGEN 1691 FT /note="K->A: Reduces phospholipid binding; when associated FT with A-1695; A-1769 and A-1771." FT /evidence="ECO:0000269|PubMed:16397625" FT MUTAGEN 1695 FT /note="R->A: Reduces phospholipid binding; when associated FT with A-1691; A-1769 and A-1771." FT /evidence="ECO:0000269|PubMed:16397625" FT MUTAGEN 1769 FT /note="R->A: Reduces phospholipid binding; when associated FT with A-1691; A-1695 and A-1771." FT /evidence="ECO:0000269|PubMed:16397625" FT MUTAGEN 1771 FT /note="K->A: Reduces phospholipid binding; when associated FT with A-1691; A-169 and A-1769." FT /evidence="ECO:0000269|PubMed:16397625, FT ECO:0000269|PubMed:21089070" FT MUTAGEN 1771 FT /note="Missing: Reduces protein stability." FT /evidence="ECO:0000269|PubMed:16397625, FT ECO:0000269|PubMed:21089070" FT CONFLICT 496 FT /note="M -> I (in Ref. 11; AAA74897/AAB59558)" FT /evidence="ECO:0000305" FT CONFLICT 1094..1095 FT /note="EL -> ST (in Ref. 14; AAA59923)" FT /evidence="ECO:0000305" FT CONFLICT 1576 FT /note="H -> HH (in Ref. 11; AAA74897/AAB59558)" FT /evidence="ECO:0000305" FT HELIX 5..18 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 31..33 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 34..46 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 47..49 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 51..66 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 73..96 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 106..111 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 114..121 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 130..146 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 150..166 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 174..181 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 187..201 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 206..226 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 228..236 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 240..256 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 260..276 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 278..285 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 294..307 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 314..331 FT /evidence="ECO:0007829|PDB:7PGP" FT STRAND 336..338 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 341..357 FT /evidence="ECO:0007829|PDB:7PGP" FT STRAND 360..362 FT /evidence="ECO:0007829|PDB:7PGP" FT STRAND 367..371 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 373..386 FT /evidence="ECO:0007829|PDB:7PGP" FT STRAND 387..389 FT /evidence="ECO:0007829|PDB:7PGU" FT HELIX 394..398 FT /evidence="ECO:0007829|PDB:7PGP" FT STRAND 399..402 FT /evidence="ECO:0007829|PDB:7PGU" FT HELIX 404..419 FT /evidence="ECO:0007829|PDB:7PGP" FT STRAND 424..426 FT /evidence="ECO:0007829|PDB:7PGU" FT HELIX 429..435 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 436..454 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 483..502 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 505..508 FT /evidence="ECO:0007829|PDB:7PGP" FT STRAND 516..518 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 522..530 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 531..534 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 539..551 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 555..558 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 559..561 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 566..568 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 569..587 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 593..617 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 678..691 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 693..696 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 700..708 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 711..720 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 724..727 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 728..730 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 735..745 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 752..762 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 763..765 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 771..793 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 832..846 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 849..851 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 890..899 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 900..903 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 907..909 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 910..923 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 927..929 FT /evidence="ECO:0007829|PDB:7PGU" FT HELIX 930..942 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 947..949 FT /evidence="ECO:0007829|PDB:7PGU" FT HELIX 955..973 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 979..983 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 989..1000 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1006..1021 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 1026..1028 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1034..1046 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 1049..1052 FT /evidence="ECO:0007829|PDB:8EDO" FT HELIX 1053..1056 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1060..1063 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1064..1080 FT /evidence="ECO:0007829|PDB:7PGP" FT STRAND 1091..1093 FT /evidence="ECO:0007829|PDB:7PGU" FT HELIX 1095..1116 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1135..1155 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1157..1160 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1162..1167 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1173..1190 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1197..1200 FT /evidence="ECO:0007829|PDB:7PGU" FT TURN 1201..1204 FT /evidence="ECO:0007829|PDB:7PGU" FT HELIX 1208..1216 FT /evidence="ECO:0007829|PDB:1NF1" FT TURN 1217..1219 FT /evidence="ECO:0007829|PDB:7PGU" FT HELIX 1220..1228 FT /evidence="ECO:0007829|PDB:6OB3" FT HELIX 1233..1235 FT /evidence="ECO:0007829|PDB:6OB3" FT HELIX 1236..1249 FT /evidence="ECO:0007829|PDB:6OB3" FT HELIX 1253..1267 FT /evidence="ECO:0007829|PDB:6OB3" FT HELIX 1271..1273 FT /evidence="ECO:0007829|PDB:6OB3" FT STRAND 1277..1279 FT /evidence="ECO:0007829|PDB:7PGU" FT HELIX 1280..1309 FT /evidence="ECO:0007829|PDB:6OB3" FT TURN 1310..1312 FT /evidence="ECO:0007829|PDB:6V6F" FT HELIX 1315..1317 FT /evidence="ECO:0007829|PDB:6OB3" FT HELIX 1323..1325 FT /evidence="ECO:0007829|PDB:6OB3" FT STRAND 1328..1330 FT /evidence="ECO:0007829|PDB:6V65" FT HELIX 1332..1351 FT /evidence="ECO:0007829|PDB:6OB3" FT HELIX 1354..1356 FT /evidence="ECO:0007829|PDB:6OB3" FT HELIX 1359..1370 FT /evidence="ECO:0007829|PDB:6OB3" FT HELIX 1392..1394 FT /evidence="ECO:0007829|PDB:6OB3" FT HELIX 1398..1400 FT /evidence="ECO:0007829|PDB:6OB3" FT HELIX 1401..1411 FT /evidence="ECO:0007829|PDB:6OB3" FT HELIX 1414..1419 FT /evidence="ECO:0007829|PDB:6OB3" FT TURN 1421..1425 FT /evidence="ECO:0007829|PDB:6OB3" FT STRAND 1426..1429 FT /evidence="ECO:0007829|PDB:6V6F" FT HELIX 1433..1451 FT /evidence="ECO:0007829|PDB:6OB3" FT HELIX 1459..1464 FT /evidence="ECO:0007829|PDB:6OB3" FT HELIX 1465..1483 FT /evidence="ECO:0007829|PDB:6OB3" FT STRAND 1490..1492 FT /evidence="ECO:0007829|PDB:7PGU" FT HELIX 1510..1514 FT /evidence="ECO:0007829|PDB:1NF1" FT HELIX 1517..1520 FT /evidence="ECO:0007829|PDB:1NF1" FT HELIX 1531..1533 FT /evidence="ECO:0007829|PDB:7PGS" FT HELIX 1535..1544 FT /evidence="ECO:0007829|PDB:1NF1" FT HELIX 1569..1578 FT /evidence="ECO:0007829|PDB:3P7Z" FT TURN 1582..1586 FT /evidence="ECO:0007829|PDB:3PG7" FT HELIX 1587..1590 FT /evidence="ECO:0007829|PDB:3PG7" FT STRAND 1592..1598 FT /evidence="ECO:0007829|PDB:3PG7" FT STRAND 1604..1609 FT /evidence="ECO:0007829|PDB:3PG7" FT HELIX 1610..1612 FT /evidence="ECO:0007829|PDB:3PG7" FT TURN 1615..1617 FT /evidence="ECO:0007829|PDB:2D4Q" FT HELIX 1620..1631 FT /evidence="ECO:0007829|PDB:3PG7" FT TURN 1632..1636 FT /evidence="ECO:0007829|PDB:3PG7" FT STRAND 1639..1644 FT /evidence="ECO:0007829|PDB:3PG7" FT HELIX 1650..1652 FT /evidence="ECO:0007829|PDB:3PG7" FT HELIX 1656..1661 FT /evidence="ECO:0007829|PDB:3PG7" FT TURN 1662..1664 FT /evidence="ECO:0007829|PDB:3PG7" FT HELIX 1668..1672 FT /evidence="ECO:0007829|PDB:3PG7" FT STRAND 1674..1681 FT /evidence="ECO:0007829|PDB:3PG7" FT HELIX 1684..1692 FT /evidence="ECO:0007829|PDB:3PG7" FT HELIX 1694..1697 FT /evidence="ECO:0007829|PDB:3PG7" FT TURN 1698..1702 FT /evidence="ECO:0007829|PDB:3PG7" FT STRAND 1706..1711 FT /evidence="ECO:0007829|PDB:3PG7" FT HELIX 1714..1717 FT /evidence="ECO:0007829|PDB:3PG7" FT HELIX 1721..1723 FT /evidence="ECO:0007829|PDB:3PG7" FT HELIX 1728..1732 FT /evidence="ECO:0007829|PDB:3PG7" FT STRAND 1738..1749 FT /evidence="ECO:0007829|PDB:3PG7" FT STRAND 1751..1757 FT /evidence="ECO:0007829|PDB:3PG7" FT STRAND 1759..1767 FT /evidence="ECO:0007829|PDB:3PG7" FT STRAND 1770..1772 FT /evidence="ECO:0007829|PDB:2D4Q" FT STRAND 1775..1777 FT /evidence="ECO:0007829|PDB:3PG7" FT STRAND 1780..1784 FT /evidence="ECO:0007829|PDB:3PG7" FT HELIX 1785..1787 FT /evidence="ECO:0007829|PDB:3PG7" FT STRAND 1788..1795 FT /evidence="ECO:0007829|PDB:3PG7" FT STRAND 1798..1803 FT /evidence="ECO:0007829|PDB:3PG7" FT STRAND 1810..1813 FT /evidence="ECO:0007829|PDB:3PG7" FT HELIX 1817..1833 FT /evidence="ECO:0007829|PDB:3PG7" FT HELIX 1847..1849 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1851..1861 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1867..1884 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1906..1918 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1920..1922 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1923..1936 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1939..1949 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1950..1952 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1957..1960 FT /evidence="ECO:0007829|PDB:7PGP" FT STRAND 1961..1963 FT /evidence="ECO:0007829|PDB:8EDO" FT STRAND 1965..1967 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1968..1984 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 1989..2000 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2004..2006 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2007..2021 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2026..2041 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2043..2057 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2058..2060 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2061..2063 FT /evidence="ECO:0007829|PDB:8EDO" FT HELIX 2069..2071 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2075..2089 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2090..2092 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2096..2108 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 2109..2112 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2116..2134 FT /evidence="ECO:0007829|PDB:7PGP" FT STRAND 2137..2139 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2143..2155 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2159..2165 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2173..2177 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 2180..2184 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2199..2219 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2225..2237 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 2242..2244 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2245..2250 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2252..2255 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2261..2280 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 2285..2287 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2289..2301 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2302..2304 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2311..2314 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2317..2323 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2328..2347 FT /evidence="ECO:0007829|PDB:7PGP" FT STRAND 2351..2354 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2356..2363 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2365..2367 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2368..2378 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 2382..2384 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2386..2392 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 2393..2395 FT /evidence="ECO:0007829|PDB:7PGS" FT HELIX 2396..2399 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2403..2424 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 2427..2429 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2434..2436 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2437..2441 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 2443..2445 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2447..2452 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 2607..2609 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2613..2629 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2633..2649 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 2651..2653 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2654..2657 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2658..2671 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2675..2690 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2700..2702 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2704..2706 FT /evidence="ECO:0007829|PDB:7PGP" FT TURN 2709..2715 FT /evidence="ECO:0007829|PDB:7PGP" FT HELIX 2728..2742 FT /evidence="ECO:0007829|PDB:7PGP" FT VARIANT P21359-2:1661 FT /note="C -> R (in NF1; dbSNP:rs1597829901)" FT /evidence="ECO:0000269|PubMed:23758643" FT /id="VAR_082822" FT VARIANT P21359-2:1918 FT /note="I -> T (in NF1; dbSNP:rs1304057833)" FT /evidence="ECO:0000269|PubMed:23758643" FT /id="VAR_082823" SQ SEQUENCE 2839 AA; 319372 MW; C079475139DBD51E CRC64; MAAHRPVEWV QAVVSRFDEQ LPIKTGQQNT HTKVSTEHNK ECLINISKYK FSLVISGLTT ILKNVNNMRI FGEAAEKNLY LSQLIILDTL EKCLAGQPKD TMRLDETMLV KQLLPEICHF LHTCREGNQH AAELRNSASG VLFSLSCNNF NAVFSRISTR LQELTVCSED NVDVHDIELL QYINVDCAKL KRLLKETAFK FKALKKVAQL AVINSLEKAF WNWVENYPDE FTKLYQIPQT DMAECAEKLF DLVDGFAEST KRKAAVWPLQ IILLILCPEI IQDISKDVVD ENNMNKKLFL DSLRKALAGH GGSRQLTESA AIACVKLCKA STYINWEDNS VIFLLVQSMV VDLKNLLFNP SKPFSRGSQP ADVDLMIDCL VSCFRISPHN NQHFKICLAQ NSPSTFHYVL VNSLHRIITN SALDWWPKID AVYCHSVELR NMFGETLHKA VQGCGAHPAI RMAPSLTFKE KVTSLKFKEK PTDLETRSYK YLLLSMVKLI HADPKLLLCN PRKQGPETQG STAELITGLV QLVPQSHMPE IAQEAMEALL VLHQLDSIDL WNPDAPVETF WEISSQMLFY ICKKLTSHQM LSSTEILKWL REILICRNKF LLKNKQADRS SCHFLLFYGV GCDIPSSGNT SQMSMDHEEL LRTPGASLRK GKGNSSMDSA AGCSGTPPIC RQAQTKLEVA LYMFLWNPDT EAVLVAMSCF RHLCEEADIR CGVDEVSVHN LLPNYNTFME FASVSNMMST GRAALQKRVM ALLRRIEHPT AGNTEAWEDT HAKWEQATKL ILNYPKAKME DGQAAESLHK TIVKRRMSHV SGGGSIDLSD TDSLQEWINM TGFLCALGGV CLQQRSNSGL ATYSPPMGPV SERKGSMISV MSSEGNADTP VSKFMDRLLS LMVCNHEKVG LQIRTNVKDL VGLELSPALY PMLFNKLKNT ISKFFDSQGQ VLLTDTNTQF VEQTIAIMKN LLDNHTEGSS EHLGQASIET MMLNLVRYVR VLGNMVHAIQ IKTKLCQLVE VMMARRDDLS FCQEMKFRNK MVEYLTDWVM GTSNQAADDD VKCLTRDLDQ ASMEAVVSLL AGLPLQPEEG DGVELMEAKS QLFLKYFTLF MNLLNDCSEV EDESAQTGGR KRGMSRRLAS LRHCTVLAMS NLLNANVDSG LMHSIGLGYH KDLQTRATFM EVLTKILQQG TEFDTLAETV LADRFERLVE LVTMMGDQGE LPIAMALANV VPCSQWDELA RVLVTLFDSR HLLYQLLWNM FSKEVELADS MQTLFRGNSL ASKIMTFCFK VYGATYLQKL LDPLLRIVIT SSDWQHVSFE VDPTRLEPSE SLEENQRNLL QMTEKFFHAI ISSSSEFPPQ LRSVCHCLYQ ATCHSLLNKA TVKEKKENKK SVVSQRFPQN SIGAVGSAMF LRFINPAIVS PYEAGILDKK PPPRIERGLK LMSKILQSIA NHVLFTKEEH MRPFNDFVKS NFDAARRFFL DIASDCPTSD AVNHSLSFIS DGNVLALHRL LWNNQEKIGQ YLSSNRDHKA VGRRPFDKMA TLLAYLGPPE HKPVADTHWS SLNLTSSKFE EFMTRHQVHE KEEFKALKTL SIFYQAGTSK AGNPIFYYVA RRFKTGQING DLLIYHVLLT LKPYYAKPYE IVVDLTHTGP SNRFKTDFLS KWFVVFPGFA YDNVSAVYIY NCNSWVREYT KYHERLLTGL KGSKRLVFID CPGKLAEHIE HEQQKLPAAT LALEEDLKVF HNALKLAHKD TKVSIKVGST AVQVTSAERT KVLGQSVFLN DIYYASEIEE ICLVDENQFT LTIANQGTPL TFMHQECEAI VQSIIHIRTR WELSQPDSIP QHTKIRPKDV PGTLLNIALL NLGSSDPSLR SAAYNLLCAL TCTFNLKIEG QLLETSGLCI PANNTLFIVS ISKTLAANEP HLTLEFLEEC ISGFSKSSIE LKHLCLEYMT PWLSNLVRFC KHNDDAKRQR VTAILDKLIT MTINEKQMYP SIQAKIWGSL GQITDLLDVV LDSFIKTSAT GGLGSIKAEV MADTAVALAS GNVKLVSSKV IGRMCKIIDK TCLSPTPTLE QHLMWDDIAI LARYMLMLSF NNSLDVAAHL PYLFHVVTFL VATGPLSLRA STHGLVINII HSLCTCSQLH FSEETKQVLR LSLTEFSLPK FYLLFGISKV KSAAVIAFRS SYRDRSFSPG SYERETFALT SLETVTEALL EIMEACMRDI PTCKWLDQWT ELAQRFAFQY NPSLQPRALV VFGCISKRVS HGQIKQIIRI LSKALESCLK GPDTYNSQVL IEATVIALTK LQPLLNKDSP LHKALFWVAV AVLQLDEVNL YSAGTALLEQ NLHTLDSLRI FNDKSPEEVF MAIRNPLEWH CKQMDHFVGL NFNSNFNFAL VGHLLKGYRH PSPAIVARTV RILHTLLTLV NKHRNCDKFE VNTQSVAYLA ALLTVSEEVR SRCSLKHRKS LLLTDISMEN VPMDTYPIHH GDPSYRTLKE TQPWSSPKGS EGYLAATYPT VGQTSPRARK SMSLDMGQPS QANTKKLLGT RKSFDHLISD TKAPKRQEME SGITTPPKMR RVAETDYEME TQRISSSQQH PHLRKVSVSE SNVLLDEEVL TDPKIQALLL TVLATLVKYT TDEFDQRILY EYLAEASVVF PKVFPVVHNL LDSKINTLLS LCQDPNLLNP IHGIVQSVVY HEESPPQYQT SYLQSFGFNG LWRFAGPFSK QTQIPDYAEL IVKFLDALID TYLPGIDEET SEESLLTPTS PYPPALQSQL SITANLNLSN SMTSLATSQH SPGIDKENVE LSPTTGHCNS GRTRHGSASQ VQKQRSAGSF KRNSIKKIV // ID PGFRB_HUMAN Reviewed; 1106 AA. AC P09619; B5A957; Q8N5L4; DT 01-JUL-1989, integrated into UniProtKB/Swiss-Prot. DT 01-JUL-1989, sequence version 1. DT 28-JAN-2026, entry version 269. DE RecName: Full=Platelet-derived growth factor receptor beta; DE Short=PDGF-R-beta; DE Short=PDGFR-beta; DE EC=2.7.10.1; DE AltName: Full=Beta platelet-derived growth factor receptor; DE AltName: Full=Beta-type platelet-derived growth factor receptor; DE AltName: Full=CD140 antigen-like family member B; DE AltName: Full=Platelet-derived growth factor receptor 1; DE Short=PDGFR-1; DE AltName: CD_antigen=CD140b; DE Flags: Precursor; GN Name=PDGFRB; Synonyms=PDGFR, PDGFR1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION AS PDGFB RECEPTOR, RP SUBCELLULAR LOCATION, AUTOPHOSPHORYLATION, AND INTERACTION WITH PDGFB. RX PubMed=2835772; DOI=10.1073/pnas.85.10.3435; RA Gronwald R.G.K., Grant F.J., Haldeman B.A., Hart C.E., O'Hara P.J., RA Hagen F.S., Ross R., Bowen-Pope D.F., Murray M.J.; RT "Cloning and expression of a cDNA coding for the human platelet-derived RT growth factor receptor: evidence for more than one receptor class."; RL Proc. Natl. Acad. Sci. U.S.A. 85:3435-3439(1988). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION AS PDGFB RECEPTOR, RP SUBCELLULAR LOCATION, GLYCOSYLATION, AUTOPHOSPHORYLATION, AND INTERACTION RP WITH PDGFA AND PDGFB. RX PubMed=2850496; DOI=10.1128/mcb.8.8.3476-3486.1988; RA Claesson-Welsh L., Eriksson A., Moren A., Severinsson L., Ek B., RA Oestman A., Betsholtz C., Heldin C.-H.; RT "cDNA cloning and expression of a human platelet-derived growth factor RT (PDGF) receptor specific for B-chain-containing PDGF molecules."; RL Mol. Cell. Biol. 8:3476-3486(1988). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND ALTERNATIVE SPLICING. RX PubMed=18593464; DOI=10.1186/ar2447; RA Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D., RA Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.; RT "Novel splice variants derived from the receptor tyrosine kinase RT superfamily are potential therapeutics for rheumatoid arthritis."; RL Arthritis Res. Ther. 10:R73-R73(2008). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15372022; DOI=10.1038/nature02919; RA Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S., RA Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M., RA She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S., RA Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M., RA Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M., RA Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T., RA Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., RA Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R., RA Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L., RA Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N., RA Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., RA Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., RA Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.; RT "The DNA sequence and comparative analysis of human chromosome 5."; RL Nature 431:268-274(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT PHE-180. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 548-569. RX PubMed=9285559; DOI=10.1038/sj.onc.1201267; RA Chi K.D., McPhee R.A., Wagner A.S., Dietz J.J., Pantazis P., Goustin A.S.; RT "Integration of proviral DNA into the PDGF beta-receptor gene in HTLV-I- RT infected T-cells results in a novel tyrosine kinase product with RT transforming activity."; RL Oncogene 15:1051-1057(1997). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 559-1106 (ISOFORM 1), AND CHROMOSOMAL RP TRANSLOCATION WITH CEP85L. RX PubMed=21938754; DOI=10.1002/gcc.20930; RA Chmielecki J., Peifer M., Viale A., Hutchinson K., Giltnane J., Socci N.D., RA Hollis C.J., Dean R.S., Yenamandra A., Jagasia M., Kim A.S., Dave U.P., RA Thomas R.K., Pao W.; RT "Systematic screen for tyrosine kinase rearrangements identifies a novel RT C6orf204-PDGFRB fusion in a patient with recurrent T-ALL and an associated RT myeloproliferative neoplasm."; RL Genes Chromosomes Cancer 51:54-65(2012). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1046-1106. RX PubMed=2846185; DOI=10.1016/0092-8674(88)90224-3; RA Roberts W.M., Look A.T., Roussel M.F., Sherr C.J.; RT "Tandem linkage of human CSF-1 receptor (c-fms) and PDGF receptor genes."; RL Cell 55:655-661(1988). RN [9] RP PROTEIN SEQUENCE OF 33-47. RX PubMed=15340161; DOI=10.1110/ps.04682504; RA Zhang Z., Henzel W.J.; RT "Signal peptide prediction based on analysis of experimentally verified RT cleavage sites."; RL Protein Sci. 13:2819-2824(2004). RN [10] RP PHOSPHORYLATION AT TYR-751 AND TYR-857. RX PubMed=2550144; DOI=10.1016/0092-8674(89)90510-2; RA Kazlauskas A., Cooper J.A.; RT "Autophosphorylation of the PDGF receptor in the kinase insert region RT regulates interactions with cell proteins."; RL Cell 58:1121-1133(1989). RN [11] RP FUNCTION AS PDGFB RECEPTOR IN CELL PROLIFERATION AND CHEMOTAXIS, AND RP SUBCELLULAR LOCATION. RX PubMed=2554309; DOI=10.1073/pnas.86.21.8314; RA Matsui T., Pierce J.H., Fleming T.P., Greenberger J.S., LaRochelle W.J., RA Ruggiero M., Aaronson S.A.; RT "Independent expression of human alpha or beta platelet-derived growth RT factor receptor cDNAs in a naive hematopoietic cell leads to functional RT coupling with mitogenic and chemotactic signaling pathways."; RL Proc. Natl. Acad. Sci. U.S.A. 86:8314-8318(1989). RN [12] RP FUNCTION IN CELL PROLIFERATION; ACTIVATION OF PLCG1 AND IN PHOSPHORYLATION RP OF PLCG1 AND RASA1/GAP, AND MUTAGENESIS OF TYR-751 AND TYR-857. RX PubMed=1653029; DOI=10.1091/mbc.2.6.413; RA Kazlauskas A., Durden D.L., Cooper J.A.; RT "Functions of the major tyrosine phosphorylation site of the PDGF receptor RT beta subunit."; RL Cell Regul. 2:413-425(1991). RN [13] RP INTERACTION WITH PDGFRA; PDGFA AND PDGFB, FUNCTION AS RECEPTOR FOR PDGFA RP AND PDGFB, AND PHOSPHORYLATION AT TYR-857 AND TYR-751. RX PubMed=1709159; DOI=10.1016/s0021-9258(18)31541-2; RA Kelly J.D., Haldeman B.A., Grant F.J., Murray M.J., Seifert R.A., RA Bowen-Pope D.F., Cooper J.A., Kazlauskas A.; RT "Platelet-derived growth factor (PDGF) stimulates PDGF receptor subunit RT dimerization and intersubunit trans-phosphorylation."; RL J. Biol. Chem. 266:8987-8992(1991). RN [14] RP FUNCTION AS RECEPTOR FOR PDGFA AND PDGFB, SUBCELLULAR LOCATION, CATALYTIC RP ACTIVITY, AND MUTAGENESIS OF LYS-634. RX PubMed=1846866; DOI=10.1083/jcb.112.3.469; RA Sorkin A., Westermark B., Heldin C.H., Claesson-Welsh L.; RT "Effect of receptor kinase inactivation on the rate of internalization and RT degradation of PDGF and the PDGF beta-receptor."; RL J. Cell Biol. 112:469-478(1991). RN [15] RP FUNCTION IN ACTIVATION OF PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY, RP INTERACTION WITH PIK3R1 AND RASA1, PHOSPHORYLATION AT TYR-740; TYR-751; RP TYR-771 AND TYR-857, AND MUTAGENESIS OF LYS-634; TYR-716; TYR-740; TYR-751; RP TYR-763; TYR-771; TYR-775; TYR-778 AND TYR-857. RX PubMed=1314164; DOI=10.1002/j.1460-2075.1992.tb05182.x; RA Kashishian A., Kazlauskas A., Cooper J.A.; RT "Phosphorylation sites in the PDGF receptor with different specificities RT for binding GAP and PI3 kinase in vivo."; RL EMBO J. 11:1373-1382(1992). RN [16] RP FUNCTION AS PDGFB RECEPTOR IN CELL PROLIFERATION AND PHOSPHORYLATION OF RP PLCG1, INTERACTION WITH PLCG1, PHOSPHORYLATION AT TYR-1009 AND TYR-1021, RP AND MUTAGENESIS OF TYR-1009 AND TYR-1021. RX PubMed=1396585; DOI=10.1002/j.1460-2075.1992.tb05484.x; RA Ronnstrand L., Mori S., Arridsson A.K., Eriksson A., Wernstedt C., RA Hellman U., Claesson-Welsh L., Heldin C.H.; RT "Identification of two C-terminal autophosphorylation sites in the PDGF RT beta-receptor: involvement in the interaction with phospholipase C-gamma."; RL EMBO J. 11:3911-3919(1992). RN [17] RP UBIQUITINATION, AND DEGRADATION. RX PubMed=1313434; DOI=10.1016/s0021-9258(18)42714-7; RA Mori S., Heldin C.H., Claesson-Welsh L.; RT "Ligand-induced polyubiquitination of the platelet-derived growth factor RT beta-receptor."; RL J. Biol. Chem. 267:6429-6434(1992). RN [18] RP INTERACTION WITH PIK3R1 AND RASA1, AND MUTAGENESIS OF TYR-740; TYR-751 AND RP TYR-771. RX PubMed=1375321; DOI=10.1128/mcb.12.6.2534-2544.1992; RA Kazlauskas A., Kashishian A., Cooper J.A., Valius M.; RT "GTPase-activating protein and phosphatidylinositol 3-kinase bind to RT distinct regions of the platelet-derived growth factor receptor beta RT subunit."; RL Mol. Cell. Biol. 12:2534-2544(1992). RN [19] RP FUNCTION AS PDGFB RECEPTOR IN CELL PROLIFERATION, PHOSPHORYLATION AT RP TYR-579 AND TYR-581; INTERACTION WITH SRC, CATALYTIC ACTIVITY, AND RP MUTAGENESIS OF TYR-579 AND TYR-581. RX PubMed=7685273; DOI=10.1002/j.1460-2075.1993.tb05879.x; RA Mori S., Ronnstrand L., Yokote K., Engstrom A., Courtneidge S.A., RA Claesson-Welsh L., Heldin C.H.; RT "Identification of two juxtamembrane autophosphorylation sites in the PDGF RT beta-receptor; involvement in the interaction with Src family tyrosine RT kinases."; RL EMBO J. 12:2257-2264(1993). RN [20] RP INTERACTION WITH DGFA AND PDGFB. RX PubMed=7679113; DOI=10.1016/s0021-9258(18)53739-x; RA Fretto L.J., Snape A.J., Tomlinson J.E., Seroogy J.J., Wolf D.L., RA LaRochelle W.J., Giese N.A.; RT "Mechanism of platelet-derived growth factor (PDGF) AA, AB, and BB binding RT to alpha and beta PDGF receptor."; RL J. Biol. Chem. 268:3625-3631(1993). RN [21] RP FUNCTION IN PHOSPHORYLATION AND ACTIVATION OF PTPN11, INTERACTION WITH RP PTPN11; PIK3R1; PLCG1 AND RASA1, AND MUTAGENESIS OF TYR-1009. RX PubMed=7691811; DOI=10.1016/s0021-9258(20)80562-6; RA Lechleider R.J., Sugimoto S., Bennett A.M., Kashishian A.S., Cooper J.A., RA Shoelson S.E., Walsh C.T., Neel B.G.; RT "Activation of the SH2-containing phosphotyrosine phosphatase SH-PTP2 by RT its binding site, phosphotyrosine 1009, on the human platelet-derived RT growth factor receptor."; RL J. Biol. Chem. 268:21478-21481(1993). RN [22] RP INTERACTION WITH NCK1 AND PIK3R1, FUNCTION IN PHOSPHORYLATION OF NCK1, AND RP MUTAGENESIS OF TYR-751. RX PubMed=7692233; DOI=10.1128/mcb.13.11.6889-6896.1993; RA Nishimura R., Li W., Kashishian A., Mondino A., Zhou M., Cooper J., RA Schlessinger J.; RT "Two signaling molecules share a phosphotyrosine-containing binding site in RT the platelet-derived growth factor receptor."; RL Mol. Cell. Biol. 13:6889-6896(1993). RN [23] RP INTERACTION WITH SHB. RX PubMed=8302579; RA Welsh M., Mares J., Karlsson T., Lavergne C., Breant B., Claesson-Welsh L.; RT "Shb is a ubiquitously expressed Src homology 2 protein."; RL Oncogene 9:19-27(1994). RN [24] RP INTERACTION WITH GRB7. RX PubMed=8940081; DOI=10.1074/jbc.271.48.30942; RA Yokote K., Margolis B., Heldin C.H., Claesson-Welsh L.; RT "Grb7 is a downstream signaling component of platelet-derived growth factor RT alpha- and beta-receptors."; RL J. Biol. Chem. 271:30942-30949(1996). RN [25] RP CHROMOSOMAL TRANSLOCATION WITH TRIP11. RX PubMed=9373237; RA Abe A., Emi N., Tanimoto M., Terasaki H., Marunouchi T., Saito H.; RT "Fusion of the platelet-derived growth factor receptor beta to a novel gene RT CEV14 in acute myelogenous leukemia after clonal evolution."; RL Blood 90:4271-4277(1997). RN [26] RP INTERACTION WITH GRB10, AND MUTAGENESIS OF TYR-579; TYR-581; TYR-716; RP TYR-740; TYR-751; TYR-771; TYR-857; TYR-1009 AND TYR-1021. RX PubMed=10454568; DOI=10.1128/mcb.19.9.6217; RA Wang J., Dai H., Yousaf N., Moussaif M., Deng Y., Boufelliga A., RA Swamy O.R., Leone M.E., Riedel H.; RT "Grb10, a positive, stimulatory signaling adapter in platelet-derived RT growth factor BB-, insulin-like growth factor I-, and insulin-mediated RT mitogenesis."; RL Mol. Cell. Biol. 19:6217-6228(1999). RN [27] RP INTERACTION WITH SH2B2/APS. RX PubMed=9989826; DOI=10.1038/sj.onc.1202326; RA Yokouchi M., Wakioka T., Sakamoto H., Yasukawa H., Ohtsuka S., Sasaki A., RA Ohtsubo M., Valius M., Inoue A., Komiya S., Yoshimura A.; RT "APS, an adaptor protein containing PH and SH2 domains, is associated with RT the PDGF receptor and c-Cbl and inhibits PDGF-induced mitogenesis."; RL Oncogene 18:759-767(1999). RN [28] RP PHOSPHORYLATION AT TYR-562; TYR-751; TYR-763; TYR-771; TYR-775; TYR-778; RP TYR-857; TYR-1009 AND TYR-1021, AND DEPHOSPHORYLATION AT TYR-751; TYR-857; RP TYR-1009 AND TYR-1021 BY PTPRJ. RX PubMed=10821867; DOI=10.1074/jbc.275.21.16219; RA Kovalenko M., Denner K., Sandstrom J., Persson C., Gross S., Jandt E., RA Vilella R., Bohmer F., Ostman A.; RT "Site-selective dephosphorylation of the platelet-derived growth factor RT beta-receptor by the receptor-like protein-tyrosine phosphatase DEP-1."; RL J. Biol. Chem. 275:16219-16226(2000). RN [29] RP INTERACTION WITH PIK3C2B. RX PubMed=10805725; DOI=10.1128/mcb.20.11.3817-3830.2000; RA Arcaro A., Zvelebil M.J., Wallasch C., Ullrich A., Waterfield M.D., RA Domin J.; RT "Class II phosphoinositide 3-kinases are downstream targets of activated RT polypeptide growth factor receptors."; RL Mol. Cell. Biol. 20:3817-3830(2000). RN [30] RP FUNCTION AS A RECEPTOR FOR PDGFC, AND INTERACTION WITH PDGFC. RX PubMed=11297552; DOI=10.1074/jbc.m101056200; RA Gilbertson D.G., Duff M.E., West J.W., Kelly J.D., Sheppard P.O., RA Hofstrand P.D., Gao Z., Shoemaker K., Bukowski T.R., Moore M., RA Feldhaus A.L., Humes J.M., Palmer T.E., Hart C.E.; RT "Platelet-derived growth factor C (PDGF-C), a novel growth factor that RT binds to PDGF alpha and beta receptor."; RL J. Biol. Chem. 276:27406-27414(2001). RN [31] RP FUNCTION AS A RECEPTOR FOR PDGFD. RX PubMed=11331881; DOI=10.1038/35074588; RA Bergsten E., Uutela M., Li X., Pietras K., Oestman A., Heldin C.-H., RA Alitalo K., Eriksson U.; RT "PDGF-D is a specific, protease-activated ligand for the PDGF beta- RT receptor."; RL Nat. Cell Biol. 3:512-516(2001). RN [32] RP CHROMOSOMAL TRANSLOCATION WITH ETV6. RX PubMed=12181402; DOI=10.1056/nejmoa020150; RA Apperley J.F., Gardembas M., Melo J.V., Russell-Jones R., Bain B.J., RA Baxter E.J., Chase A., Chessells J.M., Colombat M., Dearden C.E., RA Dimitrijevic S., Mahon F.-X., Marin D., Nikolova Z., Olavarria E., RA Silberman S., Schultheis B., Cross N.C.P., Goldman J.M.; RT "Response to imatinib mesylate in patients with chronic myeloproliferative RT diseases with rearrangements of the platelet-derived growth factor receptor RT beta."; RL N. Engl. J. Med. 347:481-487(2002). RN [33] RP CHROMOSOMAL TRANSLOCATION WITH PDE4DIP. RX PubMed=12907457; DOI=10.1182/blood-2003-04-1150; RA Wilkinson K., Velloso E.R.P., Lopes L.F., Lee C., Aster J.C., Shipp M.A., RA Aguiar R.C.T.; RT "Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated RT with eosinophilia: involvement of PDGFRB and response to imatinib."; RL Blood 102:4187-4190(2003). RN [34] RP CHROMOSOMAL TRANSLOCATION WITH SPECC1. RX PubMed=15087372; DOI=10.1158/0008-5472.can-03-4026; RA Morerio C., Acquila M., Rosanda C., Rapella A., Dufour C., Locatelli F., RA Maserati E., Pasquali F., Panarello C.; RT "HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile myelomonocytic RT leukemia with t(5;17)(q33;p11.2)."; RL Cancer Res. 64:2649-2651(2004). RN [35] RP CHROMOSOMAL TRANSLOCATION WITH TP53BP1, AND ACTIVITY REGULATION. RX PubMed=15492236; DOI=10.1158/0008-5472.can-04-2005; RA Grand F.H., Burgstaller S., Kuhr T., Baxter E.J., Webersinke G., Thaler J., RA Chase A.J., Cross N.C.; RT "p53-Binding protein 1 is fused to the platelet-derived growth factor RT receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib- RT responsive eosinophilic myeloproliferative disorder."; RL Cancer Res. 64:7216-7219(2004). RN [36] RP PHOSPHORYLATION AT TYR-579; TYR-751; TYR-771 AND TYR-1021, AND RP DEPHOSPHORYLATION AT TYR-579 AND TYR-1021 BY PTPN2. RX PubMed=14966296; DOI=10.1128/mcb.24.5.2190-2201.2004; RA Persson C., Saevenhed C., Bourdeau A., Tremblay M.L., Markova B., RA Boehmer F.D., Haj F.G., Neel B.G., Elson A., Heldin C.H., Roennstrand L., RA Ostman A., Hellberg C.; RT "Site-selective regulation of platelet-derived growth factor beta receptor RT tyrosine phosphorylation by T-cell protein tyrosine phosphatase."; RL Mol. Cell. Biol. 24:2190-2201(2004). RN [37] RP PHOSPHORYLATION AT TYR-579; TYR-581; TYR-716; TYR-740; TYR-771; TYR-857; RP TYR-1009 AND TYR-1021. RX PubMed=15902258; DOI=10.1038/nature03587; RA Choi M.H., Lee I.K., Kim G.W., Kim B.U., Han Y.H., Yu D.Y., Park H.S., RA Kim K.Y., Lee J.S., Choi C., Bae Y.S., Lee B.I., Rhee S.G., Kang S.W.; RT "Regulation of PDGF signalling and vascular remodelling by peroxiredoxin RT II."; RL Nature 435:347-353(2005). RN [38] RP INTERACTION WITH CBL, SUBCELLULAR LOCATION, MUTAGENESIS OF TYR-1021, AND RP UBIQUITINATION. RX PubMed=17620338; DOI=10.1074/jbc.m701797200; RA Reddi A.L., Ying G., Duan L., Chen G., Dimri M., Douillard P., Druker B.J., RA Naramura M., Band V., Band H.; RT "Binding of Cbl to a phospholipase Cgamma1-docking site on platelet-derived RT growth factor receptor beta provides a dual mechanism of negative RT regulation."; RL J. Biol. Chem. 282:29336-29347(2007). RN [39] RP FUNCTION AS PDGFD RECEPTOR. RX PubMed=21098708; DOI=10.1158/0008-5472.can-10-0511; RA Ustach C.V., Huang W., Conley-LaComb M.K., Lin C.Y., Che M., Abrams J., RA Kim H.R.; RT "A novel signaling axis of matriptase/PDGF-D/ss-PDGFR in human prostate RT cancer."; RL Cancer Res. 70:9631-9640(2010). RN [40] RP FUNCTION IN PHOSPHORYLATION OF CBL; STAM; PDCD6IP/ALIX; PLCG1 AND PTPN11, RP CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, SUBCELLULAR LOCATION, AND RP MUTAGENESIS OF LYS-634 AND TYR-857. RX PubMed=20494825; DOI=10.1016/j.cellsig.2010.05.004; RA Wardega P., Heldin C.H., Lennartsson J.; RT "Mutation of tyrosine residue 857 in the PDGF beta-receptor affects cell RT proliferation but not migration."; RL Cell. Signal. 22:1363-1368(2010). RN [41] RP FUNCTION. RX PubMed=20529858; DOI=10.1074/jbc.m110.102566; RA Mendelson K., Swendeman S., Saftig P., Blobel C.P.; RT "Stimulation of platelet-derived growth factor receptor beta (PDGFRbeta) RT activates ADAM17 and promotes metalloproteinase-dependent cross-talk RT between the PDGFRbeta and epidermal growth factor receptor (EGFR) signaling RT pathways."; RL J. Biol. Chem. 285:25024-25032(2010). RN [42] RP FUNCTION IN SMOOTH MUSCLE CELL PROLIFERATION AND MIGRATION. RX PubMed=21733313; DOI=10.1017/s0007114511002571; RA Kim H.J., Cha B.Y., Choi B., Lim J.S., Woo J.T., Kim J.S.; RT "Glyceollins inhibit platelet-derived growth factor-mediated human arterial RT smooth muscle cell proliferation and migration."; RL Br. J. Nutr. 107:24-35(2012). RN [43] RP INTERACTION WITH SHC1 AND GRB2, AND FUNCTION IN PHOSPHORYLATION OF SHC1. RX PubMed=8195171; DOI=10.1016/s0021-9258(17)36611-5; RA Yokote K., Mori S., Hansen K., McGlade J., Pawson T., Heldin C.H., RA Claesson-Welsh L.; RT "Direct interaction between Shc and the platelet-derived growth factor RT beta-receptor."; RL J. Biol. Chem. 269:15337-15343(1994). RN [44] RP FUNCTION IN SMOOTH MUSCLE CELL MIGRATION AND NEOINTIMA FORMATION AFTER RP BLOOD VESSEL INJURY, AND MUTAGENESIS OF TYR-740; TYR-751 AND TYR-1021. RX PubMed=21679854; DOI=10.1016/j.jacc.2011.02.037; RA Caglayan E., Vantler M., Leppanen O., Gerhardt F., Mustafov L., RA Ten Freyhaus H., Kappert K., Odenthal M., Zimmermann W.H., Tallquist M.D., RA Rosenkranz S.; RT "Disruption of platelet-derived growth factor-dependent RT phosphatidylinositol 3-kinase and phospholipase Cgamma 1 activity abolishes RT vascular smooth muscle cell proliferation and migration and attenuates RT neointima formation in vivo."; RL J. Am. Coll. Cardiol. 57:2527-2538(2011). RN [45] RP INVOLVEMENT IN PENTT, VARIANT PENTT ALA-665, AND CHARACTERIZATION OF RP VARIANT PENTT ALA-665. RX PubMed=26279204; DOI=10.1016/j.ajhg.2015.07.009; RA Johnston J.J., Sanchez-Contreras M.Y., Keppler-Noreuil K.M., Sapp J., RA Crenshaw M., Finch N.A., Cormier-Daire V., Rademakers R., Sybert V.P., RA Biesecker L.G.; RT "A point mutation in PDGFRB causes autosomal-dominant Penttinen syndrome."; RL Am. J. Hum. Genet. 97:465-474(2015). RN [46] RP INVOLVEMENT IN KOGS, AND VARIANT KOGS ARG-584. RX PubMed=25454926; DOI=10.1016/j.jpeds.2014.10.015; RA Takenouchi T., Yamaguchi Y., Tanikawa A., Kosaki R., Okano H., Kosaki K.; RT "Novel overgrowth syndrome phenotype due to recurrent de novo PDGFRB RT mutation."; RL J. Pediatr. 166:483-486(2015). RN [47] RP CHARACTERIZATION OF VARIANTS IBGC4 PRO-658; TRP-987 AND VAL-1071, AND RP FUNCTION. RX PubMed=26599395; DOI=10.1371/journal.pone.0143407; RA Vanlandewijck M., Lebouvier T., Andaloussi Maee M., Nahar K., Hornemann S., RA Kenkel D., Cunha S.I., Lennartsson J., Boss A., Heldin C.H., Keller A., RA Betsholtz C.; RT "Functional characterization of germline mutations in PDGFB and PDGFRB in RT primary familial brain calcification."; RL PLoS ONE 10:E0143407-E0143407(2015). RN [48] RP REVIEW ON SIGNALING AND AUTOPHOSPHORYLATION. RX PubMed=9739761; DOI=10.1016/s0304-419x(98)00015-8; RA Heldin C.H., Ostman A., Ronnstrand L.; RT "Signal transduction via platelet-derived growth factor receptors."; RL Biochim. Biophys. Acta 1378:F79-113(1998). RN [49] RP REVIEW. RX PubMed=15207817; DOI=10.1016/j.cytogfr.2004.03.002; RA Ostman A.; RT "PDGF receptors-mediators of autocrine tumor growth and regulators of tumor RT vasculature and stroma."; RL Cytokine Growth Factor Rev. 15:275-286(2004). RN [50] RP REVIEW. RX PubMed=17419949; DOI=10.1016/s0065-230x(06)97011-0; RA Ostman A., Heldin C.H.; RT "PDGF receptors as targets in tumor treatment."; RL Adv. Cancer Res. 97:247-274(2007). RN [51] RP REVIEW ON FUNCTION; LIGANDS; ROLE IN DEVELOPMENT AND DISEASE AND ACTIVATION RP OF SIGNALING PATHWAYS. RX PubMed=18483217; DOI=10.1101/gad.1653708; RA Andrae J., Gallini R., Betsholtz C.; RT "Role of platelet-derived growth factors in physiology and medicine."; RL Genes Dev. 22:1276-1312(2008). RN [52] RP X-RAY CRYSTALLOGRAPHY (1.79 ANGSTROMS) OF 751-755 IN COMPLEX WITH PIK3R1, RP AND COMPARISON WITH NMR ANALYSIS. RX PubMed=11567151; DOI=10.1107/s0907444901012434; RA Pauptit R.A., Dennis C.A., Derbyshire D.J., Breeze A.L., Weston S.A., RA Rowsell S., Murshudov G.N.; RT "NMR trial models: experiences with the colicin immunity protein Im7 and RT the p85alpha C-terminal SH2-peptide complex."; RL Acta Crystallogr. D 57:1397-1404(2001). RN [53] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 1102-1106 IN COMPLEX WITH NHERF1, RP AND INTERACTION WITH NHERF1. RX PubMed=11882663; DOI=10.1074/jbc.m201507200; RA Karthikeyan S., Leung T., Ladias J.A.A.; RT "Structural determinants of the Na+/H+ exchanger regulatory factor RT interaction with the beta 2 adrenergic and platelet-derived growth factor RT receptors."; RL J. Biol. Chem. 277:18973-18978(2002). RN [54] RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 33-314 IN COMPLEX WITH PDGFB, RP SUBUNIT, GLYCOSYLATION AT ASN-45; ASN-89; ASN-103; ASN-215; ASN-230; RP ASN-292 AND ASN-307, AND DISULFIDE BONDS. RX PubMed=20534510; DOI=10.1073/pnas.1000806107; RA Shim A.H., Liu H., Focia P.J., Chen X., Lin P.C., He X.; RT "Structures of a platelet-derived growth factor/propeptide complex and a RT platelet-derived growth factor/receptor complex."; RL Proc. Natl. Acad. Sci. U.S.A. 107:11307-11312(2010). RN [55] RP VARIANTS [LARGE SCALE ANALYSIS] PHE-29; LYS-282; LYS-485; HIS-589; TYR-718 RP AND ILE-882. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [56] RP VARIANT IMF1 THR-660, AND INVOLVEMENT IN IMF1. RX PubMed=23731542; DOI=10.1016/j.ajhg.2013.04.024; RA Martignetti J.A., Tian L., Li D., Ramirez M.C., Camacho-Vanegas O., RA Camacho S.C., Guo Y., Zand D.J., Bernstein A.M., Masur S.K., Kim C.E., RA Otieno F.G., Hou C., Abdel-Magid N., Tweddale B., Metry D., Fournet J.C., RA Papp E., McPherson E.W., Zabel C., Vaksmann G., Morisot C., Keating B., RA Sleiman P.M., Cleveland J.A., Everman D.B., Zackai E., Hakonarson H.; RT "Mutations in PDGFRB cause autosomal-dominant infantile myofibromatosis."; RL Am. J. Hum. Genet. 92:1001-1007(2013). RN [57] RP VARIANT IMF1 CYS-561, AND INVOLVEMENT IN IMF1. RX PubMed=23731537; DOI=10.1016/j.ajhg.2013.04.026; RA Cheung Y.H., Gayden T., Campeau P.M., Leduc C.A., Russo D., Nguyen V.H., RA Guo J., Qi M., Guan Y., Albrecht S., Moroz B., Eldin K.W., Lu J.T., RA Schwartzentruber J., Malkin D., Berghuis A.M., Emil S., Gibbs R.A., RA Burk D.L., Vanstone M., Lee B.H., Orchard D., Boycott K.M., Chung W.K., RA Jabado N.; RT "A recurrent PDGFRB mutation causes familial infantile myofibromatosis."; RL Am. J. Hum. Genet. 92:996-1000(2013). RN [58] RP VARIANTS IBGC4 PRO-658; TRP-987 AND VAL-1071, AND INVOLVEMENT IN IBGC4. RX PubMed=24065723; DOI=10.1093/brain/awt255; RG French IBGC Study Group; RA Nicolas G., Pottier C., Charbonnier C., Guyant-Marechal L., Le Ber I., RA Pariente J., Labauge P., Ayrignac X., Defebvre L., Maltete D., RA Martinaud O., Lefaucheur R., Guillin O., Wallon D., Chaumette B., RA Rondepierre P., Derache N., Fromager G., Schaeffer S., Krystkowiak P., RA Verny C., Jurici S., Sauvee M., Verin M., Lebouvier T., Rouaud O., RA Thauvin-Robinet C., Rousseau S., Rovelet-Lecrux A., Frebourg T., RA Campion D., Hannequin D.; RT "Phenotypic spectrum of probable and genetically-confirmed idiopathic basal RT ganglia calcification."; RL Brain 136:3395-3407(2013). RN [59] RP VARIANTS IBGC4 PRO-658 AND TRP-987, AND INVOLVEMENT IN IBGC4. RX PubMed=23255827; DOI=10.1212/wnl.0b013e31827ccf34; RA Nicolas G., Pottier C., Maltete D., Coutant S., Rovelet-Lecrux A., RA Legallic S., Rousseau S., Vaschalde Y., Guyant-Marechal L., Augustin J., RA Martinaud O., Defebvre L., Krystkowiak P., Pariente J., Clanet M., RA Labauge P., Ayrignac X., Lefaucheur R., Le Ber I., Frebourg T., RA Hannequin D., Campion D.; RT "Mutation of the PDGFRB gene as a cause of idiopathic basal ganglia RT calcification."; RL Neurology 80:181-187(2013). RN [60] RP VARIANT PENTT SER-666, CHARACTERIZATION OF VARIANT PENTT SER-666, AND RP INVOLVEMENT IN PENTT. RX PubMed=30573803; DOI=10.1038/s41431-018-0323-z; RA Bredrup C., Stokowy T., McGaughran J., Lee S., Sapkota D., Cristea I., RA Xu L., Tveit K.S., Hoevding G., Steen V.M., Roedahl E., Bruland O., RA Houge G.; RT "A tyrosine kinase-activating variant Asn666Ser in PDGFRB causes a RT progeria-like condition in the severe end of Penttinen syndrome."; RL Eur. J. Hum. Genet. 27:574-581(2019). RN [61] RP VARIANT OPDKD TYR-666, CHARACTERIZATION OF VARIANT OPDKD TYR-666, AND RP INVOLVEMENT IN OPDKD. RX PubMed=33450762; DOI=10.1093/hmg/ddab014; RA Bredrup C., Cristea I., Safieh L.A., Di Maria E., Gjertsen B.T., RA Tveit K.S., Thu F., Bull N., Edward D.P., Hennekam R.C.M., Hoevding G., RA Haugen O.H., Houge G., Roedahl E., Bruland O.; RT "Temperature-dependent autoactivation associated with clinical variability RT of PDGFRB Asn666 substitutions."; RL Hum. Mol. Genet. 30:72-77(2021). CC -!- FUNCTION: Tyrosine-protein kinase that acts as a cell-surface receptor CC for homodimeric PDGFB and PDGFD and for heterodimers formed by PDGFA CC and PDGFB, and plays an essential role in the regulation of embryonic CC development, cell proliferation, survival, differentiation, chemotaxis CC and migration. Plays an essential role in blood vessel development by CC promoting proliferation, migration and recruitment of pericytes and CC smooth muscle cells to endothelial cells. Plays a role in the migration CC of vascular smooth muscle cells and the formation of neointima at CC vascular injury sites. Required for normal development of the CC cardiovascular system. Required for normal recruitment of pericytes CC (mesangial cells) in the kidney glomerulus, and for normal formation of CC a branched network of capillaries in kidney glomeruli. Promotes CC rearrangement of the actin cytoskeleton and the formation of membrane CC ruffles. Binding of its cognate ligands - homodimeric PDGFB, CC heterodimers formed by PDGFA and PDGFB or homodimeric PDGFD -leads to CC the activation of several signaling cascades; the response depends on CC the nature of the bound ligand and is modulated by the formation of CC heterodimers between PDGFRA and PDGFRB. Phosphorylates PLCG1, PIK3R1, CC PTPN11, RASA1/GAP, CBL, SHC1 and NCK1. Activation of PLCG1 leads to the CC production of the cellular signaling molecules diacylglycerol and CC inositol 1,4,5-trisphosphate, mobilization of cytosolic Ca(2+) and the CC activation of protein kinase C. Phosphorylation of PIK3R1, the CC regulatory subunit of phosphatidylinositol 3-kinase, leads to the CC activation of the AKT1 signaling pathway. Phosphorylation of SHC1, or CC of the C-terminus of PTPN11, creates a binding site for GRB2, resulting CC in the activation of HRAS, RAF1 and down-stream MAP kinases, including CC MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation and activation CC of SRC family kinases. Promotes phosphorylation of PDCD6IP/ALIX and CC STAM. Receptor signaling is down-regulated by protein phosphatases that CC dephosphorylate the receptor and its down-stream effectors, and by CC rapid internalization of the activated receptor. CC {ECO:0000269|PubMed:11297552, ECO:0000269|PubMed:11331881, CC ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1396585, CC ECO:0000269|PubMed:1653029, ECO:0000269|PubMed:1709159, CC ECO:0000269|PubMed:1846866, ECO:0000269|PubMed:20494825, CC ECO:0000269|PubMed:20529858, ECO:0000269|PubMed:21098708, CC ECO:0000269|PubMed:21679854, ECO:0000269|PubMed:21733313, CC ECO:0000269|PubMed:2554309, ECO:0000269|PubMed:26599395, CC ECO:0000269|PubMed:2835772, ECO:0000269|PubMed:2850496, CC ECO:0000269|PubMed:7685273, ECO:0000269|PubMed:7691811, CC ECO:0000269|PubMed:7692233, ECO:0000269|PubMed:8195171}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:1846866, ECO:0000269|PubMed:20494825, CC ECO:0000269|PubMed:7685273}; CC -!- ACTIVITY REGULATION: Present in an inactive conformation in the absence CC of bound ligand. Binding of PDGFB and/or PDGFD leads to dimerization CC and activation by autophosphorylation on tyrosine residues. Inhibited CC by imatinib. {ECO:0000269|PubMed:15492236}. CC -!- SUBUNIT: Interacts with homodimeric PDGFB and PDGFD, and with CC heterodimers formed by PDGFA and PDGFB. May also interact with CC homodimeric PDGFC. Monomer in the absence of bound ligand. Interaction CC with homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or CC homodimeric PDGFD, leads to receptor dimerization, where both PDGFRA CC homodimers and heterodimers with PDGFRB are observed. Interacts with CC SH2B2/APS. Interacts directly (tyrosine phosphorylated) with SHB. CC Interacts (tyrosine phosphorylated) with PIK3R1 and RASA1. Interacts CC (tyrosine phosphorylated) with CBL. Interacts (tyrosine phosphorylated) CC with SRC and SRC family kinases. Interacts (tyrosine phosphorylated) CC with PIK3C2B, maybe indirectly. Interacts (tyrosine phosphorylated) CC with SHC1, GRB7, GRB10 and NCK1. Interaction with GRB2 is mediated by CC SHC1. Interacts (via C-terminus) with NHERF1. CC {ECO:0000269|PubMed:10454568, ECO:0000269|PubMed:10805725, CC ECO:0000269|PubMed:11297552, ECO:0000269|PubMed:11567151, CC ECO:0000269|PubMed:11882663, ECO:0000269|PubMed:1314164, CC ECO:0000269|PubMed:1375321, ECO:0000269|PubMed:1396585, CC ECO:0000269|PubMed:1709159, ECO:0000269|PubMed:17620338, CC ECO:0000269|PubMed:20534510, ECO:0000269|PubMed:2835772, CC ECO:0000269|PubMed:2850496, ECO:0000269|PubMed:7679113, CC ECO:0000269|PubMed:7691811, ECO:0000269|PubMed:7692233, CC ECO:0000269|PubMed:8195171, ECO:0000269|PubMed:8302579, CC ECO:0000269|PubMed:8940081, ECO:0000269|PubMed:9989826}. CC -!- INTERACTION: CC P09619; P05067: APP; NbExp=3; IntAct=EBI-641237, EBI-77613; CC P09619; Q8TAP6: CEP76; NbExp=3; IntAct=EBI-641237, EBI-742887; CC P09619; P06241: FYN; NbExp=3; IntAct=EBI-641237, EBI-515315; CC P09619; Q14451: GRB7; NbExp=4; IntAct=EBI-641237, EBI-970191; CC P09619; P14778: IL1R1; NbExp=2; IntAct=EBI-641237, EBI-525905; CC P09619; P35968: KDR; NbExp=2; IntAct=EBI-641237, EBI-1005487; CC P09619; Q53G59: KLHL12; NbExp=6; IntAct=EBI-641237, EBI-740929; CC P09619; Q5T749: KPRP; NbExp=3; IntAct=EBI-641237, EBI-10981970; CC P09619; Q15323: KRT31; NbExp=3; IntAct=EBI-641237, EBI-948001; CC P09619; O76011: KRT34; NbExp=3; IntAct=EBI-641237, EBI-1047093; CC P09619; P60411: KRTAP10-9; NbExp=3; IntAct=EBI-641237, EBI-10172052; CC P09619; P60328: KRTAP12-3; NbExp=3; IntAct=EBI-641237, EBI-11953334; CC P09619; O94898: LRIG2; NbExp=3; IntAct=EBI-641237, EBI-2830372; CC P09619; O75581: LRP6; NbExp=3; IntAct=EBI-641237, EBI-910915; CC P09619; O14745: NHERF1; NbExp=5; IntAct=EBI-641237, EBI-349787; CC P09619; Q15599: NHERF2; NbExp=2; IntAct=EBI-641237, EBI-1149760; CC P09619; P01127: PDGFB; NbExp=16; IntAct=EBI-641237, EBI-1554925; CC P09619; P27986: PIK3R1; NbExp=21; IntAct=EBI-641237, EBI-79464; CC P09619; O00459: PIK3R2; NbExp=3; IntAct=EBI-641237, EBI-346930; CC P09619; P19174: PLCG1; NbExp=7; IntAct=EBI-641237, EBI-79387; CC P09619; P60484: PTEN; NbExp=3; IntAct=EBI-641237, EBI-696162; CC P09619; P18031: PTPN1; NbExp=3; IntAct=EBI-641237, EBI-968788; CC P09619; Q06124: PTPN11; NbExp=8; IntAct=EBI-641237, EBI-297779; CC P09619; Q05209: PTPN12; NbExp=3; IntAct=EBI-641237, EBI-2266035; CC P09619; P23470: PTPRG; NbExp=2; IntAct=EBI-641237, EBI-2258115; CC P09619; Q12913: PTPRJ; NbExp=4; IntAct=EBI-641237, EBI-2264500; CC P09619; P20936: RASA1; NbExp=3; IntAct=EBI-641237, EBI-1026476; CC P09619; Q13239: SLA; NbExp=4; IntAct=EBI-641237, EBI-726214; CC P09619; Q15654: TRIP6; NbExp=3; IntAct=EBI-641237, EBI-742327; CC P09619; P07947: YES1; NbExp=3; IntAct=EBI-641237, EBI-515331; CC P09619; P0CK45: E5; Xeno; NbExp=2; IntAct=EBI-641237, EBI-7015490; CC P09619; P35918: Kdr; Xeno; NbExp=4; IntAct=EBI-641237, EBI-1555005; CC P09619; Q28619: NHERF1; Xeno; NbExp=3; IntAct=EBI-641237, EBI-7073613; CC P09619; P23727: PIK3R1; Xeno; NbExp=6; IntAct=EBI-641237, EBI-520244; CC P09619; P08487: PLCG1; Xeno; NbExp=3; IntAct=EBI-641237, EBI-8013886; CC P09619; P41499: Ptpn11; Xeno; NbExp=4; IntAct=EBI-641237, EBI-7180604; CC P09619; P25020: V-SRC; Xeno; NbExp=4; IntAct=EBI-641237, EBI-8636140; CC -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane CC protein. Cytoplasmic vesicle. Lysosome lumen. Note=After ligand CC binding, the autophosphorylated receptor is ubiquitinated and CC internalized, leading to its degradation. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P09619-1; Sequence=Displayed; CC Name=2; CC IsoId=P09619-2; Sequence=VSP_056008, VSP_056009; CC -!- PTM: Autophosphorylated on tyrosine residues upon ligand binding. CC Autophosphorylation occurs in trans, i.e. one subunit of the dimeric CC receptor phosphorylates tyrosine residues on the other subunit. CC Phosphorylation at Tyr-579, and to a lesser degree, at Tyr-581, is CC important for interaction with SRC family kinases. Phosphorylation at CC Tyr-740 and Tyr-751 is important for interaction with PIK3R1. CC Phosphorylation at Tyr-751 is important for interaction with NCK1. CC Phosphorylation at Tyr-771 and Tyr-857 is important for interaction CC with RASA1/GAP. Phosphorylation at Tyr-857 is important for efficient CC phosphorylation of PLCG1 and PTPN11, resulting in increased CC phosphorylation of AKT1, MAPK1/ERK2 and/or MAPK3/ERK1, PDCD6IP/ALIX and CC STAM, and in increased cell proliferation. Phosphorylation at Tyr-1009 CC is important for interaction with PTPN11. Phosphorylation at Tyr-1009 CC and Tyr-1021 is important for interaction with PLCG1. Phosphorylation CC at Tyr-1021 is important for interaction with CBL; PLCG1 and CBL CC compete for the same binding site. Dephosphorylated by PTPRJ at Tyr- CC 751, Tyr-857, Tyr-1009 and Tyr-1021. Dephosphorylated by PTPN2 at Tyr- CC 579 and Tyr-1021. {ECO:0000269|PubMed:10821867, CC ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1396585, CC ECO:0000269|PubMed:14966296, ECO:0000269|PubMed:15902258, CC ECO:0000269|PubMed:1709159, ECO:0000269|PubMed:2550144, CC ECO:0000269|PubMed:7685273}. CC -!- PTM: N-glycosylated. {ECO:0000269|PubMed:20534510, CC ECO:0000269|PubMed:2850496}. CC -!- PTM: Ubiquitinated. After autophosphorylation, the receptor is CC polyubiquitinated, leading to its degradation. CC {ECO:0000269|PubMed:1313434, ECO:0000269|PubMed:17620338}. CC -!- DISEASE: Note=A chromosomal aberration involving PDGFRB is found in a CC form of chronic myelomonocytic leukemia (CMML). Translocation CC t(5;12)(q33;p13) with EVT6/TEL. It is characterized by abnormal clonal CC myeloid proliferation and by progression to acute myelogenous leukemia CC (AML). CC -!- DISEASE: Myeloproliferative disorder chronic with eosinophilia (MPE) CC [MIM:131440]: A hematologic disorder characterized by malignant CC eosinophils proliferation. Note=The gene represented in this entry may CC be involved in disease pathogenesis. Chromosomal aberrations involving CC PDGFRB have been found in many instances of chronic myeloproliferative CC disorder with eosinophilia. Translocation t(5;12) with ETV6 on CC chromosome 12 creating an PDGFRB-ETV6 fusion protein (PubMed:12181402). CC Translocation t(5;15)(q33;q22) with TP53BP1 creating a PDGFRB-TP53BP1 CC fusion protein (PubMed:15492236). Translocation t(1;5)(q23;q33) that CC forms a PDE4DIP-PDGFRB fusion protein (PubMed:12907457). Translocation CC t(5;6)(q33-34;q23) with CEP85L that fuses the 5'-end of CEP85L (isoform CC 4) to the 3'-end of PDGFRB (PubMed:21938754). CC {ECO:0000269|PubMed:12181402, ECO:0000269|PubMed:12907457, CC ECO:0000269|PubMed:15492236, ECO:0000269|PubMed:21938754}. CC -!- DISEASE: Leukemia, acute myelogenous (AML) [MIM:601626]: A subtype of CC acute leukemia, a cancer of the white blood cells. AML is a malignant CC disease of bone marrow characterized by maturational arrest of CC hematopoietic precursors at an early stage of development. Clonal CC expansion of myeloid blasts occurs in bone marrow, blood, and other CC tissue. Myelogenous leukemias develop from changes in cells that CC normally produce neutrophils, basophils, eosinophils and monocytes. CC Note=The gene represented in this entry may be involved in disease CC pathogenesis. A chromosomal aberration involving PDGFRB has been found CC in a patient with AML. Translocation t(5;14)(q33;q32) with TRIP11 CC (PubMed:9373237). {ECO:0000269|PubMed:9373237}. CC -!- DISEASE: Leukemia, juvenile myelomonocytic (JMML) [MIM:607785]: An CC aggressive pediatric myelodysplastic syndrome/myeloproliferative CC disorder characterized by malignant transformation in the hematopoietic CC stem cell compartment with proliferation of differentiated progeny. CC Patients have splenomegaly, enlarged lymph nodes, rashes, and CC hemorrhages. Note=The gene represented in this entry may be involved in CC disease pathogenesis. A chromosomal aberration involving PDGFRB has CC been found in a patient with JMML. Translocation t(5;17)(q33;p11.2) CC with SPECC1 (PubMed:15087372). {ECO:0000269|PubMed:15087372}. CC -!- DISEASE: Basal ganglia calcification, idiopathic, 4 (IBGC4) CC [MIM:615007]: A form of basal ganglia calcification, an autosomal CC dominant condition characterized by symmetric calcification in the CC basal ganglia and other brain regions. Affected individuals can either CC be asymptomatic or show a wide spectrum of neuropsychiatric symptoms, CC including parkinsonism, dystonia, tremor, ataxia, dementia, psychosis, CC seizures, and chronic headache. Serum levels of calcium, phosphate, CC alkaline phosphatase and parathyroid hormone are normal. The CC neuropathological hallmark of the disease is vascular and pericapillary CC calcification, mainly of calcium phosphate, in the affected brain CC areas. {ECO:0000269|PubMed:23255827, ECO:0000269|PubMed:24065723, CC ECO:0000269|PubMed:26599395}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Myofibromatosis, infantile 1 (IMF1) [MIM:228550]: A rare CC mesenchymal disorder characterized by the development of benign tumors CC in the skin, striated muscles, bones, and, more rarely, visceral CC organs. Subcutaneous or soft tissue nodules commonly involve the skin CC of the head, neck, and trunk. Skeletal and muscular lesions occur in CC about half of the patients. Lesions may be solitary or multicentric, CC and they may be present at birth or become apparent in early infancy or CC occasionally in adult life. Visceral lesions are associated with high CC morbidity and mortality. {ECO:0000269|PubMed:23731537, CC ECO:0000269|PubMed:23731542}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Kosaki overgrowth syndrome (KOGS) [MIM:616592]: A syndrome CC characterized by somatic overgrowth, distinctive facial features, CC hyperelastic and fragile skin, and progressive neurologic deterioration CC with white matter lesions on brain imaging. CC {ECO:0000269|PubMed:25454926}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Premature aging syndrome, Penttinen type (PENTT) [MIM:601812]: CC An autosomal dominant syndrome characterized by a prematurely aged CC appearance with lipoatrophy, epidermal and dermal atrophy along with CC hypertrophic lesions that resemble scars, thin hair, proptosis, CC underdeveloped cheekbones, and marked acro-osteolysis. CC {ECO:0000269|PubMed:26279204, ECO:0000269|PubMed:30573803}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Ocular pterygium-digital keloid dysplasia syndrome (OPDKD) CC [MIM:621091]: An autosomal dominant disorder that presents in childhood CC with aggressive ingrowth of vascularized connective tissue on the CC cornea, ultimately leading to loss of vision. Later, affected CC individuals develop keloids on digits after minor trauma, but are CC otherwise healthy. {ECO:0000269|PubMed:33450762}. Note=The disease may CC be caused by variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. CSF-1/PDGF receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/21/PDGFRB"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; J03278; AAA60049.1; -; mRNA. DR EMBL; M21616; AAA36427.1; -; mRNA. DR EMBL; EU826595; ACF47631.1; -; mRNA. DR EMBL; AC005895; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC011382; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC032224; AAH32224.1; -; mRNA. DR EMBL; U33172; AAC51675.1; -; Genomic_DNA. DR CCDS; CCDS4303.1; -. [P09619-1] DR PIR; A28206; PFHUGB. DR RefSeq; NP_002600.1; NM_002609.4. [P09619-1] DR PDB; 1GQ5; X-ray; 2.20 A; A=1102-1106. DR PDB; 1H9O; X-ray; 1.79 A; B=751-755. DR PDB; 1SHA; X-ray; 1.50 A; B=751-755. DR PDB; 2IUI; X-ray; 2.40 A; C/D=748-758. DR PDB; 2L6W; NMR; -; A/B=526-563. DR PDB; 2PLD; NMR; -; B=1018-1029. DR PDB; 2PLE; NMR; -; B=1018-1029. DR PDB; 3MJG; X-ray; 2.30 A; X/Y=33-314. DR PDBsum; 1GQ5; -. DR PDBsum; 1H9O; -. DR PDBsum; 1SHA; -. DR PDBsum; 2IUI; -. DR PDBsum; 2L6W; -. DR PDBsum; 2PLD; -. DR PDBsum; 2PLE; -. DR PDBsum; 3MJG; -. DR AlphaFoldDB; P09619; -. DR BMRB; P09619; -. DR EMDB; EMD-6426; -. DR SMR; P09619; -. DR BioGRID; 111185; 211. DR ComplexPortal; CPX-2882; PDGF receptor beta - PDGF-BB complex. DR ComplexPortal; CPX-2883; PDGF receptor alpha-beta - PDGF-BB complex. DR ComplexPortal; CPX-2886; PDGF receptor beta - PDGF-AB complex. DR ComplexPortal; CPX-2888; PDGF receptor alpha-beta - PDGF-CC complex. DR ComplexPortal; CPX-2889; PDGF receptor beta - PDGF-DD complex. DR ComplexPortal; CPX-2890; PDGF receptor alpha-beta - PDGF-DD complex. DR ComplexPortal; CPX-2891; PDGF receptor beta - PDGF-CC complex. DR ComplexPortal; CPX-2892; PDGF receptor alpha-beta - PDGF-AB complex. DR CORUM; P09619; -. DR DIP; DIP-558N; -. DR FunCoup; P09619; 1764. DR IntAct; P09619; 390. DR MINT; P09619; -. DR STRING; 9606.ENSP00000261799; -. DR BindingDB; P09619; -. DR ChEMBL; CHEMBL1913; -. DR DrugBank; DB00102; Becaplermin. DR DrugBank; DB01254; Dasatinib. DR DrugBank; DB12147; Erdafitinib. DR DrugBank; DB11741; Famitinib. DR DrugBank; DB10770; Foreskin fibroblast (neonatal). DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB00619; Imatinib. DR DrugBank; DB11845; Lucitanib. DR DrugBank; DB06595; Midostaurin. DR DrugBank; DB09079; Nintedanib. DR DrugBank; DB06589; Pazopanib. DR DrugBank; DB08339; PD-166326. DR DrugBank; DB17041; PD-173952. DR DrugBank; DB02567; PD173955. DR DrugBank; DB12978; Pexidartinib. DR DrugBank; DB09221; Polaprezinc. DR DrugBank; DB15822; Pralsetinib. DR DrugBank; DB08896; Regorafenib. DR DrugBank; DB14840; Ripretinib. DR DrugBank; DB06436; Semaxanib. DR DrugBank; DB00398; Sorafenib. DR DrugBank; DB08009; SU-11652. DR DrugBank; DB01268; Sunitinib. DR DrugBank; DB13093; TAK-593. DR DrugBank; DB11800; Tivozanib. DR DrugBank; DB09283; Trapidil. DR DrugBank; DB05146; XL820. DR DrugBank; DB05014; XL999. DR DrugCentral; P09619; -. DR GuidetoPHARMACOLOGY; 1804; -. DR TCDB; 8.A.23.1.37; the basigin (basigin) family. DR GlyConnect; 1967; 4 N-Linked glycans (3 sites). DR GlyCosmos; P09619; 11 sites, 4 glycans. DR GlyGen; P09619; 13 sites, 4 N-linked glycans (3 sites), 1 O-linked glycan (1 site). DR iPTMnet; P09619; -. DR PhosphoSitePlus; P09619; -. DR BioMuta; PDGFRB; -. DR DMDM; 129890; -. DR CPTAC; CPTAC-1630; -. DR CPTAC; CPTAC-3063; -. DR jPOST; P09619; -. DR MassIVE; P09619; -. DR PaxDb; 9606-ENSP00000261799; -. DR PeptideAtlas; P09619; -. DR ProteomicsDB; 52253; -. [P09619-1] DR Pumba; P09619; -. DR ABCD; P09619; 7 sequenced antibodies. DR Antibodypedia; 3424; 2244 antibodies from 49 providers. DR DNASU; 5159; -. DR Ensembl; ENST00000261799.9; ENSP00000261799.4; ENSG00000113721.15. [P09619-1] DR GeneID; 5159; -. DR KEGG; hsa:5159; -. DR MANE-Select; ENST00000261799.9; ENSP00000261799.4; NM_002609.4; NP_002600.1. DR UCSC; uc003lro.4; human. [P09619-1] DR AGR; HGNC:8804; -. DR CIViC; 5159; 2 evidence items across 3 molecular profiles. DR ClinPGx; PA33148; -. DR CTD; 5159; -. DR DisGeNET; 5159; -. DR GeneCards; PDGFRB; -. DR GeneReviews; PDGFRB; -. DR HGNC; HGNC:8804; PDGFRB. DR HPA; ENSG00000113721; Low tissue specificity. DR MalaCards; PDGFRB; -. DR MIM; 131440; phenotype. DR MIM; 173410; gene. DR MIM; 228550; phenotype. DR MIM; 601626; phenotype. DR MIM; 601812; phenotype. DR MIM; 607785; phenotype. DR MIM; 615007; phenotype. DR MIM; 616592; phenotype. DR MIM; 621091; phenotype. DR OpenTargets; ENSG00000113721; -. DR Orphanet; 363665; Acroosteolysis-keloid-like lesions-premature aging syndrome. DR Orphanet; 1980; Bilateral striopallidodentate calcinosis. DR Orphanet; 86830; Chronic myeloproliferative disease, unclassifiable. DR Orphanet; 2591; Infantile myofibromatosis. DR Orphanet; 477831; Kosaki overgrowth syndrome. DR Orphanet; 168950; Myeloid/lymphoid neoplasm associated with PDGFRB rearrangement. DR Orphanet; 314950; Primary hypereosinophilic syndrome. DR VEuPathDB; HostDB:ENSG00000113721; -. DR eggNOG; KOG0200; Eukaryota. DR GeneTree; ENSGT00940000157138; -. DR HOGENOM; CLU_000288_49_0_1; -. DR InParanoid; P09619; -. DR OMA; WPEDQEF; -. DR OrthoDB; 9936425at2759; -. DR PAN-GO; P09619; 10 GO annotations based on evolutionary models. DR PhylomeDB; P09619; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P09619; -. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-186763; Downstream signal transduction. DR Reactome; R-HSA-186797; Signaling by PDGF. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR SignaLink; P09619; -. DR SIGNOR; P09619; -. DR Agora; ENSG00000113721; -. DR BioGRID-ORCS; 5159; 18 hits in 1194 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; PDGFRB; human. DR EvolutionaryTrace; P09619; -. DR GeneWiki; PDGFRB; -. DR GenomeRNAi; 5159; -. DR Pharos; P09619; Tclin. DR PRO; PR:P09619; -. DR Proteomes; UP000005640; Chromosome 5. DR RNAct; P09619; protein. DR Bgee; ENSG00000113721; Expressed in stromal cell of endometrium and 182 other cell types or tissues. DR ExpressionAtlas; P09619; baseline and differential. DR GO; GO:0016324; C:apical plasma membrane; ISS:UniProtKB. DR GO; GO:0005737; C:cytoplasm; ISS:UniProtKB. DR GO; GO:0031410; C:cytoplasmic vesicle; IEA:UniProtKB-SubCell. DR GO; GO:0005925; C:focal adhesion; HDA:UniProtKB. DR GO; GO:0005794; C:Golgi apparatus; IDA:HPA. DR GO; GO:0043202; C:lysosomal lumen; IEA:UniProtKB-SubCell. DR GO; GO:0016020; C:membrane; IDA:BHF-UCL. DR GO; GO:0005634; C:nucleus; ISS:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0043235; C:receptor complex; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL. DR GO; GO:0005096; F:GTPase activator activity; IMP:UniProtKB. DR GO; GO:0160185; F:phospholipase C activator activity; IMP:UniProtKB. DR GO; GO:0004992; F:platelet activating factor receptor activity; TAS:ProtInc. DR GO; GO:0005019; F:platelet-derived growth factor beta-receptor activity; IDA:UniProtKB. DR GO; GO:0048407; F:platelet-derived growth factor binding; IDA:UniProtKB. DR GO; GO:0005017; F:platelet-derived growth factor receptor activity; TAS:ProtInc. DR GO; GO:0005161; F:platelet-derived growth factor receptor binding; IPI:BHF-UCL. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0005102; F:signaling receptor binding; IPI:UniProtKB. DR GO; GO:0038085; F:vascular endothelial growth factor binding; IPI:BHF-UCL. DR GO; GO:0001525; P:angiogenesis; IBA:GO_Central. DR GO; GO:0035909; P:aorta morphogenesis; ISS:BHF-UCL. DR GO; GO:0055003; P:cardiac myofibril assembly; ISS:UniProtKB. DR GO; GO:0060326; P:cell chemotaxis; IDA:UniProtKB. DR GO; GO:0060981; P:cell migration involved in coronary angiogenesis; ISS:UniProtKB. DR GO; GO:0035441; P:cell migration involved in vasculogenesis; ISS:UniProtKB. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IBA:GO_Central. DR GO; GO:0072277; P:metanephric glomerular capillary formation; ISS:UniProtKB. DR GO; GO:0072262; P:metanephric glomerular mesangial cell proliferation involved in metanephros development; ISS:UniProtKB. DR GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB. DR GO; GO:0048008; P:platelet-derived growth factor receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0035791; P:platelet-derived growth factor receptor-beta signaling pathway; IMP:UniProtKB. DR GO; GO:0090280; P:positive regulation of calcium ion import; ISS:UniProtKB. DR GO; GO:0050850; P:positive regulation of calcium-mediated signaling; IMP:UniProtKB. DR GO; GO:0030335; P:positive regulation of cell migration; IDA:BHF-UCL. DR GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:UniProtKB. DR GO; GO:0038091; P:positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway; IDA:BHF-UCL. DR GO; GO:0050921; P:positive regulation of chemotaxis; ISS:UniProtKB. DR GO; GO:2000573; P:positive regulation of DNA biosynthetic process; ISS:UniProtKB. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB. DR GO; GO:0043406; P:positive regulation of MAP kinase activity; ISS:UniProtKB. DR GO; GO:0035793; P:positive regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathway; ISS:UniProtKB. DR GO; GO:0045840; P:positive regulation of mitotic nuclear division; ISS:UniProtKB. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:UniProtKB. DR GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; ISS:UniProtKB. DR GO; GO:0014911; P:positive regulation of smooth muscle cell migration; IMP:UniProtKB. DR GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IMP:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0032956; P:regulation of actin cytoskeleton organization; ISS:BHF-UCL. DR GO; GO:0061298; P:retina vasculature development in camera-type eye; ISS:UniProtKB. DR GO; GO:0007165; P:signal transduction; IDA:UniProtKB. DR GO; GO:0014805; P:smooth muscle adaptation; NAS:BHF-UCL. DR GO; GO:0071670; P:smooth muscle cell chemotaxis; ISS:BHF-UCL. DR CDD; cd00096; Ig; 1. DR CDD; cd05859; Ig4_PDGFR; 1. DR CDD; cd05861; IgI_PDGFR-alphabeta; 1. DR CDD; cd05107; PTKc_PDGFR_beta; 1. DR FunFam; 3.30.200.20:FF:000025; Platelet-derived growth factor receptor alpha; 1. DR FunFam; 1.10.510.10:FF:000140; Platelet-derived growth factor receptor beta; 1. DR FunFam; 2.60.40.10:FF:000223; Platelet-derived growth factor receptor beta; 1. DR FunFam; 2.60.40.10:FF:000572; Platelet-derived growth factor receptor beta; 1. DR FunFam; 2.60.40.10:FF:000715; Platelet-derived growth factor receptor beta; 1. DR FunFam; 2.60.40.10:FF:000814; Platelet-derived growth factor receptor beta; 1. DR FunFam; 2.60.40.10:FF:000982; Platelet-derived growth factor receptor beta; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 5. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR013151; Immunoglobulin_dom. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR027288; PGFRB. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR001824; Tyr_kinase_rcpt_3_CS. DR PANTHER; PTHR24416:SF53; PLATELET-DERIVED GROWTH FACTOR RECEPTOR BETA; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF00047; ig; 1. DR Pfam; PF13927; Ig_3; 1. DR Pfam; PF25305; Ig_PDGFR_d4; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PIRSF; PIRSF500948; Beta-PDGF_receptor; 1. DR PIRSF; PIRSF000615; TyrPK_CSF1-R; 1. DR PRINTS; PR01832; VEGFRECEPTOR. DR SMART; SM00409; IG; 3. DR SMART; SM00408; IGc2; 3. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF48726; Immunoglobulin; 3. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50835; IG_LIKE; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell membrane; Chemotaxis; KW Chromosomal rearrangement; Cytoplasmic vesicle; Developmental protein; KW Direct protein sequencing; Disease variant; Disulfide bond; Glycoprotein; KW Immunoglobulin domain; Kinase; Lysosome; Membrane; Nucleotide-binding; KW Phosphoprotein; Proteomics identification; Proto-oncogene; Receptor; KW Reference proteome; Repeat; Signal; Transferase; Transmembrane; KW Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation. FT SIGNAL 1..32 FT /evidence="ECO:0000269|PubMed:15340161" FT CHAIN 33..1106 FT /note="Platelet-derived growth factor receptor beta" FT /id="PRO_0000016757" FT TOPO_DOM 33..532 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 533..553 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 554..1106 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 33..120 FT /note="Ig-like C2-type 1" FT DOMAIN 129..210 FT /note="Ig-like C2-type 2" FT DOMAIN 214..309 FT /note="Ig-like C2-type 3" FT DOMAIN 331..403 FT /note="Ig-like C2-type 4" FT DOMAIN 416..524 FT /note="Ig-like C2-type 5" FT DOMAIN 600..962 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1019..1106 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1043..1060 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1066..1088 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 826 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 606..614 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 634 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305" FT SITE 527..528 FT /note="Breakpoint for insertion to form PDE4DIP-PDGFRB FT fusion protein" FT SITE 527..528 FT /note="Breakpoint for translocation to form TRIP11-PDGFRB" FT SITE 558..559 FT /note="Breakpoint for translocation to form the CEP85L- FT PDGFRB fusion protein" FT MOD_RES 562 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867" FT MOD_RES 579 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14966296, FT ECO:0000269|PubMed:15902258, ECO:0000269|PubMed:7685273" FT MOD_RES 581 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15902258, FT ECO:0000269|PubMed:7685273" FT MOD_RES 686 FT /note="Phosphotyrosine; by ABL1 and ABL2" FT /evidence="ECO:0000250|UniProtKB:P05622" FT MOD_RES 716 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15902258" FT MOD_RES 740 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:1314164, FT ECO:0000269|PubMed:15902258" FT MOD_RES 751 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867, FT ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:14966296, FT ECO:0000269|PubMed:1709159, ECO:0000269|PubMed:2550144" FT MOD_RES 763 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867" FT MOD_RES 771 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867, FT ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:14966296, FT ECO:0000269|PubMed:15902258" FT MOD_RES 775 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867" FT MOD_RES 778 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867" FT MOD_RES 857 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867, FT ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:15902258, FT ECO:0000269|PubMed:1709159, ECO:0000269|PubMed:2550144" FT MOD_RES 934 FT /note="Phosphotyrosine; by ABL1 and ABL2" FT /evidence="ECO:0000250|UniProtKB:P05622" FT MOD_RES 970 FT /note="Phosphotyrosine; by ABL1 and ABL2" FT /evidence="ECO:0000250|UniProtKB:P05622" FT MOD_RES 1009 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867, FT ECO:0000269|PubMed:1396585, ECO:0000269|PubMed:15902258" FT MOD_RES 1021 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:10821867, FT ECO:0000269|PubMed:1396585, ECO:0000269|PubMed:14966296, FT ECO:0000269|PubMed:15902258" FT CARBOHYD 45 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 89 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20534510" FT CARBOHYD 103 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20534510" FT CARBOHYD 215 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20534510" FT CARBOHYD 230 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20534510" FT CARBOHYD 292 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20534510" FT CARBOHYD 307 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20534510" FT CARBOHYD 354 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 371 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 468 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 479 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 54..100 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:20534510" FT DISULFID 149..190 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:20534510" FT DISULFID 235..291 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:20534510" FT DISULFID 436..508 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT VAR_SEQ 311..336 FT /note="VESGYVRLLGEVGTLQFAELHRSRTL -> RAATCGSWERWAHYNLLSCIGA FT GHCR (in isoform 2)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056008" FT VAR_SEQ 337..1106 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056009" FT VARIANT 29 FT /note="I -> F (in dbSNP:rs17110944)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_034377" FT VARIANT 180 FT /note="S -> F (in dbSNP:rs17853027)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_035125" FT VARIANT 282 FT /note="E -> K (in dbSNP:rs34586048)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042027" FT VARIANT 345 FT /note="P -> S (in dbSNP:rs2229558)" FT /id="VAR_049717" FT VARIANT 485 FT /note="E -> K (in dbSNP:rs41287110)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042028" FT VARIANT 561 FT /note="R -> C (in IMF1; dbSNP:rs367543286)" FT /evidence="ECO:0000269|PubMed:23731537" FT /id="VAR_069925" FT VARIANT 584 FT /note="P -> R (in KOGS; dbSNP:rs863224946)" FT /evidence="ECO:0000269|PubMed:25454926" FT /id="VAR_075865" FT VARIANT 589 FT /note="Y -> H (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042029" FT VARIANT 658 FT /note="L -> P (in IBGC4; no effect on protein abundance; FT loss of PDGF beta receptor activity; dbSNP:rs397509381)" FT /evidence="ECO:0000269|PubMed:23255827, FT ECO:0000269|PubMed:24065723, ECO:0000269|PubMed:26599395" FT /id="VAR_069320" FT VARIANT 660 FT /note="P -> T (in IMF1; dbSNP:rs144050370)" FT /evidence="ECO:0000269|PubMed:23731542" FT /id="VAR_069926" FT VARIANT 665 FT /note="V -> A (in PENTT; gain of function in protein FT tyrosine kinase activity; shows ligand-independent FT constitutive signaling; dbSNP:rs1554108211)" FT /evidence="ECO:0000269|PubMed:26279204" FT /id="VAR_075866" FT VARIANT 666 FT /note="N -> S (in PENTT; likely pathogenic; gain-of- FT function variant resulting in constitutive FT autophosphorylation and increased phosphorylation of FT downstream signaling proteins; levels of protein FT phosphorylation are similar at 32 and 37 degrees Celsius; FT dbSNP:rs2113894766)" FT /evidence="ECO:0000269|PubMed:30573803" FT /id="VAR_090402" FT VARIANT 666 FT /note="N -> Y (in OPDKD; likely pathogenic; gain-of- FT function variant resulting in temperature-dependent FT constitutive autophosphorylation and increased FT phosphorylation of downstream signaling proteins; levels of FT protein phosphorylation at 32 degrees Celsius are higher FT than at 37 degrees; dbSNP:rs797044887)" FT /evidence="ECO:0000269|PubMed:33450762" FT /id="VAR_090403" FT VARIANT 718 FT /note="N -> Y (in dbSNP:rs35322465)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042030" FT VARIANT 882 FT /note="T -> I (in a breast infiltrating ductal carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042031" FT VARIANT 987 FT /note="R -> W (in IBGC4; decreased protein abundance; no FT effect on receptor activity; decreased PDGF signaling FT pathway; dbSNP:rs397509382)" FT /evidence="ECO:0000269|PubMed:23255827, FT ECO:0000269|PubMed:24065723, ECO:0000269|PubMed:26599395" FT /id="VAR_069321" FT VARIANT 1071 FT /note="E -> V (in IBGC4; no effect on protein abundance; no FT effect on receptor activity; decreased PDGF signaling FT pathway)" FT /evidence="ECO:0000269|PubMed:24065723, FT ECO:0000269|PubMed:26599395" FT /id="VAR_075395" FT MUTAGEN 579 FT /note="Y->F: Loss of kinase activity; when associated with FT F-581. Strongly reduces interaction with SRC family FT kinases. No effect on interaction with GRB10." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:7685273" FT MUTAGEN 581 FT /note="Y->F: Loss of kinase activity; when associated with FT F-579. No effect on interaction with GRB10." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:7685273" FT MUTAGEN 634 FT /note="K->A,R: Loss of kinase activity. Abolishes FT interaction with RASA1. No effect on phosphatidylinositol FT 3-kinase activity." FT /evidence="ECO:0000269|PubMed:1314164, FT ECO:0000269|PubMed:1846866, ECO:0000269|PubMed:20494825" FT MUTAGEN 716 FT /note="Y->F: No effect neither on interaction with GRB10 FT and RASA1 nor on phosphatidylinositol 3-kinase activity." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:1314164" FT MUTAGEN 740 FT /note="Y->F: Strongly reduces up-regulation of cell FT proliferation; when associated with F-751. Strongly FT decreases phosphatidylinositol 3-kinase activity. No effect FT on interaction with GRB10 and RASA1." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1375321, FT ECO:0000269|PubMed:21679854" FT MUTAGEN 751 FT /note="Y->F: Strongly reduces up-regulation of cell FT proliferation; when associated with F-740. Abolishes FT phosphatidylinositol 3-kinase activity and interaction with FT NCK1, and slightly reduces interaction with RASA1. No FT effect on interaction with GRB10." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1375321, FT ECO:0000269|PubMed:1653029, ECO:0000269|PubMed:21679854, FT ECO:0000269|PubMed:7692233" FT MUTAGEN 763 FT /note="Y->F: No effect on interaction with RASA1 and on FT phosphatidylinositol 3-kinase activity." FT /evidence="ECO:0000269|PubMed:1314164" FT MUTAGEN 771 FT /note="Y->F: Loss of interaction with GRB10. Abolishes FT interaction with RASA1. No effect on phosphatidylinositol FT 3-kinase activity." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1375321" FT MUTAGEN 775 FT /note="Y->F: No effect on interaction with RASA1 and on FT phosphatidylinositol 3-kinase activity." FT /evidence="ECO:0000269|PubMed:1314164" FT MUTAGEN 778 FT /note="Y->F: Strongly reduces expression levels." FT /evidence="ECO:0000269|PubMed:1314164" FT MUTAGEN 857 FT /note="Y->F: Reduces kinase activity. No effect on FT interaction with GRB10. Abolishes interaction with RASA1. FT No effect on phosphatidylinositol 3-kinase activity." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:1314164, ECO:0000269|PubMed:1653029, FT ECO:0000269|PubMed:20494825" FT MUTAGEN 1009 FT /note="Y->F: No effect on interaction with GRB10. Abolishes FT interaction with PLCG1; when associated with F-1021." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:1396585, ECO:0000269|PubMed:7691811" FT MUTAGEN 1021 FT /note="Y->F: Strongly reduces up-regulation of cell FT proliferation. Abolishes interaction with PLCG1; when FT associated with F-1009. No effect on interaction with FT GRB10." FT /evidence="ECO:0000269|PubMed:10454568, FT ECO:0000269|PubMed:1396585, ECO:0000269|PubMed:17620338, FT ECO:0000269|PubMed:21679854" FT CONFLICT 241 FT /note="E -> D (in Ref. 2; AAA36427)" FT /evidence="ECO:0000305" FT STRAND 40..43 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 50..58 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 61..64 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 70..75 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 81..87 FT /evidence="ECO:0007829|PDB:3MJG" FT HELIX 92..94 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 96..101 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 114..119 FT /evidence="ECO:0007829|PDB:3MJG" FT HELIX 132..135 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 136..141 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 145..147 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 158..164 FT /evidence="ECO:0007829|PDB:3MJG" FT TURN 175..177 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 178..181 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 185..194 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 197..200 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 204..208 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 217..221 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 223..226 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 231..239 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 241..248 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 252..255 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 261..265 FT /evidence="ECO:0007829|PDB:3MJG" FT TURN 267..270 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 271..280 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 287..295 FT /evidence="ECO:0007829|PDB:3MJG" FT TURN 296..299 FT /evidence="ECO:0007829|PDB:3MJG" FT STRAND 300..311 FT /evidence="ECO:0007829|PDB:3MJG" FT HELIX 530..556 FT /evidence="ECO:0007829|PDB:2L6W" SQ SEQUENCE 1106 AA; 123968 MW; 038C15E531D6E89D CRC64; MRLPGAMPAL ALKGELLLLS LLLLLEPQIS QGLVVTPPGP ELVLNVSSTF VLTCSGSAPV VWERMSQEPP QEMAKAQDGT FSSVLTLTNL TGLDTGEYFC THNDSRGLET DERKRLYIFV PDPTVGFLPN DAEELFIFLT EITEITIPCR VTDPQLVVTL HEKKGDVALP VPYDHQRGFS GIFEDRSYIC KTTIGDREVD SDAYYVYRLQ VSSINVSVNA VQTVVRQGEN ITLMCIVIGN EVVNFEWTYP RKESGRLVEP VTDFLLDMPY HIRSILHIPS AELEDSGTYT CNVTESVNDH QDEKAINITV VESGYVRLLG EVGTLQFAEL HRSRTLQVVF EAYPPPTVLW FKDNRTLGDS SAGEIALSTR NVSETRYVSE LTLVRVKVAE AGHYTMRAFH EDAEVQLSFQ LQINVPVRVL ELSESHPDSG EQTVRCRGRG MPQPNIIWSA CRDLKRCPRE LPPTLLGNSS EEESQLETNV TYWEEEQEFE VVSTLRLQHV DRPLSVRCTL RNAVGQDTQE VIVVPHSLPF KVVVISAILA LVVLTIISLI ILIMLWQKKP RYEIRWKVIE SVSSDGHEYI YVDPMQLPYD STWELPRDQL VLGRTLGSGA FGQVVEATAH GLSHSQATMK VAVKMLKSTA RSSEKQALMS ELKIMSHLGP HLNVVNLLGA CTKGGPIYII TEYCRYGDLV DYLHRNKHTF LQHHSDKRRP PSAELYSNAL PVGLPLPSHV SLTGESDGGY MDMSKDESVD YVPMLDMKGD VKYADIESSN YMAPYDNYVP SAPERTCRAT LINESPVLSY MDLVGFSYQV ANGMEFLASK NCVHRDLAAR NVLICEGKLV KICDFGLARD IMRDSNYISK GSTFLPLKWM APESIFNSLY TTLSDVWSFG ILLWEIFTLG GTPYPELPMN EQFYNAIKRG YRMAQPAHAS DEIYEIMQKC WEEKFEIRPP FSQLVLLLER LLGEGYKKKY QQVDEEFLRS DHPAILRSQA RLPGFHGLRS PLDTSSVLYT AVQPNEGDND YIIPLPDPKP EVADEGPLEG SPSLASSTLN EVNTSSTISC DSPLEPQDEP EPEPQLELQV EPEPELEQLP DSGCPAPRAE AEDSFL // ID PTEN_HUMAN Reviewed; 403 AA. AC P60484; B2R904; F2YHV0; O00633; O02679; Q6ICT7; DT 16-FEB-2004, integrated into UniProtKB/Swiss-Prot. DT 16-FEB-2004, sequence version 1. DT 28-JAN-2026, entry version 224. DE RecName: Full=Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN {ECO:0000305|PubMed:9256433, ECO:0000305|PubMed:9811831}; DE EC=3.1.3.16 {ECO:0000269|PubMed:9256433}; DE EC=3.1.3.48 {ECO:0000269|PubMed:9187108, ECO:0000269|PubMed:9256433}; DE EC=3.1.3.67 {ECO:0000269|PubMed:16824732, ECO:0000269|PubMed:9811831}; DE AltName: Full=Inositol polyphosphate 3-phosphatase {ECO:0000305|PubMed:11418101, ECO:0000305|PubMed:9593664}; DE EC=3.1.3.- {ECO:0000305|PubMed:11418101, ECO:0000305|PubMed:9593664}; DE AltName: Full=Mutated in multiple advanced cancers 1; DE AltName: Full=Phosphatase and tensin homolog; GN Name=PTEN; Synonyms=MMAC1, TEP1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY, RP SUBCELLULAR LOCATION, AND INDUCTION. RC TISSUE=Epithelium; RX PubMed=9187108; RA Li D.M., Sun H.; RT "TEP1, encoded by a candidate tumor suppressor locus, is a novel protein RT tyrosine phosphatase regulated by transforming growth factor beta."; RL Cancer Res. 57:2124-2129(1997). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND VARIANTS RP GLIOMA SER-15; GLU-36; ARG-42; TRP-57 AND THR-319 DEL. RX PubMed=9090379; DOI=10.1038/ng0497-356; RA Steck P.A., Pershouse M.A., Jasser S.A., Lin H., Yung W.K.A., Ligon A.H., RA Langford L.A., Baumgard M.L., Hattier T., Davis T., Frye C., Hu R., RA Swedlund B., Teng D.H.-F., Tavtigian S.V.; RT "Identification of a candidate tumour suppressor gene, MMAC1, at chromosome RT 10q23.3 that is mutated in multiple advanced cancers."; RL Nat. Genet. 15:356-363(1997). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT GLIOBLASTOMA ARG-129, AND RP VARIANT PROSTATE CANCER LEU-134. RX PubMed=9072974; DOI=10.1126/science.275.5308.1943; RA Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., RA Miliaresis C., Rodgers L., McCombie R., Bigner S.H., Giovanella B.C., RA Ittmann M., Tycko B., Hibshoosh H., Wigler M.H., Parsons R.; RT "PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, RT breast, and prostate cancer."; RL Science 275:1943-1947(1997). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=10817502; DOI=10.1054/bjoc.2000.1211; RA Hamilton J.A., Stewart L.M.D., Ajayi L., Gray I.C., Gray N.E., RA Roberts K.G., Watson G.J., Kaisary A.V., Snary D.; RT "The expression profile for the tumour suppressor gene PTEN and associated RT polymorphic markers."; RL Br. J. Cancer 82:1671-1676(2000). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Wang S., Li J., Liaw D., Bose S., Podsypanina K., Parsons R.; RL Submitted (APR-1997) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Jensen K., de la Bastide M., Parsons R., Parnell L.D., Dedhia N., RA Gottesman T., Gnoj L., Kaplan N., Lodhi M., Johnson A.F., Shohdy N., RA Hasegawa A., Haberman K., Huang E.N., Schutz K., Calma C., Granat S., RA Wigler M.H., McCombie W.R.; RT "Genomic sequence of PTEN/MMAC1."; RL Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3). RA Yang C.-W., Hsu Y.-F.; RT "Homo sapiens phosphatase and tensin homolog mRNA splicing variants."; RL Submitted (JAN-2011) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (MAY-2004) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [10] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LEU-290. RG NIEHS SNPs program; RL Submitted (MAY-2005) to the EMBL/GenBank/DDBJ databases. RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [12] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [13] RP FUNCTION, CATALYTIC ACTIVITY, AND CHARACTERIZATION OF VARIANTS GLIOMA RP TRP-57; ENDOMETRIAL CANCER TYR-123; GLIOBLASTOMA ARG-129; CWS1 ARG-129; RP PROSTATE CANCER LEU-134; GLIOBLASTOMA ARG-165; BREAST CANCER PRO-167 AND BZ RP ARG-170. RX PubMed=9256433; DOI=10.1073/pnas.94.17.9052; RA Myers M.P., Stolarov J.P., Eng C., Li J., Wang S.I., Wigler M.H., RA Parsons R., Tonks N.K.; RT "P-TEN, the tumor suppressor from human chromosome 10q23, is a dual- RT specificity phosphatase."; RL Proc. Natl. Acad. Sci. U.S.A. 94:9052-9057(1997). RN [14] RP FUNCTION, CATALYTIC ACTIVITY, AND CHARACTERIZATION OF VARIANT CWS1 SER-124. RX PubMed=9593664; DOI=10.1074/jbc.273.22.13375; RA Maehama T., Dixon J.E.; RT "The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second RT messenger, phosphatidylinositol 3,4,5-trisphosphate."; RL J. Biol. Chem. 273:13375-13378(1998). RN [15] RP FUNCTION, CATALYTIC ACTIVITY, MUTAGENESIS OF ARG-130, AND CHARACTERIZATION RP OF VARIANTS CWS1 SER-124 AND CWS1 GLU-129. RX PubMed=9811831; DOI=10.1073/pnas.95.23.13513; RA Myers M.P., Pass I., Batty I.H., Van der Kaay J., Stolarov J.P., RA Hemmings B.A., Wigler M.H., Downes C.P., Tonks N.K.; RT "The lipid phosphatase activity of PTEN is critical for its tumor RT suppressor function."; RL Proc. Natl. Acad. Sci. U.S.A. 95:13513-13518(1998). RN [16] RP FUNCTION, MUTAGENESIS OF ASP-92 AND CYS-124, AND CHARACTERIZATION OF RP VARIANT GLU-129. RX PubMed=9616126; DOI=10.1126/science.280.5369.1614; RA Tamura M., Gu J., Matsumoto K., Aota S., Parsons R., Yamada K.M.; RT "Inhibition of cell migration, spreading, and focal adhesions by tumor RT suppressor PTEN."; RL Science 280:1614-1617(1998). RN [17] RP FUNCTION, DOMAIN, AND CHARACTERIZATION OF VARIANTS THR-319 DEL; GLN-345 AND RP ILE-348. RX PubMed=10468583; DOI=10.1073/pnas.96.18.10182; RA Georgescu M.-M., Kirsch K.H., Akagi T., Shishido T., Hanafusa H.; RT "The tumor-suppressor activity of PTEN is regulated by its carboxyl- RT terminal region."; RL Proc. Natl. Acad. Sci. U.S.A. 96:10182-10187(1999). RN [18] RP INTERACTION WITH DLG1 AND MAST2, AND PHOSPHORYLATION AT THR-401. RX PubMed=10646847; RA Adey N.B., Huang L., Ormonde P.A., Baumgard M.L., Pero R., Byreddy D.V., RA Tavtigian S.V., Bartel P.L.; RT "Threonine phosphorylation of the MMAC1/PTEN PDZ binding domain both RT inhibits and stimulates PDZ binding."; RL Cancer Res. 60:35-37(2000). RN [19] RP INTERACTION WITH MAGI3. RX PubMed=10748157; DOI=10.1074/jbc.m909741199; RA Wu Y., Dowbenko D., Spencer S., Laura R., Lee J., Gu Q., Lasky L.A.; RT "Interaction of the tumor suppressor PTEN/MMAC with a PDZ domain of MAGI3, RT a novel membrane-associated guanylate kinase."; RL J. Biol. Chem. 275:21477-21485(2000). RN [20] RP INTERACTION WITH MAGI2. RX PubMed=10760291; DOI=10.1073/pnas.97.8.4233; RA Wu X., Hepner K., Castelino-Prabhu S., Do D., Kaye M.B., Yuan X.-J., RA Wood J., Ross C., Sawyers C.L., Whang Y.E.; RT "Evidence for regulation of the PTEN tumor suppressor by a membrane- RT localized multi-PDZ domain containing scaffold protein MAGI-2."; RL Proc. Natl. Acad. Sci. U.S.A. 97:4233-4238(2000). RN [21] RP FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=11418101; DOI=10.1016/s0014-5793(01)02500-5; RA Caffrey J.J., Darden T., Wenk M.R., Shears S.B.; RT "Expanding coincident signaling by PTEN through its inositol 1,3,4,5,6- RT pentakisphosphate 3-phosphatase activity."; RL FEBS Lett. 499:6-10(2001). RN [22] RP PHOSPHORYLATION AT SER-370; SER-380; THR-382; THR-383 AND SER-385. RX PubMed=11035045; DOI=10.1074/jbc.m009134200; RA Torres J., Pulido R.; RT "The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at RT its C terminus. Implications for PTEN stability to proteasome-mediated RT degradation."; RL J. Biol. Chem. 276:993-998(2001). RN [23] RP FUNCTION, PHOSPHORYLATION, AND INTERACTION WITH MAGI2. RX PubMed=11707428; DOI=10.1074/jbc.c100556200; RA Vazquez F., Grossman S.R., Takahashi Y., Rokas M.V., Nakamura N., RA Sellers W.R.; RT "Phosphorylation of the PTEN tail acts as an inhibitory switch by RT preventing its recruitment into a protein complex."; RL J. Biol. Chem. 276:48627-48630(2001). RN [24] RP PHOSPHORYLATION AT THR-366; SER-370 AND SER-385. RX PubMed=12297295; DOI=10.1016/s0014-5793(02)03274-x; RA Miller S., Lou D., Seldin D., Lane W., Neel B.; RT "Direct identification of PTEN phosphorylation sites."; RL FEBS Lett. 528:145-153(2002). RN [25] RP INTERACTION WITH NOP53, REGION, AND CHARACTERIZATION OF VARIANTS CWS1 RP VAL-341; GLU-343 AND GLN-345. RX PubMed=15355975; DOI=10.1074/jbc.c400377200; RA Okahara F., Ikawa H., Kanaho Y., Maehama T.; RT "Regulation of PTEN phosphorylation and stability by a tumor suppressor RT candidate protein."; RL J. Biol. Chem. 279:45300-45303(2004). RN [26] RP INTERACTION WITH STK11, SUBCELLULAR LOCATION, AND PHOSPHORYLATION BY STK11. RX PubMed=15987703; DOI=10.1093/hmg/ddi225; RA Mehenni H., Lin-Marq N., Buchet-Poyau K., Reymond A., Collart M.A., RA Picard D., Antonarakis S.E.; RT "LKB1 interacts with and phosphorylates PTEN: a functional link between two RT proteins involved in cancer predisposing syndromes."; RL Hum. Mol. Genet. 14:2209-2219(2005). RN [27] RP INTERACTION WITH MAGI2; MAGI3; MAST1; MAST2 AND MAST3, MUTAGENESIS OF RP VAL-403, AND PHOSPHORYLATION. RX PubMed=15951562; DOI=10.1074/jbc.m504761200; RA Valiente M., Andres-Pons A., Gomar B., Torres J., Gil A., Tapparel C., RA Antonarakis S.E., Pulido R.; RT "Binding of PTEN to specific PDZ domains contributes to PTEN protein RT stability and phosphorylation by microtubule-associated serine/threonine RT kinases."; RL J. Biol. Chem. 280:28936-28943(2005). RN [28] RP FUNCTION. RX PubMed=15979280; DOI=10.1016/j.cellsig.2005.05.017; RA Deleu S., Choi K., Pesesse X., Cho J., Sulis M.L., Parsons R., Shears S.B.; RT "Physiological levels of PTEN control the size of the cellular RT Ins(1,3,4,5,6)P(5) pool."; RL Cell. Signal. 18:488-498(2006). RN [29] RP CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND FUNCTION. RX PubMed=16824732; DOI=10.1016/j.cellsig.2006.05.010; RA Vandeput F., Backers K., Villeret V., Pesesse X., Erneux C.; RT "The influence of anionic lipids on SHIP2 phosphatidylinositol 3,4,5- RT trisphosphate 5-phosphatase activity."; RL Cell. Signal. 18:2193-2199(2006). RN [30] RP INTERACTION WITH NEDD4. RX PubMed=17218260; DOI=10.1016/j.cell.2006.11.039; RA Wang X., Trotman L.C., Koppie T., Alimonti A., Chen Z., Gao Z., Wang J., RA Erdjument-Bromage H., Tempst P., Cordon-Cardo C., Pandolfi P.P., Jiang X.; RT "NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN."; RL Cell 128:129-139(2007). RN [31] RP FUNCTION, INTERACTION WITH USP7, UBIQUITINATION AT LYS-13 AND LYS-289, RP DEUBIQUITINATION BY USP7, SUBCELLULAR LOCATION, MUTAGENESIS OF LYS-13 AND RP LYS-289, AND CHARACTERIZATION OF VARIANT CWS1 GLU-289. RX PubMed=18716620; DOI=10.1038/nature07290; RA Song M.S., Salmena L., Carracedo A., Egia A., Lo-Coco F., RA Teruya-Feldstein J., Pandolfi P.P.; RT "The deubiquitinylation and localization of PTEN are regulated by a HAUSP- RT PML network."; RL Nature 455:813-817(2008). RN [32] RP INTERACTION WITH FRK, PHOSPHORYLATION AT TYR-336, AND MUTAGENESIS OF RP TYR-336. RX PubMed=19345329; DOI=10.1016/j.ccr.2009.02.012; RA Yim E.-K., Peng G., Dai H., Hu R., Li K., Lu Y., Mills G.B., RA Meric-Bernstam F., Hennessy B.T., Craven R.J., Lin S.-Y.; RT "Rak functions as a tumor suppressor by regulating PTEN protein stability RT and function."; RL Cancer Cell 15:304-314(2009). RN [33] RP UBIQUITINATION BY XIAP/BIRC4, SUBCELLULAR LOCATION, AND INTERACTION WITH RP XIAP/BIRC4. RX PubMed=19473982; DOI=10.1074/jbc.c109.009522; RA Van Themsche C., Leblanc V., Parent S., Asselin E.; RT "X-linked inhibitor of apoptosis protein (XIAP) regulates PTEN RT ubiquitination, content, and compartmentalization."; RL J. Biol. Chem. 284:20462-20466(2009). RN [34] RP PHOSPHORYLATION AT THR-366 AND SER-370, AND MUTAGENESIS OF THR-366 AND RP SER-370. RX PubMed=20940307; DOI=10.1074/jbc.m110.166462; RA Xu D., Yao Y., Jiang X., Lu L., Dai W.; RT "Regulation of PTEN stability and activity by Plk3."; RL J. Biol. Chem. 285:39935-39942(2010). RN [35] RP INTERACTION WITH NDFIP1 AND NDFIP2. RX PubMed=20534535; DOI=10.1073/pnas.0911714107; RA Mund T., Pelham H.R.; RT "Regulation of PTEN/Akt and MAP kinase signaling pathways by the ubiquitin RT ligase activators Ndfip1 and Ndfip2."; RL Proc. Natl. Acad. Sci. U.S.A. 107:11429-11434(2010). RN [36] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [37] RP FUNCTION IN CELL MIGRATION. RX PubMed=22279049; DOI=10.1101/gad.177642.111; RA Stohr N., Kohn M., Lederer M., Glass M., Reinke C., Singer R.H., RA Huttelmaier S.; RT "IGF2BP1 promotes cell migration by regulating MK5 and PTEN signaling."; RL Genes Dev. 26:176-189(2012). RN [38] RP ACETYLATION [LARGE SCALE ANALYSIS] AT THR-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [39] RP ALTERNATIVE INITIATION (ISOFORM ALPHA), CTG START CODON, FUNCTION (ISOFORM RP ALPHA), AND SUBCELLULAR LOCATION (ISOFORM ALPHA). RX PubMed=23744781; DOI=10.1126/science.1234907; RA Hopkins B.D., Fine B., Steinbach N., Dendy M., Rapp Z., Shaw J., Pappas K., RA Yu J.S., Hodakoski C., Mense S., Klein J., Pegno S., Sulis M.L., RA Goldstein H., Amendolara B., Lei L., Maurer M., Bruce J., Canoll P., RA Hibshoosh H., Parsons R.; RT "A secreted PTEN phosphatase that enters cells to alter signaling and RT survival."; RL Science 341:399-402(2013). RN [40] RP INTERACTION WITH PPP1R16B. RX PubMed=25007873; DOI=10.1152/ajprenal.00070.2014; RA Obeidat M., Li L., Ballermann B.J.; RT "TIMAP promotes angiogenesis by suppressing PTEN-mediated Akt inhibition in RT human glomerular endothelial cells."; RL Am. J. Physiol. 307:F623-F633(2014). RN [41] RP ALTERNATIVE INITIATION (ISOFORM ALPHA), CTG START CODON, SUBCELLULAR RP LOCATION (ISOFORM ALPHA), AND MUTAGENESIS OF MET-1. RX PubMed=24768297; DOI=10.1016/j.cmet.2014.03.023; RA Liang H., He S., Yang J., Jia X., Wang P., Chen X., Zhang Z., Zou X., RA McNutt M.A., Shen W.H., Yin Y.; RT "PTENalpha, a PTEN isoform translated through alternative initiation, RT regulates mitochondrial function and energy metabolism."; RL Cell Metab. 19:836-848(2014). RN [42] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-366, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [43] RP INTERACTION WITH NDFIP1, AND SUBCELLULAR LOCATION. RX PubMed=25801959; DOI=10.1093/jmcb/mjv020; RA Howitt J., Low L.H., Putz U., Doan A., Lackovic J., Goh C.P., Gunnersen J., RA Silke J., Tan S.S.; RT "Ndfip1 represses cell proliferation by controlling Pten localization and RT signaling specificity."; RL J. Mol. Cell Biol. 7:119-131(2015). RN [44] RP FUNCTION, INTERACTION WITH TNS3 AND PI3K, PHOSPHORYLATION AT THR-319 AND RP THR-321, AND MUTAGENESIS OF SER-229; THR-232; THR-319 AND THR-321. RX PubMed=26166433; DOI=10.1038/ncomms8721; RA Cao X., Kaneko T., Li J.S., Liu A.D., Voss C., Li S.S.; RT "A phosphorylation switch controls the spatiotemporal activation of Rho RT GTPases in directional cell migration."; RL Nat. Commun. 6:7721-7721(2015). RN [45] RP FUNCTION, AND UBIQUITINATION. RX PubMed=31492966; DOI=10.1007/s00018-019-03280-5; RA Zhang J., Zhang Y.L., Zhao L.W., Pi S.B., Zhang S.Y., Tong C., Fan H.Y.; RT "The CRL4-DCAF13 ubiquitin E3 ligase supports oocyte meiotic resumption by RT targeting PTEN degradation."; RL Cell. Mol. Life Sci. 77:2181-2197(2020). RN [46] RP FUNCTION, AND ISGYLATION. RX PubMed=37279284; DOI=10.1126/scisignal.abm1756; RA Du X., Sheng J., Chen Y., He S., Yang Y., Huang Y., Fu Y., Lie L., Han Z., RA Zhu B., Liu H., Wen Q., Zhou X., Zhou C., Hu S., Ma L.; RT "The E3 ligase HERC5 promotes antimycobacterial responses in macrophages by RT ISGylating the phosphatase PTEN."; RL Sci. Signal. 16:eabm1756-eabm1756(2023). RN [47] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 8-353 IN COMPLEX WITH RP L(+)-TARTRATE, SUBUNIT, DOMAIN, MUTAGENESIS OF ASP-92; HIS-93; LYS-125; RP LYS-128; THR-167; GLN-171; 263-LYS--ALA-269 AND 327-LYS--ALA-335, AND RP CATALYTIC ACTIVITY. RX PubMed=10555148; DOI=10.1016/s0092-8674(00)81663-3; RA Lee J.-O., Yang H., Georgescu M.-M., Di Cristofano A., Maehama T., Shi Y., RA Dixon J.E., Pandolfi P., Pavletich N.P.; RT "Crystal structure of the PTEN tumor suppressor: implications for its RT phosphoinositide phosphatase activity and membrane association."; RL Cell 99:323-334(1999). RN [48] RP VARIANT CWS1 ASN-137 INS. RX PubMed=9345101; DOI=10.1086/301607; RA Tsou H.C., Teng D.H.-F., Ping X.L., Brancolini V., Davis T., Hu R., RA Xie X.X., Gruener A.C., Schrager C.A., Christiano A.M., Eng C., Steck P., RA Ott J., Tavtigian S.V., Peacocke M.; RT "The role of MMAC1 mutations in early-onset breast cancer: causative in RT association with Cowden syndrome and excluded in BRCA1-negative cases."; RL Am. J. Hum. Genet. 61:1036-1043(1997). RN [49] RP VARIANTS CWS1 GLU-343 AND LEU-347. RX PubMed=9399897; DOI=10.1086/301639; RA Lynch E.D., Ostermeyer E.A., Lee M.K., Arena J.F., Ji H., Dann J., RA Swisshelm K., Suchard D., MacLeod P.M., Kvinnsland S., Gjertsen B.T., RA Heimdal K., Lubs H., Moeller P., King M.-C.; RT "Inherited mutations in PTEN that are associated with breast cancer, Cowden RT disease, and juvenile polyposis."; RL Am. J. Hum. Genet. 61:1254-1260(1997). RN [50] RP VARIANTS GLIOBLASTOMA TYR-107; PRO-121; ARG-129; ARG-165 AND GLN-345. RX PubMed=9331071; RA Wang S.I., Puc J., Li J., Bruce J.N., Cairns P., Sidransky D., Parsons R.; RT "Somatic mutations of PTEN in glioblastoma multiforme."; RL Cancer Res. 57:4183-4186(1997). RN [51] RP VARIANTS CWS1 ARG-123 AND ARG-124. RX PubMed=9259288; DOI=10.1093/hmg/6.8.1383; RA Nelen M.R., van Staveren W.C.G., Peeters E.A.J., Ben-Hassel M., RA Gorlin R.J., Hamm H., Lindboe C.F., Fryns J.-P., Sijmons R.H., Woods D.G., RA Mariman E.C.M., Padberg G.W., Kremer H.; RT "Germline mutations in the PTEN/MMAC1 gene in patients with Cowden RT disease."; RL Hum. Mol. Genet. 6:1383-1387(1997). RN [52] RP VARIANT CWS1 GLU-129. RX PubMed=9140396; DOI=10.1038/ng0597-64; RA Liaw D., Marsh D.J., Li J., Dahia P.L.M., Wang S.I., Zheng Z., Bose S., RA Call K.M., Tsou H.C., Peacocke M., Eng C., Parsons R.; RT "Germline mutations of the PTEN gene in Cowden disease, an inherited breast RT and thyroid cancer syndrome."; RL Nat. Genet. 16:64-67(1997). RN [53] RP VARIANT CWS1 ARG-170. RX PubMed=9241266; DOI=10.1038/ng0897-333; RA Marsh D.J., Dahia P.L.M., Zheng Z., Liaw D., Parsons R., Gorlin R.J., RA Eng C.; RT "Germline mutations in PTEN are present in Bannayan-Zonana syndrome."; RL Nat. Genet. 16:333-334(1997). RN [54] RP VARIANTS ENDOMETRIAL HYPERPLASIA ARG-36; LEU-130; CYS-173; ALA-191 AND RP ILE-348. RX PubMed=9635567; RA Maxwell G.L., Risinger J.I., Gumbs C., Shaw H., Bentley R.C., Barrett J.C., RA Berchuck A., Futreal P.A.; RT "Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias."; RL Cancer Res. 58:2500-2503(1998). RN [55] RP VARIANT CWS1 GLU-289. RX PubMed=9797362; DOI=10.1016/s0016-5085(98)70078-2; RA Chi S.-G., Kim H.-J., Park B.-J., Min H.-J., Park J.-H., Kim Y.-W., RA Dong S.-H., Kim B.-H., Lee J.-I., Chang Y.-W., Chang R., Kim W.-K., RA Yang M.-H.; RT "Mutational abrogation of the PTEN/MMAC1 gene in gastrointestinal polyps in RT patients with Cowden disease."; RL Gastroenterology 115:1084-1089(1998). RN [56] RP VARIANTS CWS1 HIS-68 AND PRO-112. RX PubMed=9600246; DOI=10.1007/s004390050723; RA Tsou H.C., Ping X.L., Xie X.X., Gruener A.C., Zhang H., Nini R., RA Swisshelm K., Sybert V., Diamond T.M., Sutphen R., Peacocke M.; RT "The genetic basis of Cowden's syndrome: three novel mutations in RT PTEN/MMAC1/TEP1."; RL Hum. Genet. 102:467-473(1998). RN [57] RP VARIANTS CWS1 ARG-67 AND VAL-165. RX PubMed=9467011; DOI=10.1093/hmg/7.3.507; RA Marsh D.J., Coulon V., Lunetta K.L., Rocca-Serra P., Dahia P.L.M., RA Zheng Z., Liaw D., Caron S., Duboue B., Lin A.Y., Richardson A.-L., RA Bonnetblanc J.-M., Bressieux J.-M., Cabarrot-Moreau A., Chompret A., RA Demange L., Eeles R.A., Yahanda A.M., Fearon E.R., Fricker J.-P., RA Gorlin R.J., Hodgson S.V., Huson S., Lacombe D., Leprat F., Odent S., RA Toulouse C., Olopade O.I., Sobol H., Tishler S., Woods C.G., Robinson B.G., RA Weber H.C., Parsons R., Peacocke M., Longy M., Eng C.; RT "Mutation spectrum and genotype-phenotype analyses in Cowden disease and RT Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN RT mutation."; RL Hum. Mol. Genet. 7:507-515(1998). RN [58] RP VARIANT CWS1 TYR-136. RX PubMed=9735393; DOI=10.3892/ijo.13.4.665; RA Scala S., Bruni P., Lo Muzio L., Mignogna M., Viglietto G., Fusco A.; RT "Novel mutation of the PTEN gene in an Italian Cowden's disease kindred."; RL Int. J. Oncol. 13:665-668(1998). RN [59] RP VARIANT CWS1 PRO-70. RX PubMed=9832031; DOI=10.1136/jmg.35.11.881; RA Marsh D.J., Dahia P.L.M., Caron S., Kum J.B., Frayling I.M., RA Tomlinson I.P.M., Hughes K.S., Eeles R.A., Hodgson S.V., Murday V.A., RA Houlston R., Eng C.; RT "Germline PTEN mutations in Cowden syndrome-like families."; RL J. Med. Genet. 35:881-885(1998). RN [60] RP VARIANT CWS1 ARG-35. RX PubMed=9425889; DOI=10.1038/ng0198-12; RA Olschwang S., Serova-Sinilnikova O.M., Lenoir G.M., Thomas G.; RT "PTEN germ-line mutations in juvenile polyposis coli."; RL Nat. Genet. 18:12-14(1998). RN [61] RP VARIANT CWS1 GLN-130. RX PubMed=9915974; DOI=10.1086/302207; RA Kurose K., Araki T., Matsunaka T., Takada Y., Emi M.; RT "Variant manifestation of Cowden disease in Japan: hamartomatous polyposis RT of the digestive tract with mutation of the PTEN gene."; RL Am. J. Hum. Genet. 64:308-310(1999). RN [62] RP VARIANT CWS1/LDD PRO-112. RX PubMed=10051160; RX DOI=10.1002/(sici)1096-8628(19990212)82:4<290::aid-ajmg3>3.0.co;2-0; RA Sutphen R., Diamond T.M., Minton S.E., Peacocke M., Tsou H.C., Root A.W.; RT "Severe Lhermitte-Duclos disease with unique germline mutation of PTEN."; RL Am. J. Med. Genet. 82:290-293(1999). RN [63] RP VARIANTS CWS1 ILE-33 DEL; ARG-123; ARG-124 AND GLU-165. RX PubMed=10234502; DOI=10.1038/sj.ejhg.5200289; RA Nelen M.R., Kremer H., Konings I.B.M., Schoute F., van Essen A.J., Koch R., RA Woods C.G., Fryns J.-P., Hamel B.C.J., Hoefsloot L.H., Peeters E.A.J., RA Padberg G.W.; RT "Novel PTEN mutations in patients with Cowden disease: absence of clear RT genotype-phenotype correlations."; RL Eur. J. Hum. Genet. 7:267-273(1999). RN [64] RP VARIANTS CWS1 ASP-34; HIS-68; TYR-105; VAL-135; ARG-170 AND LEU-246. RX PubMed=10400993; DOI=10.1093/hmg/8.8.1461; RA Marsh D.J., Kum J.B., Lunetta K.L., Bennett M.J., Gorlin R.J., Ahmed S.F., RA Bodurtha J., Crowe C., Curtis M.A., Dasouki M., Dunn T., Feit H., RA Geraghty M.T., Graham J.M. Jr., Hodgson S.V., Hunter A., Korf B.R., RA Manchester D., Miesfeldt S., Murday V.A., Nathanson K.L., Parisi M., RA Pober B., Romano C., Tolmie J.L., Trembath R., Winter R.M., Zackai E.H., RA Zori R.T., Weng L.-P., Dahia P.L.M., Eng C.; RT "PTEN mutation spectrum and genotype-phenotype correlations in Bannayan- RT Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome."; RL Hum. Mol. Genet. 8:1461-1472(1999). RN [65] RP CHARACTERIZATION OF VARIANTS ASN-10; CYS-16; GLU-20; SER-27; ARG-61; RP HIS-68; ARG-112; PRO-121; ARG-129; GLY-130; ILE-133; LEU-134; ARG-165; RP ASN-170; CYS-173; HIS-173; PRO-173; ASN-174; PHE-227; CYS-251; GLN-345; RP GLY-369 AND ILE-401, AND CHARACTERIZATION OF VARIANTS CWS1 TYR-71; TYR-93; RP PHE-105; TYR-107; PRO-112; ARG-124; GLU-129; LEU-130; GLN-130; TYR-136; RP CYS-155; ARG-170; GLU-289; GLY-331; VAL-341; ASN-342; GLU-343 AND LEU-347. RX PubMed=10866302; RA Han S.-Y., Kato H., Kato S., Suzuki T., Shibata H., Ishii S., Shiiba K., RA Matsuno S., Kanamaru R., Ishioka C.; RT "Functional evaluation of PTEN missense mutations using in vitro RT phosphoinositide phosphatase assay."; RL Cancer Res. 60:3147-3151(2000). RN [66] RP VARIANT CWS1 ARG-36. RX PubMed=10772390; DOI=10.1034/j.1600-0625.2000.009002152.x; RA Celebi J.T., Ping X.L., Zhang H., Remington T., Sulica V.I., Tsou H.C., RA Peacocke M.; RT "Germline PTEN mutations in three families with Cowden syndrome."; RL Exp. Dermatol. 9:152-156(2000). RN [67] RP VARIANTS MULTIPLE CANCERS LEU-119 AND LEU-158. RX PubMed=10807691; DOI=10.1136/jmg.37.5.336; RA De Vivo I., Gertig D.M., Nagase S., Hankinson S.E., O'Brien R., RA Speizer F.E., Parsons R., Hunter D.J.; RT "Novel germline mutations in the PTEN tumour suppressor gene found in women RT with multiple cancers."; RL J. Med. Genet. 37:336-341(2000). RN [68] RP VARIANTS MALIGNANT MELANOMA ASN-19 AND ILE-217. RX PubMed=10978354; DOI=10.1136/jmg.37.9.653; RA Celebi J.T., Shendrik I., Silvers D.N., Peacocke M.; RT "Identification of PTEN mutations in metastatic melanoma specimens."; RL J. Med. Genet. 37:653-657(2000). RN [69] RP CHARACTERIZATION OF VARIANTS CWS1 SER-124 AND GLU-129. RX PubMed=11230179; DOI=10.1093/hmg/10.6.599; RA Weng L.-P., Brown J.L., Eng C.; RT "PTEN coordinates G1 arrest by down-regulating cyclin D1 via its protein RT phosphatase activity and up-regulating p27 via its lipid phosphatase RT activity in a breast cancer model."; RL Hum. Mol. Genet. 10:599-604(2001). RN [70] RP VARIANT ASP-61. RX PubMed=11748304; DOI=10.1136/jmg.38.12.820; RA Reardon W., Zhou X.-P., Eng C.; RT "A novel germline mutation of the PTEN gene in a patient with macrocephaly, RT ventricular dilatation, and features of VATER association."; RL J. Med. Genet. 38:820-823(2001). RN [71] RP VARIANTS CWS1 ASP-34; GLY-47; HIS-68; TYR-105; VAL-135 AND ARG-170. RX PubMed=11494117; DOI=10.1038/sj.neo.7900154; RA Marsh D.J., Theodosopoulos G., Howell V., Richardson A.-L., Benn D.E., RA Proos A.L., Eng C., Robinson B.G.; RT "Rapid mutation scanning of genes associated with familial cancer syndromes RT using denaturing high-performance liquid chromatography."; RL Neoplasia 3:236-244(2001). RN [72] RP VARIANT GLM2 GLN-234, AND CHARACTERIZATION OF VARIANT GLM2 GLN-234. RX PubMed=12085208; DOI=10.1038/sj.bjc.6600206; RA Staal F.J.T., van der Luijt R.B., Baert M.R.M., van Drunen J., RA van Bakel H., Peters E., de Valk I., van Amstel H.K.P., Taphoorn M.J.B., RA Jansen G.H., van Veelen C.W.M., Burgering B., Staal G.E.J.; RT "A novel germline mutation of PTEN associated with brain tumours of RT multiple lineages."; RL Br. J. Cancer 86:1586-1591(2002). RN [73] RP VARIANT HNSCC GLY-121. RX PubMed=11801303; DOI=10.1016/s0165-4608(01)00509-x; RA Poetsch M., Lorenz G., Kleist B.; RT "Detection of new PTEN/MMAC1 mutations in head and neck squamous cell RT carcinomas with loss of chromosome 10."; RL Cancer Genet. Cytogenet. 132:20-24(2002). RN [74] RP DISCUSSION OF PTEN INVOLVEMENT IN PROTEUS SYNDROME. RX PubMed=12471211; DOI=10.1136/jmg.39.12.937; RA Smith J.M., Kirk E.P.E., Theodosopoulos G., Marshall G.M., Walker J., RA Rogers M., Field M., Brereton J.J., Marsh D.J.; RT "Germline mutation of the tumour suppressor PTEN in Proteus syndrome."; RL J. Med. Genet. 39:937-940(2002). RN [75] RP VARIANTS MCEPHAS ARG-93; SER-241 AND GLY-252. RX PubMed=15805158; DOI=10.1136/jmg.2004.024646; RA Butler M.G., Dasouki M.J., Zhou X.-P., Talebizadeh Z., Brown M., RA Takahashi T.N., Miles J.H., Wang C.H., Stratton R., Pilarski R., Eng C.; RT "Subset of individuals with autism spectrum disorders and extreme RT macrocephaly associated with germline PTEN tumour suppressor gene RT mutations."; RL J. Med. Genet. 42:318-321(2005). RN [76] RP VARIANT ENDMC GLU-36. RX PubMed=16506206; DOI=10.1002/ijc.21862; RA Bilbao C., Rodriguez G., Ramirez R., Falcon O., Leon L., Chirino R., RA Rivero J.F., Falcon O. Jr., Diaz-Chico B.N., Diaz-Chico J.C., Perucho M.; RT "The relationship between microsatellite instability and PTEN gene RT mutations in endometrial cancer."; RL Int. J. Cancer 119:563-570(2006). RN [77] RP INVOLVEMENT IN CHROMOSOME 10Q23 DELETION SYNDROME. RX PubMed=17436248; DOI=10.1086/513607; RA Balciuniene J., Feng N., Iyadurai K., Hirsch B., Charnas L., Bill B.R., RA Easterday M.C., Staaf J., Oseth L., Czapansky-Beilman D., Avramopoulos D., RA Thomas G.H., Borg A., Valle D., Schimmenti L.A., Selleck S.B.; RT "Recurrent 10q22-q23 deletions: a genomic disorder on 10q associated with RT cognitive and behavioral abnormalities."; RL Am. J. Hum. Genet. 80:938-947(2007). RN [78] RP VARIANT VAL-132. RX PubMed=16752378; DOI=10.1002/ajmg.a.31273; RA Tekin M., Hismi B.O., Fitoz S., Yalcinkaya F., Ekim M., Kansu A., Ertem M., RA Deda G., Tutar E., Arsan S., Zhou X.-P., Pilarski R., Eng C., Akar N.; RT "A germline PTEN mutation with manifestations of prenatal onset and RT verrucous epidermal nevus."; RL Am. J. Med. Genet. A 140:1472-1475(2006). RN [79] RP VARIANTS CWS1 SER-15; ASP-34; ARG-36; ARG-61; HIS-68; GLU-129; GLY-130; RP LEU-130; GLN-130; TYR-136; ARG-165; ARG-170; GLY-252 AND LEU-347. RX PubMed=21659347; DOI=10.1136/jmg.2011.088807; RA Pilarski R., Stephens J.A., Noss R., Fisher J.L., Prior T.W.; RT "Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan- RT Riley-Ruvalcaba syndrome clinical features."; RL J. Med. Genet. 48:505-512(2011). RN [80] RP VARIANTS MCEPHAS ILE-131 AND ASN-167. RX PubMed=23160955; DOI=10.1126/science.1227764; RA O'Roak B.J., Vives L., Fu W., Egertson J.D., Stanaway I.B., Phelps I.G., RA Carvill G., Kumar A., Lee C., Ankenman K., Munson J., Hiatt J.B., RA Turner E.H., Levy R., O'Day D.R., Krumm N., Coe B.P., Martin B.K., RA Borenstein E., Nickerson D.A., Mefford H.C., Doherty D., Akey J.M., RA Bernier R., Eichler E.E., Shendure J.; RT "Multiplex targeted sequencing identifies recurrently mutated genes in RT autism spectrum disorders."; RL Science 338:1619-1622(2012). RN [81] RP VARIANTS CWS1 ARG-61; TYR-93; GLY-130; GLN-130; LEU-130 AND CYS-173. RX PubMed=24778394; DOI=10.1200/jco.2013.53.6656; RA Ngeow J., Stanuch K., Mester J.L., Barnholtz-Sloan J.S., Eng C.; RT "Second malignant neoplasms in patients with Cowden syndrome with RT underlying germline PTEN mutations."; RL J. Clin. Oncol. 32:1818-1824(2014). RN [82] RP VARIANT MCEPHAS 65-TYR--VAL-403 DEL. RX PubMed=26637798; DOI=10.1016/j.neuron.2015.11.009; RA D'Gama A.M., Pochareddy S., Li M., Jamuar S.S., Reiff R.E., Lam A.T., RA Sestan N., Walsh C.A.; RT "Targeted DNA Sequencing from Autism Spectrum Disorder Brains Implicates RT Multiple Genetic Mechanisms."; RL Neuron 88:910-917(2015). RN [83] RP VARIANT PROSTATE CANCER GLY-126, CHARACTERIZATION OF VARIANT GLY-126, RP MUTAGENESIS OF ALA-126, AND FUNCTION. RX PubMed=26504226; DOI=10.1073/pnas.1422504112; RA Costa H.A., Leitner M.G., Sos M.L., Mavrantoni A., Rychkova A., RA Johnson J.R., Newton B.W., Yee M.C., De La Vega F.M., Ford J.M., RA Krogan N.J., Shokat K.M., Oliver D., Halaszovich C.R., Bustamante C.D.; RT "Discovery and functional characterization of a neomorphic PTEN mutation."; RL Proc. Natl. Acad. Sci. U.S.A. 112:13976-13981(2015). RN [84] RP VARIANT ASN-174. RX PubMed=39316756; DOI=10.1158/0008-5472.can-23-2216; RA Plitt G., Brewer T., Yehia L., Rabinowitz L., Griffith C.C., Eng C.; RT "The genomic landscape of benign and malignant thyroid tumors from RT individuals carrying germline PTEN variants is distinct from sporadic RT thyroid cancers."; RL Cancer Res. 84:3657-3668(2024). CC -!- FUNCTION: Dual-specificity protein phosphatase, dephosphorylating CC tyrosine-, serine- and threonine-phosphorylated proteins CC (PubMed:9187108, PubMed:9256433, PubMed:9616126). Also functions as a CC lipid phosphatase, removing the phosphate in the D3 position of the CC inositol ring of PtdIns(3,4,5)P3/phosphatidylinositol 3,4,5- CC trisphosphate, PtdIns(3,4)P2/phosphatidylinositol 3,4-diphosphate and CC PtdIns3P/phosphatidylinositol 3-phosphate with a preference for CC PtdIns(3,4,5)P3 (PubMed:16824732, PubMed:26504226, PubMed:9593664, CC PubMed:9811831). Furthermore, this enzyme can also act as a cytosolic CC inositol 3-phosphatase acting on Ins(1,3,4,5,6)P5/inositol 1,3,4,5,6 CC pentakisphosphate and possibly Ins(1,3,4,5)P4/1D-myo-inositol 1,3,4,5- CC tetrakisphosphate (PubMed:11418101, PubMed:15979280). Antagonizes the CC PI3K-AKT/PKB signaling pathway by dephosphorylating phosphoinositides CC and thereby modulating cell cycle progression and cell survival CC (PubMed:31492966, PubMed:37279284). The unphosphorylated form CC cooperates with MAGI2 to suppress AKT1 activation (PubMed:11707428). In CC motile cells, suppresses the formation of lateral pseudopods and CC thereby promotes cell polarization and directed movement CC (PubMed:22279049). Dephosphorylates tyrosine-phosphorylated focal CC adhesion kinase and inhibits cell migration and integrin-mediated cell CC spreading and focal adhesion formation (PubMed:22279049). Required for CC growth factor-induced epithelial cell migration; growth factor CC stimulation induces PTEN phosphorylation which changes its binding CC preference from the p85 regulatory subunit of the PI3K kinase complex CC to DLC1 and results in translocation of the PTEN-DLC1 complex to the CC posterior of migrating cells to promote RHOA activation CC (PubMed:26166433). Meanwhile, TNS3 switches binding preference from CC DLC1 to p85 and the TNS3-p85 complex translocates to the leading edge CC of migrating cells to activate RAC1 activation (PubMed:26166433). Plays CC a role as a key modulator of the AKT-mTOR signaling pathway controlling CC the tempo of the process of newborn neurons integration during adult CC neurogenesis, including correct neuron positioning, dendritic CC development and synapse formation (By similarity). Involved in the CC regulation of synaptic function in excitatory hippocampal synapses. CC Recruited to the postsynaptic membrane upon NMDA receptor activation, CC is required for the modulation of synaptic activity during plasticity. CC Enhancement of lipid phosphatase activity is able to drive depression CC of AMPA receptor-mediated synaptic responses, activity required for CC NMDA receptor-dependent long-term depression (LTD) (By similarity). May CC be a negative regulator of insulin signaling and glucose metabolism in CC adipose tissue. The nuclear monoubiquitinated form possesses greater CC apoptotic potential, whereas the cytoplasmic nonubiquitinated form CC induces less tumor suppressive ability (PubMed:10468583, CC PubMed:18716620). {ECO:0000250|UniProtKB:O08586, CC ECO:0000250|UniProtKB:O54857, ECO:0000269|PubMed:10468583, CC ECO:0000269|PubMed:11418101, ECO:0000269|PubMed:11707428, CC ECO:0000269|PubMed:15979280, ECO:0000269|PubMed:16824732, CC ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:22279049, CC ECO:0000269|PubMed:26166433, ECO:0000269|PubMed:26504226, CC ECO:0000269|PubMed:31492966, ECO:0000269|PubMed:37279284, CC ECO:0000269|PubMed:9187108, ECO:0000269|PubMed:9256433, CC ECO:0000269|PubMed:9593664, ECO:0000269|PubMed:9616126, CC ECO:0000269|PubMed:9811831}. CC -!- FUNCTION: [Isoform alpha]: Functional kinase, like isoform 1 it CC antagonizes the PI3K-AKT/PKB signaling pathway. Plays a role in CC mitochondrial energetic metabolism by promoting COX activity and ATP CC production, via collaboration with isoform 1 in increasing protein CC levels of PINK1. {ECO:0000269|PubMed:23744781}. CC -!- CATALYTIC ACTIVITY: CC Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5- CC trisphosphate) + H2O = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo- CC inositol-4,5-bisphosphate) + phosphate; Xref=Rhea:RHEA:25017, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:57836, CC ChEBI:CHEBI:58456; EC=3.1.3.67; CC Evidence={ECO:0000269|PubMed:16824732, ECO:0000269|PubMed:9811831}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:25018; CC Evidence={ECO:0000305|PubMed:16824732}; CC -!- CATALYTIC ACTIVITY: CC Reaction=O-phospho-L-seryl-[protein] + H2O = L-seryl-[protein] + CC phosphate; Xref=Rhea:RHEA:20629, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15377, ChEBI:CHEBI:29999, ChEBI:CHEBI:43474, CC ChEBI:CHEBI:83421; EC=3.1.3.16; CC Evidence={ECO:0000269|PubMed:9256433}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:20630; CC Evidence={ECO:0000305|PubMed:9256433}; CC -!- CATALYTIC ACTIVITY: CC Reaction=O-phospho-L-threonyl-[protein] + H2O = L-threonyl-[protein] + CC phosphate; Xref=Rhea:RHEA:47004, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15377, ChEBI:CHEBI:30013, ChEBI:CHEBI:43474, CC ChEBI:CHEBI:61977; EC=3.1.3.16; CC Evidence={ECO:0000269|PubMed:9256433}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:47005; CC Evidence={ECO:0000305|PubMed:9256433}; CC -!- CATALYTIC ACTIVITY: CC Reaction=O-phospho-L-tyrosyl-[protein] + H2O = L-tyrosyl-[protein] + CC phosphate; Xref=Rhea:RHEA:10684, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978; EC=3.1.3.48; Evidence={ECO:0000269|PubMed:9187108, CC ECO:0000269|PubMed:9256433}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:10685; CC Evidence={ECO:0000305|PubMed:9256433}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5- CC trisphosphate) + H2O = 1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo- CC inositol-4,5-bisphosphate) + phosphate; Xref=Rhea:RHEA:43552, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:83416, CC ChEBI:CHEBI:83419; Evidence={ECO:0000269|PubMed:16824732, CC ECO:0000269|PubMed:9593664}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43553; CC Evidence={ECO:0000305|PubMed:16824732}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1,2-dihexadecanoyl-sn-glycero-3-phospho-(1D-myo-inositol- CC 3,4,5-trisphosphate) + H2O = 1,2-dihexadecanoyl-sn-glycero-3-phospho- CC (1D-myo-inositol-4,5-bisphosphate) + phosphate; Xref=Rhea:RHEA:43560, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:83420, CC ChEBI:CHEBI:83423; Evidence={ECO:0000269|PubMed:16824732, CC ECO:0000269|PubMed:9593664}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43561; CC Evidence={ECO:0000305|PubMed:16824732}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1D-myo-inositol 1,3,4,5,6-pentakisphosphate + H2O = 1D-myo- CC inositol 1,4,5,6-tetrakisphosphate + phosphate; Xref=Rhea:RHEA:77143, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:57627, CC ChEBI:CHEBI:57733; Evidence={ECO:0000269|PubMed:11418101}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:77144; CC Evidence={ECO:0000269|PubMed:11418101}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1D-myo-inositol 1,3,4,5-tetrakisphosphate + H2O = 1D-myo- CC inositol 1,4,5-trisphosphate + phosphate; Xref=Rhea:RHEA:77155, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:57895, CC ChEBI:CHEBI:203600; Evidence={ECO:0000269|PubMed:9593664}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:77156; CC Evidence={ECO:0000305|PubMed:9593664}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- ACTIVITY REGULATION: Enzymatic activity is enhanced in the presence of CC phosphatidylserine. {ECO:0000269|PubMed:16824732}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=26 uM for PtdIns(3,4,5)P3 {ECO:0000269|PubMed:11418101}; CC KM=11.5 uM for 1D-myo-inositol 1,3,4-trisphosphate CC {ECO:0000269|PubMed:11418101}; CC KM=4.6 uM for 1D-myo-inositol 1,3,4,5-tetrakisphosphate CC {ECO:0000269|PubMed:11418101}; CC KM=7.1 uM for 1D-myo-inositol 1,3,4,5,6-pentakisphosphate CC {ECO:0000269|PubMed:11418101}; CC Vmax=60 nmol/min/mg enzyme with PtdIns(3,4,5)P3 as substrate CC {ECO:0000269|PubMed:11418101}; CC Vmax=24 nmol/min/mg enzyme with 1D-myo-inositol 1,3,4-trisphosphate CC as substrate {ECO:0000269|PubMed:11418101}; CC Vmax=112 nmol/min/mg enzyme with 1D-myo-inositol 1,3,4,5- CC tetrakisphosphate as substrate {ECO:0000269|PubMed:11418101}; CC Vmax=67 nmol/min/mg enzyme with 1D-myo-inositol 1,3,4,5,6- CC pentakisphosphate as substrate {ECO:0000269|PubMed:11418101}; CC -!- SUBUNIT: Monomer. The unphosphorylated form interacts with the second CC PDZ domain of MAGI2 and with DLG1 and MAST2 in vitro (PubMed:10646847, CC PubMed:10760291, PubMed:11707428). Interacts with MAGI2, MAGI3, MAST1 CC and MAST3, but neither with MAST4 nor with DLG5; interaction with MAGI2 CC increases protein stability (PubMed:10748157, PubMed:15951562). CC Interacts with NEDD4 (PubMed:17218260). Interacts with NDFIP1 and CC NDFIP2; in the presence of NEDD4 or ITCH, this interaction promotes CC PTEN ubiquitination (PubMed:20534535, PubMed:25801959). Interacts (via CC C2 domain) with FRK (PubMed:19345329). Interacts with USP7; the CC interaction is direct (PubMed:18716620). Interacts with ROCK1 (By CC similarity). Interacts with XIAP/BIRC4 (PubMed:19473982). Interacts CC with STK11; the interaction phosphorylates PTEN (PubMed:15987703). CC Interacts with PPP1R16B (PubMed:25007873). Interacts with NOP53; CC regulates PTEN phosphorylation and increases its stability CC (PubMed:15355975). Interacts (via PDZ domain-binding motif) with DLG4; CC the interaction is induced by NMDA and is required for PTEN location at CC postsynaptic density (By similarity). Interacts with the regulatory p85 CC subunit of the PI3K kinase complex and with Rho GTPase-activating CC protein DLC1; in resting cells, interacts (via C2 tensin-type domain) CC with p85 but, following growth factor stimulation, PTEN is CC phosphorylated which leads to weakened interaction with p85 and CC enhanced interaction (via C2 tensin-type domain) with DLC1 while p85 CC interaction with TNS3 increases (PubMed:26166433). CC {ECO:0000250|UniProtKB:O08586, ECO:0000250|UniProtKB:O54857, CC ECO:0000269|PubMed:10555148, ECO:0000269|PubMed:10646847, CC ECO:0000269|PubMed:10748157, ECO:0000269|PubMed:10760291, CC ECO:0000269|PubMed:11707428, ECO:0000269|PubMed:15355975, CC ECO:0000269|PubMed:15951562, ECO:0000269|PubMed:15987703, CC ECO:0000269|PubMed:17218260, ECO:0000269|PubMed:18716620, CC ECO:0000269|PubMed:19345329, ECO:0000269|PubMed:19473982, CC ECO:0000269|PubMed:20534535, ECO:0000269|PubMed:25007873, CC ECO:0000269|PubMed:25801959, ECO:0000269|PubMed:26166433}. CC -!- INTERACTION: CC P60484; Q9ULX6: AKAP8L; NbExp=2; IntAct=EBI-696162, EBI-357530; CC P60484; Q9NZN5-2: ARHGEF12; NbExp=4; IntAct=EBI-696162, EBI-10984307; CC P60484; P35226: BMI1; NbExp=7; IntAct=EBI-696162, EBI-2341576; CC P60484; P30260: CDC27; NbExp=7; IntAct=EBI-696162, EBI-994813; CC P60484; Q9P0U4: CXXC1; NbExp=2; IntAct=EBI-696162, EBI-949911; CC P60484; Q16643: DBN1; NbExp=5; IntAct=EBI-696162, EBI-351394; CC P60484; Q12959: DLG1; NbExp=2; IntAct=EBI-696162, EBI-357481; CC P60484; Q15700: DLG2; NbExp=2; IntAct=EBI-696162, EBI-80426; CC P60484; P78352: DLG4; NbExp=3; IntAct=EBI-696162, EBI-80389; CC P60484; P42685: FRK; NbExp=7; IntAct=EBI-696162, EBI-1383583; CC P60484; Q9HD26: GOPC; NbExp=4; IntAct=EBI-696162, EBI-349832; CC P60484; A4D2P6: GRID2IP; NbExp=4; IntAct=EBI-696162, EBI-15893226; CC P60484; Q92743: HTRA1; NbExp=4; IntAct=EBI-696162, EBI-352256; CC P60484; Q96QZ7: MAGI1; NbExp=5; IntAct=EBI-696162, EBI-924464; CC P60484; Q86UL8: MAGI2; NbExp=6; IntAct=EBI-696162, EBI-311035; CC P60484; Q5TCQ9: MAGI3; NbExp=9; IntAct=EBI-696162, EBI-310506; CC P60484; Q9Y2H9: MAST1; NbExp=4; IntAct=EBI-696162, EBI-3385920; CC P60484; Q6P0Q8: MAST2; NbExp=4; IntAct=EBI-696162, EBI-493777; CC P60484; O60307: MAST3; NbExp=4; IntAct=EBI-696162, EBI-311420; CC P60484; O75970: MPDZ; NbExp=4; IntAct=EBI-696162, EBI-821405; CC P60484; Q9Y6Q9: NCOA3; NbExp=2; IntAct=EBI-696162, EBI-81196; CC P60484; P46934: NEDD4; NbExp=4; IntAct=EBI-696162, EBI-726944; CC P60484; O14745: NHERF1; NbExp=9; IntAct=EBI-696162, EBI-349787; CC P60484; Q15599: NHERF2; NbExp=6; IntAct=EBI-696162, EBI-1149760; CC P60484; Q8NI35: PATJ; NbExp=3; IntAct=EBI-696162, EBI-724390; CC P60484; P09619: PDGFRB; NbExp=3; IntAct=EBI-696162, EBI-641237; CC P60484; Q9H5P4: PDZD7; NbExp=4; IntAct=EBI-696162, EBI-20859318; CC P60484; Q9NRD5: PICK1; NbExp=2; IntAct=EBI-696162, EBI-79165; CC P60484; P62136: PPP1CA; NbExp=2; IntAct=EBI-696162, EBI-357253; CC P60484; Q06830: PRDX1; NbExp=7; IntAct=EBI-696162, EBI-353193; CC P60484; P60484: PTEN; NbExp=19; IntAct=EBI-696162, EBI-696162; CC P60484; Q14160: SCRIB; NbExp=4; IntAct=EBI-696162, EBI-357345; CC P60484; Q13424: SNTA1; NbExp=4; IntAct=EBI-696162, EBI-717191; CC P60484; Q13884: SNTB1; NbExp=5; IntAct=EBI-696162, EBI-295843; CC P60484; Q9NY99: SNTG2; NbExp=3; IntAct=EBI-696162, EBI-8556870; CC P60484; Q96L92: SNX27; NbExp=4; IntAct=EBI-696162, EBI-2514865; CC P60484; O43791: SPOP; NbExp=4; IntAct=EBI-696162, EBI-743549; CC P60484; Q62696: Dlg1; Xeno; NbExp=2; IntAct=EBI-696162, EBI-389325; CC P60484; O88382: Magi2; Xeno; NbExp=3; IntAct=EBI-696162, EBI-696179; CC P60484; Q9JK71: Magi3; Xeno; NbExp=3; IntAct=EBI-696162, EBI-696226; CC P60484; Q9R1L5: Mast1; Xeno; NbExp=3; IntAct=EBI-696162, EBI-491771; CC P60484; Q60592: Mast2; Xeno; NbExp=4; IntAct=EBI-696162, EBI-493888; CC P60484; Q9JHL1: Nherf2; Xeno; NbExp=2; IntAct=EBI-696162, EBI-538451; CC P60484-1; Q19T08: ECSCR; NbExp=4; IntAct=EBI-15722967, EBI-15778214; CC P60484-1; Q5T2D3: OTUD3; NbExp=9; IntAct=EBI-15722967, EBI-16170539; CC P60484-1; P60484-1: PTEN; NbExp=3; IntAct=EBI-15722967, EBI-15722967; CC P60484-1; Q93009: USP7; NbExp=5; IntAct=EBI-15722967, EBI-302474; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15987703, CC ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:19473982, CC ECO:0000269|PubMed:25801959, ECO:0000269|PubMed:9187108}. Nucleus CC {ECO:0000269|PubMed:15987703, ECO:0000269|PubMed:18716620, CC ECO:0000269|PubMed:19473982, ECO:0000269|PubMed:25801959}. Nucleus, PML CC body {ECO:0000269|PubMed:18716620}. Cell projection, dendritic spine CC {ECO:0000250|UniProtKB:O54857}. Postsynaptic density CC {ECO:0000250|UniProtKB:O54857}. Note=Monoubiquitinated form is nuclear. CC Nonubiquitinated form is cytoplasmic. Colocalized with PML and USP7 in CC PML nuclear bodies (PubMed:18716620). XIAP/BIRC4 promotes its nuclear CC localization (PubMed:19473982). Associares with the postsynaptic CC density in response to NMDAR activation (By similarity). CC {ECO:0000250|UniProtKB:O54857, ECO:0000269|PubMed:18716620, CC ECO:0000269|PubMed:19473982}. CC -!- SUBCELLULAR LOCATION: [Isoform alpha]: Secreted CC {ECO:0000269|PubMed:23744781, ECO:0000269|PubMed:24768297}. Note=May be CC secreted via a classical signal peptide and reenter into cells with the CC help of a poly-Arg motif. {ECO:0000269|PubMed:23744781, CC ECO:0000269|PubMed:24768297}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing, Alternative initiation; Named isoforms=3; CC Name=1; Synonyms=55kDa; CC IsoId=P60484-1; Sequence=Displayed; CC Name=alpha; Synonyms=70kDa, PTEN-long; CC IsoId=P60484-2; Sequence=VSP_055420; CC Name=3; CC IsoId=P60484-3; Sequence=VSP_055421, VSP_055422, VSP_055423; CC -!- TISSUE SPECIFICITY: Expressed at a relatively high level in all adult CC tissues, including heart, brain, placenta, lung, liver, muscle, kidney CC and pancreas. {ECO:0000269|PubMed:9090379}. CC -!- INDUCTION: Down-regulated by TGFB1. {ECO:0000269|PubMed:9187108}. CC -!- DOMAIN: The C2 domain binds phospholipid membranes in vitro in a CC Ca(2+)-independent manner; this binding is important for its tumor CC suppressor function. {ECO:0000269|PubMed:10468583, CC ECO:0000269|PubMed:10555148}. CC -!- PTM: Constitutively phosphorylated by CK2 under normal conditions. CC Phosphorylated in vitro by MAST1, MAST2, MAST3 and STK11. CC Phosphorylation results in an inhibited activity towards PIP3. CC Phosphorylation can both inhibit or promote PDZ-binding. CC Phosphorylation at Tyr-336 by FRK/PTK5 protects this protein from CC ubiquitin-mediated degradation probably by inhibiting its binding to CC NEDD4. Phosphorylation by ROCK1 is essential for its stability and CC activity. Phosphorylation by PLK3 promotes its stability and prevents CC its degradation by the proteasome. Phosphorylated on Thr-319 and Thr- CC 321 in the C2-type tensin domain following EGF stimulation which CC changes its binding preference from the p85 regulatory subunit of the CC PI3K kinase complex to DLC1 (PubMed:26166433). CC {ECO:0000269|PubMed:10646847, ECO:0000269|PubMed:11035045, CC ECO:0000269|PubMed:11707428, ECO:0000269|PubMed:12297295, CC ECO:0000269|PubMed:15951562, ECO:0000269|PubMed:15987703, CC ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:19345329, CC ECO:0000269|PubMed:20940307, ECO:0000269|PubMed:26166433}. CC -!- PTM: Monoubiquitinated; monoubiquitination is increased in presence of CC retinoic acid. Deubiquitinated by USP7; leading to its nuclear CC exclusion. Monoubiquitination of one of either Lys-13 and Lys-289 amino CC acid is sufficient to modulate PTEN compartmentalization. Ubiquitinated CC by XIAP/BIRC4. {ECO:0000269|PubMed:18716620, CC ECO:0000269|PubMed:19473982}. CC -!- PTM: Ubiquitinated by the DCX(DCAF13) E3 ubiquitin ligase complex, CC leading to its degradation. {ECO:0000269|PubMed:31492966}. CC -!- PTM: ISGylated. ISGylation promotes PTEN degradation. CC {ECO:0000269|PubMed:37279284}. CC -!- DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant CC hamartomatous polyposis syndrome with age-related penetrance. Cowden CC syndrome is characterized by hamartomatous lesions affecting CC derivatives of ectodermal, mesodermal and endodermal layers, CC macrocephaly, facial trichilemmomas (benign tumors of the hair follicle CC infundibulum), acral keratoses, papillomatous papules, and elevated CC risk for development of several types of malignancy, particularly CC breast carcinoma in women and thyroid carcinoma in both men and women. CC Colon cancer and renal cell carcinoma have also been reported. CC Hamartomas can be found in virtually every organ, but most commonly in CC the skin, gastrointestinal tract, breast and thyroid. CC {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, CC ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:10772390, CC ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:11230179, CC ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:15355975, CC ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:21659347, CC ECO:0000269|PubMed:24778394, ECO:0000269|PubMed:9140396, CC ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9259288, CC ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, CC ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9467011, CC ECO:0000269|PubMed:9593664, ECO:0000269|PubMed:9600246, CC ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, CC ECO:0000269|PubMed:9811831, ECO:0000269|PubMed:9832031, CC ECO:0000269|PubMed:9915974}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease CC characterized by the occurrence of a slowly enlarging mass within the CC cerebellar cortex corresponding histologically to a cerebellar CC hamartoma. It manifests, most commonly in the third and fourth decades CC of life, with increased intracranial pressure, headache, nausea, CC cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual CC disturbances and other cranial nerve palsies. Various associated CC abnormalities may be present such as megalencephaly, microgyria, CC hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part CC of the PTEN hamartoma tumor syndromes spectrum that also includes CC Cowden syndrome. Note=The disease is caused by variants affecting the CC gene represented in this entry. CC -!- DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) CC [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. CC The hallmark of cutaneous SCC is malignant transformation of normal CC epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of CC endometrium, the mucous lining of the uterus. Most endometrial cancers CC are adenocarcinomas, cancers that begin in cells that make and release CC mucus and other fluids. {ECO:0000269|PubMed:16506206}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Note=PTEN mutations are found in a subset of patients with CC Proteus syndrome, a genetically heterogeneous condition. The molecular CC diagnosis of PTEN mutation positive cases classifies Proteus syndrome CC patients as part of the PTEN hamartoma syndrome spectrum. As such, CC patients surviving the early years of Proteus syndrome are likely at a CC greater risk of developing malignancies. CC -!- DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant CC central nervous system neoplasms derived from glial cells. They CC comprise astrocytomas and glioblastoma multiforme that are derived from CC astrocytes, oligodendrogliomas derived from oligodendrocytes and CC ependymomas derived from ependymocytes. {ECO:0000269|PubMed:12085208}. CC Note=Disease susceptibility is associated with variants affecting the CC gene represented in this entry. CC -!- DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in CC tissues of the prostate. Most prostate cancers are adenocarcinomas that CC develop in the acini of the prostatic ducts. Other rare histopathologic CC types of prostate cancer that occur in approximately 5% of patients CC include small cell carcinoma, mucinous carcinoma, prostatic ductal CC carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal CC cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell CC carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:26504226, CC ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients CC have autism spectrum disorders and macrocephaly, with head CC circumferences ranging from +2.5 to +8 SD for age and sex (average head CC circumference +4.0 SD). {ECO:0000269|PubMed:15805158, CC ECO:0000269|PubMed:23160955, ECO:0000269|PubMed:26637798}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and CC PTEN is a cause of chromosome 10q23 deletion syndrome, which shows CC overlapping features of the following three disorders: Bannayan-Zonana CC syndrome, Cowden disease and juvenile polyposis syndrome. CC -!- MISCELLANEOUS: [Isoform alpha]: Produced by alternative initiation at CC an upstream CTG start codon. May contain a signal peptide at positions CC 1-21. {ECO:0000269|PubMed:23744781, ECO:0000269|PubMed:24768297}. CC -!- SIMILARITY: Belongs to the PTEN phosphatase protein family. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/158/PTEN"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U96180; AAB66902.1; -; mRNA. DR EMBL; U92436; AAC51182.1; -; mRNA. DR EMBL; U93051; AAC51183.1; -; mRNA. DR EMBL; AF143315; AAD38372.1; -; Genomic_DNA. DR EMBL; AF143312; AAD38372.1; JOINED; Genomic_DNA. DR EMBL; AF143313; AAD38372.1; JOINED; Genomic_DNA. DR EMBL; AF143314; AAD38372.1; JOINED; Genomic_DNA. DR EMBL; AF000734; AAC08699.1; -; Genomic_DNA. DR EMBL; AF000726; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000727; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000728; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000729; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000730; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000731; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000732; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000733; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF067844; AAD13528.1; -; Genomic_DNA. DR EMBL; JF268690; ADZ48535.1; -; mRNA. DR EMBL; CR450306; CAG29302.1; -; mRNA. DR EMBL; AK313581; BAG36351.1; -; mRNA. DR EMBL; DQ073384; AAY57327.1; -; Genomic_DNA. DR EMBL; CH471066; EAW50174.1; -; Genomic_DNA. DR EMBL; BC005821; AAH05821.1; -; mRNA. DR CCDS; CCDS31238.1; -. [P60484-1] DR RefSeq; NP_000305.3; NM_000314.6. [P60484-1] DR RefSeq; NP_001291647.1; NM_001304718.1. DR PDB; 1D5R; X-ray; 2.10 A; A=8-353. DR PDB; 2KYL; NMR; -; B=391-403. DR PDB; 4O1V; X-ray; 2.00 A; B=354-368. DR PDB; 5BUG; X-ray; 2.40 A; A/B/C/D=14-351. DR PDB; 5BZX; X-ray; 2.50 A; A/B/C/D=14-351. DR PDB; 5BZZ; X-ray; 2.20 A; A/B/C/D=14-351. DR PDB; 7JTX; X-ray; 3.23 A; A=7-395. DR PDB; 7JUK; X-ray; 3.15 A; A=7-353, A=378-390. DR PDB; 7JUL; X-ray; 2.53 A; A=7-353, A=378-390. DR PDB; 7JVX; X-ray; 3.20 A; A=1-403. DR PDB; 7PC7; X-ray; 2.10 A; E/F=394-403. DR PDB; 8X3S; X-ray; 1.87 A; B=29-41. DR PDBsum; 1D5R; -. DR PDBsum; 2KYL; -. DR PDBsum; 4O1V; -. DR PDBsum; 5BUG; -. DR PDBsum; 5BZX; -. DR PDBsum; 5BZZ; -. DR PDBsum; 7JTX; -. DR PDBsum; 7JUK; -. DR PDBsum; 7JUL; -. DR PDBsum; 7JVX; -. DR PDBsum; 7PC7; -. DR PDBsum; 8X3S; -. DR AlphaFoldDB; P60484; -. DR SMR; P60484; -. DR BioGRID; 111700; 852. DR ComplexPortal; CPX-3153; PTEN phosphatase complex. DR CORUM; P60484; -. DR DIP; DIP-35019N; -. DR ELM; P60484; -. DR FunCoup; P60484; 3633. DR IntAct; P60484; 439. DR MINT; P60484; -. DR STRING; 9606.ENSP00000361021; -. DR BindingDB; P60484; -. DR ChEMBL; CHEMBL2052032; -. DR DrugBank; DB04327; Phosphatidylethanolamine. DR GuidetoPHARMACOLOGY; 2497; -. DR SwissLipids; SLP:000000849; -. DR TCDB; 1.A.51.2.4; the voltage-gated proton channel (vpc) family. DR CarbonylDB; P60484; -. DR DEPOD; PTEN; -. DR GlyGen; P60484; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; P60484; -. DR MetOSite; P60484; -. DR PhosphoSitePlus; P60484; -. DR BioMuta; PTEN; -. DR DMDM; 42560209; -. DR CPTAC; CPTAC-5746; -. DR CPTAC; CPTAC-5747; -. DR CPTAC; CPTAC-5748; -. DR CPTAC; non-CPTAC-5426; -. DR CPTAC; non-CPTAC-5429; -. DR CPTAC; non-CPTAC-5430; -. DR CPTAC; non-CPTAC-5566; -. DR CPTAC; non-CPTAC-5567; -. DR jPOST; P60484; -. DR MassIVE; P60484; -. DR PaxDb; 9606-ENSP00000361021; -. DR PeptideAtlas; P60484; -. DR ProteomicsDB; 57209; -. [P60484-1] DR Pumba; P60484; -. DR Antibodypedia; 3420; 1732 antibodies from 53 providers. DR CPTC; P60484; 8 antibodies. DR DNASU; 5728; -. DR Ensembl; ENST00000371953.8; ENSP00000361021.3; ENSG00000171862.16. [P60484-1] DR Ensembl; ENST00000644628.2; ENSP00000494918.2; ENSG00000284792.2. [P60484-1] DR Ensembl; ENST00000688308.1; ENSP00000508752.1; ENSG00000171862.16. [P60484-1] DR Ensembl; ENST00000710385.1; ENSP00000518242.1; ENSG00000284792.2. [P60484-1] DR Ensembl; ENST00000710387.1; ENSP00000518244.1; ENSG00000284792.2. [P60484-2] DR GeneID; 5728; -. DR KEGG; hsa:5728; -. DR MANE-Select; ENST00000371953.8; ENSP00000361021.3; NM_000314.8; NP_000305.3. DR UCSC; uc001kfb.4; human. [P60484-1] DR AGR; HGNC:9588; -. DR CIViC; 5728; 123 evidence items across 65 molecular profiles. DR ClinPGx; PA33942; -. DR CTD; 5728; -. DR DisGeNET; 5728; -. DR GeneCards; PTEN; -. DR GeneReviews; PTEN; -. DR HGNC; HGNC:9588; PTEN. DR HPA; ENSG00000171862; Low tissue specificity. DR MalaCards; PTEN; -. DR MIM; 137800; phenotype. DR MIM; 158350; phenotype. DR MIM; 176807; phenotype. DR MIM; 275355; phenotype. DR MIM; 601728; gene. DR MIM; 605309; phenotype. DR MIM; 608089; phenotype. DR MIM; 612242; phenotype. DR MIM; 613028; phenotype. DR OpenTargets; ENSG00000171862; -. DR Orphanet; 109; Bannayan-Riley-Ruvalcaba syndrome. DR Orphanet; 201; Cowden syndrome. DR Orphanet; 145; Hereditary breast and/or ovarian cancer syndrome. DR Orphanet; 79076; Juvenile polyposis of infancy. DR Orphanet; 65285; Lhermitte-Duclos disease. DR Orphanet; 210548; Macrocephaly-intellectual disability-autism syndrome. DR Orphanet; 2969; Proteus-like syndrome. DR Orphanet; 137608; Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome. DR Orphanet; 494547; Squamous cell carcinoma of the hypopharynx. DR Orphanet; 494550; Squamous cell carcinoma of the larynx. DR Orphanet; 502366; Squamous cell carcinoma of the lip. DR Orphanet; 500464; Squamous cell carcinoma of the nasal cavity and paranasal sinuses. DR Orphanet; 502363; Squamous cell carcinoma of the oral cavity. DR Orphanet; 500478; Squamous cell carcinoma of the oropharynx. DR VEuPathDB; HostDB:ENSG00000171862; -. DR eggNOG; KOG2283; Eukaryota. DR GeneTree; ENSGT00940000154335; -. DR HOGENOM; CLU_020105_5_2_1; -. DR InParanoid; P60484; -. DR OMA; CKKFKQR; -. DR OrthoDB; 16692at2759; -. DR PAN-GO; P60484; 12 GO annotations based on evolutionary models. DR PhylomeDB; P60484; -. DR BioCyc; MetaCyc:HS10404-MONOMER; -. DR BRENDA; 3.1.3.16; 2681. DR BRENDA; 3.1.3.67; 2681. DR PathwayCommons; P60484; -. DR Reactome; R-HSA-1660499; Synthesis of PIPs at the plasma membrane. DR Reactome; R-HSA-1855204; Synthesis of IP3 and IP4 in the cytosol. DR Reactome; R-HSA-199418; Negative regulation of the PI3K/AKT network. DR Reactome; R-HSA-202424; Downstream TCR signaling. DR Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes. DR Reactome; R-HSA-5674404; PTEN Loss of Function in Cancer. DR Reactome; R-HSA-5689880; Ub-specific processing proteases. DR Reactome; R-HSA-5689896; Ovarian tumor domain proteases. DR Reactome; R-HSA-8943723; Regulation of PTEN mRNA translation. DR Reactome; R-HSA-8948747; Regulation of PTEN localization. DR Reactome; R-HSA-8948751; Regulation of PTEN stability and activity. DR Reactome; R-HSA-8986944; Transcriptional Regulation by MECP2. DR SignaLink; P60484; -. DR SIGNOR; P60484; -. DR Agora; ENSG00000171862; -. DR BioGRID-ORCS; 5728; 85 hits in 1159 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; B5B9A610; PML body. DR ChiTaRS; PTEN; human. DR EvolutionaryTrace; P60484; -. DR GeneWiki; PTEN_(gene); -. DR GenomeRNAi; 5728; -. DR Pharos; P60484; Tchem. DR PRO; PR:P60484; -. DR Proteomes; UP000005640; Chromosome 10. DR RNAct; P60484; protein. DR Bgee; ENSG00000171862; Expressed in sperm and 191 other cell types or tissues. DR ExpressionAtlas; P60484; baseline and differential. DR GO; GO:0016324; C:apical plasma membrane; IMP:UniProtKB. DR GO; GO:0042995; C:cell projection; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0009898; C:cytoplasmic side of plasma membrane; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0043197; C:dendritic spine; IEA:UniProtKB-SubCell. DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell. DR GO; GO:0035749; C:myelin sheath adaxonal region; ISS:BHF-UCL. DR GO; GO:0043005; C:neuron projection; ISS:BHF-UCL. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0016605; C:PML body; IEA:UniProtKB-SubCell. DR GO; GO:0014069; C:postsynaptic density; IEA:UniProtKB-SubCell. DR GO; GO:0043220; C:Schmidt-Lanterman incisure; ISS:BHF-UCL. DR GO; GO:0097225; C:sperm midpiece; IDA:HPA. DR GO; GO:0097228; C:sperm principal piece; IDA:HPA. DR GO; GO:0010997; F:anaphase-promoting complex binding; IPI:BHF-UCL. DR GO; GO:0008013; F:beta-catenin binding; IPI:BHF-UCL. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0030351; F:inositol-1,3,4,5,6-pentakisphosphate 3-phosphatase activity; IDA:UniProtKB. DR GO; GO:0051717; F:inositol-1,3,4,5-tetrakisphosphate 3-phosphatase activity; IDA:UniProtKB. DR GO; GO:0008289; F:lipid binding; IEA:UniProtKB-KW. DR GO; GO:0140678; F:molecular function inhibitor activity; IMP:DisProt. DR GO; GO:0030165; F:PDZ domain binding; IPI:UniProtKB. DR GO; GO:0052866; F:phosphatidylinositol phosphate phosphatase activity; IDA:UniProt. DR GO; GO:0016314; F:phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase activity; IDA:UniProtKB. DR GO; GO:0051800; F:phosphatidylinositol-3,4-bisphosphate 3-phosphatase activity; IDA:UniProtKB. DR GO; GO:0004438; F:phosphatidylinositol-3-phosphate phosphatase activity; IDA:UniProtKB. DR GO; GO:0004721; F:phosphoprotein phosphatase activity; IDA:BHF-UCL. DR GO; GO:0004722; F:protein serine/threonine phosphatase activity; IDA:UniProtKB. DR GO; GO:0004725; F:protein tyrosine phosphatase activity; IDA:UniProtKB. DR GO; GO:1990757; F:ubiquitin ligase activator activity; ISS:BHF-UCL. DR GO; GO:1990381; F:ubiquitin-specific protease binding; IPI:MGI. DR GO; GO:0030534; P:adult behavior; ISS:BHF-UCL. DR GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW. DR GO; GO:0016477; P:cell migration; ISS:UniProtKB. DR GO; GO:0048870; P:cell motility; IBA:GO_Central. DR GO; GO:0071257; P:cellular response to electrical stimulus; IMP:BHF-UCL. DR GO; GO:0007417; P:central nervous system development; ISS:UniProtKB. DR GO; GO:0032286; P:central nervous system myelin maintenance; ISS:BHF-UCL. DR GO; GO:0021955; P:central nervous system neuron axonogenesis; ISS:BHF-UCL. DR GO; GO:0060997; P:dendritic spine morphogenesis; ISS:BHF-UCL. DR GO; GO:0021542; P:dentate gyrus development; ISS:BHF-UCL. DR GO; GO:0048853; P:forebrain morphogenesis; ISS:BHF-UCL. DR GO; GO:0007507; P:heart development; ISS:UniProtKB. DR GO; GO:0007611; P:learning or memory; ISS:BHF-UCL. DR GO; GO:0045475; P:locomotor rhythm; ISS:BHF-UCL. DR GO; GO:0007626; P:locomotory behavior; ISS:BHF-UCL. DR GO; GO:0042711; P:maternal behavior; ISS:BHF-UCL. DR GO; GO:0033555; P:multicellular organismal response to stress; ISS:BHF-UCL. DR GO; GO:0050771; P:negative regulation of axonogenesis; ISS:BHF-UCL. DR GO; GO:1902807; P:negative regulation of cell cycle G1/S phase transition; IDA:UniProtKB. DR GO; GO:0030336; P:negative regulation of cell migration; IMP:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:BHF-UCL. DR GO; GO:0045792; P:negative regulation of cell size; ISS:BHF-UCL. DR GO; GO:2000773; P:negative regulation of cellular senescence; ISS:BHF-UCL. DR GO; GO:0010719; P:negative regulation of epithelial to mesenchymal transition; IMP:BHF-UCL. DR GO; GO:0090394; P:negative regulation of excitatory postsynaptic potential; ISS:BHF-UCL. DR GO; GO:0051895; P:negative regulation of focal adhesion assembly; IMP:UniProtKB. DR GO; GO:2000134; P:negative regulation of G1/S transition of mitotic cell cycle; IDA:BHF-UCL. DR GO; GO:0051548; P:negative regulation of keratinocyte migration; IMP:BHF-UCL. DR GO; GO:0010977; P:negative regulation of neuron projection development; ISS:ARUK-UCL. DR GO; GO:0046621; P:negative regulation of organ growth; ISS:BHF-UCL. DR GO; GO:0045668; P:negative regulation of osteoblast differentiation; IDA:UniProt. DR GO; GO:0033137; P:negative regulation of peptidyl-serine phosphorylation; IMP:UniProtKB. DR GO; GO:0051898; P:negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:UniProt. DR GO; GO:2000808; P:negative regulation of synaptic vesicle clustering; ISS:BHF-UCL. DR GO; GO:1904706; P:negative regulation of vascular associated smooth muscle cell proliferation; IMP:BHF-UCL. DR GO; GO:1903690; P:negative regulation of wound healing, spreading of epidermal cells; IMP:BHF-UCL. DR GO; GO:0007270; P:neuron-neuron synaptic transmission; ISS:BHF-UCL. DR GO; GO:0043491; P:phosphatidylinositol 3-kinase/protein kinase B signal transduction; IBA:GO_Central. DR GO; GO:0006661; P:phosphatidylinositol biosynthetic process; TAS:Reactome. DR GO; GO:0046856; P:phosphatidylinositol dephosphorylation; IDA:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; ISS:BHF-UCL. DR GO; GO:2000463; P:positive regulation of excitatory postsynaptic potential; ISS:BHF-UCL. DR GO; GO:1902533; P:positive regulation of intracellular signal transduction; IMP:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:BHF-UCL. DR GO; GO:2000060; P:positive regulation of ubiquitin-dependent protein catabolic process; IDA:BHF-UCL. DR GO; GO:0097107; P:postsynaptic density assembly; ISS:BHF-UCL. DR GO; GO:0060134; P:prepulse inhibition; ISS:BHF-UCL. DR GO; GO:0097105; P:presynaptic membrane assembly; ISS:BHF-UCL. DR GO; GO:0006470; P:protein dephosphorylation; IDA:UniProtKB. DR GO; GO:0050821; P:protein stabilization; IDA:BHF-UCL. DR GO; GO:0010975; P:regulation of neuron projection development; ISS:UniProtKB. DR GO; GO:0051896; P:regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IBA:GO_Central. DR GO; GO:0031647; P:regulation of protein stability; IMP:UniProtKB. DR GO; GO:0060024; P:rhythmic synaptic transmission; ISS:BHF-UCL. DR GO; GO:0035176; P:social behavior; ISS:BHF-UCL. DR GO; GO:0007056; P:spindle assembly involved in female meiosis; IDA:UniProt. DR GO; GO:0007416; P:synapse assembly; ISS:BHF-UCL. DR GO; GO:0060074; P:synapse maturation; ISS:BHF-UCL. DR CDD; cd14509; PTP_PTEN; 1. DR DisProt; DP03296; -. DR DisProt; DP03399; -. [P60484-2] DR FunFam; 2.60.40.1110:FF:000003; Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN; 1. DR FunFam; 3.90.190.10:FF:000029; Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN; 1. DR Gene3D; 2.60.40.1110; -; 1. DR Gene3D; 3.90.190.10; Protein tyrosine phosphatase superfamily; 1. DR InterPro; IPR017361; Bifunc_PIno_P3_Pase/Pase_PTEN. DR InterPro; IPR035892; C2_domain_sf. DR InterPro; IPR051281; Dual-spec_lipid-protein_phosph. DR InterPro; IPR029021; Prot-tyrosine_phosphatase-like. DR InterPro; IPR045101; PTP_PTEN. DR InterPro; IPR014020; Tensin_C2-dom. DR InterPro; IPR029023; Tensin_phosphatase. DR InterPro; IPR016130; Tyr_Pase_AS. DR InterPro; IPR003595; Tyr_Pase_cat. DR InterPro; IPR000387; Tyr_Pase_dom. DR PANTHER; PTHR12305; PHOSPHATASE WITH HOMOLOGY TO TENSIN; 1. DR PANTHER; PTHR12305:SF81; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE 3-PHOSPHATASE AND DUAL-SPECIFICITY PROTEIN PHOSPHATASE PTEN; 1. DR Pfam; PF10409; PTEN_C2; 1. DR Pfam; PF22785; Tc-R-P; 1. DR PIRSF; PIRSF038025; PTEN; 1. DR SMART; SM01326; PTEN_C2; 1. DR SMART; SM00404; PTPc_motif; 1. DR SMART; SM01301; PTPlike_phytase; 1. DR SUPFAM; SSF52799; (Phosphotyrosine protein) phosphatases II; 1. DR SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1. DR PROSITE; PS51182; C2_TENSIN; 1. DR PROSITE; PS51181; PPASE_TENSIN; 1. DR PROSITE; PS50056; TYR_PHOSPHATASE_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative initiation; Alternative splicing; KW Apoptosis; Autism spectrum disorder; Cell projection; Cytoplasm; KW Disease variant; Hydrolase; Isopeptide bond; Lipid metabolism; KW Lipid-binding; Neurogenesis; Nucleus; Phosphoprotein; Protein phosphatase; KW Proteomics identification; Reference proteome; Secreted; Synapse; KW Tumor suppressor; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22814378" FT CHAIN 2..403 FT /note="Phosphatidylinositol 3,4,5-trisphosphate 3- FT phosphatase and dual-specificity protein phosphatase PTEN" FT /id="PRO_0000215904" FT DOMAIN 14..185 FT /note="Phosphatase tensin-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00590" FT DOMAIN 190..350 FT /note="C2 tensin-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00589" FT REGION 338..348 FT /note="Required for interaction with NOP53" FT /evidence="ECO:0000269|PubMed:15355975" FT REGION 352..403 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 401..403 FT /note="PDZ domain-binding" FT /evidence="ECO:0000250|UniProtKB:O08586" FT COMPBIAS 360..369 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 383..393 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 124 FT /note="Phosphocysteine intermediate" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00590" FT MOD_RES 2 FT /note="N-acetylthreonine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 294 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O08586" FT MOD_RES 319 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:26166433" FT MOD_RES 321 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:26166433" FT MOD_RES 336 FT /note="Phosphotyrosine; by FRK" FT /evidence="ECO:0000269|PubMed:19345329" FT MOD_RES 366 FT /note="Phosphothreonine; by GSK3-beta and PLK3" FT /evidence="ECO:0000269|PubMed:12297295, FT ECO:0000269|PubMed:20940307, ECO:0007744|PubMed:24275569" FT MOD_RES 370 FT /note="Phosphoserine; by CK2 and PLK3" FT /evidence="ECO:0000269|PubMed:11035045, FT ECO:0000269|PubMed:12297295, ECO:0000269|PubMed:20940307" FT MOD_RES 380 FT /note="Phosphoserine; by ROCK1 and CK2" FT /evidence="ECO:0000269|PubMed:11035045" FT MOD_RES 382 FT /note="Phosphothreonine; by ROCK1 and CK2" FT /evidence="ECO:0000269|PubMed:11035045" FT MOD_RES 383 FT /note="Phosphothreonine; by ROCK1 and CK2" FT /evidence="ECO:0000269|PubMed:11035045" FT MOD_RES 385 FT /note="Phosphoserine; by CK2" FT /evidence="ECO:0000269|PubMed:11035045, FT ECO:0000269|PubMed:12297295" FT MOD_RES 401 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:10646847" FT CROSSLNK 13 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:18716620" FT CROSSLNK 289 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:18716620" FT VAR_SEQ 1 FT /note="M -> MERGGEAAAAAAAAAAAPGRGSESPVTISRAGNAGELVSPLLLPPTR FT RRRRRHIQGPGPVLNLPCAAAAPPVARAPEAAGGGSRSEDYSSSPHSAAAAARPLAAEE FT KQAQSLQPSSSRRSSHYPAAVQSQAAAERGASATAKSRAISILQKKPRHQQLLPSLSSF FT FFSHRLPDM (in isoform alpha)" FT /evidence="ECO:0000305" FT /id="VSP_055420" FT VAR_SEQ 55..70 FT /note="RFLDSKHKNHYKIYNL -> S (in isoform 3)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_055421" FT VAR_SEQ 165..190 FT /note="GVTIPSQRRYVYYYSYLLKNHLDYRP -> ADPTGGIPDKGIIVIGDGSSMD FT VIAP (in isoform 3)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_055422" FT VAR_SEQ 191..403 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_055423" FT VARIANT 10 FT /note="S -> N (retains phosphatase activity towards FT Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains the ability to FT bind phospholipid membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026248" FT VARIANT 15 FT /note="R -> S (in CWS1; also found in glioma; FT dbSNP:rs1064794096)" FT /evidence="ECO:0000269|PubMed:21659347, FT ECO:0000269|PubMed:9090379" FT /id="VAR_007457" FT VARIANT 16 FT /note="Y -> C (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; retains the ability to bind phospholipid FT membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026249" FT VARIANT 19 FT /note="D -> N (in malignant melanoma; somatic mutation; FT dbSNP:rs121909233)" FT /evidence="ECO:0000269|PubMed:10978354" FT /id="VAR_018100" FT VARIANT 20 FT /note="G -> E (reduced phosphatase activity towards FT Ins(1,3,4,5)P4; retains phosphatase activity towards FT PtdIns(3,4,5)P3; dbSNP:rs1064795967)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026250" FT VARIANT 27 FT /note="Y -> S (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; dbSNP:rs886041877)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026251" FT VARIANT 33 FT /note="Missing (in CWS1; dbSNP:rs1554893765)" FT /evidence="ECO:0000269|PubMed:10234502" FT /id="VAR_008733" FT VARIANT 34 FT /note="A -> D (in CWS1)" FT /evidence="ECO:0000269|PubMed:10400993, FT ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:21659347" FT /id="VAR_008734" FT VARIANT 35 FT /note="M -> R (in CWS1; dbSNP:rs121909225)" FT /evidence="ECO:0000269|PubMed:9425889" FT /id="VAR_008036" FT VARIANT 36 FT /note="G -> E (in ENDMC; also found in glioma; FT dbSNP:rs1554893792)" FT /evidence="ECO:0000269|PubMed:16506206, FT ECO:0000269|PubMed:9090379" FT /id="VAR_007458" FT VARIANT 36 FT /note="G -> R (in CWS1; also found in a patient with FT endometrial hyperplasia; dbSNP:rs786204854)" FT /evidence="ECO:0000269|PubMed:10772390, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9635567" FT /id="VAR_026252" FT VARIANT 42 FT /note="L -> R (in glioma; retains phosphatase activity FT towards Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains the FT ability to bind phospholipid membranes)" FT /evidence="ECO:0000269|PubMed:9090379" FT /id="VAR_007459" FT VARIANT 47 FT /note="R -> G (in CWS1; dbSNP:rs786204855)" FT /evidence="ECO:0000269|PubMed:11494117" FT /id="VAR_011587" FT VARIANT 57 FT /note="L -> W (in glioma; likely pathogenic; loss of FT protein phosphatase activity; dbSNP:rs786202398)" FT /evidence="ECO:0000269|PubMed:9090379, FT ECO:0000269|PubMed:9256433" FT /id="VAR_007460" FT VARIANT 61 FT /note="H -> D (found in a patient with congenital cardiac FT disease, macrocephaly, ventriculomegaly, skeletal defects, FT anal atresia, tracheoesophageal fistula, renal anomalies; FT likely pathogenic; dbSNP:rs121909236)" FT /evidence="ECO:0000269|PubMed:11748304" FT /id="VAR_018101" FT VARIANT 61 FT /note="H -> R (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4; dbSNP:rs398123316)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:24778394" FT /id="VAR_026253" FT VARIANT 65..403 FT /note="Missing (in MCEPHAS)" FT /evidence="ECO:0000269|PubMed:26637798" FT /id="VAR_078705" FT VARIANT 67 FT /note="I -> R (in CWS1)" FT /evidence="ECO:0000269|PubMed:9467011" FT /id="VAR_007461" FT VARIANT 68 FT /note="Y -> H (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains the FT ability to bind phospholipid membranes; dbSNP:rs398123317)" FT /evidence="ECO:0000269|PubMed:10400993, FT ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:11494117, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9600246" FT /id="VAR_007462" FT VARIANT 70 FT /note="L -> P (in CWS1; dbSNP:rs121909226)" FT /evidence="ECO:0000269|PubMed:9832031" FT /id="VAR_018102" FT VARIANT 71 FT /note="C -> Y (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026254" FT VARIANT 93 FT /note="H -> R (in MCEPHAS; dbSNP:rs121909238)" FT /evidence="ECO:0000269|PubMed:15805158" FT /id="VAR_032634" FT VARIANT 93 FT /note="H -> Y (in CWS1; dbSNP:rs786204927)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:24778394" FT /id="VAR_026255" FT VARIANT 105 FT /note="C -> F (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026256" FT VARIANT 105 FT /note="C -> Y (in CWS1; dbSNP:rs587782343)" FT /evidence="ECO:0000269|PubMed:10400993, FT ECO:0000269|PubMed:11494117" FT /id="VAR_008735" FT VARIANT 107 FT /note="D -> Y (in CWS1; also found in glioblastoma; loss of FT phosphatase activity towards Ins(1,3,4,5)P4; FT dbSNP:rs57374291)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:9331071" FT /id="VAR_026257" FT VARIANT 112 FT /note="L -> P (in CWS1 and LDD; loss of phosphatase FT activity towards Ins(1,3,4,5)P4; dbSNP:rs121909230)" FT /evidence="ECO:0000269|PubMed:10051160, FT ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:9600246" FT /id="VAR_007807" FT VARIANT 112 FT /note="L -> R (loss of phosphatase activity towards FT Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026258" FT VARIANT 119 FT /note="V -> L (in multiple cancers; dbSNP:rs139767111)" FT /evidence="ECO:0000269|PubMed:10807691" FT /id="VAR_011588" FT VARIANT 121 FT /note="A -> G (in HNSCC; dbSNP:rs121909237)" FT /evidence="ECO:0000269|PubMed:11801303" FT /id="VAR_018103" FT VARIANT 121 FT /note="A -> P (in glioblastoma; loss of phosphatase FT activity towards Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:9331071" FT /id="VAR_026259" FT VARIANT 123 FT /note="H -> R (in CWS1; dbSNP:rs121909222)" FT /evidence="ECO:0000269|PubMed:10234502, FT ECO:0000269|PubMed:9259288" FT /id="VAR_007463" FT VARIANT 123 FT /note="H -> Y (in endometrial cancer; loss of protein FT phosphatase activity; dbSNP:rs786204931)" FT /evidence="ECO:0000269|PubMed:9256433" FT /id="VAR_026260" FT VARIANT 124 FT /note="C -> R (in CWS1; dbSNP:rs121909223)" FT /evidence="ECO:0000269|PubMed:10234502, FT ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:9259288" FT /id="VAR_007464" FT VARIANT 124 FT /note="C -> S (in CWS1; phosphatase-dead protein with FT neither lipid nor protein phosphatase activity; loss of FT phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase FT activity; dbSNP:rs121909223)" FT /evidence="ECO:0000269|PubMed:11230179, FT ECO:0000269|PubMed:9593664, ECO:0000269|PubMed:9811831" FT /id="VAR_018104" FT VARIANT 126 FT /note="A -> G (in a patient with prostate cancer; reduced FT phosphatase activity towards PtdIns(3,4,5); shifts its FT activity from phosphatidylinositol phosphate 3-phosphatase FT to phosphatidylinositol phosphate 5-phosphatase; disrupts FT PI3K/ATK signaling; reduced cell migration)" FT /evidence="ECO:0000269|PubMed:26504226" FT /id="VAR_076551" FT VARIANT 129 FT /note="G -> E (in CWS1; no lipid phosphatase activity but FT retains protein phosphatase activity; retains ability to FT inhibit focal adhesion formation; dbSNP:rs121909218)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:11230179, ECO:0000269|PubMed:21659347, FT ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9616126, FT ECO:0000269|PubMed:9811831" FT /id="VAR_007465" FT VARIANT 129 FT /note="G -> R (in glioblastoma; severely reduced protein FT phosphatase activity; loss of phosphatase activity towards FT Ins(1,3,4,5)P4; dbSNP:rs786204929)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:9072974, ECO:0000269|PubMed:9256433, FT ECO:0000269|PubMed:9331071" FT /id="VAR_007466" FT VARIANT 130 FT /note="R -> G (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; FT dbSNP:rs121909224)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:24778394" FT /id="VAR_026261" FT VARIANT 130 FT /note="R -> L (in CWS1; also found in endometrial FT hyperplasia; loss of phosphatase activity towards FT Ins(1,3,4,5)P4; retains ability to bind phospholipid FT membranes; dbSNP:rs121909229)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:24778394, FT ECO:0000269|PubMed:9635567" FT /id="VAR_007467" FT VARIANT 130 FT /note="R -> Q (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4; retains ability to bind FT phospholipid membranes; dbSNP:rs121909229)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:24778394, FT ECO:0000269|PubMed:9915974" FT /id="VAR_007468" FT VARIANT 131 FT /note="T -> I (in MCEPHAS; dbSNP:rs397514560)" FT /evidence="ECO:0000269|PubMed:23160955" FT /id="VAR_076762" FT VARIANT 132 FT /note="G -> V (in one patient with clinical findings FT suggesting hamartoma tumor syndrome; dbSNP:rs121909241)" FT /evidence="ECO:0000269|PubMed:16752378" FT /id="VAR_032635" FT VARIANT 133 FT /note="V -> I (loss of phosphatase activity towards FT Ins(1,3,4,5)P3)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026262" FT VARIANT 134 FT /note="M -> L (in prostate cancer; no effect on protein FT phosphatase activity; reduced phosphatase activity towards FT Ins(1,3,4,5)P3 but retains PtdIns(3,4,5)P3 phosphatase FT activity)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:9072974, ECO:0000269|PubMed:9256433" FT /id="VAR_007469" FT VARIANT 135 FT /note="I -> V (in CWS1; dbSNP:rs587782360)" FT /evidence="ECO:0000269|PubMed:10400993, FT ECO:0000269|PubMed:11494117" FT /id="VAR_008736" FT VARIANT 136 FT /note="C -> Y (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P3; dbSNP:rs786204859)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9735393" FT /id="VAR_007808" FT VARIANT 137 FT /note="A -> AN (in CWS1)" FT /evidence="ECO:0000269|PubMed:9345101" FT /id="VAR_008737" FT VARIANT 155 FT /note="Y -> C (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4; dbSNP:rs1060500126)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026263" FT VARIANT 158 FT /note="V -> L (in multiple cancers)" FT /evidence="ECO:0000269|PubMed:10807691" FT /id="VAR_011589" FT VARIANT 165 FT /note="G -> E (in CWS1)" FT /evidence="ECO:0000269|PubMed:10234502" FT /id="VAR_008739" FT VARIANT 165 FT /note="G -> R (in CWS1; also found in glioblastoma; FT severely reduced protein phosphatase activity; loss of FT phosphatase activity towards Ins(1,3,4,5)P4; retains FT ability to bind phospholipid membranes; dbSNP:rs587782603)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9256433, FT ECO:0000269|PubMed:9331071" FT /id="VAR_026264" FT VARIANT 165 FT /note="G -> V (in CWS1; dbSNP:rs786204863)" FT /evidence="ECO:0000269|PubMed:9467011" FT /id="VAR_008738" FT VARIANT 167 FT /note="T -> N (in MCEPHAS; dbSNP:rs397514559)" FT /evidence="ECO:0000269|PubMed:23160955" FT /id="VAR_076763" FT VARIANT 167 FT /note="T -> P (in breast cancer; severely reduced protein FT phosphatase activity)" FT /evidence="ECO:0000269|PubMed:9256433" FT /id="VAR_026265" FT VARIANT 170 FT /note="S -> N (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; retains ability to bind phospholipid FT membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026266" FT VARIANT 170 FT /note="S -> R (in CWS1; severely reduced protein FT phosphatase activity; loss of phosphatase activity towards FT Ins(1,3,4,5)P4; dbSNP:rs121909221)" FT /evidence="ECO:0000269|PubMed:10400993, FT ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:11494117, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9241266, FT ECO:0000269|PubMed:9256433" FT /id="VAR_007470" FT VARIANT 173 FT /note="R -> C (in CWS1; also found in endometrial FT hyperplasia; loss of phosphatase activity towards FT Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains ability to bind FT phospholipid membranes; dbSNP:rs121913293)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:24778394, ECO:0000269|PubMed:9635567" FT /id="VAR_026267" FT VARIANT 173 FT /note="R -> H (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; dbSNP:rs121913294)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026268" FT VARIANT 173 FT /note="R -> P (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; dbSNP:rs121913294)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026269" FT VARIANT 174 FT /note="Y -> N (found in a thyroid tumor; somatic variant; FT loss of phosphatase activity towards Ins(1,3,4,5)P4; FT dbSNP:rs587782316)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:39316756" FT /id="VAR_026270" FT VARIANT 191 FT /note="V -> A (in endometrial hyperplasia)" FT /evidence="ECO:0000269|PubMed:9635567" FT /id="VAR_026271" FT VARIANT 217 FT /note="V -> I (in malignant melanoma; somatic mutation; FT dbSNP:rs121909234)" FT /evidence="ECO:0000269|PubMed:10978354" FT /id="VAR_018105" FT VARIANT 227 FT /note="S -> F (reduced phosphatase activity towards FT Ins(1,3,4,5)P4; retains PtdIns(3,4,5)P3 phosphatase FT activity; dbSNP:rs905615413)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026272" FT VARIANT 234 FT /note="R -> Q (in GLM2; uncertain significance; not capable FT of inducing apoptosis; induced increased cell FT proliferation; led to high constitutive AKT1 activation FT which could not be increased further by stimulation with FT insulin; dbSNP:rs121909235)" FT /evidence="ECO:0000269|PubMed:12085208" FT /id="VAR_018106" FT VARIANT 241 FT /note="F -> S (in MCEPHAS; dbSNP:rs121909240)" FT /evidence="ECO:0000269|PubMed:15805158" FT /id="VAR_032636" FT VARIANT 246 FT /note="P -> L (in CWS1; dbSNP:rs587782350)" FT /evidence="ECO:0000269|PubMed:10400993" FT /id="VAR_008740" FT VARIANT 251 FT /note="G -> C (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; retains ability to bind phospholipid FT membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026273" FT VARIANT 252 FT /note="D -> G (in MCEPHAS and CWS1; dbSNP:rs121909239)" FT /evidence="ECO:0000269|PubMed:15805158, FT ECO:0000269|PubMed:21659347" FT /id="VAR_032637" FT VARIANT 289 FT /note="K -> E (in CWS1; reduced phosphatase activity FT towards Ins(1,3,4,5)P4; retains ability to bind FT phospholipid membranes; predominantly nuclear; FT dbSNP:rs562015640)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:9797362" FT /id="VAR_008741" FT VARIANT 290 FT /note="V -> L (in dbSNP:rs35600253)" FT /evidence="ECO:0000269|Ref.10" FT /id="VAR_025167" FT VARIANT 319 FT /note="Missing (in glioma; reduced tumor suppressor FT activity; fails to inactivate AKT/PKB)" FT /evidence="ECO:0000269|PubMed:10468583, FT ECO:0000269|PubMed:9090379" FT /id="VAR_026274" FT VARIANT 331 FT /note="D -> G (in CWS1; reduced phosphatase activity FT towards Ins(1,3,4,5)P4; retains ability to bind FT phospholipid membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026275" FT VARIANT 341 FT /note="F -> V (in CWS1; loss of interaction with NOP53; FT decreased phosphorylation at S-380; decreased stability; FT loss of phosphatase activity towards Ins(1,3,4,5)P4; FT dbSNP:rs1554825652)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:15355975" FT /id="VAR_026276" FT VARIANT 342 FT /note="K -> N (in CWS1; reduced phosphatase activity FT towards Ins(1,3,4,5)P4 but PtdIns(3,4,5)P3 phosphatase FT activity is similar to wild-type; dbSNP:rs398123314)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026277" FT VARIANT 343 FT /note="V -> E (in CWS1; loss of interaction with NOP53; FT decreased phosphorylation at S-380; decreased stability; FT loss of phosphatase activity towards Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:15355975, ECO:0000269|PubMed:9399897" FT /id="VAR_008742" FT VARIANT 345 FT /note="L -> Q (in glioblastoma; reduced tumor suppressor FT activity; loss of interaction with NOP53; decreased FT phosphorylation at S-380; decreased stability; loss of FT phosphatase activity towards Ins(1,3,4,5)P4; reduced FT ability to inactivate AKT/PKB; retains ability to bind FT phospholipid membranes)" FT /evidence="ECO:0000269|PubMed:10468583, FT ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:15355975, FT ECO:0000269|PubMed:9331071" FT /id="VAR_026278" FT VARIANT 347 FT /note="F -> L (in CWS1; reduced phosphatase activity FT towards Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9399897" FT /id="VAR_008743" FT VARIANT 348 FT /note="T -> I (in endometrial hyperplasia; reduced FT phosphatase activity towards PtdIns(3,4,5)P3; mildly FT reduced tumor suppressor activity; reduced ability to FT inactivate AKT/PKB)" FT /evidence="ECO:0000269|PubMed:10468583, FT ECO:0000269|PubMed:9635567" FT /id="VAR_026279" FT VARIANT 369 FT /note="V -> G (retains Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3 FT phosphatase activity; retains ability to bind phospholipid FT membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026280" FT VARIANT 401 FT /note="T -> I (retains Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3 FT phosphatase activity; retains ability to bind phospholipid FT membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026281" FT MUTAGEN 1 FT /note="M->I: Prevents expression of isoform 1 and increased FT expression of isoform alpha." FT /evidence="ECO:0000269|PubMed:24768297" FT MUTAGEN 13 FT /note="K->E: Nuclear. Cytoplasmic; when associated with E- FT 289. Shows less tumor suppressive ability; when associated FT with E-289." FT /evidence="ECO:0000269|PubMed:18716620" FT MUTAGEN 92 FT /note="D->A: 700-fold reduction in phosphatase activity FT towards PtdIns(3,4,5)P3. Loss of protein phosphatase FT activity. Unable to inhibit focal adhesion formation." FT /evidence="ECO:0000269|PubMed:10555148, FT ECO:0000269|PubMed:9616126" FT MUTAGEN 93 FT /note="H->A: 75% reduction in phosphatase activity towards FT PtdIns(3,4,5)P3. Modest reduction in phosphatase activity FT towards PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 124 FT /note="C->A: Loss of protein phosphatase activity. Unable FT to inhibit focal adhesion formation." FT /evidence="ECO:0000269|PubMed:9616126" FT MUTAGEN 125 FT /note="K->M: Reduced phosphatase activity towards FT PtdIns(3,4,5)P3, PtdIns(3,4)P2 and PtdIns(3)P." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 126 FT /note="A->P: Does not reduce phosphatase activity towards FT PtdIns(3,4,5)P3 and PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:26504226" FT MUTAGEN 126 FT /note="A->S: Does not reduce phosphatase activity towards FT PtdIns(3,4,5)P3 and PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:26504226" FT MUTAGEN 126 FT /note="A->V: Does not reduce phosphatase activity towards FT PtdIns(3,4,5)P3 and PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:26504226" FT MUTAGEN 128 FT /note="K->M: 85% reduction in phosphatase activity towards FT PtdIns(3,4,5)P3." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 128 FT /note="K->R: Does not reduce phosphatase activity towards FT PtdIns(3,4,5)P3." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 130 FT /note="R->M: Does not affect the ability to inhibit AKT/PKB FT activation." FT /evidence="ECO:0000269|PubMed:9811831" FT MUTAGEN 167 FT /note="T->A,D: 60% reduction in phosphatase activity FT towards PtdIns(3,4,5)P3." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 171 FT /note="Q->A,E: 75% reduction in phosphatase activity FT towards PtdIns(3,4,5)P3." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 229 FT /note="S->A: No effect on interaction with DLC1 or p85." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 232 FT /note="T->A: No effect on interaction with DLC1 or p85." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 263..269 FT /note="KMLKKDK->AAGAADA: Reduces the growth suppression FT activity and cells show anchorage-independent growth. FT Reduces binding to phospholipid membranes in vitro. FT Phosphatase activity towards PtdIns(3,4,5)P3 is not FT affected." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 289 FT /note="K->E: Cytoplasmic; when associated with E-13. Shows FT less tumor suppressive ability; when associated with E-13." FT /evidence="ECO:0000269|PubMed:18716620" FT MUTAGEN 319 FT /note="T->A: Reduces phosphorylation of the C2 tensin-like FT domain and abolishes interaction with DLC1 following EGF FT stimulation. Abolishes phosphorylation of the C2 tensin- FT like domain; when associated with A-321." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 319 FT /note="T->E: Constitutive interaction with DLC1." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 319 FT /note="T->Y: Constitutive interaction with DLC1 and FT interaction with p85 following EGF stimulation." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 321 FT /note="T->A: Reduces phosphorylation of the C2 tensin-like FT domain and abolishes interaction with DLC1 following EGF FT stimulation. Abolishes phosphorylation of the C2 tensin- FT like domain; when associated with A-319." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 321 FT /note="T->E: Constitutive interaction with DLC1." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 327..335 FT /note="KANKDKANR->AAGADAANA: Reduces growth suppression FT activity and promotes anchorage-independent growth. Reduces FT binding to phospholipid membranes in vitro; phosphatase FT activity towards PtdIns(3,4,5)P3 is not affected." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 336 FT /note="Y->F: Significantly lower phosphatase activity, FT reduced protein stability and decreased growth-inhibitory FT effect." FT /evidence="ECO:0000269|PubMed:19345329" FT MUTAGEN 366 FT /note="T->A: Decreased stability." FT /evidence="ECO:0000269|PubMed:20940307" FT MUTAGEN 370 FT /note="S->A: Decreased stability." FT /evidence="ECO:0000269|PubMed:20940307" FT MUTAGEN 401 FT /note="T->A: Loss of DLG1-binding. No effect on MAGI2- and FT MAST2-binding." FT MUTAGEN 402 FT /note="K->A: No effect on MAGI2-, MAST2- and DLG1-binding." FT MUTAGEN 402 FT /note="K->W: Loss of DLG1-, MAGI2-, MAGI3- and MAST2- FT binding. Decrease of protein stability." FT MUTAGEN 403 FT /note="V->A: Loss of DLG1-, MAGI2-, MAGI3-, MAST1-, FT MAST2- and MAST3-binding." FT /evidence="ECO:0000269|PubMed:15951562" FT HELIX 8..10 FT /evidence="ECO:0007829|PDB:7JUL" FT TURN 19..22 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 23..29 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 32..35 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 39..41 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 44..47 FT /evidence="ECO:0007829|PDB:5BZZ" FT HELIX 50..60 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 61..63 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 65..73 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 78..80 FT /evidence="ECO:0007829|PDB:5BZZ" FT STRAND 81..83 FT /evidence="ECO:0007829|PDB:5BZZ" FT STRAND 85..90 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 98..100 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 101..112 FT /evidence="ECO:0007829|PDB:1D5R" FT TURN 113..115 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 118..123 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 125..128 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 129..141 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 148..159 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 161..163 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 169..184 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 192..202 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 206..209 FT /evidence="ECO:0007829|PDB:5BZZ" FT STRAND 213..219 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 222..226 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 232..235 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 238..259 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 262..264 FT /evidence="ECO:0007829|PDB:5BZZ" FT STRAND 268..276 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 277..279 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 280..284 FT /evidence="ECO:0007829|PDB:5BZZ" FT STRAND 310..312 FT /evidence="ECO:0007829|PDB:5BZX" FT STRAND 315..321 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 322..324 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 328..330 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 335..337 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 342..349 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 395..403 FT /evidence="ECO:0007829|PDB:2KYL" SQ SEQUENCE 403 AA; 47166 MW; 75F97C3DD6802BA9 CRC64; MTAIIKEIVS RNKRRYQEDG FDLDLTYIYP NIIAMGFPAE RLEGVYRNNI DDVVRFLDSK HKNHYKIYNL CAERHYDTAK FNCRVAQYPF EDHNPPQLEL IKPFCEDLDQ WLSEDDNHVA AIHCKAGKGR TGVMICAYLL HRGKFLKAQE ALDFYGEVRT RDKKGVTIPS QRRYVYYYSY LLKNHLDYRP VALLFHKMMF ETIPMFSGGT CNPQFVVCQL KVKIYSSNSG PTRREDKFMY FEFPQPLPVC GDIKVEFFHK QNKMLKKDKM FHFWVNTFFI PGPEETSEKV ENGSLCDQEI DSICSIERAD NDKEYLVLTL TKNDLDKANK DKANRYFSPN FKVKLYFTKT VEEPSNPEAS SSTSVTPDVS DNEPDHYRYS DTTDSDPENE PFDEDQHTQI TKV // ID RAF1_HUMAN Reviewed; 648 AA. AC P04049; B0LPH8; B2R5N3; Q15278; Q9UC20; DT 01-NOV-1986, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1986, sequence version 1. DT 28-JAN-2026, entry version 269. DE RecName: Full=RAF proto-oncogene serine/threonine-protein kinase {ECO:0000305}; DE EC=2.7.11.1 {ECO:0000269|PubMed:17603483}; DE AltName: Full=Proto-oncogene c-RAF; DE Short=cRaf; DE AltName: Full=Raf-1; GN Name=RAF1 {ECO:0000312|HGNC:HGNC:9829}; Synonyms=RAF; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=3003687; DOI=10.1093/nar/14.2.1009; RA Bonner T.I., Oppermann H., Seeburg P., Kerby S.B., Gunnell M.A., RA Young A.C., Rapp U.R.; RT "The complete coding sequence of the human raf oncogene and the RT corresponding structure of the c-raf-1 gene."; RL Nucleic Acids Res. 14:1009-1015(1986). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT LEU-308. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LEU-308. RG NIEHS SNPs program; RL Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Pancreas; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 228-648. RX PubMed=2993863; DOI=10.1128/mcb.5.6.1400-1407.1985; RA Bonner T.I., Kerby S.B., Sutrave P., Gunnell M.A., Mark G., Rapp U.R.; RT "Structure and biological activity of human homologs of the raf/mil RT oncogene."; RL Mol. Cell. Biol. 5:1400-1407(1985). RN [7] RP PROTEIN SEQUENCE OF 42-53; 60-65; 310-316 AND 564-572, INTERACTION WITH RP PRMT5, METHYLATION AT ARG-563, PHOSPHORYLATION AT SER-289; SER-296; RP SER-301; SER-338 AND SER-621, AND MUTAGENESIS OF ARG-563. RX PubMed=21917714; DOI=10.1126/scisignal.2001936; RA Andreu-Perez P., Esteve-Puig R., de Torre-Minguela C., Lopez-Fauqued M., RA Bech-Serra J.J., Tenbaum S., Garcia-Trevijano E.R., Canals F., Merlino G., RA Avila M.A., Recio J.A.; RT "Protein arginine methyltransferase 5 regulates ERK1/2 signal transduction RT amplitude and cell fate through CRAF."; RL Sci. Signal. 4:RA58-RA58(2011). RN [8] RP PROTEIN SEQUENCE OF 254-278, AND PHOSPHORYLATION AT THR-269. RX PubMed=7477354; DOI=10.1038/378307a0; RA Yao B., Zhang Y., Delikat S., Mathias S., Basu S., Kolesnick R.; RT "Phosphorylation of Raf by ceramide-activated protein kinase."; RL Nature 378:307-310(1995). RN [9] RP PARTIAL NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING, AND TISSUE RP SPECIFICITY. RC TISSUE=Placenta; RX PubMed=1886707; RA Dozier C., Ansieau S., Ferreira E., Coll J., Stehelin D.; RT "An alternatively spliced c-mil/raf mRNA is predominantly expressed in RT chicken muscular tissues and conserved among vertebrate species."; RL Oncogene 6:1307-1311(1991). RN [10] RP PHOSPHORYLATION AT SER-43; SER-259; THR-268; SER-499 AND SER-621. RX PubMed=8349614; DOI=10.1016/s0021-9258(19)85336-x; RA Morrison D.K., Heidecker G., Rapp U.R., Copeland T.D.; RT "Identification of the major phosphorylation sites of the Raf-1 kinase."; RL J. Biol. Chem. 268:17309-17316(1993). RN [11] RP INTERACTION WITH YWHAZ, AND FUNCTION. RX PubMed=9360956; DOI=10.1074/jbc.272.46.28882; RA Dubois T., Rommel C., Howell S., Steinhussen U., Soneji Y., Morrice N., RA Moelling K., Aitken A.; RT "14-3-3 is phosphorylated by casein kinase I on residue 233. RT Phosphorylation at this site in vivo regulates Raf/14-3-3 interaction."; RL J. Biol. Chem. 272:28882-28888(1997). RN [12] RP PHOSPHORYLATION. RX PubMed=9823899; DOI=10.1038/24184; RA King A.J., Sun H., Diaz B., Barnard D., Miao W., Bagrodia S., RA Marshall M.S.; RT "The protein kinase Pak3 positively regulates Raf-1 activity through RT phosphorylation of serine 338."; RL Nature 396:180-183(1998). RN [13] RP ERRATUM OF PUBMED:9823899. RA King A.J., Sun H., Diaz B., Barnard D., Miao W., Bagrodia S., RA Marshall M.S.; RL Nature 406:439-439(2000). RN [14] RP PHOSPHORYLATION AT SER-259 BY PKB/AKT1, ACTIVITY REGULATION, AND RP INTERACTION WITH PKB/AKT1. RX PubMed=10576742; DOI=10.1126/science.286.5445.1741; RA Zimmermann S., Moelling K.; RT "Phosphorylation and regulation of Raf by Akt (protein kinase B)."; RL Science 286:1741-1744(1999). RN [15] RP PHOSPHORYLATION AT SER-259 AND SER-621, DEPHOSPHORYLATION AT SER-43; RP SER-259 AND SER-621, ACTIVITY REGULATION, AND INTERACTION WITH PPP2CA AND RP PPP2R1B. RX PubMed=10801873; DOI=10.1074/jbc.m003259200; RA Abraham D., Podar K., Pacher M., Kubicek M., Welzel N., Hemmings B.A., RA Dilworth S.M., Mischak H., Kolch W., Baccarini M.; RT "Raf-1-associated protein phosphatase 2A as a positive regulator of kinase RT activation."; RL J. Biol. Chem. 275:22300-22304(2000). RN [16] RP ACTIVITY REGULATION, AND PHOSPHORYLATION AT THR-491 AND SER-494. RX PubMed=11447113; DOI=10.1093/emboj/20.14.3716; RA Chong H., Lee J., Guan K.L.; RT "Positive and negative regulation of Raf kinase activity and function by RT phosphorylation."; RL EMBO J. 20:3716-3727(2001). RN [17] RP FUNCTION, AND INTERACTION WITH MAP3K5/ASK1. RX PubMed=11427728; DOI=10.1073/pnas.141224398; RA Chen J., Fujii K., Zhang L., Roberts T., Fu H.; RT "Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating RT kinase 1 through a MEK-ERK independent mechanism."; RL Proc. Natl. Acad. Sci. U.S.A. 98:7783-7788(2001). RN [18] RP FUNCTION IN PHOSPHORYLATION OF PPP1R12A, AND INTERACTION WITH PPP1R12A. RX PubMed=11719507; DOI=10.1074/jbc.m106343200; RA Broustas C.G., Grammatikakis N., Eto M., Dent P., Brautigan D.L., Kasid U.; RT "Phosphorylation of the myosin-binding subunit of myosin phosphatase by RT Raf-1 and inhibition of phosphatase activity."; RL J. Biol. Chem. 277:3053-3059(2002). RN [19] RP PHOSPHORYLATION AT SER-338 BY PAK1, ACTIVITY REGULATION, AND INTERACTION RP WITH PAK1. RX PubMed=11733498; DOI=10.1074/jbc.m110000200; RA Zang M., Hayne C., Luo Z.; RT "Interaction between active Pak1 and Raf-1 is necessary for phosphorylation RT and activation of Raf-1."; RL J. Biol. Chem. 277:4395-4405(2002). RN [20] RP PHOSPHORYLATION AT SER-259, DEPHOSPHORYLATION AT SER-259, AND SUBCELLULAR RP LOCATION. RX PubMed=11756411; DOI=10.1074/jbc.m108733200; RA Kubicek M., Pacher M., Abraham D., Podar K., Eulitz M., Baccarini M.; RT "Dephosphorylation of Ser-259 regulates Raf-1 membrane association."; RL J. Biol. Chem. 277:7913-7919(2002). RN [21] RP COMPETITION WITH RIN1. RX PubMed=11784866; DOI=10.1128/mcb.22.3.916-926.2001; RA Wang Y., Waldron R.T., Dhaka A., Patel A., Riley M.M., Rozengurt E., RA Colicelli J.; RT "The RAS effector RIN1 directly competes with RAF and is regulated by 14-3- RT 3 proteins."; RL Mol. Cell. Biol. 22:916-926(2002). RN [22] RP ACTIVITY REGULATION, AND INTERACTION WITH SPRY2 AND SPRY4. RX PubMed=12717443; DOI=10.1038/ncb978; RA Sasaki A., Taketomi T., Kato R., Saeki K., Nonami A., Sasaki M., RA Kuriyama M., Saito N., Shibuya M., Yoshimura A.; RT "Mammalian Sprouty4 suppresses Ras-independent ERK activation by binding to RT Raf1."; RL Nat. Cell Biol. 5:427-432(2003). RN [23] RP PHOSPHORYLATION AT SER-259. RX PubMed=15047712; DOI=10.1074/jbc.m314192200; RA Kunapuli P., Kasyapa C.S., Hawthorn L., Cowell J.K.; RT "LGI1, a putative tumor metastasis suppressor gene, controls in vitro RT invasiveness and expression of matrix metalloproteinases in glioma cells RT through the ERK1/2 pathway."; RL J. Biol. Chem. 279:23151-23157(2004). RN [24] RP ERRATUM OF PUBMED:15047712. RA Kunapuli P., Kasyapa C.S., Hawthorn L., Cowell J.K.; RL J. Biol. Chem. 282:2752-2752(2007). RN [25] RP FUNCTION IN PHOSPHORYLATION OF ADCY2; ADCY5 AND ADCY6, AND INTERACTION WITH RP ADCY2; ADCY5 AND ADCY6. RX PubMed=15385642; DOI=10.1124/mol.66.4.921; RA Ding Q., Gros R., Gray I.D., Taussig R., Ferguson S.S., Feldman R.D.; RT "Raf kinase activation of adenylyl cyclases: isoform-selective RT regulation."; RL Mol. Pharmacol. 66:921-928(2004). RN [26] RP INTERACTION WITH STK3/MST2, AND FUNCTION. RX PubMed=15618521; DOI=10.1126/science.1103233; RA O'Neill E., Rushworth L., Baccarini M., Kolch W.; RT "Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene RT product Raf-1."; RL Science 306:2267-2270(2004). RN [27] RP INTERACTION WITH RCAN1/DSCR1. RX PubMed=15935327; DOI=10.1016/j.abb.2005.05.002; RA Cho Y.J., Abe M., Kim S.Y., Sato Y.; RT "Raf-1 is a binding partner of DSCR1."; RL Arch. Biochem. Biophys. 439:121-128(2005). RN [28] RP REVIEW ON FUNCTION. RX PubMed=15943972; DOI=10.1016/j.febslet.2005.03.024; RA Baccarini M.; RT "Second nature: biological functions of the Raf-1 'kinase'."; RL FEBS Lett. 579:3271-3277(2005). RN [29] RP FUNCTION IN PHOSPHORYLATION OF BAD, PHOSPHORYLATION AT SER-338 AND SER-339 RP BY PAK1, SUBCELLULAR LOCATION, AND INTERACTION WITH BCL2. RX PubMed=15849194; DOI=10.1074/jbc.m413374200; RA Jin S., Zhuo Y., Guo W., Field J.; RT "p21-activated Kinase 1 (Pak1)-dependent phosphorylation of Raf-1 regulates RT its mitochondrial localization, phosphorylation of BAD, and Bcl-2 RT association."; RL J. Biol. Chem. 280:24698-24705(2005). RN [30] RP PHOSPHORYLATION AT SER-471. RX PubMed=16093354; DOI=10.1091/mbc.e05-02-0090; RA Zhu J., Balan V., Bronisz A., Balan K., Sun H., Leicht D.T., Luo Z., RA Qin J., Avruch J., Tzivion G.; RT "Identification of Raf-1 S471 as a novel phosphorylation site critical for RT Raf-1 and B-Raf kinase activities and for MEK binding."; RL Mol. Biol. Cell 16:4733-4744(2005). RN [31] RP IDENTIFICATION IN A COMPLEX WITH PP1CA; PPP1CB; PPP1CC; SHOC2 AND MRAS, RP PHOSPHORYLATION AT SER-259, AND CHARACTERIZATION OF VARIANT ALA-259. RX PubMed=16630891; DOI=10.1016/j.molcel.2006.03.027; RA Rodriguez-Viciana P., Oses-Prieto J., Burlingame A., Fried M., RA McCormick F.; RT "A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit RT of PP1 functions as an M-Ras effector to modulate Raf activity."; RL Mol. Cell 22:217-230(2006). RN [32] RP SUBUNIT. RX PubMed=16508002; DOI=10.1128/mcb.26.6.2262-2272.2006; RA Rushworth L.K., Hindley A.D., O'Neill E., Kolch W.; RT "Regulation and role of Raf-1/B-Raf heterodimerization."; RL Mol. Cell. Biol. 26:2262-2272(2006). RN [33] RP FUNCTION AS KINASE, ACTIVITY REGULATION, PHOSPHORYLATION AT SER-259; RP SER-338; TYR-340; TYR-341 AND SER-621, DEPHOSPHORYLATION AT SER-338 BY RP PPP5C, AND MUTAGENESIS OF 338-SER-SER-339; 340-TYR-TYR-341; THR-491 AND RP SER-494. RX PubMed=16892053; DOI=10.1038/ncb1465; RA von Kriegsheim A., Pitt A., Grindlay G.J., Kolch W., Dhillon A.S.; RT "Regulation of the Raf-MEK-ERK pathway by protein phosphatase 5."; RL Nat. Cell Biol. 8:1011-1016(2006). RN [34] RP REVIEW ON REGULATION. RX PubMed=17218791; DOI=10.4161/cc.6.1.3593; RA Dhillon A.S., von Kriegsheim A., Grindlay J., Kolch W.; RT "Phosphatase and feedback regulation of Raf-1 signaling."; RL Cell Cycle 6:3-7(2007). RN [35] RP FUNCTION. RX PubMed=16924233; DOI=10.1038/sj.onc.1209902; RA Wang Z., Wade P., Mandell K.J., Akyildiz A., Parkos C.A., Mrsny R.J., RA Nusrat A.; RT "Raf 1 represses expression of the tight junction protein occludin via RT activation of the zinc-finger transcription factor slug."; RL Oncogene 26:1222-1230(2007). RN [36] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-252, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17525332; DOI=10.1126/science.1140321; RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., RA Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., RA Gygi S.P., Elledge S.J.; RT "ATM and ATR substrate analysis reveals extensive protein networks RT responsive to DNA damage."; RL Science 316:1160-1166(2007). RN [37] RP ACTIVITY REGULATION, AND INTERACTION WITH PEBP1/RKIP. RX PubMed=18294816; DOI=10.1016/j.cellsig.2008.01.012; RA Rath O., Park S., Tang H.H., Banfield M.J., Brady R.L., Lee Y.C., RA Dignam J.D., Sedivy J.M., Kolch W., Yeung K.C.; RT "The RKIP (Raf-1 Kinase Inhibitor Protein) conserved pocket binds to the RT phosphorylated N-region of Raf-1 and inhibits the Raf-1-mediated activated RT phosphorylation of MEK."; RL Cell. Signal. 20:935-941(2008). RN [38] RP PHOSPHORYLATION AT SER-338 BY PAK5. RX PubMed=18465753; DOI=10.1002/jcb.21809; RA Wu X., Carr H.S., Dan I., Ruvolo P.P., Frost J.A.; RT "p21 activated kinase 5 activates Raf-1 and targets it to mitochondria."; RL J. Cell. Biochem. 105:167-175(2008). RN [39] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [40] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [41] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-642, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [42] RP SUBCELLULAR LOCATION. RX PubMed=19298812; DOI=10.1016/j.yexcr.2009.03.004; RA Smith J., Bunaciu R.P., Reiterer G., Coder D., George T., Asaly M., Yen A.; RT "Retinoic acid induces nuclear accumulation of Raf1 during differentiation RT of HL-60 cells."; RL Exp. Cell Res. 315:2241-2248(2009). RN [43] RP ACTIVITY REGULATION, SUBUNIT, SUBCELLULAR LOCATION, AND INTERACTION WITH RP DGKH. RX PubMed=19710016; DOI=10.1074/jbc.m109.043604; RA Yasuda S., Kai M., Imai S., Takeishi K., Taketomi A., Toyota M., Kanoh H., RA Sakane F.; RT "Diacylglycerol kinase eta augments C-Raf activity and B-Raf/C-Raf RT heterodimerization."; RL J. Biol. Chem. 284:29559-29570(2009). RN [44] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-289 AND SER-301, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [45] RP REVIEW. RX PubMed=20674547; DOI=10.1016/j.bbrc.2010.07.092; RA Roskoski R. Jr.; RT "RAF protein-serine/threonine kinases: structure and regulation."; RL Biochem. Biophys. Res. Commun. 399:313-317(2010). RN [46] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [47] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [48] RP REVIEW. RX PubMed=21779496; DOI=10.1177/1947601911407323; RA Matallanas D., Birtwistle M., Romano D., Zebisch A., Rauch J., RA von Kriegsheim A., Kolch W.; RT "Raf family kinases: old dogs have learned new tricks."; RL Genes Cancer 2:232-260(2011). RN [49] RP MUTAGENESIS OF LYS-375, AND INTERACTION WITH NEK10 AND MAP2K1. RX PubMed=20956560; DOI=10.1128/mcb.00648-10; RA Moniz L.S., Stambolic V.; RT "Nek10 mediates G2/M cell cycle arrest and MEK autoactivation in response RT to UV irradiation."; RL Mol. Cell. Biol. 31:30-42(2011). RN [50] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [51] RP INTERACTION WITH FAM83B. RX PubMed=22886302; DOI=10.1172/jci60517; RA Cipriano R., Graham J., Miskimen K.L., Bryson B.L., Bruntz R.C., RA Scott S.A., Brown H.A., Stark G.R., Jackson M.W.; RT "FAM83B mediates EGFR- and RAS-driven oncogenic transformation."; RL J. Clin. Invest. 122:3197-3210(2012). RN [52] RP INTERACTION WITH GLS. RX PubMed=22538822; DOI=10.1073/pnas.1116573109; RA Thangavelu K., Pan C.Q., Karlberg T., Balaji G., Uttamchandani M., RA Suresh V., Schuler H., Low B.C., Sivaraman J.; RT "Structural basis for the allosteric inhibitory mechanism of human kidney- RT type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in RT cancer cell metabolism."; RL Proc. Natl. Acad. Sci. U.S.A. 109:7705-7710(2012). RN [53] RP INTERACTION WITH MFHAS1. RX PubMed=23327923; DOI=10.1182/blood-2011-10-385252; RA Kumkhaek C., Aerbajinai W., Liu W., Zhu J., Uchida N., Kurlander R., RA Hsieh M.M., Tisdale J.F., Rodgers G.P.; RT "MASL1 induces erythroid differentiation in human erythropoietin-dependent RT CD34+ cells through the Raf/MEK/ERK pathway."; RL Blood 121:3216-3227(2013). RN [54] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-296; SER-301 AND SER-642, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [55] RP INTERACTION WITH PDE8A. RX PubMed=23509299; DOI=10.1073/pnas.1303004110; RA Brown K.M., Day J.P., Huston E., Zimmermann B., Hampel K., Christian F., RA Romano D., Terhzaz S., Lee L.C., Willis M.J., Morton D.B., Beavo J.A., RA Shimizu-Albergine M., Davies S.A., Kolch W., Houslay M.D., Baillie G.S.; RT "Phosphodiesterase-8A binds to and regulates Raf-1 kinase."; RL Proc. Natl. Acad. Sci. U.S.A. 110:E1533-E1542(2013). RN [56] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [57] RP IDENTIFICATION IN A COMPLEX WITH HSP90; HSP70; CDC37; PPP5C; TSC1; TSC2; RP AKT; CDK4 AND NR3C1. RX PubMed=29127155; DOI=10.15252/embj.201796700; RA Woodford M.R., Sager R.A., Marris E., Dunn D.M., Blanden A.R., Murphy R.L., RA Rensing N., Shapiro O., Panaretou B., Prodromou C., Loh S.N., Gutmann D.H., RA Bourboulia D., Bratslavsky G., Wong M., Mollapour M.; RT "Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding RT of kinase and non-kinase clients."; RL EMBO J. 36:3650-3665(2017). RN [58] RP INTERACTION WITH LZTR1. RX PubMed=30368668; DOI=10.1007/s00439-018-1951-7; RA Umeki I., Niihori T., Abe T., Kanno S.I., Okamoto N., Mizuno S., RA Kurosawa K., Nagasaki K., Yoshida M., Ohashi H., Inoue S.I., Matsubara Y., RA Fujiwara I., Kure S., Aoki Y.; RT "Delineation of LZTR1 mutation-positive patients with Noonan syndrome and RT identification of LZTR1 binding to RAF1-PPP1CB complexes."; RL Hum. Genet. 138:21-35(2019). RN [59] RP INTERACTION WITH YWHAZ. RX PubMed=31024343; DOI=10.3389/fphys.2019.00388; RA Popov I.K., Hiatt S.M., Whalen S., Keren B., Ruivenkamp C., RA van Haeringen A., Chen M.J., Cooper G.M., Korf B.R., Chang C.; RT "A YWHAZ variant associated with cardiofaciocutaneous syndrome activates RT the RAF-ERK pathway."; RL Front. Physiol. 10:388-388(2019). RN [60] RP DEPHOSPHORYLATION AT SER-259 BY SMP COMPLEX. RX PubMed=35768504; DOI=10.1038/s41586-022-04838-3; RA Liau N.P.D., Johnson M.C., Izadi S., Gerosa L., Hammel M., Bruning J.M., RA Wendorff T.J., Phung W., Hymowitz S.G., Sudhamsu J.; RT "Structural basis for SHOC2 modulation of RAS signalling."; RL Nature 609:400-407(2022). RN [61] RP DEPHOSPHORYLATION AT SER-259 BY SMP COMPLEX. RX PubMed=35831509; DOI=10.1038/s41586-022-04928-2; RA Kwon J.J., Hajian B., Bian Y., Young L.C., Amor A.J., Fuller J.R., RA Fraley C.V., Sykes A.M., So J., Pan J., Baker L., Lee S.J., Wheeler D.B., RA Mayhew D.L., Persky N.S., Yang X., Root D.E., Barsotti A.M., Stamford A.W., RA Perry C.K., Burgin A., McCormick F., Lemke C.T., Hahn W.C., Aguirre A.J.; RT "Structure-function analysis of the SHOC2-MRAS-PP1c holophosphatase RT complex."; RL Nature 609:408-415(2022). RN [62] RP DEPHOSPHORYLATION AT SER-259 BY SMP COMPLEX. RX PubMed=35830882; DOI=10.1038/s41586-022-05086-1; RA Hauseman Z.J., Fodor M., Dhembi A., Viscomi J., Egli D., Bleu M., Katz S., RA Park E., Jang D.M., Porter K.A., Meili F., Guo H., Kerr G., Molle S., RA Velez-Vega C., Beyer K.S., Galli G.G., Maira S.M., Stams T., Clark K., RA Eck M.J., Tordella L., Thoma C.R., King D.A.; RT "Structure of the MRAS-SHOC2-PP1C phosphatase complex."; RL Nature 609:416-423(2022). RN [63] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 51-131. RX PubMed=7791872; DOI=10.1038/375554a0; RA Nassar N., Horn G., Herrmann C., Scherer A., McCormick F., Wittinghofer A.; RT "The 2.2 A crystal structure of the Ras-binding domain of the RT serine/threonine kinase c-Raf1 in complex with Rap1A and a GTP analogue."; RL Nature 375:554-560(1995). RN [64] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 56-131. RX PubMed=8756332; DOI=10.1038/nsb0896-723; RA Nassar N., Horn G., Herrmann C., Block C., Janknecht R., Wittinghofer A.; RT "Ras/Rap effector specificity determined by charge reversal."; RL Nat. Struct. Biol. 3:723-729(1996). RN [65] RP STRUCTURE BY NMR OF 55-132. RX PubMed=7766599; DOI=10.1021/bi00021a001; RA Emerson S.D., Madison V.S., Palermo R.E., Waugh D.S., Scheffler J.E., RA Tsao K.L., Kiefer S.E., Liu S.P., Fry D.C.; RT "Solution structure of the Ras-binding domain of c-Raf-1 and identification RT of its Ras interaction surface."; RL Biochemistry 34:6911-6918(1995). RN [66] RP STRUCTURE BY NMR OF 136-187. RX PubMed=8710867; DOI=10.1073/pnas.93.16.8312; RA Mott H.R., Carpenter J.W., Zhong S., Ghosh S., Bell R.M., Campbell S.L.; RT "The solution structure of the Raf-1 cysteine-rich domain: a novel ras and RT phospholipid binding site."; RL Proc. Natl. Acad. Sci. U.S.A. 93:8312-8317(1996). RN [67] RP VARIANTS NS5 SER-256; LEU-257; PHE-259; ARG-260; LEU-261; SER-261; ASN-486; RP GLY-486; ILE-491; ARG-491 AND THR-612, VARIANT HYPERTROPHIC CARDIOMYOPATHY RP ILE-260, VARIANTS LPRD2 LEU-257 AND VAL-613, CHARACTERIZATION OF VARIANTS RP NS5 SER-261; ASN-486 AND ILE-491, CHARACTERIZATION OF VARIANT LPRD2 RP VAL-613, AND CATALYTIC ACTIVITY. RX PubMed=17603483; DOI=10.1038/ng2073; RA Pandit B., Sarkozy A., Pennacchio L.A., Carta C., Oishi K., Martinelli S., RA Pogna E.A., Schackwitz W., Ustaszewska A., Landstrom A., Bos J.M., RA Ommen S.R., Esposito G., Lepri F., Faul C., Mundel P., Lopez Siguero J.P., RA Tenconi R., Selicorni A., Rossi C., Mazzanti L., Torrente I., Marino B., RA Digilio M.C., Zampino G., Ackerman M.J., Dallapiccola B., Tartaglia M., RA Gelb B.D.; RT "Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with RT hypertrophic cardiomyopathy."; RL Nat. Genet. 39:1007-1012(2007). RN [68] RP VARIANTS NS5 LEU-257; ALA-261; SER-261; ALA-263 AND VAL-613, AND RP CHARACTERIZATION OF VARIANTS NS5 LEU-257; ALA-261; SER-261; ALA-263 AND RP VAL-613. RX PubMed=17603482; DOI=10.1038/ng2078; RA Razzaque M.A., Nishizawa T., Komoike Y., Yagi H., Furutani M., Amo R., RA Kamisago M., Momma K., Katayama H., Nakagawa M., Fujiwara Y., RA Matsushima M., Mizuno K., Tokuyama M., Hirota H., Muneuchi J., RA Higashinakagawa T., Matsuoka R.; RT "Germline gain-of-function mutations in RAF1 cause Noonan syndrome."; RL Nat. Genet. 39:1013-1017(2007). RN [69] RP VARIANTS [LARGE SCALE ANALYSIS] ALA-259 AND HIS-335. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [70] RP VARIANT NS5 SER-261. RX PubMed=20683980; DOI=10.1002/ajmg.a.33564; RA Longoni M., Moncini S., Cisternino M., Morella I.M., Ferraiuolo S., RA Russo S., Mannarino S., Brazzelli V., Coi P., Zippel R., Venturin M., RA Riva P.; RT "Noonan syndrome associated with both a new Jnk-activating familial SOS1 RT and a de novo RAF1 mutations."; RL Am. J. Med. Genet. A 152:2176-2184(2010). RN [71] RP INVOLVEMENT IN CMD1NN, VARIANTS CMD1NN THR-237; ALA-310; ALA-332; PRO-603; RP ARG-626 AND MET-641, AND CHARACTERIZATION OF VARIANTS CMD1NN THR-237; RP ALA-310; ALA-332; PRO-603; ARG-626 AND MET-641. RX PubMed=24777450; DOI=10.1038/ng.2963; RA Dhandapany P.S., Razzaque M.A., Muthusami U., Kunnoth S., Edwards J.J., RA Mulero-Navarro S., Riess I., Pardo S., Sheng J., Rani D.S., Rani B., RA Govindaraj P., Flex E., Yokota T., Furutani M., Nishizawa T., Nakanishi T., RA Robbins J., Limongelli G., Hajjar R.J., Lebeche D., Bahl A., Khullar M., RA Rathinavel A., Sadler K.C., Tartaglia M., Matsuoka R., Thangaraj K., RA Gelb B.D.; RT "RAF1 mutations in childhood-onset dilated cardiomyopathy."; RL Nat. Genet. 46:635-639(2014). CC -!- FUNCTION: Serine/threonine-protein kinase that acts as a regulatory CC link between the membrane-associated Ras GTPases and the MAPK/ERK CC cascade, and this critical regulatory link functions as a switch CC determining cell fate decisions including proliferation, CC differentiation, apoptosis, survival and oncogenic transformation. RAF1 CC activation initiates a mitogen-activated protein kinase (MAPK) cascade CC that comprises a sequential phosphorylation of the dual-specific MAPK CC kinases (MAP2K1/MEK1 and MAP2K2/MEK2) and the extracellular signal- CC regulated kinases (MAPK3/ERK1 and MAPK1/ERK2). The phosphorylated form CC of RAF1 (on residues Ser-338 and Ser-339, by PAK1) phosphorylates CC BAD/Bcl2-antagonist of cell death at 'Ser-75'. Phosphorylates adenylyl CC cyclases: ADCY2, ADCY5 and ADCY6, resulting in their activation. CC Phosphorylates PPP1R12A resulting in inhibition of the phosphatase CC activity. Phosphorylates TNNT2/cardiac muscle troponin T. Can promote CC NF-kB activation and inhibit signal transducers involved in motility CC (ROCK2), apoptosis (MAP3K5/ASK1 and STK3/MST2), proliferation and CC angiogenesis (RB1). Can protect cells from apoptosis also by CC translocating to the mitochondria where it binds BCL2 and displaces CC BAD/Bcl2-antagonist of cell death. Regulates Rho signaling and CC migration, and is required for normal wound healing. Plays a role in CC the oncogenic transformation of epithelial cells via repression of the CC TJ protein, occludin (OCLN) by inducing the up-regulation of a CC transcriptional repressor SNAI2/SLUG, which induces down-regulation of CC OCLN. Restricts caspase activation in response to selected stimuli, CC notably Fas stimulation, pathogen-mediated macrophage apoptosis, and CC erythroid differentiation. {ECO:0000269|PubMed:11427728, CC ECO:0000269|PubMed:11719507, ECO:0000269|PubMed:15385642, CC ECO:0000269|PubMed:15618521, ECO:0000269|PubMed:15849194, CC ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:16924233, CC ECO:0000269|PubMed:9360956}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:17603483}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990; CC Evidence={ECO:0000269|PubMed:17603483}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:17603483}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46609; CC Evidence={ECO:0000269|PubMed:17603483}; CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; CC Note=Binds 2 Zn(2+) ions per subunit.; CC -!- ACTIVITY REGULATION: Regulation is a highly complex process involving CC membrane recruitment, protein-protein interactions, dimerization, and CC phosphorylation/dephosphorylation events. Ras-GTP recruits RAF1 to the CC membrane, thereby promoting its activation. The inactive conformation CC of RAF1 is maintained by autoinhibitory interactions occurring between CC the N-terminal regulatory and the C-terminal catalytic domains and by CC the binding of a 14-3-3 protein that contacts two phosphorylation CC sites, Ser-259 and Ser-621. Upon mitogenic stimulation, Ras and PPP2R1A CC cooperate to release autoinhibition and the subsequent phosphorylation CC of activating sites: Ser-338, Tyr-341, Thr-491, and Ser-494, yields a CC fully active kinase. Through a negative feedback mechanism involving CC MAPK1/ERK2, RAF1 is phosphorylated on Ser-29, Ser-43, Ser-289, Ser-296, CC Ser-301 and Ser-642 by MAPK1/ERK2, which yields an inactive, CC desensitized kinase. The signaling-competent conformation of RAF1 is CC finally re-established by the coordinated action of PIN1, a prolyl CC isomerase that converts pSer and pThr residues from the cis to the CC trans conformation, which is preferentially recognized and CC dephosphorylated by PPP2R1A. Activated by homodimerization and CC heterodimerization (with BRAF). Also regulated through association with CC other proteins such as KSR2, CNKSR1/CNK1, PEBP1/RKIP, PHB/prohibitin CC and SPRY4. PEBP1/RKIP acts by dissociating RAF1 from its substrates CC MAP2K1/MEK1 and MAP2K2/MEK2. PHB/prohibitin facilitates the CC displacement of 14-3-3 from RAF1 by activated Ras, thereby promoting CC cell membrane localization and phosphorylation of RAF1 at the CC activating Ser-338. SPRY4 inhibits Ras-independent, but not Ras- CC dependent, activation of RAF1. CNKSR1/CNK1 regulates Src-mediated RAF1 CC activation. {ECO:0000269|PubMed:10576742, ECO:0000269|PubMed:10801873, CC ECO:0000269|PubMed:11447113, ECO:0000269|PubMed:11733498, CC ECO:0000269|PubMed:12717443, ECO:0000269|PubMed:16892053, CC ECO:0000269|PubMed:18294816, ECO:0000269|PubMed:19710016}. CC -!- SUBUNIT: Monomer. Homodimer. Heterodimerizes with BRAF and this CC heterodimer possesses a highly increased kinase activity compared to CC the respective homodimers or monomers (PubMed:16508002). CC Heterodimerization is mitogen-regulated and enhanced by 14-3-3 proteins CC (PubMed:16508002). MAPK1/ERK2 activation can induce a negative feedback CC that promotes the dissociation of the heterodimer (PubMed:16508002). CC Forms a multiprotein complex with Ras (M-Ras/MRAS), SHOC2 and protein CC phosphatase 1 (PPP1CA, PPP1CB and PPP1CC) (PubMed:16630891). Interacts CC with LZTR1 (PubMed:30368668). Interacts with Ras proteins; the CC interaction is antagonized by RIN1 (PubMed:11784866). Weakly interacts CC with RIT1. Interacts (via N-terminus) with RGS14 (via RBD domains); the CC interaction mediates the formation of a ternary complex with BRAF, a CC ternary complex inhibited by GNAI1 (By similarity). Probably forms a CC complex composed of chaperones HSP90 and HSP70, co-chaperones CDC37, CC PPP5C, TSC1 and client protein TSC2, CDK4, AKT, RAF1 and NR3C1; this CC complex does not contain co-chaperones STIP1/HOP and PTGES3/p23 CC (PubMed:29127155). Interacts with STK3/MST2; the interaction inhibits CC its pro-apoptotic activity (PubMed:15618521). Interacts (when CC phosphorylated at Ser-259) with YWHAZ (unphosphorylated at 'Thr-232') CC (PubMed:31024343, PubMed:9360956). Interacts with MAP2K1/MEK1 and CC MAP2K2/MEK2 (By similarity). Interacts with MAP3K5/ASF1 (via N- CC terminus) and this interaction inhibits the proapoptotic function of CC MAP3K5/ASK1 (PubMed:11427728). Interacts with PAK1 (via kinase domain) CC (PubMed:11733498). The phosphorylated form interacts with PIN1 (By CC similarity). The Ser-338 and Ser-339 phosphorylated form (by PAK1) CC interacts with BCL2 (PubMed:15849194). Interacts with PEBP1/RKIP and CC this interaction is enhanced if RAF1 is phosphorylated on residues Ser- CC 338, Ser-339, Tyr-340 and Tyr-341 (PubMed:18294816). Interacts with CC ADCY2, ADCY5, ADCY6, DGKH, RCAN1/DSCR1, PPP1R12A, PKB/AKT1, PPP2CA, CC PPP2R1B, SPRY2, SPRY4, CNKSR1/CNK1, KSR2 and PHB/prohibitin CC (PubMed:10576742, PubMed:10801873, PubMed:11719507, PubMed:12717443, CC PubMed:15385642, PubMed:15935327, PubMed:19710016). Interacts with CC ROCK2 (By similarity). In its active form, interacts with PRMT5 CC (PubMed:21917714). Interacts with FAM83B; displaces 14-3-3 proteins CC from RAF1 and activates RAF1 (PubMed:22886302). Interacts with PDE8A; CC the interaction promotes RAF1 activity (PubMed:23509299). Interacts CC with MFHAS1 (PubMed:23327923). Interacts with GLS (PubMed:22538822). CC Interacts with NEK10 and MAP2K1; the interaction is direct with NEK10 CC and required for ERK1/2-signaling pathway activation in response to UV CC irradiation (PubMed:20956560). {ECO:0000250|UniProtKB:P11345, CC ECO:0000250|UniProtKB:Q99N57, ECO:0000269|PubMed:10576742, CC ECO:0000269|PubMed:10801873, ECO:0000269|PubMed:11427728, CC ECO:0000269|PubMed:11719507, ECO:0000269|PubMed:11733498, CC ECO:0000269|PubMed:11784866, ECO:0000269|PubMed:12717443, CC ECO:0000269|PubMed:15385642, ECO:0000269|PubMed:15618521, CC ECO:0000269|PubMed:15849194, ECO:0000269|PubMed:15935327, CC ECO:0000269|PubMed:16508002, ECO:0000269|PubMed:16630891, CC ECO:0000269|PubMed:18294816, ECO:0000269|PubMed:19710016, CC ECO:0000269|PubMed:20956560, ECO:0000269|PubMed:21917714, CC ECO:0000269|PubMed:22538822, ECO:0000269|PubMed:22886302, CC ECO:0000269|PubMed:23327923, ECO:0000269|PubMed:23509299, CC ECO:0000269|PubMed:29127155, ECO:0000269|PubMed:30368668, CC ECO:0000269|PubMed:9360956}. CC -!- INTERACTION: CC P04049; P31749: AKT1; NbExp=3; IntAct=EBI-365996, EBI-296087; CC P04049; P05067: APP; NbExp=3; IntAct=EBI-365996, EBI-77613; CC P04049; Q99933: BAG1; NbExp=2; IntAct=EBI-365996, EBI-1030678; CC P04049; O95816: BAG2; NbExp=12; IntAct=EBI-365996, EBI-355275; CC P04049; P15056: BRAF; NbExp=73; IntAct=EBI-365996, EBI-365980; CC P04049; Q14790: CASP8; NbExp=3; IntAct=EBI-365996, EBI-78060; CC P04049; P49368: CCT3; NbExp=8; IntAct=EBI-365996, EBI-356673; CC P04049; P30304: CDC25A; NbExp=4; IntAct=EBI-365996, EBI-747671; CC P04049; Q16543: CDC37; NbExp=20; IntAct=EBI-365996, EBI-295634; CC P04049; P31327: CPS1; NbExp=4; IntAct=EBI-365996, EBI-536811; CC P04049; P00533: EGFR; NbExp=3; IntAct=EBI-365996, EBI-297353; CC P04049; O15371: EIF3D; NbExp=4; IntAct=EBI-365996, EBI-353818; CC P04049; O95714: HERC2; NbExp=6; IntAct=EBI-365996, EBI-1058922; CC P04049; P01112: HRAS; NbExp=30; IntAct=EBI-365996, EBI-350145; CC P04049; P07900: HSP90AA1; NbExp=15; IntAct=EBI-365996, EBI-296047; CC P04049; P08238: HSP90AB1; NbExp=17; IntAct=EBI-365996, EBI-352572; CC P04049; P11021: HSPA5; NbExp=5; IntAct=EBI-365996, EBI-354921; CC P04049; P01116: KRAS; NbExp=6; IntAct=EBI-365996, EBI-367415; CC P04049; P01116-2: KRAS; NbExp=3; IntAct=EBI-365996, EBI-367427; CC P04049; P05783: KRT18; NbExp=5; IntAct=EBI-365996, EBI-297888; CC P04049; P08727: KRT19; NbExp=2; IntAct=EBI-365996, EBI-742756; CC P04049; Q8IVT5: KSR1; NbExp=5; IntAct=EBI-365996, EBI-486984; CC P04049; Q02750: MAP2K1; NbExp=39; IntAct=EBI-365996, EBI-492564; CC P04049; P36507: MAP2K2; NbExp=7; IntAct=EBI-365996, EBI-1056930; CC P04049; Q15773: MLF2; NbExp=4; IntAct=EBI-365996, EBI-1051875; CC P04049; Q12968: NFATC3; NbExp=2; IntAct=EBI-365996, EBI-5278441; CC P04049; P01111: NRAS; NbExp=12; IntAct=EBI-365996, EBI-721993; CC P04049; O43482: OIP5; NbExp=4; IntAct=EBI-365996, EBI-536879; CC P04049; Q13153: PAK1; NbExp=2; IntAct=EBI-365996, EBI-1307; CC P04049; Q13177: PAK2; NbExp=2; IntAct=EBI-365996, EBI-1045887; CC P04049; Q6TCH7: PAQR3; NbExp=3; IntAct=EBI-365996, EBI-15654365; CC P04049; P30086: PEBP1; NbExp=10; IntAct=EBI-365996, EBI-716384; CC P04049; Q96S96: PEBP4; NbExp=4; IntAct=EBI-365996, EBI-8563667; CC P04049; Q13526: PIN1; NbExp=2; IntAct=EBI-365996, EBI-714158; CC P04049; P14618: PKM; NbExp=3; IntAct=EBI-365996, EBI-353408; CC P04049; P62136: PPP1CA; NbExp=2; IntAct=EBI-365996, EBI-357253; CC P04049; P67775: PPP2CA; NbExp=2; IntAct=EBI-365996, EBI-712311; CC P04049; Q13362: PPP2R5C; NbExp=2; IntAct=EBI-365996, EBI-1266156; CC P04049; P04049: RAF1; NbExp=6; IntAct=EBI-365996, EBI-365996; CC P04049; P62834: RAP1A; NbExp=2; IntAct=EBI-365996, EBI-491414; CC P04049; P06400: RB1; NbExp=3; IntAct=EBI-365996, EBI-491274; CC P04049; P53805-2: RCAN1; NbExp=4; IntAct=EBI-365996, EBI-1541912; CC P04049; P31947: SFN; NbExp=9; IntAct=EBI-365996, EBI-476295; CC P04049; Q13485: SMAD4; NbExp=6; IntAct=EBI-365996, EBI-347263; CC P04049; Q13188: STK3; NbExp=6; IntAct=EBI-365996, EBI-992580; CC P04049; Q9UNE7: STUB1; NbExp=8; IntAct=EBI-365996, EBI-357085; CC P04049; Q3ZCQ8: TIMM50; NbExp=7; IntAct=EBI-365996, EBI-355175; CC P04049; P31946: YWHAB; NbExp=39; IntAct=EBI-365996, EBI-359815; CC P04049; P62258: YWHAE; NbExp=24; IntAct=EBI-365996, EBI-356498; CC P04049; P61981: YWHAG; NbExp=25; IntAct=EBI-365996, EBI-359832; CC P04049; Q04917: YWHAH; NbExp=27; IntAct=EBI-365996, EBI-306940; CC P04049; P27348: YWHAQ; NbExp=25; IntAct=EBI-365996, EBI-359854; CC P04049; P63104: YWHAZ; NbExp=35; IntAct=EBI-365996, EBI-347088; CC P04049; P32883: Kras; Xeno; NbExp=2; IntAct=EBI-365996, EBI-644267; CC P04049; P28301: Lox; Xeno; NbExp=2; IntAct=EBI-365996, EBI-642911; CC P04049; Q9ESN9-2: Mapk8ip3; Xeno; NbExp=2; IntAct=EBI-365996, EBI-9549291; CC P04049; P03495: NS; Xeno; NbExp=2; IntAct=EBI-365996, EBI-2548993; CC P04049; O39474: NS5A; Xeno; NbExp=4; IntAct=EBI-365996, EBI-7016711; CC P04049; P01120: RAS2; Xeno; NbExp=2; IntAct=EBI-365996, EBI-14838; CC -!- SUBCELLULAR LOCATION: Cytoplasm. Cell membrane. Mitochondrion. Nucleus. CC Note=Colocalizes with RGS14 and BRAF in both the cytoplasm and CC membranes. Phosphorylation at Ser-259 impairs its membrane CC accumulation. Recruited to the cell membrane by the active Ras protein. CC Phosphorylation at Ser-338 and Ser-339 by PAK1 is required for its CC mitochondrial localization. Retinoic acid-induced Ser-621 CC phosphorylated form of RAF1 is predominantly localized at the nucleus. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; Synonyms=6C; CC IsoId=P04049-1; Sequence=Displayed; CC Name=2; Synonyms=1A; CC IsoId=P04049-2; Sequence=VSP_034649; CC -!- TISSUE SPECIFICITY: In skeletal muscle, isoform 1 is more abundant than CC isoform 2. {ECO:0000269|PubMed:1886707}. CC -!- PTM: Phosphorylation at Thr-269, Ser-338, Tyr-341, Thr-491 and Ser-494 CC results in its activation. Phosphorylation at Ser-29, Ser-43, Ser-289, CC Ser-296, Ser-301 and Ser-642 by MAPK1/ERK2 results in its inactivation. CC Phosphorylation at Ser-259 induces the interaction with YWHAZ and CC inactivates kinase activity. Dephosphorylation of Ser-259 by the SHOC2- CC MRAS-PP1c (SMP) complex consisting of SHOC2, GTP-bound M-Ras/MRAS and CC the catalytic subunit of protein phosphatase 1 (PPP1CA, PPP1CB or CC PPP1CC); this relieves inactivation and stimulates kinase activity CC (PubMed:35768504, PubMed:35831509, PubMed:35830882). Phosphorylation at CC Ser-338 by PAK1 and PAK5 and Ser-339 by PAK1 is required for its CC mitochondrial localization. Phosphorylation at Ser-621 in response to CC growth factor treatment stabilizes the protein, possibly by preventing CC proteasomal degradation. Phosphorylation at Ser-289, Ser-296, Ser-301, CC Ser-338 and Ser-621 are somehow linked to the methylation potential of CC cells. Treatment of cells with HGF in the presence of the methylation CC inhibitor 5'-methylthioadenosine (MTA) results in increased CC phosphorylation at Ser-338 and Ser-621 and decreased phosphorylation at CC Ser-296, Ser-301 and Ser-338. Dephosphorylation at Ser-338 by PPP5C CC results in an activity decrease. {ECO:0000269|PubMed:10576742, CC ECO:0000269|PubMed:10801873, ECO:0000269|PubMed:11447113, CC ECO:0000269|PubMed:11733498, ECO:0000269|PubMed:11756411, CC ECO:0000269|PubMed:15047712, ECO:0000269|PubMed:15849194, CC ECO:0000269|PubMed:16093354, ECO:0000269|PubMed:16630891, CC ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:18465753, CC ECO:0000269|PubMed:21917714, ECO:0000269|PubMed:35768504, CC ECO:0000269|PubMed:35830882, ECO:0000269|PubMed:35831509, CC ECO:0000269|PubMed:7477354, ECO:0000269|PubMed:8349614, CC ECO:0000269|PubMed:9823899}. CC -!- PTM: Methylated at Arg-563 in response to EGF treatment. This CC modification leads to destabilization of the protein, possibly through CC proteasomal degradation. {ECO:0000269|PubMed:21917714}. CC -!- DISEASE: Noonan syndrome 5 (NS5) [MIM:611553]: A form of Noonan CC syndrome, a disease characterized by short stature, facial dysmorphic CC features such as hypertelorism, a downward eyeslant and low-set CC posteriorly rotated ears, and a high incidence of congenital heart CC defects and hypertrophic cardiomyopathy. Other features can include a CC short neck with webbing or redundancy of skin, deafness, motor delay, CC variable intellectual deficits, multiple skeletal defects, CC cryptorchidism, and bleeding diathesis. Individuals with Noonan CC syndrome are at risk of juvenile myelomonocytic leukemia, a CC myeloproliferative disorder characterized by excessive production of CC myelomonocytic cells. {ECO:0000269|PubMed:17603482, CC ECO:0000269|PubMed:17603483, ECO:0000269|PubMed:20683980}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: LEOPARD syndrome 2 (LPRD2) [MIM:611554]: A disorder CC characterized by lentigines, electrocardiographic conduction CC abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities CC of genitalia, retardation of growth, and sensorineural deafness. CC {ECO:0000269|PubMed:17603483}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Cardiomyopathy, dilated, 1NN (CMD1NN) [MIM:615916]: A disorder CC characterized by ventricular dilation and impaired systolic function, CC resulting in congestive heart failure and arrhythmia. Patients are at CC risk of premature death. {ECO:0000269|PubMed:24777450}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr CC protein kinase family. RAF subfamily. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/42032/RAF1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X03484; CAA27204.1; -; mRNA. DR EMBL; AY271661; AAP03432.1; -; Genomic_DNA. DR EMBL; AK312248; BAG35180.1; -; mRNA. DR EMBL; EU332868; ABY87557.1; -; Genomic_DNA. DR EMBL; CH471055; EAW64134.1; -; Genomic_DNA. DR EMBL; BC018119; AAH18119.1; -; mRNA. DR EMBL; L00212; AAA60247.1; -; Genomic_DNA. DR EMBL; L00206; AAA60247.1; JOINED; Genomic_DNA. DR EMBL; L00207; AAA60247.1; JOINED; Genomic_DNA. DR EMBL; L00208; AAA60247.1; JOINED; Genomic_DNA. DR EMBL; L00209; AAA60247.1; JOINED; Genomic_DNA. DR EMBL; L00210; AAA60247.1; JOINED; Genomic_DNA. DR EMBL; L00211; AAA60247.1; JOINED; Genomic_DNA. DR EMBL; L00213; AAA60247.1; JOINED; Genomic_DNA. DR EMBL; M11376; AAA60247.1; JOINED; Genomic_DNA. DR EMBL; X54851; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR CCDS; CCDS2612.1; -. [P04049-1] DR CCDS; CCDS87047.1; -. [P04049-2] DR PIR; A00637; TVHUF6. DR PIR; S60341; S60341. DR RefSeq; NP_001341618.1; NM_001354689.3. [P04049-2] DR RefSeq; NP_001341619.1; NM_001354690.3. [P04049-1] DR RefSeq; NP_002871.1; NM_002880.4. [P04049-1] DR RefSeq; XP_011532276.1; XM_011533974.3. [P04049-1] DR RefSeq; XP_047304605.1; XM_047448649.1. [P04049-1] DR RefSeq; XP_047304606.1; XM_047448650.1. [P04049-1] DR RefSeq; XP_054203389.1; XM_054347414.1. [P04049-1] DR RefSeq; XP_054203390.1; XM_054347415.1. [P04049-1] DR RefSeq; XP_054203391.1; XM_054347416.1. [P04049-1] DR PDB; 1C1Y; X-ray; 1.90 A; B=55-131. DR PDB; 1FAQ; NMR; -; A=136-187. DR PDB; 1FAR; NMR; -; A=136-187. DR PDB; 1GUA; X-ray; 2.00 A; B=51-131. DR PDB; 1RFA; NMR; -; A=55-132. DR PDB; 3CU8; X-ray; 2.40 A; P/Q=256-264. DR PDB; 3IQJ; X-ray; 1.15 A; P=255-264. DR PDB; 3IQU; X-ray; 1.05 A; P=255-260. DR PDB; 3IQV; X-ray; 1.20 A; P=255-260. DR PDB; 3KUC; X-ray; 1.92 A; B=51-131. DR PDB; 3KUD; X-ray; 2.15 A; B=51-131. DR PDB; 3NKX; X-ray; 2.40 A; P/Q=255-264. DR PDB; 3O8I; X-ray; 2.00 A; B=255-264. DR PDB; 3OMV; X-ray; 4.00 A; A/B=323-618. DR PDB; 4FJ3; X-ray; 1.95 A; P=229-264. DR PDB; 4G0N; X-ray; 2.45 A; B=54-131. DR PDB; 4G3X; X-ray; 3.25 A; B=55-131. DR PDB; 4IEA; X-ray; 1.70 A; P=618-625. DR PDB; 4IHL; X-ray; 2.20 A; P=229-264. DR PDB; 6NTC; X-ray; 2.90 A; B=55-131. DR PDB; 6NTD; X-ray; 3.15 A; B=55-131. DR PDB; 6PTS; NMR; -; D=56-187. DR PDB; 6PTW; NMR; -; D=56-187. DR PDB; 6VJJ; X-ray; 1.40 A; B=52-131. DR PDB; 6XGU; X-ray; 2.70 A; B=52-188. DR PDB; 6XGV; X-ray; 2.11 A; B=52-188. DR PDB; 6XHA; X-ray; 2.87 A; B=52-188. DR PDB; 6XHB; X-ray; 2.50 A; B=52-188. DR PDB; 6XI7; X-ray; 1.95 A; B=52-188. DR PDB; 7JHP; X-ray; 2.77 A; C=55-187. DR PDB; 7Z37; EM; 3.67 A; CP1=1-648. DR PDB; 7Z38; EM; 3.16 A; C=1-648. DR PDB; 8A68; X-ray; 1.60 A; B=255-263. DR PDB; 8A6F; X-ray; 1.60 A; P=255-264. DR PDB; 8A6H; X-ray; 1.60 A; P=255-264. DR PDB; 8ATR; X-ray; 1.70 A; P=255-263. DR PDB; 8ATS; X-ray; 1.40 A; P=255-263. DR PDB; 8AV0; X-ray; 1.50 A; P=256-264. DR PDB; 8CHF; EM; 4.25 A; A/B=1-648. DR PDB; 8CPD; EM; 3.46 A; A/B=1-648. DR PDB; 8EPW; X-ray; 2.00 A; B=52-131. DR PDB; 8GAE; EM; 3.30 A; D=404-610. DR PDB; 8GFT; EM; 3.80 A; D=336-618. DR PDB; 8JOF; NMR; -; A=51-131. DR PDB; 8JOG; NMR; -; A=51-131. DR PDB; 8Q5C; X-ray; 2.00 A; P=255-264. DR PDB; 8S42; X-ray; 1.70 A; P=255-263. DR PDB; 8T74; X-ray; 1.65 A; B=52-131. DR PDB; 8T75; X-ray; 2.65 A; B/D/F/H=52-188. DR PDB; 8U1L; EM; 3.70 A; C=2-648. DR PDB; 9AXA; EM; 4.36 A; A/C=306-648. DR PDB; 9AXC; EM; 4.16 A; A/C=306-648. DR PDB; 9AY7; X-ray; 2.41 A; A=337-615. DR PDB; 9AYA; X-ray; 2.59 A; A/C=337-615. DR PDB; 9EW1; X-ray; 1.40 A; P=255-263. DR PDB; 9EW3; X-ray; 1.40 A; P=255-263. DR PDB; 9EW4; X-ray; 1.60 A; P=255-263. DR PDB; 9EW5; X-ray; 1.50 A; C/F=255-265. DR PDB; 9EW7; X-ray; 1.80 A; P=255-264. DR PDBsum; 1C1Y; -. DR PDBsum; 1FAQ; -. DR PDBsum; 1FAR; -. DR PDBsum; 1GUA; -. DR PDBsum; 1RFA; -. DR PDBsum; 3CU8; -. DR PDBsum; 3IQJ; -. DR PDBsum; 3IQU; -. DR PDBsum; 3IQV; -. DR PDBsum; 3KUC; -. DR PDBsum; 3KUD; -. DR PDBsum; 3NKX; -. DR PDBsum; 3O8I; -. DR PDBsum; 3OMV; -. DR PDBsum; 4FJ3; -. DR PDBsum; 4G0N; -. DR PDBsum; 4G3X; -. DR PDBsum; 4IEA; -. DR PDBsum; 4IHL; -. DR PDBsum; 6NTC; -. DR PDBsum; 6NTD; -. DR PDBsum; 6PTS; -. DR PDBsum; 6PTW; -. DR PDBsum; 6VJJ; -. DR PDBsum; 6XGU; -. DR PDBsum; 6XGV; -. DR PDBsum; 6XHA; -. DR PDBsum; 6XHB; -. DR PDBsum; 6XI7; -. DR PDBsum; 7JHP; -. DR PDBsum; 7Z37; -. DR PDBsum; 7Z38; -. DR PDBsum; 8A68; -. DR PDBsum; 8A6F; -. DR PDBsum; 8A6H; -. DR PDBsum; 8ATR; -. DR PDBsum; 8ATS; -. DR PDBsum; 8AV0; -. DR PDBsum; 8CHF; -. DR PDBsum; 8CPD; -. DR PDBsum; 8EPW; -. DR PDBsum; 8GAE; -. DR PDBsum; 8GFT; -. DR PDBsum; 8JOF; -. DR PDBsum; 8JOG; -. DR PDBsum; 8Q5C; -. DR PDBsum; 8S42; -. DR PDBsum; 8T74; -. DR PDBsum; 8T75; -. DR PDBsum; 8U1L; -. DR PDBsum; 9AXA; -. DR PDBsum; 9AXC; -. DR PDBsum; 9AY7; -. DR PDBsum; 9AYA; -. DR PDBsum; 9EW1; -. DR PDBsum; 9EW3; -. DR PDBsum; 9EW4; -. DR PDBsum; 9EW5; -. DR PDBsum; 9EW7; -. DR AlphaFoldDB; P04049; -. DR BMRB; P04049; -. DR EMDB; EMD-14472; -. DR EMDB; EMD-14473; -. DR EMDB; EMD-16660; -. DR EMDB; EMD-16779; -. DR EMDB; EMD-29895; -. DR EMDB; EMD-29949; -. DR EMDB; EMD-29957; -. DR EMDB; EMD-29973; -. DR EMDB; EMD-29976; -. DR EMDB; EMD-29984; -. DR EMDB; EMD-41816; -. DR EMDB; EMD-43931; -. DR EMDB; EMD-43932; -. DR SMR; P04049; -. DR BioGRID; 111831; 1867. DR CORUM; P04049; -. DR DIP; DIP-1048N; -. DR FunCoup; P04049; 4763. DR IntAct; P04049; 435. DR MINT; P04049; -. DR STRING; 9606.ENSP00000401888; -. DR BindingDB; P04049; -. DR ChEMBL; CHEMBL1906; -. DR DrugBank; DB15254; Avutometinib. DR DrugBank; DB17568; Belvarafenib. DR DrugBank; DB08862; Cholecystokinin. DR DrugBank; DB08912; Dabrafenib. DR DrugBank; DB04367; Debromohymenialdisine. DR DrugBank; DB11718; Encorafenib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB05268; iCo-007. DR DrugBank; DB04973; LErafAON. DR DrugBank; DB18865; Naporafenib. DR DrugBank; DB08896; Regorafenib. DR DrugBank; DB12094; Semapimod. DR DrugBank; DB00398; Sorafenib. DR DrugBank; DB15266; Tovorafenib. DR DrugBank; DB05190; XL281. DR DrugCentral; P04049; -. DR GuidetoPHARMACOLOGY; 2184; -. DR MoonDB; P04049; Predicted. DR GlyCosmos; P04049; 1 site, 1 glycan. DR GlyGen; P04049; 3 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site). DR iPTMnet; P04049; -. DR PhosphoSitePlus; P04049; -. DR SwissPalm; P04049; -. DR BioMuta; RAF1; -. DR DMDM; 125651; -. DR CPTAC; CPTAC-1335; -. DR CPTAC; CPTAC-1336; -. DR CPTAC; CPTAC-1546; -. DR CPTAC; CPTAC-1762; -. DR CPTAC; CPTAC-5778; -. DR CPTAC; CPTAC-5779; -. DR CPTAC; CPTAC-5780; -. DR CPTAC; CPTAC-5828; -. DR CPTAC; CPTAC-5829; -. DR CPTAC; non-CPTAC-5431; -. DR CPTAC; non-CPTAC-5432; -. DR CPTAC; non-CPTAC-5433; -. DR CPTAC; non-CPTAC-5569; -. DR CPTAC; non-CPTAC-5570; -. DR CPTAC; non-CPTAC-5734; -. DR jPOST; P04049; -. DR MassIVE; P04049; -. DR PaxDb; 9606-ENSP00000251849; -. DR PeptideAtlas; P04049; -. DR ProteomicsDB; 51637; -. [P04049-1] DR ProteomicsDB; 51638; -. [P04049-2] DR Pumba; P04049; -. DR ABCD; P04049; 5 sequenced antibodies. DR Antibodypedia; 1131; 3127 antibodies from 52 providers. DR CPTC; P04049; 8 antibodies. DR DNASU; 5894; -. DR Ensembl; ENST00000251849.9; ENSP00000251849.4; ENSG00000132155.15. [P04049-1] DR Ensembl; ENST00000442415.7; ENSP00000401888.2; ENSG00000132155.15. [P04049-2] DR Ensembl; ENST00000685653.1; ENSP00000509968.1; ENSG00000132155.15. [P04049-1] DR Ensembl; ENST00000691899.1; ENSP00000508763.1; ENSG00000132155.15. [P04049-1] DR GeneID; 5894; -. DR KEGG; hsa:5894; -. DR MANE-Select; ENST00000251849.9; ENSP00000251849.4; NM_002880.4; NP_002871.1. DR UCSC; uc003bxf.5; human. [P04049-1] DR AGR; HGNC:9829; -. DR CIViC; 5894; 7 evidence items across 4 molecular profiles. DR ClinPGx; PA34183; -. DR CTD; 5894; -. DR DisGeNET; 5894; -. DR GeneCards; RAF1; -. DR GeneReviews; RAF1; -. DR HGNC; HGNC:9829; RAF1. DR HPA; ENSG00000132155; Low tissue specificity. DR MalaCards; RAF1; -. DR MIM; 164760; gene. DR MIM; 611553; phenotype. DR MIM; 611554; phenotype. DR MIM; 615916; phenotype. DR OpenTargets; ENSG00000132155; -. DR Orphanet; 154; Familial isolated dilated cardiomyopathy. DR Orphanet; 626; Large/giant congenital melanocytic nevus. DR Orphanet; 648; Noonan syndrome. DR Orphanet; 500; Noonan syndrome with multiple lentigines. DR Orphanet; 251615; Pilomyxoid astrocytoma. DR VEuPathDB; HostDB:ENSG00000132155; -. DR eggNOG; KOG0193; Eukaryota. DR GeneTree; ENSGT00940000156084; -. DR InParanoid; P04049; -. DR OMA; SAYKRHA; -. DR OrthoDB; 774951at2759; -. DR PAN-GO; P04049; 5 GO annotations based on evolutionary models. DR PhylomeDB; P04049; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; P04049; -. DR Reactome; R-HSA-2672351; Stimuli-sensing channels. DR Reactome; R-HSA-392517; Rap1 signalling. DR Reactome; R-HSA-430116; GP1b-IX-V activation signalling. DR Reactome; R-HSA-5621575; CD209 (DC-SIGN) signaling. DR Reactome; R-HSA-5673000; RAF activation. DR Reactome; R-HSA-5674135; MAP2K and MAPK activation. DR Reactome; R-HSA-5674499; Negative feedback regulation of MAPK pathway. DR Reactome; R-HSA-5675221; Negative regulation of MAPK pathway. DR Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants. DR Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants. DR Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions. DR Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF. DR Reactome; R-HSA-9649948; Signaling downstream of RAS mutants. DR Reactome; R-HSA-9656223; Signaling by RAF1 mutants. DR Reactome; R-HSA-9726840; SHOC2 M1731 mutant abolishes MRAS complex function. DR Reactome; R-HSA-9726842; Gain-of-function MRAS complexes activate RAF signaling. DR Reactome; R-HSA-9732724; IFNG signaling activates MAPKs. DR SignaLink; P04049; -. DR SIGNOR; P04049; -. DR Agora; ENSG00000132155; -. DR BioGRID-ORCS; 5894; 99 hits in 1206 CRISPR screens. DR CD-CODE; D57F7ABA; Synthetic Condensate 000274. DR ChiTaRS; RAF1; human. DR EvolutionaryTrace; P04049; -. DR GeneWiki; C-Raf; -. DR GenomeRNAi; 5894; -. DR Pharos; P04049; Tclin. DR PRO; PR:P04049; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; P04049; protein. DR Bgee; ENSG00000132155; Expressed in gastrocnemius and 214 other cell types or tissues. DR ExpressionAtlas; P04049; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:MGI. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005794; C:Golgi apparatus; IPI:MGI. DR GO; GO:0005741; C:mitochondrial outer membrane; TAS:ProtInc. DR GO; GO:0005739; C:mitochondrion; IBA:GO_Central. DR GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0031143; C:pseudopodium; IEA:Ensembl. DR GO; GO:0010856; F:adenylate cyclase activator activity; IDA:BHF-UCL. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0004709; F:MAP kinase kinase kinase activity; IBA:GO_Central. DR GO; GO:0004672; F:protein kinase activity; EXP:Reactome. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0006915; P:apoptotic process; TAS:GO_Central. DR GO; GO:0071550; P:death-inducing signaling complex assembly; IEA:Ensembl. DR GO; GO:0038133; P:ERBB2-ERBB3 signaling pathway; IEA:Ensembl. DR GO; GO:0008625; P:extrinsic apoptotic signaling pathway via death domain receptors; IEA:Ensembl. DR GO; GO:0060324; P:face development; IEA:Ensembl. DR GO; GO:0008286; P:insulin receptor signaling pathway; IEA:Ensembl. DR GO; GO:0035773; P:insulin secretion involved in cellular response to glucose stimulus; IEA:Ensembl. DR GO; GO:0048009; P:insulin-like growth factor receptor signaling pathway; IEA:Ensembl. DR GO; GO:0045104; P:intermediate filament cytoskeleton organization; IEA:Ensembl. DR GO; GO:0000165; P:MAPK cascade; IBA:GO_Central. DR GO; GO:0042552; P:myelination; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:BHF-UCL. DR GO; GO:1902042; P:negative regulation of extrinsic apoptotic signaling pathway via death domain receptors; IEA:Ensembl. DR GO; GO:0031333; P:negative regulation of protein-containing complex assembly; IDA:UniProtKB. DR GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; IEA:Ensembl. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:GO_Central. DR GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:UniProtKB. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IEA:Ensembl. DR GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc. DR GO; GO:0042981; P:regulation of apoptotic process; TAS:UniProtKB. DR GO; GO:0045595; P:regulation of cell differentiation; TAS:UniProtKB. DR GO; GO:0035023; P:regulation of Rho protein signal transduction; TAS:UniProtKB. DR GO; GO:0035994; P:response to muscle stretch; IEA:Ensembl. DR GO; GO:0014044; P:Schwann cell development; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0035019; P:somatic stem cell population maintenance; IEA:Ensembl. DR GO; GO:0048538; P:thymus development; IEA:Ensembl. DR GO; GO:0030878; P:thyroid gland development; IEA:Ensembl. DR GO; GO:0044342; P:type B pancreatic cell proliferation; IEA:Ensembl. DR GO; GO:0060333; P:type II interferon-mediated signaling pathway; TAS:Reactome. DR GO; GO:0042060; P:wound healing; TAS:UniProtKB. DR CDD; cd20870; C1_A_C-Raf; 1. DR CDD; cd17135; RBD_CRAF; 1. DR CDD; cd14149; STKc_C-Raf; 1. DR DisProt; DP00171; -. DR FunFam; 3.10.20.90:FF:000015; B-Raf proto-oncogene serine/threonine-protein kinase; 1. DR FunFam; 3.30.200.20:FF:000024; B-Raf proto-oncogene serine/threonine-protein kinase; 1. DR FunFam; 3.30.60.20:FF:000004; B-Raf proto-oncogene serine/threonine-protein kinase; 1. DR FunFam; 1.10.510.10:FF:000036; RAF proto-oncogene serine/threonine-protein kinase; 1. DR Gene3D; 3.30.60.20; -; 1. DR Gene3D; 3.10.20.90; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00292; -. DR InterPro; IPR046349; C1-like_sf. DR InterPro; IPR020454; DAG/PE-bd. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR002219; PKC_DAG/PE. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR003116; RBD_dom. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR051681; Ser/Thr_Kinases-Pseudokinases. DR InterPro; IPR029071; Ubiquitin-like_domsf. DR PANTHER; PTHR44329:SF22; RAF PROTO-ONCOGENE SERINE_THREONINE-PROTEIN KINASE; 1. DR PANTHER; PTHR44329; SERINE/THREONINE-PROTEIN KINASE TNNI3K-RELATED; 1. DR Pfam; PF00130; C1_1; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF02196; RBD; 1. DR PRINTS; PR00008; DAGPEDOMAIN. DR SMART; SM00109; C1; 1. DR SMART; SM00455; RBD; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF57889; Cysteine-rich domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF54236; Ubiquitin-like; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS50898; RBD; 1. DR PROSITE; PS00479; ZF_DAG_PE_1; 1. DR PROSITE; PS50081; ZF_DAG_PE_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cardiomyopathy; KW Cell membrane; Cytoplasm; Deafness; Direct protein sequencing; KW Disease variant; Kinase; Membrane; Metal-binding; Methylation; KW Mitochondrion; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Proto-oncogene; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger. FT CHAIN 1..648 FT /note="RAF proto-oncogene serine/threonine-protein kinase" FT /id="PRO_0000086596" FT DOMAIN 56..131 FT /note="RBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00262" FT DOMAIN 349..609 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT ZN_FING 138..184 FT /note="Phorbol-ester/DAG-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT REGION 220..334 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 331..349 FT /note="Interaction with PEBP1/RKIP" FT COMPBIAS 239..271 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 275..285 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 286..301 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 468 FT /note="Proton acceptor" FT BINDING 139 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT BINDING 152 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT BINDING 155 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT BINDING 165 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT BINDING 168 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT BINDING 173 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT BINDING 176 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="2" FT BINDING 184 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /ligand_label="1" FT BINDING 355..363 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 375 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 29 FT /note="Phosphoserine; by MAPK1" FT /evidence="ECO:0000250|UniProtKB:Q99N57" FT MOD_RES 43 FT /note="Phosphoserine; by PKA and MAPK1" FT /evidence="ECO:0000269|PubMed:8349614" FT MOD_RES 252 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17525332" FT MOD_RES 259 FT /note="Phosphoserine; by PKA, PKC and PKB/AKT1" FT /evidence="ECO:0000269|PubMed:10576742, FT ECO:0000269|PubMed:10801873, ECO:0000269|PubMed:11756411, FT ECO:0000269|PubMed:15047712, ECO:0000269|PubMed:16630891, FT ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:8349614" FT MOD_RES 268 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:8349614" FT MOD_RES 269 FT /note="Phosphothreonine; by PKA" FT /evidence="ECO:0000269|PubMed:7477354" FT MOD_RES 289 FT /note="Phosphoserine; by MAPK1" FT /evidence="ECO:0000269|PubMed:21917714, FT ECO:0007744|PubMed:19690332" FT MOD_RES 296 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 301 FT /note="Phosphoserine; by MAPK1" FT /evidence="ECO:0000269|PubMed:21917714, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163" FT MOD_RES 338 FT /note="Phosphoserine; by PAK1, PAK2, PAK3 and PAK5" FT /evidence="ECO:0000269|PubMed:11733498, FT ECO:0000269|PubMed:15849194, ECO:0000269|PubMed:16892053, FT ECO:0000269|PubMed:18465753, ECO:0000269|PubMed:21917714" FT MOD_RES 339 FT /note="Phosphoserine; by PAK1, PAK2 and PAK3" FT /evidence="ECO:0000269|PubMed:15849194" FT MOD_RES 340 FT /note="Phosphotyrosine; by SRC" FT /evidence="ECO:0000269|PubMed:16892053" FT MOD_RES 341 FT /note="Phosphotyrosine; by SRC" FT /evidence="ECO:0000269|PubMed:16892053" FT MOD_RES 471 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:16093354" FT MOD_RES 491 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:11447113" FT MOD_RES 494 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:11447113" FT MOD_RES 499 FT /note="Phosphoserine; by PKC" FT /evidence="ECO:0000269|PubMed:8349614" FT MOD_RES 563 FT /note="Symmetric dimethylarginine; by PRMT5" FT /evidence="ECO:0000269|PubMed:21917714" FT MOD_RES 621 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:10801873, FT ECO:0000269|PubMed:16892053, ECO:0000269|PubMed:21917714, FT ECO:0000269|PubMed:8349614" FT MOD_RES 642 FT /note="Phosphoserine; by MAPK1" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT VAR_SEQ 278 FT /note="E -> ENNNLSASPRAWSRRFCLRGR (in isoform 2)" FT /evidence="ECO:0000305" FT /id="VSP_034649" FT VARIANT 237 FT /note="A -> T (in CMD1NN; shows a mild increase in kinase FT activity; dbSNP:rs587777588)" FT /evidence="ECO:0000269|PubMed:24777450" FT /id="VAR_071844" FT VARIANT 256 FT /note="R -> S (in NS5; dbSNP:rs397516826)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037807" FT VARIANT 257 FT /note="S -> L (in NS5 and LPRD2; shows in vitro greater FT kinase activity and enhanced ERK activation than wild-type; FT dbSNP:rs80338796)" FT /evidence="ECO:0000269|PubMed:17603482, FT ECO:0000269|PubMed:17603483" FT /id="VAR_037808" FT VARIANT 259 FT /note="S -> A (in an ovarian serous carcinoma sample; FT somatic mutation; increased ERK activation; FT dbSNP:rs3730271)" FT /evidence="ECO:0000269|PubMed:16630891, FT ECO:0000269|PubMed:17344846" FT /id="VAR_041037" FT VARIANT 259 FT /note="S -> F (in NS5; dbSNP:rs397516827)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037809" FT VARIANT 260 FT /note="T -> I (in hypertrophic cardiomyopathy; uncertain FT significance; dbSNP:rs869025501)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037810" FT VARIANT 260 FT /note="T -> R (in NS5)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037811" FT VARIANT 261 FT /note="P -> A (in NS5; shows in vitro greater kinase FT activity and enhanced MAPK1 activation than wild-type; FT dbSNP:rs121434594)" FT /evidence="ECO:0000269|PubMed:17603482" FT /id="VAR_037812" FT VARIANT 261 FT /note="P -> L (in NS5; shows greater kinase activity and FT enhanced MAPK1 activation than wild-type; FT dbSNP:rs397516828)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037813" FT VARIANT 261 FT /note="P -> S (in NS5; shows in vitro greater kinase FT activity and enhanced MAPK1 activation than wild-type; FT dbSNP:rs121434594)" FT /evidence="ECO:0000269|PubMed:17603482, FT ECO:0000269|PubMed:17603483, ECO:0000269|PubMed:20683980" FT /id="VAR_037814" FT VARIANT 263 FT /note="V -> A (in NS5; shows in vitro greater kinase FT activity and enhanced MAPK1 activation than wild-type; FT dbSNP:rs397516830)" FT /evidence="ECO:0000269|PubMed:17603482" FT /id="VAR_037815" FT VARIANT 308 FT /note="P -> L (in dbSNP:rs5746220)" FT /evidence="ECO:0000269|PubMed:14702039, ECO:0000269|Ref.3" FT /id="VAR_018840" FT VARIANT 310 FT /note="T -> A (in CMD1NN; shows a mild increase in kinase FT activity; dbSNP:rs778155315)" FT /evidence="ECO:0000269|PubMed:24777450" FT /id="VAR_071845" FT VARIANT 332 FT /note="P -> A (in CMD1NN; shows a mild increase in kinase FT activity; dbSNP:rs1057403865)" FT /evidence="ECO:0000269|PubMed:24777450" FT /id="VAR_071846" FT VARIANT 335 FT /note="Q -> H (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041038" FT VARIANT 486 FT /note="D -> G (in NS5; dbSNP:rs397516815)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037816" FT VARIANT 486 FT /note="D -> N (in NS5; has reduced or absent kinase FT activity; dbSNP:rs80338798)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037817" FT VARIANT 491 FT /note="T -> I (in NS5; has reduced or absent kinase FT activity; dbSNP:rs80338799)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037818" FT VARIANT 491 FT /note="T -> R (in NS5; dbSNP:rs80338799)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037819" FT VARIANT 603 FT /note="L -> P (in CMD1NN; shows impaired kinase activity FT and reduced MAPK3 activation with this mutation; FT dbSNP:rs587777586)" FT /evidence="ECO:0000269|PubMed:24777450" FT /id="VAR_071847" FT VARIANT 612 FT /note="S -> T (in NS5; dbSNP:rs1448392469)" FT /evidence="ECO:0000269|PubMed:17603483" FT /id="VAR_037820" FT VARIANT 613 FT /note="L -> V (in NS5 and LPRD2; shows in vitro greater FT kinase activity and enhanced MAPK1 activation than wild- FT type; dbSNP:rs80338797)" FT /evidence="ECO:0000269|PubMed:17603482, FT ECO:0000269|PubMed:17603483" FT /id="VAR_037821" FT VARIANT 626 FT /note="H -> R (in CMD1NN; shows a mild increase in kinase FT activity; dbSNP:rs1553609795)" FT /evidence="ECO:0000269|PubMed:24777450" FT /id="VAR_071848" FT VARIANT 641 FT /note="T -> M (in CMD1NN; shows a mild increase in kinase FT activity; dbSNP:rs587777587)" FT /evidence="ECO:0000269|PubMed:24777450" FT /id="VAR_071849" FT MUTAGEN 338..339 FT /note="SS->AA: Reduced kinase activity; when associated FT with 340-D-D-341." FT /evidence="ECO:0000269|PubMed:16892053" FT MUTAGEN 338..339 FT /note="SS->DE: Non-inhibited by PPP5C. Constitutively FT active and non-inhibited by PPP5C; when associated with FT 340-D-D-341." FT /evidence="ECO:0000269|PubMed:16892053" FT MUTAGEN 340..341 FT /note="YY->DD: Constitutively active and highly FT phosphorylated on S-338, inhibited by PPP5C. Reduced kinase FT activity; when associated with 338-A-A-339. Constitutively FT active and non-inhibited by PPP5C; when associated with FT 338-D-E-339." FT /evidence="ECO:0000269|PubMed:16892053" FT MUTAGEN 375 FT /note="K->W: Catalytically inactive." FT /evidence="ECO:0000269|PubMed:20956560" FT MUTAGEN 491 FT /note="T->D: Increased kinase activity but can still be FT inhibited by PPP5C; when associated with D-494." FT /evidence="ECO:0000269|PubMed:16892053" FT MUTAGEN 494 FT /note="S->D: Increased kinase activity but can still be FT inhibited by PPP5C; when associated with D-491." FT /evidence="ECO:0000269|PubMed:16892053" FT MUTAGEN 563 FT /note="R->K: Loss of methylation. Increased stability and FT catalytic activity in response to EGF treatment." FT /evidence="ECO:0000269|PubMed:21917714" FT CONFLICT 240 FT /note="F -> L (in Ref. 6; AAA60247)" FT /evidence="ECO:0000305" FT CONFLICT 542 FT /note="M -> I (in Ref. 6; AAA60247)" FT /evidence="ECO:0000305" FT STRAND 57..61 FT /evidence="ECO:0007829|PDB:6VJJ" FT TURN 63..65 FT /evidence="ECO:0007829|PDB:8T74" FT STRAND 67..71 FT /evidence="ECO:0007829|PDB:6VJJ" FT HELIX 78..88 FT /evidence="ECO:0007829|PDB:6VJJ" FT HELIX 93..95 FT /evidence="ECO:0007829|PDB:6VJJ" FT STRAND 96..100 FT /evidence="ECO:0007829|PDB:6VJJ" FT STRAND 103..107 FT /evidence="ECO:0007829|PDB:6VJJ" FT STRAND 110..112 FT /evidence="ECO:0007829|PDB:8T74" FT HELIX 118..121 FT /evidence="ECO:0007829|PDB:6VJJ" FT STRAND 125..130 FT /evidence="ECO:0007829|PDB:6VJJ" FT STRAND 132..134 FT /evidence="ECO:0007829|PDB:6PTW" FT STRAND 135..137 FT /evidence="ECO:0007829|PDB:6XGV" FT STRAND 141..145 FT /evidence="ECO:0007829|PDB:6XI7" FT TURN 153..155 FT /evidence="ECO:0007829|PDB:6XI7" FT STRAND 160..165 FT /evidence="ECO:0007829|PDB:6XI7" FT TURN 166..168 FT /evidence="ECO:0007829|PDB:6XI7" FT STRAND 170..172 FT /evidence="ECO:0007829|PDB:7JHP" FT HELIX 174..179 FT /evidence="ECO:0007829|PDB:6XI7" FT STRAND 182..185 FT /evidence="ECO:0007829|PDB:6XGV" FT STRAND 350..353 FT /evidence="ECO:0007829|PDB:8CPD" FT STRAND 363..376 FT /evidence="ECO:0007829|PDB:8CPD" FT HELIX 384..397 FT /evidence="ECO:0007829|PDB:8CPD" FT STRAND 408..412 FT /evidence="ECO:0007829|PDB:8CPD" FT STRAND 414..416 FT /evidence="ECO:0007829|PDB:8CPD" FT STRAND 418..422 FT /evidence="ECO:0007829|PDB:8CPD" FT STRAND 429..431 FT /evidence="ECO:0007829|PDB:7Z38" FT TURN 434..437 FT /evidence="ECO:0007829|PDB:7Z38" FT HELIX 442..461 FT /evidence="ECO:0007829|PDB:7Z38" FT HELIX 471..473 FT /evidence="ECO:0007829|PDB:7Z38" FT TURN 478..480 FT /evidence="ECO:0007829|PDB:8GAE" FT STRAND 481..484 FT /evidence="ECO:0007829|PDB:8GAE" FT STRAND 510..512 FT /evidence="ECO:0007829|PDB:7Z38" FT HELIX 514..518 FT /evidence="ECO:0007829|PDB:7Z38" FT STRAND 520..522 FT /evidence="ECO:0007829|PDB:7Z38" FT HELIX 527..542 FT /evidence="ECO:0007829|PDB:7Z38" FT TURN 547..550 FT /evidence="ECO:0007829|PDB:7Z38" FT HELIX 554..563 FT /evidence="ECO:0007829|PDB:7Z38" FT HELIX 580..588 FT /evidence="ECO:0007829|PDB:7Z38" FT TURN 593..595 FT /evidence="ECO:0007829|PDB:7Z38" FT HELIX 599..611 FT /evidence="ECO:0007829|PDB:7Z38" FT TURN 612..614 FT /evidence="ECO:0007829|PDB:7Z38" SQ SEQUENCE 648 AA; 73052 MW; EF821B5349711BC3 CRC64; MEHIQGAWKT ISNGFGFKDA VFDGSSCISP TIVQQFGYQR RASDDGKLTD PSKTSNTIRV FLPNKQRTVV NVRNGMSLHD CLMKALKVRG LQPECCAVFR LLHEHKGKKA RLDWNTDAAS LIGEELQVDF LDHVPLTTHN FARKTFLKLA FCDICQKFLL NGFRCQTCGY KFHEHCSTKV PTMCVDWSNI RQLLLFPNST IGDSGVPALP SLTMRRMRES VSRMPVSSQH RYSTPHAFTF NTSSPSSEGS LSQRQRSTST PNVHMVSTTL PVDSRMIEDA IRSHSESASP SALSSSPNNL SPTGWSQPKT PVPAQRERAP VSGTQEKNKI RPRGQRDSSY YWEIEASEVM LSTRIGSGSF GTVYKGKWHG DVAVKILKVV DPTPEQFQAF RNEVAVLRKT RHVNILLFMG YMTKDNLAIV TQWCEGSSLY KHLHVQETKF QMFQLIDIAR QTAQGMDYLH AKNIIHRDMK SNNIFLHEGL TVKIGDFGLA TVKSRWSGSQ QVEQPTGSVL WMAPEVIRMQ DNNPFSFQSD VYSYGIVLYE LMTGELPYSH INNRDQIIFM VGRGYASPDL SKLYKNCPKA MKRLVADCVK KVKEERPLFP QILSSIELLQ HSLPKINRSA SEPSLHRAAH TEDINACTLT TSPRLPVF // ID RASK_HUMAN Reviewed; 189 AA. AC P01116; A8K8Z5; B0LPF9; P01118; Q96D10; DT 21-JUL-1986, integrated into UniProtKB/Swiss-Prot. DT 21-JUL-1986, sequence version 1. DT 28-JAN-2026, entry version 268. DE RecName: Full=GTPase KRas; DE EC=3.6.5.2 {ECO:0000269|PubMed:20949621, ECO:0000269|PubMed:39809765}; DE AltName: Full=K-Ras 2; DE AltName: Full=Ki-Ras; DE AltName: Full=c-K-ras; DE AltName: Full=c-Ki-ras; DE Contains: DE RecName: Full=GTPase KRas, N-terminally processed; DE Flags: Precursor; GN Name=KRAS; Synonyms=KRAS2, RASK2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 2A AND 2B). RX PubMed=6308466; DOI=10.1038/304501a0; RA McGrath J.P., Capon D.J., Smith D.H., Chen E.Y., Seeburg P.H., RA Goeddel D.V., Levinson A.D.; RT "Structure and organization of the human Ki-ras proto-oncogene and a RT related processed pseudogene."; RL Nature 304:501-506(1983). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 2A AND 2B). RC TISSUE=Lung carcinoma; RX PubMed=6308465; DOI=10.1038/304497a0; RA Shimizu K., Birnbaum D., Ruley M.A., Fasano O., Suard Y., Edlund L., RA Taparowsky E., Goldfarb M., Wigler M.; RT "Structure of the Ki-ras gene of the human lung carcinoma cell line Calu- RT 1."; RL Nature 304:497-500(1983). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 2A AND 2B). RC TISSUE=Colon carcinoma, and Lung; RX PubMed=6308467; DOI=10.1038/304507a0; RA Capon D.J., Seeburg P.H., McGrath J.P., Hayflick J.S., Edman U., RA Levinson A.D., Goeddel D.V.; RT "Activation of Ki-ras2 gene in human colon and lung carcinomas by two RT different point mutations."; RL Nature 304:507-513(1983). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 2A AND 2B), AND VARIANT COLON RP CANCER VAL-12. RC TISSUE=Colon carcinoma; RX PubMed=6092920; DOI=10.1128/mcb.4.8.1577-1582.1984; RA McCoy M.S., Bargmann C.I., Weinberg R.A.; RT "Human colon carcinoma Ki-ras2 oncogene and its corresponding proto- RT oncogene."; RL Mol. Cell. Biol. 4:1577-1582(1984). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2B). RX PubMed=3310850; RA Kahn S., Yamamoto F., Almoguera C., Winter E., Forrester K., Jordano J., RA Perucho M.; RT "The c-K-ras gene and human cancer (review)."; RL Anticancer Res. 7:639-652(1987). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2B). RC TISSUE=Brain; RA Puhl H.L. III, Ikeda S.R., Aronstam R.S.; RT "cDNA clones of human proteins involved in signal transduction sequenced by RT the Guthrie cDNA resource center (www.cdna.org)."; RL Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2B), AND VARIANT LUNG RP CARCINOMA HIS-61. RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2B). RC TISSUE=Testis; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [9] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG SeattleSNPs variation discovery resource; RL Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2B), AND VARIANT LUNG RP CARCINOMA HIS-61. RC TISSUE=Lung carcinoma; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [12] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-37, AND VARIANT LUNG CARCINOMA RP CYS-12. RC TISSUE=Lung carcinoma; RX PubMed=6320174; DOI=10.1073/pnas.81.1.71; RA Nakano H., Yamamoto F., Neville C., Evans D., Mizuno T., Perucho M.; RT "Isolation of transforming sequences of two human lung carcinomas: RT structural and functional analysis of the activated c-K-ras oncogenes."; RL Proc. Natl. Acad. Sci. U.S.A. 81:71-75(1984). RN [13] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-96. RC TISSUE=Pancreatic carcinoma; RX PubMed=3855240; DOI=10.1016/s0006-291x(85)80140-6; RA Hirai H., Okabe T., Anraku Y., Fujisawa M., Urabe A., Takaku F.; RT "Activation of the c-K-ras oncogene in a human pancreas carcinoma."; RL Biochem. Biophys. Res. Commun. 127:168-174(1985). RN [14] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-37, AND VARIANT GASC VAL-12. RX PubMed=3034404; RA Deng G., Lu Y., Chen S., Miao J., Lu G., Li H., Cai H., Xu X., Zheng E., RA Liu P.; RT "Activated c-Ha-ras oncogene with a guanine to thymine transversion at the RT twelfth codon in a human stomach cancer cell line."; RL Cancer Res. 47:3195-3198(1987). RN [15] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-36, AND VARIANT BLADDER/LUNG CANCER RP ARG-12. RC TISSUE=Lung carcinoma; RX PubMed=6695174; DOI=10.1126/science.6695174; RA Santos E., Martin-Zanca D., Reddy P.E., Pierotti M.A., Porta G., RA Barbacid M.; RT "Malignant activation of a K-ras oncogene in lung carcinoma but not in RT normal tissue of the same patient."; RL Science 223:661-664(1984). RN [16] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-37. RX PubMed=3932274; RA Sekiya T., Tokunaga A., Fushimi M.; RT "Essential region for transforming activity of human c-Ha-ras-1."; RL Jpn. J. Cancer Res. 76:787-791(1985). RN [17] RP PROTEIN SEQUENCE OF 1-41; 43-147 AND 150-161, CLEAVAGE OF INITIATOR RP METHIONINE, ACETYLATION AT MET-1 AND THR-2, AND IDENTIFICATION BY MASS RP SPECTROMETRY. RC TISSUE=Cervix carcinoma; RA Bienvenut W.V., Calvo F., Kolch W.; RL Submitted (FEB-2008) to UniProtKB. RN [18] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-96. RC TISSUE=Lung carcinoma; RX PubMed=6096811; DOI=10.1093/nar/12.23.8873; RA Yamamoto F., Perucho M.; RT "Activation of a human c-K-ras oncogene."; RL Nucleic Acids Res. 12:8873-8885(1984). RN [19] RP GLYCOSYLATION AT THR-35 (MICROBIAL INFECTION). RX PubMed=19744486; DOI=10.1016/j.febslet.2009.09.006; RA Huelsenbeck S.C., Klose I., Reichenbach M., Huelsenbeck J., Genth H.; RT "Distinct kinetics of (H/K/N)Ras glucosylation and Rac1 glucosylation RT catalysed by Clostridium sordellii lethal toxin."; RL FEBS Lett. 583:3133-3139(2009). RN [20] RP INTERACTION WITH RAP1GDS1. RX PubMed=20709748; DOI=10.1074/jbc.m110.129916; RA Berg T.J., Gastonguay A.J., Lorimer E.L., Kuhnmuench J.R., Li R., RA Fields A.P., Williams C.L.; RT "Splice variants of SmgGDS control small GTPase prenylation and membrane RT localization."; RL J. Biol. Chem. 285:35255-35266(2010). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [22] RP ACETYLATION AT LYS-104, VARIANT VAL-12, FUNCTION, AND ACTIVITY REGULATION. RX PubMed=22711838; DOI=10.1073/pnas.1201487109; RA Yang M.H., Nickerson S., Kim E.T., Liot C., Laurent G., Spang R., RA Philips M.R., Shan Y., Shaw D.E., Bar-Sagi D., Haigis M.C., Haigis K.M.; RT "Regulation of RAS oncogenicity by acetylation."; RL Proc. Natl. Acad. Sci. U.S.A. 109:10843-10848(2012). RN [23] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PDE6D. RX PubMed=23698361; DOI=10.1038/nature12205; RA Zimmermann G., Papke B., Ismail S., Vartak N., Chandra A., Hoffmann M., RA Hahn S.A., Triola G., Wittinghofer A., Bastiaens P.I., Waldmann H.; RT "Small molecule inhibition of the KRAS-PDE? interaction impairs oncogenic RT KRAS signalling."; RL Nature 497:638-642(2013). RN [24] RP FUNCTION, AND CHARACTERIZATION OF VARIANT COLON CANCER VAL-12. RX PubMed=24623306; DOI=10.7554/elife.02313; RA Serra R.W., Fang M., Park S.M., Hutchinson L., Green M.R.; RT "A KRAS-directed transcriptional silencing pathway that mediates the CpG RT island methylator phenotype."; RL Elife 3:E02313-E02313(2014). RN [25] RP INTERACTION WITH RAP1GDS1, AND ISOPRENYLATION AT CYS-186. RX PubMed=24415755; DOI=10.1074/jbc.m113.527192; RA Schuld N.J., Vervacke J.S., Lorimer E.L., Simon N.C., Hauser A.D., RA Barbieri J.T., Distefano M.D., Williams C.L.; RT "The chaperone protein SmgGDS interacts with small GTPases entering the RT prenylation pathway by recognizing the last amino acid in the CAAX motif."; RL J. Biol. Chem. 289:6862-6876(2014). RN [26] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25944712; DOI=10.1002/pmic.201400617; RA Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D., RA Lane L., Bairoch A., Van Dorsselaer A., Carapito C.; RT "N-terminome analysis of the human mitochondrial proteome."; RL Proteomics 15:2519-2524(2015). RN [27] RP PALMITOYLATION AT CYS-180; LYS-182; LYS-184 AND LYS-185, DEPALMITOYLATION RP BY SIRT2, SUBCELLULAR LOCATION, AND MUTAGENESIS OF CYS-180 AND RP 182-LYS--LYS-185. RX PubMed=29239724; DOI=10.7554/elife.32436; RA Jing H., Zhang X., Wisner S.A., Chen X., Spiegelman N.A., Linder M.E., RA Lin H.; RT "SIRT2 and lysine fatty acylation regulate the transforming activity of K- RT Ras4a."; RL Elife 6:0-0(2017). RN [28] RP INTERACTION WITH GPR31. RX PubMed=28619714; DOI=10.1083/jcb.201609096; RA Fehrenbacher N., Tojal da Silva I., Ramirez C., Zhou Y., Cho K.J., RA Kuchay S., Shi J., Thomas S., Pagano M., Hancock J.F., Bar-Sagi D., RA Philips M.R.; RT "The G protein-coupled receptor GPR31 promotes membrane association of RT KRAS."; RL J. Cell Biol. 216:2329-2338(2017). RN [29] RP UBIQUITINATION AT LYS-170. RX PubMed=30442762; DOI=10.1126/science.aap7607; RA Steklov M., Pandolfi S., Baietti M.F., Batiuk A., Carai P., Najm P., RA Zhang M., Jang H., Renzi F., Cai Y., Abbasi Asbagh L., Pastor T., RA De Troyer M., Simicek M., Radaelli E., Brems H., Legius E., Tavernier J., RA Gevaert K., Impens F., Messiaen L., Nussinov R., Heymans S., Eyckerman S., RA Sablina A.A.; RT "Mutations in LZTR1 drive human disease by dysregulating RAS RT ubiquitination."; RL Science 362:1177-1182(2018). RN [30] RP UBIQUITINATION. RX PubMed=30442766; DOI=10.1126/science.aap8210; RA Bigenzahn J.W., Collu G.M., Kartnig F., Pieraks M., Vladimer G.I., RA Heinz L.X., Sedlyarov V., Schischlik F., Fauster A., Rebsamen M., RA Parapatics K., Blomen V.A., Mueller A.C., Winter G.E., Kralovics R., RA Brummelkamp T.R., Mlodzik M., Superti-Furga G.; RT "LZTR1 is a regulator of RAS ubiquitination and signaling."; RL Science 362:1171-1177(2018). RN [31] RP INTERACTION WITH PPP1CA; PPP1CB AND SHOC2. RX PubMed=36175670; DOI=10.1038/s41594-022-00841-4; RA Bonsor D.A., Alexander P., Snead K., Hartig N., Drew M., Messing S., RA Finci L.I., Nissley D.V., McCormick F., Esposito D., Rodriguez-Viciana P., RA Stephen A.G., Simanshu D.K.; RT "Structure of the SHOC2-MRAS-PP1c complex provides insights into RAF RT activation and Noonan syndrome."; RL Nat. Struct. Mol. Biol. 29:966-977(2022). RN [32] RP INTERACTION WITH PPP1CA; PPP1CB; PPP1CC AND SHOC2. RX PubMed=35768504; DOI=10.1038/s41586-022-04838-3; RA Liau N.P.D., Johnson M.C., Izadi S., Gerosa L., Hammel M., Bruning J.M., RA Wendorff T.J., Phung W., Hymowitz S.G., Sudhamsu J.; RT "Structural basis for SHOC2 modulation of RAS signalling."; RL Nature 609:400-407(2022). RN [33] RP INTERACTION WITH PPP1CA; PPP1CB; PPP1CC AND SHOC2, AND CHARACTERIZATION OF RP VARIANT GLN-61. RX PubMed=35831509; DOI=10.1038/s41586-022-04928-2; RA Kwon J.J., Hajian B., Bian Y., Young L.C., Amor A.J., Fuller J.R., RA Fraley C.V., Sykes A.M., So J., Pan J., Baker L., Lee S.J., Wheeler D.B., RA Mayhew D.L., Persky N.S., Yang X., Root D.E., Barsotti A.M., Stamford A.W., RA Perry C.K., Burgin A., McCormick F., Lemke C.T., Hahn W.C., Aguirre A.J.; RT "Structure-function analysis of the SHOC2-MRAS-PP1c holophosphatase RT complex."; RL Nature 609:408-415(2022). RN [34] RP INTERACTION WITH PPP1CA AND SHOC2, AND CHARACTERIZATION OF VARIANT GLN-61. RX PubMed=35830882; DOI=10.1038/s41586-022-05086-1; RA Hauseman Z.J., Fodor M., Dhembi A., Viscomi J., Egli D., Bleu M., Katz S., RA Park E., Jang D.M., Porter K.A., Meili F., Guo H., Kerr G., Molle S., RA Velez-Vega C., Beyer K.S., Galli G.G., Maira S.M., Stams T., Clark K., RA Eck M.J., Tordella L., Thoma C.R., King D.A.; RT "Structure of the MRAS-SHOC2-PP1C phosphatase complex."; RL Nature 609:416-423(2022). RN [35] RP X-RAY CRYSTALLOGRAPHY (1.35 ANGSTROMS) OF 1-164 IN COMPLEX WITH THE GTP RP ANALOG GUANOSINE-5'-DIPHOSPHATE, AND ACTIVITY REGULATION. RX PubMed=22566140; DOI=10.1002/anie.201201358; RA Sun Q., Burke J.P., Phan J., Burns M.C., Olejniczak E.T., Waterson A.G., RA Lee T., Rossanese O.W., Fesik S.W.; RT "Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated RT activation."; RL Angew. Chem. Int. Ed. Engl. 51:6140-6143(2012). RN [36] RP X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 2-164 IN COMPLEX WITH GTP ANALOGS RP AND MAGNESIUM, FUNCTION, ACTIVITY REGULATION, INTERACTION WITH SOS1, AND RP SUBCELLULAR LOCATION. RX PubMed=22431598; DOI=10.1073/pnas.1116510109; RA Maurer T., Garrenton L.S., Oh A., Pitts K., Anderson D.J., Skelton N.J., RA Fauber B.P., Pan B., Malek S., Stokoe D., Ludlam M.J., Bowman K.K., Wu J., RA Giannetti A.M., Starovasnik M.A., Mellman I., Jackson P.K., Rudolph J., RA Wang W., Fang G.; RT "Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS- RT mediated nucleotide exchange activity."; RL Proc. Natl. Acad. Sci. U.S.A. 109:5299-5304(2012). RN [37] {ECO:0007744|PDB:5TAR, ECO:0007744|PDB:5TB5} RP X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 2-164, ISOPRENYLATION AT CYS-186, RP AND METHYLATION AT CYS-186. RX PubMed=27791178; DOI=10.1073/pnas.1615316113; RA Dharmaiah S., Bindu L., Tran T.H., Gillette W.K., Frank P.H., Ghirlando R., RA Nissley D.V., Esposito D., McCormick F., Stephen A.G., Simanshu D.K.; RT "Structural basis of recognition of farnesylated and methylated KRAS4b by RT PDEdelta."; RL Proc. Natl. Acad. Sci. U.S.A. 113:E6766-E6775(2016). RN [38] {ECO:0007744|PDB:7LC1, ECO:0007744|PDB:7LC2} RP X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS) IN COMPLEX WITH MAPKAP1, INTERACTION RP WITH MAPKAP1, AND MUTAGENESIS OF ASP-38 AND TYR-40. RX PubMed=34380736; DOI=10.1073/pnas.2103261118; RA Castel P., Dharmaiah S., Sale M.J., Messing S., Rizzuto G., RA Cuevas-Navarro A., Cheng A., Trnka M.J., Urisman A., Esposito D., RA Simanshu D.K., McCormick F.; RT "RAS interaction with Sin1 is dispensable for mTORC2 assembly and RT activity."; RL Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021). RN [39] {ECO:0007744|PDB:7VVB} RP X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) IN COMPLEX WITH MAPKAP1, AND RP INTERACTION WITH MAPKAP1. RX PubMed=35522713; DOI=10.1073/pnas.2119990119; RA Zheng Y., Ding L., Meng X., Potter M., Kearney A.L., Zhang J., Sun J., RA James D.E., Yang G., Zhou C.; RT "Structural insights into Ras regulation by SIN1."; RL Proc. Natl. Acad. Sci. U.S.A. 119:e2119990119-e2119990119(2022). RN [40] RP VARIANT BREAST CANCER ASP-13. RX PubMed=3627975; DOI=10.1093/nar/15.15.5963; RA Kozma S.C., Bogaard M.E., Buser K., Saurer S.M., Bos J.L., Groner B., RA Hynes N.E.; RT "The human c-Kirsten ras gene is activated by a novel mutation in codon 13 RT in the breast carcinoma cell line MDA-MB231."; RL Nucleic Acids Res. 15:5963-5971(1987). RN [41] RP VARIANT BLADDER CANCER THR-59. RX PubMed=1553789; DOI=10.1007/bf00296523; RA Grimmond S.M., Raghavan D., Russell P.J.; RT "Detection of a rare point mutation in Ki-ras of a human bladder cancer RT xenograft by polymerase chain reaction and direct sequencing."; RL Urol. Res. 20:121-126(1992). RN [42] RP VARIANTS PANCREATIC CARCINOMA ASP-12 AND VAL-12. RX PubMed=8439212; DOI=10.1097/00000658-199302000-00007; RA Motojima K., Urano T., Nagata Y., Shiku H., Tsurifune T., Kanematsu T.; RT "Detection of point mutations in the Kirsten-ras oncogene provides evidence RT for the multicentricity of pancreatic carcinoma."; RL Ann. Surg. 217:138-143(1993). RN [43] RP VARIANTS GASC SER-12 AND ASP-12. RX PubMed=7773929; RX DOI=10.1002/1097-0142(19950615)75:12<2794::aid-cncr2820751203>3.0.co;2-f; RA Lee K.H., Lee J.S., Suh C., Kim S.W., Kim S.B., Lee J.H., Lee M.S., RA Park M.Y., Sun H.S., Kim S.H.; RT "Clinicopathologic significance of the K-ras gene codon 12 point mutation RT in stomach cancer. An analysis of 140 cases."; RL Cancer 75:2794-2801(1995). RN [44] RP INVOLVEMENT IN AML, VARIANT GLY-10 INS, AND CHARACTERIZATION OF VARIANT RP GLY-10 INS. RX PubMed=8955068; DOI=10.1074/jbc.271.51.32491; RA Bollag G., Adler F., elMasry N., McCabe P.C., Conner E. Jr., Thompson P., RA McCormick F., Shannon K.; RT "Biochemical characterization of a novel KRAS insertion mutation from a RT human leukemia."; RL J. Biol. Chem. 271:32491-32494(1996). RN [45] RP VARIANTS GASC ASN-5; VAL-12; ASP-13 AND THR-59. RX PubMed=14534542; DOI=10.1038/sj.onc.1206749; RA Lee S.H., Lee J.W., Soung Y.H., Kim H.S., Park W.S., Kim S.Y., Lee J.H., RA Park J.Y., Cho Y.G., Kim C.J., Nam S.W., Kim S.H., Lee J.Y., Yoo N.J.; RT "BRAF and KRAS mutations in stomach cancer."; RL Oncogene 22:6942-6945(2003). RN [46] RP VARIANT PYLOCYTIC ASTROCYTOMA ARG-13. RX PubMed=16247081; DOI=10.1212/01.wnl.0000180409.78098.d7; RA Sharma M.K., Zehnbauer B.A., Watson M.A., Gutmann D.H.; RT "RAS pathway activation and an oncogenic RAS mutation in sporadic pilocytic RT astrocytoma."; RL Neurology 65:1335-1336(2005). RN [47] RP VARIANTS NS3 GLY-152 AND VAL-153 (ISOFORM 2). RX PubMed=16773572; DOI=10.1086/504394; RA Carta C., Pantaleoni F., Bocchinfuso G., Stella L., Vasta I., Sarkozy A., RA Digilio C., Palleschi A., Pizzuti A., Grammatico P., Zampino G., RA Dallapiccola B., Gelb B.D., Tartaglia M.; RT "Germline missense mutations affecting KRAS Isoform B are associated with a RT severe Noonan syndrome phenotype."; RL Am. J. Hum. Genet. 79:129-135(2006). RN [48] RP VARIANTS LUNG CARCINOMA CYS-12; ASP-12; SER-12; VAL-12 AND HIS-61. RX PubMed=16533793; DOI=10.1158/1078-0432.ccr-05-1981; RA Tam I.Y.S., Chung L.P., Suen W.S., Wang E., Wong M.C.M., Ho K.K., Lam W.K., RA Chiu S.W., Girard L., Minna J.D., Gazdar A.F., Wong M.P.; RT "Distinct epidermal growth factor receptor and KRAS mutation patterns in RT non-small cell lung cancer patients with different tobacco exposure and RT clinicopathologic features."; RL Clin. Cancer Res. 12:1647-1653(2006). RN [49] RP VARIANT CFC2 ARG-60. RX PubMed=16474404; DOI=10.1038/ng1749; RA Niihori T., Aoki Y., Narumi Y., Neri G., Cave H., Verloes A., Okamoto N., RA Hennekam R.C.M., Gillessen-Kaesbach G., Wieczorek D., Kavamura M.I., RA Kurosawa K., Ohashi H., Wilson L., Heron D., Bonneau D., Corona G., RA Kaname T., Naritomi K., Baumann C., Matsumoto N., Kato K., Kure S., RA Matsubara Y.; RT "Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome."; RL Nat. Genet. 38:294-296(2006). RN [50] RP VARIANTS NS3 ILE-14 AND ILE-58, VARIANT CFC2 ARG-34, AND CHARACTERIZATION RP OF VARIANTS NS3 ILE-14 AND ILE-58. RX PubMed=16474405; DOI=10.1038/ng1748; RA Schubbert S., Zenker M., Rowe S.L., Boell S., Klein C., Bollag G., RA van der Burgt I., Musante L., Kalscheuer V., Wehner L.-E., Nguyen H., RA West B., Zhang K.Y.J., Sistermans E., Rauch A., Niemeyer C.M., Shannon K., RA Kratz C.P.; RT "Germline KRAS mutations cause Noonan syndrome."; RL Nat. Genet. 38:331-336(2006). RN [51] RP VARIANTS [LARGE SCALE ANALYSIS] ALA-12; ASP-12; SER-12; VAL-12; ASP-13; RP ARG-61; ASN-117 AND THR-146. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [52] RP VARIANTS JMML ASP-12; SER-12 AND ASP-13. RX PubMed=17332249; DOI=10.1182/blood-2006-09-046649; RA Matsuda K., Shimada A., Yoshida N., Ogawa A., Watanabe A., Yajima S., RA Iizuka S., Koike K., Yanai F., Kawasaki K., Yanagimachi M., Kikuchi A., RA Ohtsuka Y., Hidaka E., Yamauchi K., Tanaka M., Yanagisawa R., Nakazawa Y., RA Shiohara M., Manabe A., Kojima S., Koike K.; RT "Spontaneous improvement of hematologic abnormalities in patients having RT juvenile myelomonocytic leukemia with specific RAS mutations."; RL Blood 109:5477-5480(2007). RN [53] RP VARIANT NS3 GLU-5. RX PubMed=17468812; DOI=10.1007/s10038-007-0146-1; RA Bertola D.R., Pereira A.C., Brasil A.S., Albano L.M., Kim C.A., RA Krieger J.E.; RT "Further evidence of genetic heterogeneity in Costello syndrome: RT involvement of the KRAS gene."; RL J. Hum. Genet. 52:521-526(2007). RN [54] RP VARIANTS NS3 ILE-14; ARG-22; LEU-34; GLN-34; MET-36; VAL-153 AND ILE-156 RP (ISOFORM 2), VARIANT CFC2 GLU-22, AND VARIANTS ASN-5 AND LEU-156 (ISOFORM RP 2). RX PubMed=17056636; DOI=10.1136/jmg.2006.046300; RA Zenker M., Lehmann K., Schulz A.L., Barth H., Hansmann D., Koenig R., RA Korinthenberg R., Kreiss-Nachtsheim M., Meinecke P., Morlot S., Mundlos S., RA Quante A.S., Raskin S., Schnabel D., Wehner L.E., Kratz C.P., Horn D., RA Kutsche K.; RT "Expansion of the genotypic and phenotypic spectrum in patients with KRAS RT germline mutations."; RL J. Med. Genet. 44:131-135(2007). RN [55] RP VARIANTS NS3 ILE-58 AND SER-60. RX PubMed=19396835; DOI=10.1002/ajmg.a.32786; RA Kratz C.P., Zampino G., Kriek M., Kant S.G., Leoni C., Pantaleoni F., RA Oudesluys-Murphy A.M., Di Rocco C., Kloska S.P., Tartaglia M., Zenker M.; RT "Craniosynostosis in patients with Noonan syndrome caused by germline KRAS RT mutations."; RL Am. J. Med. Genet. A 149:1036-1040(2009). RN [56] RP CHARACTERIZATION OF VARIANTS NS3 ILE-14; ARG-22; LEU-34; ILE-58 AND VAL-153 RP (ISOFORM 2), CHARACTERIZATION OF VARIANTS CFC2 GLU-22; ARG-34 AND ARG-60, RP CHARACTERIZATION OF VARIANTS ASN-5 AND LEU-156 (ISOFORM 2), FUNCTION, AND RP CATALYTIC ACTIVITY. RX PubMed=20949621; DOI=10.1002/humu.21377; RA Gremer L., Merbitz-Zahradnik T., Dvorsky R., Cirstea I.C., Kratz C.P., RA Zenker M., Wittinghofer A., Ahmadian M.R.; RT "Germline KRAS mutations cause aberrant biochemical and physical properties RT leading to developmental disorders."; RL Hum. Mutat. 32:33-43(2011). RN [57] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, CHARACTERIZATION OF RP VARIANT VAL-12, AND MUTAGENESIS OF GLN-61. RX PubMed=39809765; DOI=10.1038/s41467-025-55967-y; RA Bernal Astrain G., Strakhova R., Jo C.H., Teszner E., Killoran R.C., RA Smith M.J.; RT "The small GTPase MRAS is a broken switch."; RL Nat. Commun. 16:647-647(2025). RN [58] RP VARIANTS CFC2 HIS-71 AND GLU-147. RX PubMed=21797849; DOI=10.1111/j.1399-0004.2011.01754.x; RA Stark Z., Gillessen-Kaesbach G., Ryan M.M., Cirstea I.C., Gremer L., RA Ahmadian M.R., Savarirayan R., Zenker M.; RT "Two novel germline KRAS mutations: expanding the molecular and clinical RT phenotype."; RL Clin. Genet. 81:590-594(2012). RN [59] RP VARIANTS OES ASP-13 AND PHE-19, AND INVOLVEMENT IN OES. RX PubMed=25808193; DOI=10.1002/ajmg.a.37048; RA Peacock J.D., Dykema K.J., Toriello H.V., Mooney M.R., Scholten D.J. II, RA Winn M.E., Borgman A., Duesbery N.S., Hiemenga J.A., Liu C., Campbell S., RA Nickoloff B.P., Williams B.O., Steensma M.; RT "Oculoectodermal syndrome is a mosaic RASopathy associated with KRAS RT alterations."; RL Am. J. Med. Genet. A 167:1429-1435(2015). RN [60] RP VARIANTS OES THR-146 AND VAL-146, AND INVOLVEMENT IN OES. RX PubMed=26970110; DOI=10.1111/cge.12775; RA Boppudi S., Boegershausen N., Hove H.B., Percin E.F., Aslan D., Dvorsky R., RA Kayhan G., Li Y., Cursiefen C., Tantcheva-Poor I., Toft P.B., Bartsch O., RA Lissewski C., Wieland I., Jakubiczka S., Wollnik B., Ahmadian M.R., RA Heindl L.M., Zenker M.; RT "Specific mosaic KRAS mutations affecting codon 146 cause oculoectodermal RT syndrome and encephalocraniocutaneous lipomatosis."; RL Clin. Genet. 90:334-342(2016). RN [61] RP VARIANT SFM ASP-12, VARIANTS OES THR-146 AND VAL-146, INVOLVEMENT IN SFM, RP AND INVOLVEMENT IN OES. RX PubMed=30891959; DOI=10.1002/mgg3.625; RA Chacon-Camacho O.F., Lopez-Moreno D., Morales-Sanchez M.A., Hofmann E., RA Pacheco-Quito M., Wieland I., Cortes-Gonzalez V., Villanueva-Mendoza C., RA Zenker M., Zenteno J.C.; RT "Expansion of the phenotypic spectrum and description of molecular findings RT in a cohort of patients with oculocutaneous mosaic RASopathies."; RL Mol. Genet. Genomic Med. 7:E625-E625(2019). RN [62] RP VARIANTS ALA-12; ASP-12; CYS-12; VAL-12; ASN-117 AND THR-146. RX PubMed=34820593; DOI=10.1200/po.21.00223; RA van 't Erve I., Wesdorp N.J., Medina J.E., Ferreira L., Leal A., RA Huiskens J., Bolhuis K., van Waesberghe J.T.M., Swijnenburg R.J., RA van den Broek D., Velculescu V.E., Kazemier G., Punt C.J.A., Meijer G.A., RA Fijneman R.J.A.; RT "KRAS A146 mutations are associated with distinct clinical behavior in RT patients with colorectal liver metastases."; RL JCO Precis. Oncol. 5:0-0(2021). CC -!- FUNCTION: Ras proteins bind GDP/GTP and possess intrinsic GTPase CC activity (PubMed:20949621, PubMed:39809765). Plays an important role in CC the regulation of cell proliferation (PubMed:22711838, CC PubMed:23698361). Activates MAPK1/MAPK3 resulting in phosphorylation CC and ultimately degradation of GJA1 (By similarity). Plays a role in CC promoting oncogenic events by inducing transcriptional silencing of CC tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a CC ZNF304-dependent manner (PubMed:24623306). CC {ECO:0000250|UniProtKB:P08644, ECO:0000269|PubMed:20949621, CC ECO:0000269|PubMed:22711838, ECO:0000269|PubMed:23698361, CC ECO:0000269|PubMed:24623306, ECO:0000269|PubMed:39809765}. CC -!- CATALYTIC ACTIVITY: CC Reaction=GTP + H2O = GDP + phosphate + H(+); Xref=Rhea:RHEA:19669, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:37565, CC ChEBI:CHEBI:43474, ChEBI:CHEBI:58189; EC=3.6.5.2; CC Evidence={ECO:0000269|PubMed:20949621, ECO:0000269|PubMed:39809765}; CC -!- ACTIVITY REGULATION: Alternates between an inactive form bound to GDP CC and an active form bound to GTP (PubMed:22566140, PubMed:22431598, CC PubMed:39809765). Activated by a guanine nucleotide-exchange factor CC (GEF) and inactivated by a GTPase-activating protein (GAP) CC (PubMed:22711838). Interaction with SOS1 promotes exchange of bound GDP CC to GTP (PubMed:22566140, PubMed:22431598, PubMed:39809765). CC {ECO:0000269|PubMed:22431598, ECO:0000269|PubMed:22566140, CC ECO:0000269|PubMed:22711838, ECO:0000269|PubMed:39809765}. CC -!- SUBUNIT: Interacts with PHLPP (By similarity). Interacts (active GTP- CC bound form preferentially) with RGS14 (By similarity). Interacts (when CC farnesylated) with PDE6D; this promotes dissociation from the cell CC membrane (PubMed:23698361). Interacts with SOS1 (PubMed:22431598). CC Interacts (when farnesylated) with GPR31 (PubMed:28619714). Interacts CC with RAP1GDS1 (PubMed:20709748, PubMed:24415755). Interacts (active CC GTP-bound form) with both SHOC2 and PP1c (all isoforms) to form a CC tertiary complex; SHOC2 and PP1c preferably bind M-Ras/MRAS, but they CC also bind K-Ras/KRAS, N-Ras/NRAS and H-Ras/HRAS (PubMed:35768504, CC PubMed:35830882, PubMed:35831509, PubMed:36175670). Interacts (GTP- CC bound form) with MAPKAP1/SIN1; inhibiting K-Ras/KRAS activity CC (PubMed:34380736, PubMed:35522713). {ECO:0000250|UniProtKB:P08644, CC ECO:0000269|PubMed:20709748, ECO:0000269|PubMed:22431598, CC ECO:0000269|PubMed:23698361, ECO:0000269|PubMed:24415755, CC ECO:0000269|PubMed:28619714, ECO:0000269|PubMed:34380736, CC ECO:0000269|PubMed:35522713, ECO:0000269|PubMed:35768504, CC ECO:0000269|PubMed:35830882, ECO:0000269|PubMed:35831509, CC ECO:0000269|PubMed:36175670}. CC -!- SUBUNIT: [Isoform 2B]: Interacts with GPR31; in a farnelysation- CC dependent manner. {ECO:0000269|PubMed:28619714}. CC -!- INTERACTION: CC P01116; Q96II5: ARAF; NbExp=3; IntAct=EBI-367415, EBI-9383168; CC P01116; Q99755: PIP5K1A; NbExp=9; IntAct=EBI-367415, EBI-726414; CC P01116; P04049: RAF1; NbExp=6; IntAct=EBI-367415, EBI-365996; CC P01116; P50749: RASSF2; NbExp=2; IntAct=EBI-367415, EBI-960081; CC P01116-2; P05067: APP; NbExp=3; IntAct=EBI-367427, EBI-77613; CC P01116-2; P49354: FNTA; NbExp=2; IntAct=EBI-367427, EBI-602336; CC P01116-2; O00270: GPR31; NbExp=4; IntAct=EBI-367427, EBI-34583813; CC P01116-2; P01116-2: KRAS; NbExp=6; IntAct=EBI-367427, EBI-367427; CC P01116-2; P04049: RAF1; NbExp=3; IntAct=EBI-367427, EBI-365996; CC P01116-2; Q04631: Fnta; Xeno; NbExp=3; IntAct=EBI-367427, EBI-602447; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:22431598, CC ECO:0000269|PubMed:23698361, ECO:0000269|PubMed:29239724}; Lipid-anchor CC {ECO:0000269|PubMed:29239724, ECO:0000305|PubMed:23698361}; Cytoplasmic CC side {ECO:0000305|PubMed:23698361}. Endomembrane system CC {ECO:0000269|PubMed:29239724}. Cytoplasm, cytosol CC {ECO:0000269|PubMed:23698361}. CC -!- SUBCELLULAR LOCATION: [Isoform 2B]: Cell membrane CC {ECO:0000269|PubMed:28619714}; Lipid-anchor CC {ECO:0000305|PubMed:28619714}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Comment=Isoforms differ in the C-terminal region which is encoded by CC two alternative exons (IVA and IVB).; CC Name=2A; Synonyms=K-Ras4A {ECO:0000303|PubMed:29239724}; CC IsoId=P01116-1; Sequence=Displayed; CC Name=2B; Synonyms=K-Ras4B; CC IsoId=P01116-2, P01118-1; CC Sequence=VSP_011140, VSP_011141; CC -!- PTM: Acetylation at Lys-104 prevents interaction with guanine CC nucleotide exchange factors (GEFs). {ECO:0000269|PubMed:22711838, CC ECO:0000269|Ref.17}. CC -!- PTM: Palmitoylated at Lys-182, Lys-184 and Lys-185 (PubMed:29239724). CC Palmitoylation on lysine residues is promoted by palmitoylation at Cys- CC 180 (PubMed:29239724). Lysine-depalmitoylation by SIRT2 promotes its CC localization to endomembranes in endocytic pathways (PubMed:29239724). CC {ECO:0000269|PubMed:29239724}. CC -!- PTM: Ubiquitinated by the BCR(LZTR1) E3 ubiquitin ligase complex at CC Lys-170 in a non-degradative manner, leading to inhibit Ras signaling CC by decreasing Ras association with membranes. CC {ECO:0000305|PubMed:30442762, ECO:0000305|PubMed:30442766}. CC -!- PTM: (Microbial infection) Glucosylated at Thr-35 by P.sordellii toxin CC TcsL. {ECO:0000269|PubMed:19744486}. CC -!- DISEASE: Leukemia, acute myelogenous (AML) [MIM:601626]: A subtype of CC acute leukemia, a cancer of the white blood cells. AML is a malignant CC disease of bone marrow characterized by maturational arrest of CC hematopoietic precursors at an early stage of development. Clonal CC expansion of myeloid blasts occurs in bone marrow, blood, and other CC tissue. Myelogenous leukemias develop from changes in cells that CC normally produce neutrophils, basophils, eosinophils and monocytes. CC {ECO:0000269|PubMed:8955068}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Leukemia, juvenile myelomonocytic (JMML) [MIM:607785]: An CC aggressive pediatric myelodysplastic syndrome/myeloproliferative CC disorder characterized by malignant transformation in the hematopoietic CC stem cell compartment with proliferation of differentiated progeny. CC Patients have splenomegaly, enlarged lymph nodes, rashes, and CC hemorrhages. {ECO:0000269|PubMed:17332249}. Note=The disease is caused CC by variants affecting the gene represented in this entry. CC -!- DISEASE: Noonan syndrome 3 (NS3) [MIM:609942]: A form of Noonan CC syndrome, a disease characterized by short stature, facial dysmorphic CC features such as hypertelorism, a downward eyeslant and low-set CC posteriorly rotated ears, and a high incidence of congenital heart CC defects and hypertrophic cardiomyopathy. Other features can include a CC short neck with webbing or redundancy of skin, deafness, motor delay, CC variable intellectual deficits, multiple skeletal defects, CC cryptorchidism, and bleeding diathesis. Individuals with Noonan CC syndrome are at risk of juvenile myelomonocytic leukemia, a CC myeloproliferative disorder characterized by excessive production of CC myelomonocytic cells. {ECO:0000269|PubMed:16474405, CC ECO:0000269|PubMed:16773572, ECO:0000269|PubMed:17056636, CC ECO:0000269|PubMed:17468812, ECO:0000269|PubMed:19396835, CC ECO:0000269|PubMed:20949621}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Gastric cancer (GASC) [MIM:613659]: A malignant disease which CC starts in the stomach, can spread to the esophagus or the small CC intestine, and can extend through the stomach wall to nearby lymph CC nodes and organs. It also can metastasize to other parts of the body. CC The term gastric cancer or gastric carcinoma refers to adenocarcinoma CC of the stomach that accounts for most of all gastric malignant tumors. CC Two main histologic types are recognized, diffuse type and intestinal CC type carcinomas. Diffuse tumors are poorly differentiated infiltrating CC lesions, resulting in thickening of the stomach. In contrast, CC intestinal tumors are usually exophytic, often ulcerating, and CC associated with intestinal metaplasia of the stomach, most often CC observed in sporadic disease. {ECO:0000269|PubMed:14534542, CC ECO:0000269|PubMed:3034404, ECO:0000269|PubMed:7773929}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Note=Defects in KRAS are a cause of pylocytic astrocytoma CC (PA). Pylocytic astrocytomas are neoplasms of the brain and spinal cord CC derived from glial cells which vary from histologically benign forms to CC highly anaplastic and malignant tumors. {ECO:0000269|PubMed:16247081}. CC -!- DISEASE: Cardiofaciocutaneous syndrome 2 (CFC2) [MIM:615278]: A form of CC cardiofaciocutaneous syndrome, a multiple congenital anomaly disorder CC characterized by a distinctive facial appearance, heart defects and CC intellectual disability. Heart defects include pulmonic stenosis, CC atrial septal defects and hypertrophic cardiomyopathy. Some affected CC individuals present with ectodermal abnormalities such as sparse, CC friable hair, hyperkeratotic skin lesions and a generalized ichthyosis- CC like condition. Typical facial features are similar to Noonan syndrome. CC They include high forehead with bitemporal constriction, hypoplastic CC supraorbital ridges, downslanting palpebral fissures, a depressed nasal CC bridge, and posteriorly angulated ears with prominent helices. CFC2 CC patients often do not have the skin abnormalities, such as ichthyosis, CC hyperkeratosis, and hemangioma observed in CFC1. CC {ECO:0000269|PubMed:16474404, ECO:0000269|PubMed:16474405, CC ECO:0000269|PubMed:17056636, ECO:0000269|PubMed:20949621, CC ECO:0000269|PubMed:21797849}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Note=KRAS mutations are involved in cancer development. CC {ECO:0000269|PubMed:14534542, ECO:0000269|PubMed:1553789, CC ECO:0000269|PubMed:16533793, ECO:0000269|PubMed:24623306, CC ECO:0000269|PubMed:3034404, ECO:0000269|PubMed:3627975, CC ECO:0000269|PubMed:6092920, ECO:0000269|PubMed:6695174, CC ECO:0000269|PubMed:7773929}. CC -!- DISEASE: Oculoectodermal syndrome (OES) [MIM:600268]: A syndrome CC characterized by the association of epibulbar dermoids and aplasia CC cutis congenita. Affected individuals show multiple, asymmetric, CC atrophic, non-scarring and hairless regions that may be associated with CC hamartomas. Ectodermal changes include linear hyperpigmentation that CC may follow the lines of Blaschko and rarely epidermal nevus-like CC lesions. Epibulbar dermoids may be uni-or bilateral. Additional ocular CC anomalies such as skin tags of the upper eyelid, rarely optic nerve or CC retinal changes, and microphthalmia can be present. The phenotypic CC expression is highly variable, and various other abnormalities have CC occasionally been reported including growth failure, lymphedema, CC cardiovascular defects, as well as neurodevelopmental symptoms like CC developmental delay, epilepsy, learning difficulties, and behavioral CC abnormalities. Benign tumor-like lesions such as nonossifying fibromas CC of the long bones and giant cell granulomas of the jaws have repeatedly CC been observed and appear to be age-dependent, becoming a common CC manifestation in individuals aged 5 years or older. CC {ECO:0000269|PubMed:25808193, ECO:0000269|PubMed:26970110, CC ECO:0000269|PubMed:30891959}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Schimmelpenning-Feuerstein-Mims syndrome (SFM) [MIM:163200]: A CC disease characterized by sebaceous nevi, often on the face, associated CC with variable ipsilateral abnormalities of the central nervous system, CC ocular anomalies, and skeletal defects. Many oral manifestations have CC been reported, not only including hypoplastic and malformed teeth, and CC mucosal papillomatosis, but also ankyloglossia, hemihyperplastic CC tongue, intraoral nevus, giant cell granuloma, ameloblastoma, bone CC cysts, follicular cysts, oligodontia, and odontodysplasia. Sebaceous CC nevi follow the lines of Blaschko and these can continue as linear CC intraoral lesions, as in mucosal papillomatosis. CC {ECO:0000269|PubMed:30891959}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the small GTPase superfamily. Ras family. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/91/KRAS"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L00049; AAB59444.1; -; Genomic_DNA. DR EMBL; L00045; AAB59444.1; JOINED; Genomic_DNA. DR EMBL; L00046; AAB59444.1; JOINED; Genomic_DNA. DR EMBL; L00047; AAB59444.1; JOINED; Genomic_DNA. DR EMBL; L00048; AAB59445.1; -; Genomic_DNA. DR EMBL; L00045; AAB59445.1; JOINED; Genomic_DNA. DR EMBL; L00046; AAB59445.1; JOINED; Genomic_DNA. DR EMBL; L00047; AAB59445.1; JOINED; Genomic_DNA. DR EMBL; M54968; AAB41942.1; -; mRNA. DR EMBL; AF493917; AAM12631.1; -; mRNA. DR EMBL; BT007153; AAP35817.1; -; mRNA. DR EMBL; AK292510; BAF85199.1; -; mRNA. DR EMBL; CH471094; EAW96511.1; -; Genomic_DNA. DR EMBL; CH471094; EAW96512.1; -; Genomic_DNA. DR EMBL; EU332849; ABY87538.1; -; Genomic_DNA. DR EMBL; BC013572; AAH13572.1; -; mRNA. DR EMBL; K01519; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; K01520; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; M25876; AAA35683.1; -; Genomic_DNA. DR EMBL; M34904; AAA36149.1; -; Genomic_DNA. DR EMBL; M30539; AAA36557.1; -; Genomic_DNA. DR EMBL; X01669; CAA25828.1; -; Genomic_DNA. DR EMBL; X02825; CAA26593.1; -; Genomic_DNA. DR EMBL; K03210; AAA36554.1; -; Genomic_DNA. DR EMBL; K03209; AAA36554.1; JOINED; Genomic_DNA. DR CCDS; CCDS8702.1; -. [P01116-2] DR CCDS; CCDS8703.1; -. [P01116-1] DR PIR; A93311; TVHUK. DR PIR; B93311; TVHU2K. DR RefSeq; NP_001356715.1; NM_001369786.1. [P01116-1] DR RefSeq; NP_001356716.1; NM_001369787.1. [P01116-2] DR RefSeq; NP_004976.2; NM_004985.4. [P01116-2] DR RefSeq; NP_203524.1; NM_033360.4. [P01116-1] DR PDB; 1D8D; X-ray; 2.00 A; P=178-188. DR PDB; 1D8E; X-ray; 3.00 A; P=178-188. DR PDB; 1KZO; X-ray; 2.20 A; C=169-173. DR PDB; 1KZP; X-ray; 2.10 A; C=169-173. DR PDB; 1N4P; X-ray; 2.65 A; M/N=185-189. DR PDB; 1N4Q; X-ray; 2.40 A; M/N/O/P/Q/R=185-189. DR PDB; 1N4R; X-ray; 2.80 A; M/N/O/P/Q/R=185-189. DR PDB; 1N4S; X-ray; 2.60 A; M/N/O/P/Q/R=185-189. DR PDB; 2MSC; NMR; -; B=1-186. DR PDB; 2MSD; NMR; -; B=1-186. DR PDB; 2MSE; NMR; -; B=1-186. DR PDB; 3GFT; X-ray; 2.27 A; A/B/C/D/E/F=1-164. DR PDB; 4DSN; X-ray; 2.03 A; A=2-164. DR PDB; 4DSO; X-ray; 1.85 A; A=2-164. DR PDB; 4EPR; X-ray; 2.00 A; A=1-164. DR PDB; 4EPT; X-ray; 2.00 A; A=1-164. DR PDB; 4EPV; X-ray; 1.35 A; A=1-164. DR PDB; 4EPW; X-ray; 1.70 A; A=1-164. DR PDB; 4EPX; X-ray; 1.76 A; A=1-164. DR PDB; 4EPY; X-ray; 1.80 A; A=1-164. DR PDB; 4L8G; X-ray; 1.52 A; A=1-169. DR PDB; 4LDJ; X-ray; 1.15 A; A=1-164. DR PDB; 4LPK; X-ray; 1.50 A; A/B=1-169. DR PDB; 4LRW; X-ray; 2.15 A; A/B=1-169. DR PDB; 4LUC; X-ray; 1.29 A; A/B=1-169. DR PDB; 4LV6; X-ray; 1.50 A; A/B=1-169. DR PDB; 4LYF; X-ray; 1.57 A; A/B/C=1-169. DR PDB; 4LYH; X-ray; 1.37 A; A/B/C=1-169. DR PDB; 4LYJ; X-ray; 1.93 A; A=1-169. DR PDB; 4M1O; X-ray; 1.57 A; A/B/C=1-169. DR PDB; 4M1S; X-ray; 1.55 A; A/B/C=1-169. DR PDB; 4M1T; X-ray; 1.70 A; A/B/C=1-169. DR PDB; 4M1W; X-ray; 1.58 A; A/B/C=1-169. DR PDB; 4M1Y; X-ray; 1.49 A; A/B/C=1-169. DR PDB; 4M21; X-ray; 1.94 A; A/B/C=1-169. DR PDB; 4M22; X-ray; 2.09 A; A/B/C=1-169. DR PDB; 4NMM; X-ray; 1.89 A; A=1-164. DR PDB; 4OBE; X-ray; 1.24 A; A/B=1-164. DR PDB; 4PZY; X-ray; 1.88 A; A/B=1-164. DR PDB; 4PZZ; X-ray; 1.40 A; A=1-164. DR PDB; 4Q01; X-ray; 1.29 A; A/B=1-164. DR PDB; 4Q02; X-ray; 1.70 A; A=1-164. DR PDB; 4Q03; X-ray; 1.20 A; A=1-164. DR PDB; 4QL3; X-ray; 1.04 A; A=1-11, A=13-164. DR PDB; 4TQ9; X-ray; 1.49 A; A/B=1-164. DR PDB; 4TQA; X-ray; 1.13 A; A/B=1-164. DR PDB; 4WA7; X-ray; 1.99 A; A=1-164. DR PDB; 5F2E; X-ray; 1.40 A; A=1-169. DR PDB; 5KYK; X-ray; 2.70 A; A/B/C=1-167. DR PDB; 5MLA; X-ray; 2.19 A; A=1-166. DR PDB; 5MLB; X-ray; 3.22 A; A/C/E/G=1-166. DR PDB; 5O2S; X-ray; 3.22 A; A/C/E/G=1-166. DR PDB; 5O2T; X-ray; 2.19 A; A=1-166. DR PDB; 5OCG; X-ray; 1.48 A; A=2-189. DR PDB; 5OCO; X-ray; 1.66 A; A/B/C/D/E/F=1-169. DR PDB; 5OCT; X-ray; 2.07 A; A/B/C/D/E/F=1-169. DR PDB; 5TAR; X-ray; 1.90 A; A=2-164. DR PDB; 5TB5; X-ray; 2.00 A; A/C=2-164. DR PDB; 5UFE; X-ray; 2.30 A; A=1-166. DR PDB; 5UFQ; X-ray; 2.20 A; A/B=1-166. DR PDB; 5UK9; X-ray; 1.89 A; A/B=1-166. DR PDB; 5UQW; X-ray; 1.50 A; A/B=1-164. DR PDB; 5US4; X-ray; 1.83 A; A/B=1-164. DR PDB; 5USJ; X-ray; 1.94 A; A/B/C/D/E/F=1-164. DR PDB; 5V6S; X-ray; 1.70 A; A=1-169. DR PDB; 5V6V; X-ray; 1.72 A; A/B=1-169. DR PDB; 5V71; X-ray; 2.23 A; A/B/C/D/E/F=1-167. DR PDB; 5V9L; X-ray; 1.98 A; A/B/C=1-167. DR PDB; 5V9O; X-ray; 1.56 A; A=1-167. DR PDB; 5V9U; X-ray; 1.38 A; A/B=1-169. DR PDB; 5VBM; X-ray; 1.49 A; A=1-169. DR PDB; 5VP7; X-ray; 1.70 A; A/F=1-169. DR PDB; 5VPI; X-ray; 1.62 A; A/B=1-169. DR PDB; 5VPY; X-ray; 2.00 A; A/B=1-169. DR PDB; 5VPZ; X-ray; 1.85 A; A/B=1-169. DR PDB; 5VQ0; X-ray; 2.30 A; A/B=1-169. DR PDB; 5VQ1; X-ray; 1.78 A; A/B=1-169. DR PDB; 5VQ2; X-ray; 1.96 A; A/B=1-169. DR PDB; 5VQ6; X-ray; 1.99 A; A/B=1-169. DR PDB; 5VQ8; X-ray; 2.30 A; A/B=1-169. DR PDB; 5W22; X-ray; 1.76 A; A/B=1-169. DR PDB; 5WHA; X-ray; 2.04 A; A/D/G/J=1-166. DR PDB; 5WHB; X-ray; 2.18 A; A/D/G/J=1-166. DR PDB; 5WHD; X-ray; 1.64 A; A/B/C/D=1-166. DR PDB; 5WHE; X-ray; 1.91 A; A/D/G/J=1-166. DR PDB; 5WLB; X-ray; 1.72 A; A/D=1-166. DR PDB; 5WPM; X-ray; 1.72 A; A=1-166. DR PDB; 5XCO; X-ray; 1.25 A; A=1-169. DR PDB; 5YXZ; X-ray; 1.70 A; A=1-169. DR PDB; 5YY1; X-ray; 1.69 A; A=1-169. DR PDB; 6ARK; X-ray; 1.75 A; A=1-169. DR PDB; 6ASA; X-ray; 2.54 A; A=1-167. DR PDB; 6ASE; X-ray; 1.55 A; A=1-169. DR PDB; 6B0V; X-ray; 1.29 A; A/B=1-169. DR PDB; 6B0Y; X-ray; 1.43 A; A/B=1-169. DR PDB; 6BOF; X-ray; 1.40 A; A/B=2-169. DR PDB; 6BP1; X-ray; 2.00 A; A=1-169. DR PDB; 6CC9; NMR; -; B=1-186. DR PDB; 6CCH; NMR; -; B=1-186. DR PDB; 6CCX; NMR; -; B=1-186. DR PDB; 6CU6; X-ray; 1.50 A; A/B/C=1-169. DR PDB; 6E6F; X-ray; 3.40 A; A/B=1-166. DR PDB; 6E6G; X-ray; 1.93 A; A=1-166. DR PDB; 6EPL; X-ray; 2.55 A; R=1-169. DR PDB; 6EPM; X-ray; 2.50 A; R=1-169. DR PDB; 6EPN; X-ray; 2.50 A; R=1-169. DR PDB; 6EPO; X-ray; 2.40 A; R=1-169. DR PDB; 6EPP; X-ray; 2.40 A; R=1-169. DR PDB; 6F76; X-ray; 2.20 A; A/B/C/D/E/F=1-169. DR PDB; 6FA1; X-ray; 1.97 A; A/C/D/F=1-167, B/E=1-169. DR PDB; 6FA2; X-ray; 2.60 A; A/B/C/D/E/F=1-167. DR PDB; 6FA3; X-ray; 1.82 A; A/B/C/D/E/F=1-167. DR PDB; 6FA4; X-ray; 2.02 A; A/B/C/D/E/F=1-169. DR PDB; 6GJ5; X-ray; 1.50 A; A/B=1-169. DR PDB; 6GJ6; X-ray; 1.76 A; A=1-169. DR PDB; 6GJ7; X-ray; 1.67 A; A=1-169. DR PDB; 6GJ8; X-ray; 1.65 A; A=1-167. DR PDB; 6GOD; X-ray; 1.71 A; A=2-173. DR PDB; 6GOE; X-ray; 1.60 A; A=2-169. DR PDB; 6GOF; X-ray; 1.98 A; A=2-173. DR PDB; 6GOG; X-ray; 2.05 A; A/B/C/D/E/F=1-169. DR PDB; 6GOM; X-ray; 1.63 A; A/B/C/D/E/F=1-167. DR PDB; 6GQT; X-ray; 1.69 A; A/B/C/D/E/F=1-167. DR PDB; 6GQW; X-ray; 2.80 A; A/B/C/D/E/F=1-167. DR PDB; 6GQX; X-ray; 2.20 A; A/B/C/D/E/F=1-167. DR PDB; 6GQY; X-ray; 2.75 A; A/B/C/D/E/F=1-167. DR PDB; 6H46; X-ray; 2.22 A; A=1-166. DR PDB; 6H47; X-ray; 1.70 A; A=1-166. DR PDB; 6JTN; X-ray; 1.90 A; C=10-19. DR PDB; 6JTO; X-ray; 1.70 A; C=10-19. DR PDB; 6JTP; X-ray; 1.90 A; C=10-18. DR PDB; 6M9W; X-ray; 1.50 A; A=2-169. DR PDB; 6MBQ; X-ray; 1.35 A; A=2-166. DR PDB; 6MBT; X-ray; 1.45 A; A/B=1-169. DR PDB; 6MBU; X-ray; 1.45 A; A/B=1-169. DR PDB; 6MNX; X-ray; 2.20 A; A/B/C/D/E/F=1-169. DR PDB; 6MQG; X-ray; 1.50 A; A=3-169. DR PDB; 6MQN; X-ray; 1.60 A; A/B/C=1-169. DR PDB; 6MS9; X-ray; 1.49 A; A/B/C=1-169. DR PDB; 6MTA; X-ray; 2.15 A; A/B/C=1-169. DR PDB; 6N2J; X-ray; 1.80 A; A=1-169. DR PDB; 6N2K; X-ray; 1.72 A; A=1-169. DR PDB; 6O36; X-ray; 2.00 A; A/B/C=1-167. DR PDB; 6O46; X-ray; 1.90 A; A/B/C=1-167. DR PDB; 6O4Y; X-ray; 1.58 A; C=7-14. DR PDB; 6O4Z; X-ray; 1.50 A; C=5-12. DR PDB; 6O51; X-ray; 1.55 A; C=6-14. DR PDB; 6O53; X-ray; 1.40 A; C=5-14. DR PDB; 6OB2; X-ray; 2.85 A; A/C=1-169. DR PDB; 6OB3; X-ray; 2.10 A; A/C=1-169. DR PDB; 6OIM; X-ray; 1.65 A; A=1-169. DR PDB; 6P0Z; X-ray; 1.01 A; A/B=2-169. DR PDB; 6P8W; X-ray; 2.10 A; A/B=1-169. DR PDB; 6P8X; X-ray; 2.11 A; A/B/C/D=1-169. DR PDB; 6P8Y; X-ray; 2.31 A; A/B=1-169. DR PDB; 6P8Z; X-ray; 1.65 A; A/B=1-169. DR PDB; 6PGO; X-ray; 1.60 A; A/B=1-169. DR PDB; 6PGP; X-ray; 1.50 A; A/B=1-169. DR PDB; 6PQ3; X-ray; 1.75 A; A=1-169. DR PDB; 6PTS; NMR; -; B=1-186. DR PDB; 6PTW; NMR; -; B=1-186. DR PDB; 6QUU; X-ray; 1.48 A; A/B=1-169. DR PDB; 6QUV; X-ray; 1.48 A; A/B=1-169. DR PDB; 6QUW; X-ray; 1.24 A; A/B=1-169. DR PDB; 6QUX; X-ray; 1.62 A; A/B=1-169. DR PDB; 6T5B; X-ray; 1.37 A; A=1-169. DR PDB; 6T5U; X-ray; 1.72 A; B=1-166. DR PDB; 6T5V; X-ray; 1.31 A; A=1-169. DR PDB; 6TAM; X-ray; 1.64 A; A=1-169. DR PDB; 6TAN; X-ray; 1.16 A; A=1-169. DR PDB; 6USX; X-ray; 2.27 A; A/B=1-169. DR PDB; 6USZ; X-ray; 2.03 A; A=1-169. DR PDB; 6UT0; X-ray; 1.94 A; A/B/C/D=1-169. DR PDB; 6V5L; NMR; -; A=1-169. DR PDB; 6V65; X-ray; 2.76 A; C=1-169. DR PDB; 6V6F; X-ray; 2.54 A; C=1-169. DR PDB; 6VC8; X-ray; 2.50 A; A/B/C=1-169. DR PDB; 6VJJ; X-ray; 1.40 A; A=1-169. DR PDB; 6W4E; NMR; -; B/C=2-186. DR PDB; 6W4F; NMR; -; B/C=2-186. DR PDB; 6WGN; X-ray; 1.60 A; A/B/C=1-169. DR PDB; 6WS2; X-ray; 1.59 A; A/B/C/D=1-169. DR PDB; 6WS4; X-ray; 1.84 A; A/B/C/D=1-169. DR PDB; 6XGU; X-ray; 2.70 A; A=1-169. DR PDB; 6XGV; X-ray; 2.11 A; A=1-169. DR PDB; 6XHA; X-ray; 2.87 A; A=1-169. DR PDB; 6XHB; X-ray; 2.50 A; A=1-169. DR PDB; 6YR8; X-ray; 1.90 A; A=1-166. DR PDB; 6YXW; X-ray; 2.06 A; A/C=1-167. DR PDB; 6ZL5; X-ray; 1.65 A; A=1-169. DR PDB; 6ZLI; X-ray; 1.73 A; A/B=1-169. DR PDB; 7A1W; X-ray; 1.76 A; A=1-169. DR PDB; 7A1X; X-ray; 1.32 A; A=1-164. DR PDB; 7A1Y; X-ray; 2.00 A; A=1-164. DR PDB; 7A47; X-ray; 2.16 A; A/C/E=1-169. DR PDB; 7ACA; X-ray; 1.57 A; A/B/C/D=1-169. DR PDB; 7ACF; X-ray; 1.91 A; A/B/C/D=1-169. DR PDB; 7ACH; X-ray; 1.90 A; A/B=1-169. DR PDB; 7ACQ; X-ray; 1.86 A; A/B/C=1-169. DR PDB; 7C40; X-ray; 2.52 A; A=1-167. DR PDB; 7C41; X-ray; 2.28 A; A/G/J/M=1-167. DR PDB; 7EW9; X-ray; 2.13 A; A/B/C=1-169. DR PDB; 7EWA; X-ray; 2.25 A; A/B/C=1-169. DR PDB; 7EWB; X-ray; 1.99 A; A/B/C=1-169. DR PDB; 7EYX; X-ray; 1.82 A; A=2-169. DR PDB; 7F0W; X-ray; 1.39 A; A=2-169. DR PDB; 7KFZ; EM; 3.47 A; A/C=1-169. DR PDB; 7KMR; X-ray; 1.51 A; A=1-186. DR PDB; 7KYZ; NMR; -; A=1-189. DR PDB; 7LC1; X-ray; 2.35 A; A/C=1-169. DR PDB; 7LC2; X-ray; 2.70 A; A/B=1-169. DR PDB; 7LGI; NMR; -; A=1-169. DR PDB; 7LZ5; X-ray; 1.50 A; A=1-164. DR PDB; 7MDP; X-ray; 1.96 A; A=1-169. DR PDB; 7MQU; NMR; -; A=1-169. DR PDB; 7NY8; X-ray; 1.80 A; A/B=1-167. DR PDB; 7O70; X-ray; 1.18 A; A/D=1-169. DR PDB; 7OK3; X-ray; 1.60 A; A=1-169. DR PDB; 7OK4; X-ray; 1.70 A; A=1-169. DR PDB; 7OO7; X-ray; 1.48 A; A/D=1-164. DR PDB; 7Q9U; X-ray; 2.24 A; AAA/BBB=1-176. DR PDB; 7R0M; X-ray; 1.61 A; A/B=1-169. DR PDB; 7R0N; X-ray; 1.20 A; A=1-169. DR PDB; 7R0Q; X-ray; 1.95 A; A/B=1-169. DR PDB; 7ROV; X-ray; 1.32 A; A/B=1-189. DR PDB; 7RP2; X-ray; 2.20 A; A=1-169. DR PDB; 7RP3; X-ray; 2.00 A; A=2-169. DR PDB; 7RP4; X-ray; 2.15 A; A/B=2-169. DR PDB; 7RPZ; X-ray; 1.30 A; A=1-169. DR PDB; 7RSC; NMR; -; A/B=2-186. DR PDB; 7RSE; NMR; -; A/B=2-186. DR PDB; 7RT1; X-ray; 1.27 A; A=1-169. DR PDB; 7RT2; X-ray; 1.59 A; A=1-169. DR PDB; 7RT3; X-ray; 1.56 A; A=1-169. DR PDB; 7RT4; X-ray; 2.10 A; A=1-169. DR PDB; 7RT5; X-ray; 1.29 A; A=1-169. DR PDB; 7SCW; X-ray; 1.98 A; A=1-189. DR PDB; 7SCX; X-ray; 1.96 A; A=1-189. DR PDB; 7STF; EM; 3.14 A; C=7-16. DR PDB; 7T1F; X-ray; 2.20 A; A/B/C=1-169. DR PDB; 7T47; X-ray; 1.27 A; A=1-164. DR PDB; 7TLE; X-ray; 1.99 A; A=1-164. DR PDB; 7TLG; X-ray; 1.80 A; A/B=1-164. DR PDB; 7TLK; X-ray; 1.71 A; A/B=1-164. DR PDB; 7U8H; X-ray; 1.70 A; A/B/C/D=1-169. DR PDB; 7VVB; X-ray; 1.70 A; A=1-189. DR PDB; 7W5R; X-ray; 3.87 A; A/E/I/M/Q/U=1-167. DR PDB; 7YCC; X-ray; 1.79 A; A/B/C=1-169. DR PDB; 7YCE; X-ray; 1.80 A; A=1-169. DR PDB; 7YUZ; X-ray; 1.88 A; A=2-174. DR PDB; 7YV1; X-ray; 1.45 A; A=2-174. DR PDB; 8AFB; X-ray; 1.12 A; A=1-164. DR PDB; 8AFC; X-ray; 2.41 A; A/B=1-164. DR PDB; 8AFD; X-ray; 1.63 A; A/B/C/D=1-164. DR PDB; 8AQ5; X-ray; 1.80 A; A=1-169. DR PDB; 8AQ7; X-ray; 1.65 A; A/B=1-169. DR PDB; 8AZR; X-ray; 1.60 A; A=1-164. DR PDB; 8AZV; X-ray; 1.05 A; A=1-164. DR PDB; 8AZX; X-ray; 1.04 A; A=1-164. DR PDB; 8AZY; X-ray; 1.09 A; A=1-169. DR PDB; 8AZZ; X-ray; 1.02 A; A=1-164. DR PDB; 8B00; X-ray; 1.04 A; A=1-164. DR PDB; 8B69; X-ray; 3.07 A; B/D=1-169. DR PDB; 8B6I; X-ray; 1.70 A; A/B=1-169. DR PDB; 8B78; X-ray; 1.11 A; A=1-164. DR PDB; 8BE3; X-ray; 1.85 A; A/R=1-169. DR PDB; 8BE4; X-ray; 1.90 A; R=1-169. DR PDB; 8BE5; X-ray; 3.13 A; R=1-169. DR PDB; 8BLR; X-ray; 1.40 A; A=2-169. DR PDB; 8CPR; X-ray; 2.00 A; A=2-169. DR PDB; 8CX5; X-ray; 1.72 A; A/B=1-169. DR PDB; 8DGS; EM; 4.30 A; E=1-169. DR PDB; 8DGT; EM; 3.90 A; F=1-169. DR PDB; 8DNI; X-ray; 1.50 A; A=1-169. DR PDB; 8DNJ; X-ray; 1.81 A; A/B/C=1-169. DR PDB; 8DNK; X-ray; 2.23 A; A=1-169. DR PDB; 8DVG; X-ray; 2.59 A; C=7-16. DR PDB; 8EBZ; X-ray; 1.20 A; A=1-169. DR PDB; 8ECR; X-ray; 1.42 A; A/B=1-186. DR PDB; 8EDY; X-ray; 1.18 A; A=1-186. DR PDB; 8EER; X-ray; 1.18 A; A=1-186. DR PDB; 8EIE; X-ray; 1.41 A; A=1-186. DR PDB; 8EPW; X-ray; 2.00 A; A=1-169. DR PDB; 8EZG; X-ray; 2.52 A; A=1-167. DR PDB; 8F0M; X-ray; 2.44 A; A/C=1-169. DR PDB; 8FMI; X-ray; 1.12 A; A=1-169. DR PDB; 8FMJ; X-ray; 1.33 A; A=1-169. DR PDB; 8FMK; X-ray; 1.48 A; A=1-169. DR PDB; 8G42; EM; 3.02 A; B=1-169. DR PDB; 8G47; EM; 3.19 A; B=1-169. DR PDB; 8G4F; EM; 2.91 A; B=1-166. DR PDB; 8G4H; EM; 2.87 A; B=1-169. DR PDB; 8G9P; X-ray; 1.50 A; A/B=1-169. DR PDB; 8G9Q; X-ray; 1.40 A; A=1-169. DR PDB; 8I5C; X-ray; 3.34 A; C/H/M/R/W/b/g/l/q/v=8-16. DR PDB; 8I5D; X-ray; 3.30 A; P=8-16. DR PDB; 8I5E; X-ray; 2.20 A; P=8-16. DR PDB; 8JGD; X-ray; 1.60 A; A=1-169. DR PDB; 8JHL; X-ray; 2.10 A; A=1-169. DR PDB; 8JJS; X-ray; 1.53 A; A=2-174. DR PDB; 8K4T; X-ray; 2.30 A; C/F=7-16. DR PDB; 8K4V; X-ray; 3.10 A; C/F/I/L=7-16. DR PDB; 8K50; X-ray; 2.80 A; C/F/I/L=7-16. DR PDB; 8ONV; X-ray; 1.01 A; A=1-164. DR PDB; 8PI0; NMR; -; A=1-167. DR PDB; 8PIY; NMR; -; A=1-169. DR PDB; 8QU8; EM; 3.50 A; F=1-164. DR PDB; 8QUG; X-ray; 1.56 A; A=1-164. DR PDB; 8QVU; X-ray; 2.24 A; A/E=1-189. DR PDB; 8QW6; X-ray; 2.20 A; A/E=1-169. DR PDB; 8QW7; X-ray; 2.36 A; A/E=1-169. DR PDB; 8R7W; X-ray; 1.16 A; A/B=1-169. DR PDB; 8R7X; X-ray; 1.31 A; A/B=1-169. DR PDB; 8RNI; X-ray; 2.49 A; C=7-16. DR PDB; 8RRO; X-ray; 3.50 A; E/J/O/T/Y/d/i/n=7-16. DR PDB; 8S8C; X-ray; 1.90 A; A=1-169. DR PDB; 8STM; X-ray; 2.00 A; A/B/C/D=1-169. DR PDB; 8STN; X-ray; 2.03 A; A/B=1-169. DR PDB; 8T4V; X-ray; 1.47 A; A/B=1-169. DR PDB; 8T71; X-ray; 1.80 A; A/B=1-177. DR PDB; 8T72; X-ray; 1.60 A; A/B/C=1-177. DR PDB; 8T73; X-ray; 1.50 A; A/B=1-169. DR PDB; 8T74; X-ray; 1.65 A; A=1-177. DR PDB; 8T75; X-ray; 2.65 A; A/C/E/G=1-177. DR PDB; 8TBF; X-ray; 1.50 A; A/B=1-169. DR PDB; 8TBH; X-ray; 1.50 A; A/B=1-169. DR PDB; 8TBJ; X-ray; 1.45 A; A/B=1-169. DR PDB; 8TBK; X-ray; 1.26 A; A/B=1-169. DR PDB; 8TBL; X-ray; 1.88 A; A/B=1-169. DR PDB; 8TBM; X-ray; 1.57 A; A/B=1-169. DR PDB; 8TBN; X-ray; 1.46 A; A/B=1-169. DR PDB; 8TVK; X-ray; 1.04 A; A=1-169. DR PDB; 8TXE; X-ray; 1.35 A; A/B=1-169. DR PDB; 8TXG; X-ray; 1.50 A; A=1-169. DR PDB; 8TXH; X-ray; 1.20 A; A/B=1-169. DR PDB; 8TXJ; X-ray; 1.40 A; A=1-169. DR PDB; 8TXK; X-ray; 1.38 A; A=1-169. DR PDB; 8TY2; X-ray; 1.41 A; A=1-169. DR PDB; 8TY8; X-ray; 1.40 A; A=1-169. DR PDB; 8TY9; X-ray; 1.43 A; A=1-169. DR PDB; 8UDR; EM; 3.10 A; C=7-16. DR PDB; 8UN3; X-ray; 2.07 A; A/B/C/D=2-167. DR PDB; 8UN4; X-ray; 1.57 A; A=2-169. DR PDB; 8UN5; X-ray; 1.31 A; A/B=2-167. DR PDB; 8V39; X-ray; 2.10 A; A/B/C=1-169. DR PDB; 8V3A; X-ray; 1.67 A; A/B=1-169. DR PDB; 8VGQ; EM; 2.80 A; A=1-169. DR PDB; 8VJZ; X-ray; 1.90 A; C=7-16. DR PDB; 8VR9; EM; 3.06 A; C=8-16. DR PDB; 8VRA; EM; 3.12 A; C=7-16. DR PDB; 8VRB; EM; 3.25 A; C=7-16. DR PDB; 8WTE; X-ray; 2.17 A; G/J=8-16. DR PDB; 8WUL; X-ray; 2.36 A; K/N/Q/T=8-16. DR PDB; 8X6R; X-ray; 1.85 A; A/B/C/D/E/F=1-169. DR PDB; 8YIV; X-ray; 2.10 A; C=55-64. DR PDB; 8YJ2; X-ray; 2.26 A; C=55-64. DR PDB; 9AX6; X-ray; 1.65 A; A/B=1-169. DR PDB; 9BAI; X-ray; 1.49 A; A/B/C/D=1-169. DR PDB; 9BAJ; X-ray; 1.49 A; A/B/C/D=1-169. DR PDB; 9BAK; X-ray; 1.67 A; A/B/C/D=1-169. DR PDB; 9BFV; X-ray; 1.20 A; A/B=1-169. DR PDB; 9BFW; X-ray; 1.20 A; A=1-169. DR PDB; 9BFX; X-ray; 1.40 A; A/B=1-169. DR PDB; 9BFY; X-ray; 1.26 A; A/B=1-169. DR PDB; 9BFZ; X-ray; 1.80 A; A/B=1-169. DR PDB; 9BG1; X-ray; 1.51 A; A/B=1-169. DR PDB; 9BG2; X-ray; 1.64 A; A/B=1-169. DR PDB; 9BG4; X-ray; 1.14 A; A/B=1-169. DR PDB; 9BG5; X-ray; 1.67 A; A/B=1-164. DR PDB; 9BG6; X-ray; 1.66 A; A/B=1-169. DR PDB; 9BG7; X-ray; 1.60 A; A/B=1-169. DR PDB; 9BG9; X-ray; 1.58 A; A/B=1-164. DR PDB; 9BGA; X-ray; 1.41 A; A/B=1-169. DR PDB; 9BGB; X-ray; 1.68 A; A/B=1-164. DR PDB; 9BGC; X-ray; 1.87 A; A/B=1-169. DR PDB; 9BHO; X-ray; 1.89 A; A/C=1-169. DR PDB; 9BHP; X-ray; 2.10 A; A/C=1-169. DR PDB; 9BHQ; X-ray; 1.90 A; A/C=1-169. DR PDB; 9BI1; X-ray; 1.65 A; A/C=1-169. DR PDB; 9BI2; X-ray; 2.15 A; A/C=1-169. DR PDB; 9BL0; X-ray; 1.66 A; A/B=1-169. DR PDB; 9C15; X-ray; 2.81 A; B=1-169. DR PDB; 9DMM; X-ray; 1.90 A; A=1-169. DR PDB; 9E5D; X-ray; 1.36 A; A=1-169. DR PDB; 9E5F; X-ray; 1.35 A; A=1-169. DR PDB; 9E9H; X-ray; 1.65 A; A=1-169. DR PDB; 9E9I; X-ray; 1.18 A; A=1-169. DR PDB; 9G0Y; X-ray; 1.31 A; A=1-169. DR PDB; 9G4B; X-ray; 1.14 A; A=1-169. DR PDB; 9GBJ; X-ray; 1.71 A; A=1-169. DR PDB; 9GGT; X-ray; 1.71 A; A=1-169. DR PDB; 9GGU; X-ray; 1.60 A; A=1-169. DR PDB; 9GGV; X-ray; 1.19 A; A=1-169. DR PDB; 9GGW; X-ray; 1.82 A; A/B=1-169. DR PDB; 9GGX; X-ray; 1.30 A; A=1-169. DR PDB; 9GGY; X-ray; 1.27 A; A=1-169. DR PDB; 9GGZ; X-ray; 1.37 A; A=1-169. DR PDB; 9GH0; X-ray; 1.57 A; A=1-169. DR PDB; 9GH1; X-ray; 1.33 A; A=1-169. DR PDB; 9GH2; X-ray; 1.35 A; A=1-169. DR PDB; 9KPM; X-ray; 1.41 A; A=1-169. DR PDB; 9KPN; X-ray; 1.29 A; A/B=1-169. DR PDBsum; 1D8D; -. DR PDBsum; 1D8E; -. DR PDBsum; 1KZO; -. DR PDBsum; 1KZP; -. DR PDBsum; 1N4P; -. DR PDBsum; 1N4Q; -. DR PDBsum; 1N4R; -. DR PDBsum; 1N4S; -. DR PDBsum; 2MSC; -. DR PDBsum; 2MSD; -. DR PDBsum; 2MSE; -. DR PDBsum; 3GFT; -. DR PDBsum; 4DSN; -. DR PDBsum; 4DSO; -. DR PDBsum; 4EPR; -. DR PDBsum; 4EPT; -. DR PDBsum; 4EPV; -. DR PDBsum; 4EPW; -. DR PDBsum; 4EPX; -. DR PDBsum; 4EPY; -. DR PDBsum; 4L8G; -. DR PDBsum; 4LDJ; -. DR PDBsum; 4LPK; -. DR PDBsum; 4LRW; -. DR PDBsum; 4LUC; -. DR PDBsum; 4LV6; -. DR PDBsum; 4LYF; -. DR PDBsum; 4LYH; -. DR PDBsum; 4LYJ; -. DR PDBsum; 4M1O; -. DR PDBsum; 4M1S; -. DR PDBsum; 4M1T; -. DR PDBsum; 4M1W; -. DR PDBsum; 4M1Y; -. DR PDBsum; 4M21; -. DR PDBsum; 4M22; -. DR PDBsum; 4NMM; -. DR PDBsum; 4OBE; -. DR PDBsum; 4PZY; -. DR PDBsum; 4PZZ; -. DR PDBsum; 4Q01; -. DR PDBsum; 4Q02; -. DR PDBsum; 4Q03; -. DR PDBsum; 4QL3; -. DR PDBsum; 4TQ9; -. DR PDBsum; 4TQA; -. DR PDBsum; 4WA7; -. DR PDBsum; 5F2E; -. DR PDBsum; 5KYK; -. DR PDBsum; 5MLA; -. DR PDBsum; 5MLB; -. DR PDBsum; 5O2S; -. DR PDBsum; 5O2T; -. DR PDBsum; 5OCG; -. DR PDBsum; 5OCO; -. DR PDBsum; 5OCT; -. DR PDBsum; 5TAR; -. DR PDBsum; 5TB5; -. DR PDBsum; 5UFE; -. DR PDBsum; 5UFQ; -. DR PDBsum; 5UK9; -. DR PDBsum; 5UQW; -. DR PDBsum; 5US4; -. DR PDBsum; 5USJ; -. DR PDBsum; 5V6S; -. DR PDBsum; 5V6V; -. DR PDBsum; 5V71; -. DR PDBsum; 5V9L; -. DR PDBsum; 5V9O; -. DR PDBsum; 5V9U; -. DR PDBsum; 5VBM; -. DR PDBsum; 5VP7; -. DR PDBsum; 5VPI; -. DR PDBsum; 5VPY; -. DR PDBsum; 5VPZ; -. DR PDBsum; 5VQ0; -. DR PDBsum; 5VQ1; -. DR PDBsum; 5VQ2; -. DR PDBsum; 5VQ6; -. DR PDBsum; 5VQ8; -. DR PDBsum; 5W22; -. DR PDBsum; 5WHA; -. DR PDBsum; 5WHB; -. DR PDBsum; 5WHD; -. DR PDBsum; 5WHE; -. DR PDBsum; 5WLB; -. DR PDBsum; 5WPM; -. DR PDBsum; 5XCO; -. DR PDBsum; 5YXZ; -. DR PDBsum; 5YY1; -. DR PDBsum; 6ARK; -. DR PDBsum; 6ASA; -. DR PDBsum; 6ASE; -. DR PDBsum; 6B0V; -. DR PDBsum; 6B0Y; -. DR PDBsum; 6BOF; -. DR PDBsum; 6BP1; -. DR PDBsum; 6CC9; -. DR PDBsum; 6CCH; -. DR PDBsum; 6CCX; -. DR PDBsum; 6CU6; -. DR PDBsum; 6E6F; -. DR PDBsum; 6E6G; -. DR PDBsum; 6EPL; -. DR PDBsum; 6EPM; -. DR PDBsum; 6EPN; -. DR PDBsum; 6EPO; -. DR PDBsum; 6EPP; -. DR PDBsum; 6F76; -. DR PDBsum; 6FA1; -. DR PDBsum; 6FA2; -. DR PDBsum; 6FA3; -. DR PDBsum; 6FA4; -. DR PDBsum; 6GJ5; -. DR PDBsum; 6GJ6; -. DR PDBsum; 6GJ7; -. DR PDBsum; 6GJ8; -. DR PDBsum; 6GOD; -. DR PDBsum; 6GOE; -. DR PDBsum; 6GOF; -. DR PDBsum; 6GOG; -. DR PDBsum; 6GOM; -. DR PDBsum; 6GQT; -. DR PDBsum; 6GQW; -. DR PDBsum; 6GQX; -. DR PDBsum; 6GQY; -. DR PDBsum; 6H46; -. DR PDBsum; 6H47; -. DR PDBsum; 6JTN; -. DR PDBsum; 6JTO; -. DR PDBsum; 6JTP; -. DR PDBsum; 6M9W; -. DR PDBsum; 6MBQ; -. DR PDBsum; 6MBT; -. DR PDBsum; 6MBU; -. DR PDBsum; 6MNX; -. DR PDBsum; 6MQG; -. DR PDBsum; 6MQN; -. DR PDBsum; 6MS9; -. DR PDBsum; 6MTA; -. DR PDBsum; 6N2J; -. DR PDBsum; 6N2K; -. DR PDBsum; 6O36; -. DR PDBsum; 6O46; -. DR PDBsum; 6O4Y; -. DR PDBsum; 6O4Z; -. DR PDBsum; 6O51; -. DR PDBsum; 6O53; -. DR PDBsum; 6OB2; -. DR PDBsum; 6OB3; -. DR PDBsum; 6OIM; -. DR PDBsum; 6P0Z; -. DR PDBsum; 6P8W; -. DR PDBsum; 6P8X; -. DR PDBsum; 6P8Y; -. DR PDBsum; 6P8Z; -. DR PDBsum; 6PGO; -. DR PDBsum; 6PGP; -. DR PDBsum; 6PQ3; -. DR PDBsum; 6PTS; -. DR PDBsum; 6PTW; -. DR PDBsum; 6QUU; -. DR PDBsum; 6QUV; -. DR PDBsum; 6QUW; -. DR PDBsum; 6QUX; -. DR PDBsum; 6T5B; -. DR PDBsum; 6T5U; -. DR PDBsum; 6T5V; -. DR PDBsum; 6TAM; -. DR PDBsum; 6TAN; -. DR PDBsum; 6USX; -. DR PDBsum; 6USZ; -. DR PDBsum; 6UT0; -. DR PDBsum; 6V5L; -. DR PDBsum; 6V65; -. DR PDBsum; 6V6F; -. DR PDBsum; 6VC8; -. DR PDBsum; 6VJJ; -. DR PDBsum; 6W4E; -. DR PDBsum; 6W4F; -. DR PDBsum; 6WGN; -. DR PDBsum; 6WS2; -. DR PDBsum; 6WS4; -. DR PDBsum; 6XGU; -. DR PDBsum; 6XGV; -. DR PDBsum; 6XHA; -. DR PDBsum; 6XHB; -. DR PDBsum; 6YR8; -. DR PDBsum; 6YXW; -. DR PDBsum; 6ZL5; -. DR PDBsum; 6ZLI; -. DR PDBsum; 7A1W; -. DR PDBsum; 7A1X; -. DR PDBsum; 7A1Y; -. DR PDBsum; 7A47; -. DR PDBsum; 7ACA; -. DR PDBsum; 7ACF; -. DR PDBsum; 7ACH; -. DR PDBsum; 7ACQ; -. DR PDBsum; 7C40; -. DR PDBsum; 7C41; -. DR PDBsum; 7EW9; -. DR PDBsum; 7EWA; -. DR PDBsum; 7EWB; -. DR PDBsum; 7EYX; -. DR PDBsum; 7F0W; -. DR PDBsum; 7KFZ; -. DR PDBsum; 7KMR; -. DR PDBsum; 7KYZ; -. DR PDBsum; 7LC1; -. DR PDBsum; 7LC2; -. DR PDBsum; 7LGI; -. DR PDBsum; 7LZ5; -. DR PDBsum; 7MDP; -. DR PDBsum; 7MQU; -. DR PDBsum; 7NY8; -. DR PDBsum; 7O70; -. DR PDBsum; 7OK3; -. DR PDBsum; 7OK4; -. DR PDBsum; 7OO7; -. DR PDBsum; 7Q9U; -. DR PDBsum; 7R0M; -. DR PDBsum; 7R0N; -. DR PDBsum; 7R0Q; -. DR PDBsum; 7ROV; -. DR PDBsum; 7RP2; -. DR PDBsum; 7RP3; -. DR PDBsum; 7RP4; -. DR PDBsum; 7RPZ; -. DR PDBsum; 7RSC; -. DR PDBsum; 7RSE; -. DR PDBsum; 7RT1; -. DR PDBsum; 7RT2; -. DR PDBsum; 7RT3; -. DR PDBsum; 7RT4; -. DR PDBsum; 7RT5; -. DR PDBsum; 7SCW; -. DR PDBsum; 7SCX; -. DR PDBsum; 7STF; -. DR PDBsum; 7T1F; -. DR PDBsum; 7T47; -. DR PDBsum; 7TLE; -. DR PDBsum; 7TLG; -. DR PDBsum; 7TLK; -. DR PDBsum; 7U8H; -. DR PDBsum; 7VVB; -. DR PDBsum; 7W5R; -. DR PDBsum; 7YCC; -. DR PDBsum; 7YCE; -. DR PDBsum; 7YUZ; -. DR PDBsum; 7YV1; -. DR PDBsum; 8AFB; -. DR PDBsum; 8AFC; -. DR PDBsum; 8AFD; -. DR PDBsum; 8AQ5; -. DR PDBsum; 8AQ7; -. DR PDBsum; 8AZR; -. DR PDBsum; 8AZV; -. DR PDBsum; 8AZX; -. DR PDBsum; 8AZY; -. DR PDBsum; 8AZZ; -. DR PDBsum; 8B00; -. DR PDBsum; 8B69; -. DR PDBsum; 8B6I; -. DR PDBsum; 8B78; -. DR PDBsum; 8BE3; -. DR PDBsum; 8BE4; -. DR PDBsum; 8BE5; -. DR PDBsum; 8BLR; -. DR PDBsum; 8CPR; -. DR PDBsum; 8CX5; -. DR PDBsum; 8DGS; -. DR PDBsum; 8DGT; -. DR PDBsum; 8DNI; -. DR PDBsum; 8DNJ; -. DR PDBsum; 8DNK; -. DR PDBsum; 8DVG; -. DR PDBsum; 8EBZ; -. DR PDBsum; 8ECR; -. DR PDBsum; 8EDY; -. DR PDBsum; 8EER; -. DR PDBsum; 8EIE; -. DR PDBsum; 8EPW; -. DR PDBsum; 8EZG; -. DR PDBsum; 8F0M; -. DR PDBsum; 8FMI; -. DR PDBsum; 8FMJ; -. DR PDBsum; 8FMK; -. DR PDBsum; 8G42; -. DR PDBsum; 8G47; -. DR PDBsum; 8G4F; -. DR PDBsum; 8G4H; -. DR PDBsum; 8G9P; -. DR PDBsum; 8G9Q; -. DR PDBsum; 8I5C; -. DR PDBsum; 8I5D; -. DR PDBsum; 8I5E; -. DR PDBsum; 8JGD; -. DR PDBsum; 8JHL; -. DR PDBsum; 8JJS; -. DR PDBsum; 8K4T; -. DR PDBsum; 8K4V; -. DR PDBsum; 8K50; -. DR PDBsum; 8ONV; -. DR PDBsum; 8PI0; -. DR PDBsum; 8PIY; -. DR PDBsum; 8QU8; -. DR PDBsum; 8QUG; -. DR PDBsum; 8QVU; -. DR PDBsum; 8QW6; -. DR PDBsum; 8QW7; -. DR PDBsum; 8R7W; -. DR PDBsum; 8R7X; -. DR PDBsum; 8RNI; -. DR PDBsum; 8RRO; -. DR PDBsum; 8S8C; -. DR PDBsum; 8STM; -. DR PDBsum; 8STN; -. DR PDBsum; 8T4V; -. DR PDBsum; 8T71; -. DR PDBsum; 8T72; -. DR PDBsum; 8T73; -. DR PDBsum; 8T74; -. DR PDBsum; 8T75; -. DR PDBsum; 8TBF; -. DR PDBsum; 8TBH; -. DR PDBsum; 8TBJ; -. DR PDBsum; 8TBK; -. DR PDBsum; 8TBL; -. DR PDBsum; 8TBM; -. DR PDBsum; 8TBN; -. DR PDBsum; 8TVK; -. DR PDBsum; 8TXE; -. DR PDBsum; 8TXG; -. DR PDBsum; 8TXH; -. DR PDBsum; 8TXJ; -. DR PDBsum; 8TXK; -. DR PDBsum; 8TY2; -. DR PDBsum; 8TY8; -. DR PDBsum; 8TY9; -. DR PDBsum; 8UDR; -. DR PDBsum; 8UN3; -. DR PDBsum; 8UN4; -. DR PDBsum; 8UN5; -. DR PDBsum; 8V39; -. DR PDBsum; 8V3A; -. DR PDBsum; 8VGQ; -. DR PDBsum; 8VJZ; -. DR PDBsum; 8VR9; -. DR PDBsum; 8VRA; -. DR PDBsum; 8VRB; -. DR PDBsum; 8WTE; -. DR PDBsum; 8WUL; -. DR PDBsum; 8X6R; -. DR PDBsum; 8YIV; -. DR PDBsum; 8YJ2; -. DR PDBsum; 9AX6; -. DR PDBsum; 9BAI; -. DR PDBsum; 9BAJ; -. DR PDBsum; 9BAK; -. DR PDBsum; 9BFV; -. DR PDBsum; 9BFW; -. DR PDBsum; 9BFX; -. DR PDBsum; 9BFY; -. DR PDBsum; 9BFZ; -. DR PDBsum; 9BG1; -. DR PDBsum; 9BG2; -. DR PDBsum; 9BG4; -. DR PDBsum; 9BG5; -. DR PDBsum; 9BG6; -. DR PDBsum; 9BG7; -. DR PDBsum; 9BG9; -. DR PDBsum; 9BGA; -. DR PDBsum; 9BGB; -. DR PDBsum; 9BGC; -. DR PDBsum; 9BHO; -. DR PDBsum; 9BHP; -. DR PDBsum; 9BHQ; -. DR PDBsum; 9BI1; -. DR PDBsum; 9BI2; -. DR PDBsum; 9BL0; -. DR PDBsum; 9C15; -. DR PDBsum; 9DMM; -. DR PDBsum; 9E5D; -. DR PDBsum; 9E5F; -. DR PDBsum; 9E9H; -. DR PDBsum; 9E9I; -. DR PDBsum; 9G0Y; -. DR PDBsum; 9G4B; -. DR PDBsum; 9GBJ; -. DR PDBsum; 9GGT; -. DR PDBsum; 9GGU; -. DR PDBsum; 9GGV; -. DR PDBsum; 9GGW; -. DR PDBsum; 9GGX; -. DR PDBsum; 9GGY; -. DR PDBsum; 9GGZ; -. DR PDBsum; 9GH0; -. DR PDBsum; 9GH1; -. DR PDBsum; 9GH2; -. DR PDBsum; 9KPM; -. DR PDBsum; 9KPN; -. DR AlphaFoldDB; P01116; -. DR BMRB; P01116; -. DR EMDB; EMD-18657; -. DR EMDB; EMD-22857; -. DR EMDB; EMD-29713; -. DR EMDB; EMD-29715; -. DR EMDB; EMD-29719; -. DR EMDB; EMD-29720; -. DR EMDB; EMD-42151; -. DR EMDB; EMD-43221; -. DR EMDB; EMD-43478; -. DR EMDB; EMD-43479; -. DR EMDB; EMD-43480; -. DR EMDB; EMD-70124; -. DR SASBDB; P01116; -. DR SMR; P01116; -. DR BioGRID; 110043; 3005. DR ComplexPortal; CPX-26355; SHOC2-KRAS-PPP1CA complex. DR CORUM; P01116; -. DR DIP; DIP-33951N; -. DR FunCoup; P01116; 3194. DR IntAct; P01116; 549. DR MINT; P01116; -. DR STRING; 9606.ENSP00000256078; -. DR BindingDB; P01116; -. DR ChEMBL; CHEMBL2189121; -. DR DrugBank; DB07771; [(3,7,11-TRIMETHYL-DODECA-2,6,10-TRIENYLOXYCARBAMOYL)-METHYL]-PHOSPHONIC ACID. DR DrugBank; DB15568; Adagrasib. DR DrugBank; DB07780; Farnesyl diphosphate. DR DrugBank; DB15569; Sotorasib. DR DrugCentral; P01116; -. DR GuidetoPHARMACOLOGY; 2824; -. DR GlyCosmos; P01116; 1 site, No reported glycans. DR GlyGen; P01116; 1 site. DR iPTMnet; P01116; -. DR PhosphoSitePlus; P01116; -. DR SwissPalm; P01116; -. DR BioMuta; KRAS; -. DR DMDM; 131875; -. DR CPTAC; CPTAC-1550; -. DR jPOST; P01116; -. DR MassIVE; P01116; -. DR PaxDb; 9606-ENSP00000256078; -. DR PeptideAtlas; P01116; -. DR ProteomicsDB; 51323; -. [P01116-1] DR ProteomicsDB; 51324; -. [P01116-2] DR Pumba; P01116; -. DR TopDownProteomics; P01116-2; -. [P01116-2] DR ABCD; P01116; 18 sequenced antibodies. DR Antibodypedia; 24248; 916 antibodies from 40 providers. DR CPTC; P01116; 6 antibodies. DR DNASU; 3845; -. DR Ensembl; ENST00000256078.10; ENSP00000256078.5; ENSG00000133703.15. [P01116-1] DR Ensembl; ENST00000311936.8; ENSP00000308495.3; ENSG00000133703.15. [P01116-2] DR Ensembl; ENST00000685328.1; ENSP00000508921.1; ENSG00000133703.15. [P01116-2] DR Ensembl; ENST00000688940.1; ENSP00000509238.1; ENSG00000133703.15. [P01116-2] DR GeneID; 3845; -. DR KEGG; hsa:3845; -. DR MANE-Select; ENST00000311936.8; ENSP00000308495.3; NM_004985.5; NP_004976.2. [P01116-2] DR UCSC; uc001rgp.3; human. [P01116-1] DR AGR; HGNC:6407; -. DR CIViC; 3845; 1 clinical assertion and 480 evidence items across 102 molecular profiles. DR ClinPGx; PA30196; -. DR CTD; 3845; -. DR DisGeNET; 3845; -. DR GeneCards; KRAS; -. DR GeneReviews; KRAS; -. DR HGNC; HGNC:6407; KRAS. DR HPA; ENSG00000133703; Low tissue specificity. DR MalaCards; KRAS; -. DR MIM; 163200; phenotype. DR MIM; 190070; gene. DR MIM; 600268; phenotype. DR MIM; 601626; phenotype. DR MIM; 607785; phenotype. DR MIM; 609942; phenotype. DR MIM; 613659; phenotype. DR MIM; 615278; phenotype. DR OpenTargets; ENSG00000133703; -. DR Orphanet; 1340; Cardiofaciocutaneous syndrome. DR Orphanet; 146; Differentiated thyroid carcinoma. DR Orphanet; 2396; Encephalocraniocutaneous lipomatosis. DR Orphanet; 1333; Familial pancreatic carcinoma. DR Orphanet; 86834; Juvenile myelomonocytic leukemia. DR Orphanet; 2612; Linear nevus sebaceus syndrome. DR Orphanet; 144; Lynch syndrome. DR Orphanet; 648; Noonan syndrome. DR Orphanet; 3339; Oculoectodermal syndrome. DR Orphanet; 251615; Pilomyxoid astrocytoma. DR Orphanet; 268114; RAS-associated autoimmune leukoproliferative disease. DR VEuPathDB; HostDB:ENSG00000133703; -. DR eggNOG; KOG0395; Eukaryota. DR GeneTree; ENSGT00940000155871; -. DR HOGENOM; CLU_041217_9_8_1; -. DR InParanoid; P01116; -. DR OMA; CCGGCVI; -. DR OrthoDB; 5976022at2759; -. DR PAN-GO; P01116; 5 GO annotations based on evolutionary models. DR PhylomeDB; P01116; -. DR BRENDA; 3.6.5.2; 2681. DR PathwayCommons; P01116; -. DR Reactome; R-HSA-112412; SOS-mediated signalling. DR Reactome; R-HSA-1169092; Activation of RAS in B cells. DR Reactome; R-HSA-1236382; Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants. DR Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling. DR Reactome; R-HSA-1250347; SHC1 events in ERBB4 signaling. DR Reactome; R-HSA-1433557; Signaling by SCF-KIT. DR Reactome; R-HSA-167044; Signalling to RAS. DR Reactome; R-HSA-171007; p38MAPK events. DR Reactome; R-HSA-179812; GRB2 events in EGFR signaling. DR Reactome; R-HSA-180336; SHC1 events in EGFR signaling. DR Reactome; R-HSA-186763; Downstream signal transduction. DR Reactome; R-HSA-1963640; GRB2 events in ERBB2 signaling. DR Reactome; R-HSA-210993; Tie2 Signaling. DR Reactome; R-HSA-2179392; EGFR Transactivation by Gastrin. DR Reactome; R-HSA-2424491; DAP12 signaling. DR Reactome; R-HSA-2428933; SHC-related events triggered by IGF1R. DR Reactome; R-HSA-2871796; FCERI mediated MAPK activation. DR Reactome; R-HSA-375165; NCAM signaling for neurite out-growth. DR Reactome; R-HSA-4086398; Ca2+ pathway. [P01116-2] DR Reactome; R-HSA-442982; Ras activation upon Ca2+ influx through NMDA receptor. DR Reactome; R-HSA-5218921; VEGFR2 mediated cell proliferation. DR Reactome; R-HSA-5621575; CD209 (DC-SIGN) signaling. DR Reactome; R-HSA-5637810; Constitutive Signaling by EGFRvIII. DR Reactome; R-HSA-5654688; SHC-mediated cascade:FGFR1. DR Reactome; R-HSA-5654693; FRS-mediated FGFR1 signaling. DR Reactome; R-HSA-5654699; SHC-mediated cascade:FGFR2. DR Reactome; R-HSA-5654700; FRS-mediated FGFR2 signaling. DR Reactome; R-HSA-5654704; SHC-mediated cascade:FGFR3. DR Reactome; R-HSA-5654706; FRS-mediated FGFR3 signaling. DR Reactome; R-HSA-5654712; FRS-mediated FGFR4 signaling. DR Reactome; R-HSA-5654719; SHC-mediated cascade:FGFR4. DR Reactome; R-HSA-5655253; Signaling by FGFR2 in disease. DR Reactome; R-HSA-5655291; Signaling by FGFR4 in disease. DR Reactome; R-HSA-5655302; Signaling by FGFR1 in disease. DR Reactome; R-HSA-5655332; Signaling by FGFR3 in disease. DR Reactome; R-HSA-5658442; Regulation of RAS by GAPs. DR Reactome; R-HSA-5673000; RAF activation. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-5674135; MAP2K and MAPK activation. DR Reactome; R-HSA-5675221; Negative regulation of MAPK pathway. DR Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants. DR Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants. DR Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions. DR Reactome; R-HSA-6802953; RAS signaling downstream of NF1 loss-of-function variants. DR Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF. DR Reactome; R-HSA-74751; Insulin receptor signalling cascade. DR Reactome; R-HSA-8849471; PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases. DR Reactome; R-HSA-8851805; MET activates RAS signaling. DR Reactome; R-HSA-8951936; RUNX3 regulates p14-ARF. DR Reactome; R-HSA-9026519; Activated NTRK2 signals through RAS. DR Reactome; R-HSA-9027284; Erythropoietin activates RAS. DR Reactome; R-HSA-9028731; Activated NTRK2 signals through FRS2 and FRS3. DR Reactome; R-HSA-9034864; Activated NTRK3 signals through RAS. DR Reactome; R-HSA-9607240; FLT3 Signaling. DR Reactome; R-HSA-9634285; Constitutive Signaling by Overexpressed ERBB2. DR Reactome; R-HSA-9634635; Estrogen-stimulated signaling through PRKCZ. DR Reactome; R-HSA-9648002; RAS processing. DR Reactome; R-HSA-9649948; Signaling downstream of RAS mutants. DR Reactome; R-HSA-9656223; Signaling by RAF1 mutants. DR Reactome; R-HSA-9664565; Signaling by ERBB2 KD Mutants. DR Reactome; R-HSA-9665348; Signaling by ERBB2 ECD mutants. DR Reactome; R-HSA-9665686; Signaling by ERBB2 TMD/JMD mutants. DR Reactome; R-HSA-9670439; Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants. DR Reactome; R-HSA-9673767; Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants. DR Reactome; R-HSA-9673770; Signaling by PDGFRA extracellular domain mutants. DR Reactome; R-HSA-9674555; Signaling by CSF3 (G-CSF). DR Reactome; R-HSA-9680350; Signaling by CSF1 (M-CSF) in myeloid cells. DR Reactome; R-HSA-9703465; Signaling by FLT3 fusion proteins. DR Reactome; R-HSA-9703648; Signaling by FLT3 ITD and TKD mutants. DR Reactome; R-HSA-9753510; Signaling by RAS GAP mutants. DR Reactome; R-HSA-9753512; Signaling by RAS GTPase mutants. DR SignaLink; P01116; -. DR SIGNOR; P01116; -. DR Agora; ENSG00000133703; -. DR BioGRID-ORCS; 3845; 259 hits in 1133 CRISPR screens. DR CD-CODE; D57F7ABA; Synthetic Condensate 000274. DR CD-CODE; DEE660B4; Stress granule. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; KRAS; human. DR EvolutionaryTrace; P01116; -. DR GeneWiki; KRAS; -. DR GenomeRNAi; 3845; -. DR Pharos; P01116; Tclin. DR PRO; PR:P01116; -. DR Proteomes; UP000005640; Chromosome 12. DR RNAct; P01116; protein. DR Bgee; ENSG00000133703; Expressed in trigeminal ganglion and 218 other cell types or tissues. DR ExpressionAtlas; P01116; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0009898; C:cytoplasmic side of plasma membrane; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome. DR GO; GO:0005925; C:focal adhesion; HDA:UniProtKB. DR GO; GO:0000139; C:Golgi membrane; TAS:Reactome. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0005741; C:mitochondrial outer membrane; TAS:Reactome. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0003925; F:G protein activity; IEA:UniProtKB-EC. DR GO; GO:0019003; F:GDP binding; IBA:GO_Central. DR GO; GO:0019002; F:GMP binding; IEA:Ensembl. DR GO; GO:0005525; F:GTP binding; IBA:GO_Central. DR GO; GO:0003924; F:GTPase activity; IMP:DisProt. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0030275; F:LRR domain binding; IEA:Ensembl. DR GO; GO:0044877; F:protein-containing complex binding; IDA:MGI. DR GO; GO:0043495; F:protein-membrane adaptor activity; IEA:Ensembl. DR GO; GO:0030036; P:actin cytoskeleton organization; IEA:Ensembl. DR GO; GO:0060038; P:cardiac muscle cell proliferation; IEA:Ensembl. DR GO; GO:0019221; P:cytokine-mediated signaling pathway; IEA:Ensembl. DR GO; GO:0060441; P:epithelial tube branching involved in lung morphogenesis; IEA:Ensembl. DR GO; GO:0007565; P:female pregnancy; IEA:Ensembl. DR GO; GO:0021897; P:forebrain astrocyte development; IEA:Ensembl. DR GO; GO:0010467; P:gene expression; IEA:Ensembl. DR GO; GO:0014009; P:glial cell proliferation; IEA:Ensembl. DR GO; GO:0048873; P:homeostasis of number of cells within a tissue; IEA:Ensembl. DR GO; GO:0001889; P:liver development; IEA:Ensembl. DR GO; GO:0000165; P:MAPK cascade; TAS:Reactome. DR GO; GO:0051450; P:myoblast proliferation; IEA:Ensembl. DR GO; GO:0030857; P:negative regulation of epithelial cell differentiation; IEA:Ensembl. DR GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl. DR GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl. DR GO; GO:2000774; P:positive regulation of cellular senescence; IEA:Ensembl. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL. DR GO; GO:0060252; P:positive regulation of glial cell proliferation; IEA:Ensembl. DR GO; GO:0035022; P:positive regulation of Rac protein signal transduction; IEA:Ensembl. DR GO; GO:0016601; P:Rac protein signal transduction; IEA:Ensembl. DR GO; GO:0007265; P:Ras protein signal transduction; IBA:GO_Central. DR GO; GO:0048169; P:regulation of long-term neuronal synaptic plasticity; IEA:Ensembl. DR GO; GO:0032228; P:regulation of synaptic transmission, GABAergic; IEA:Ensembl. DR GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl. DR GO; GO:0009629; P:response to gravity; IEA:Ensembl. DR GO; GO:0035900; P:response to isolation stress; IEA:Ensembl. DR GO; GO:0051385; P:response to mineralocorticoid; IEA:Ensembl. DR GO; GO:0035914; P:skeletal muscle cell differentiation; IEA:Ensembl. DR GO; GO:0051146; P:striated muscle cell differentiation; IEA:Ensembl. DR GO; GO:0060509; P:type I pneumocyte differentiation; IEA:Ensembl. DR GO; GO:0008542; P:visual learning; IEA:Ensembl. DR CDD; cd04138; H_N_K_Ras_like; 1. DR DisProt; DP03860; -. DR FunFam; 3.40.50.300:FF:000096; KRAS proto-oncogene, GTPase; 1. DR Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1. DR InterPro; IPR027417; P-loop_NTPase. DR InterPro; IPR005225; Small_GTP-bd. DR InterPro; IPR001806; Small_GTPase. DR InterPro; IPR020849; Small_GTPase_Ras-type. DR NCBIfam; TIGR00231; small_GTP; 1. DR PANTHER; PTHR24070; RAS, DI-RAS, AND RHEB FAMILY MEMBERS OF SMALL GTPASE SUPERFAMILY; 1. DR Pfam; PF00071; Ras; 1. DR PRINTS; PR00449; RASTRNSFRMNG. DR SMART; SM00175; RAB; 1. DR SMART; SM00176; RAN; 1. DR SMART; SM00173; RAS; 1. DR SMART; SM00174; RHO; 1. DR SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1. DR PROSITE; PS51421; RAS; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Cardiomyopathy; KW Cell membrane; Cytoplasm; Deafness; Direct protein sequencing; KW Disease variant; Ectodermal dysplasia; Glycoprotein; GTP-binding; KW Hydrolase; Intellectual disability; Isopeptide bond; Lipoprotein; Membrane; KW Methylation; Nucleotide-binding; Palmitate; Prenylation; KW Proteomics identification; Proto-oncogene; Reference proteome; KW Ubl conjugation. FT CHAIN 1..186 FT /note="GTPase KRas" FT /id="PRO_0000082641" FT INIT_MET 1 FT /note="Removed; alternate" FT /evidence="ECO:0000269|Ref.17" FT CHAIN 2..186 FT /note="GTPase KRas, N-terminally processed" FT /id="PRO_0000326480" FT PROPEP 187..189 FT /note="Removed in mature form" FT /evidence="ECO:0000305|PubMed:27791178" FT /id="PRO_0000281291" FT REGION 166..185 FT /note="Hypervariable region" FT MOTIF 32..40 FT /note="Effector region" FT BINDING 10..18 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000269|PubMed:22431598, FT ECO:0000269|PubMed:22566140, ECO:0000305|PubMed:34380736, FT ECO:0000305|PubMed:35522713" FT BINDING 29..35 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000269|PubMed:22431598, FT ECO:0000269|PubMed:22566140, ECO:0000305|PubMed:34380736, FT ECO:0000305|PubMed:35522713" FT BINDING 59..60 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000269|PubMed:22431598, FT ECO:0000269|PubMed:22566140, ECO:0000305|PubMed:34380736, FT ECO:0000305|PubMed:35522713" FT BINDING 116..119 FT /ligand="GTP" FT /ligand_id="ChEBI:CHEBI:37565" FT /evidence="ECO:0000269|PubMed:22431598, FT ECO:0000269|PubMed:22566140, ECO:0000305|PubMed:34380736, FT ECO:0000305|PubMed:35522713" FT MOD_RES 1 FT /note="N-acetylmethionine; in GTPase KRas; alternate" FT /evidence="ECO:0000269|Ref.17" FT MOD_RES 2 FT /note="N-acetylthreonine; in GTPase KRas, N-terminally FT processed" FT /evidence="ECO:0000269|Ref.17" FT MOD_RES 104 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:22711838" FT MOD_RES 186 FT /note="Cysteine methyl ester" FT /evidence="ECO:0000269|PubMed:27791178, FT ECO:0007744|PDB:5TAR, ECO:0007744|PDB:5TB5" FT LIPID 180 FT /note="S-palmitoyl cysteine" FT /evidence="ECO:0000305|PubMed:29239724" FT LIPID 182 FT /note="N6-palmitoyl lysine" FT /evidence="ECO:0000269|PubMed:29239724" FT LIPID 184 FT /note="N6-palmitoyl lysine" FT /evidence="ECO:0000305|PubMed:29239724" FT LIPID 185 FT /note="N6-palmitoyl lysine" FT /evidence="ECO:0000305|PubMed:29239724" FT LIPID 186 FT /note="S-farnesyl cysteine" FT /evidence="ECO:0000269|PubMed:27791178, FT ECO:0000305|PubMed:24415755, ECO:0007744|PDB:5TAR, FT ECO:0007744|PDB:5TB5" FT CARBOHYD 35 FT /note="(Microbial infection) O-linked (Glc) threonine; by FT P.sordellii toxin TcsL" FT /evidence="ECO:0000269|PubMed:19744486" FT CROSSLNK 170 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000305|PubMed:30442762" FT VAR_SEQ 151..153 FT /note="RVE -> GVD (in isoform 2B)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:3310850, FT ECO:0000303|Ref.6, ECO:0000303|Ref.7" FT /id="VSP_011140" FT VAR_SEQ 165..189 FT /note="QYRLKKISKEEKTPGCVKIKKCIIM -> KHKEKMSKDGKKKKKKSKTKCVI FT M (in isoform 2B)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:3310850, FT ECO:0000303|Ref.6, ECO:0000303|Ref.7" FT /id="VSP_011141" FT VARIANT 5 FT /note="K -> E (in NS3; dbSNP:rs193929331)" FT /evidence="ECO:0000269|PubMed:17468812" FT /id="VAR_065144" FT VARIANT 5 FT /note="K -> N (in GASC; found also in a patient with FT Costello syndrome; exhibits only minor alterations in its FT in vitro biochemical behavior compared to wild-type FT protein; dbSNP:rs104894361)" FT /evidence="ECO:0000269|PubMed:14534542" FT /id="VAR_064849" FT VARIANT 10 FT /note="G -> GG (in AML; expression in 3T3 cell causes FT cellular transformation; expression in COS cells activates FT the Ras-MAPK signaling pathway; lower GTPase activity; FT faster GDP dissociation rate)" FT /evidence="ECO:0000269|PubMed:8955068" FT /id="VAR_034601" FT VARIANT 12 FT /note="G -> A (in colorectal cancer samples; somatic FT mutation; dbSNP:rs121913529)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:34820593" FT /id="VAR_036305" FT VARIANT 12 FT /note="G -> C (in lung carcinoma; somatic mutation; also FT found in metastatic colorectal cancer; dbSNP:rs121913530)" FT /evidence="ECO:0000269|PubMed:16533793, FT ECO:0000269|PubMed:34820593, ECO:0000269|PubMed:6320174" FT /id="VAR_006839" FT VARIANT 12 FT /note="G -> D (in GASC, JMML and SFM; somatic mutation; FT also found in pancreatic carcinoma and lung carcinoma; also FT found in metastatic colorectal cancer; dbSNP:rs121913529)" FT /evidence="ECO:0000269|PubMed:16533793, FT ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:17332249, FT ECO:0000269|PubMed:30891959, ECO:0000269|PubMed:34820593, FT ECO:0000269|PubMed:7773929, ECO:0000269|PubMed:8439212" FT /id="VAR_016026" FT VARIANT 12 FT /note="G -> R (in lung cancer and bladder cancer; somatic FT mutation; dbSNP:rs121913530)" FT /evidence="ECO:0000269|PubMed:6695174" FT /id="VAR_016027" FT VARIANT 12 FT /note="G -> S (in GASC and JMML; also found in lung FT carcinoma; somatic mutation; dbSNP:rs121913530)" FT /evidence="ECO:0000269|PubMed:16533793, FT ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:17332249, FT ECO:0000269|PubMed:7773929" FT /id="VAR_016028" FT VARIANT 12 FT /note="G -> V (in GASC; also found in lung carcinoma, FT pancreatic carcinoma and colon cancer; also found in FT metastatic colorectal cancer; somatic mutation; it is FT constitutively activated and stimulates transcription FT activation of tumor suppressor genes in non-transformed FT fibroblasts; promotes GTP binding; dbSNP:rs121913529)" FT /evidence="ECO:0000269|PubMed:14534542, FT ECO:0000269|PubMed:16533793, ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:22711838, ECO:0000269|PubMed:24623306, FT ECO:0000269|PubMed:3034404, ECO:0000269|PubMed:34820593, FT ECO:0000269|PubMed:39809765, ECO:0000269|PubMed:6092920, FT ECO:0000269|PubMed:8439212" FT /id="VAR_006840" FT VARIANT 13 FT /note="G -> D (in GASC, JMML and OES; also found in a FT breast carcinoma cell line; somatic mutation; FT dbSNP:rs112445441)" FT /evidence="ECO:0000269|PubMed:14534542, FT ECO:0000269|PubMed:16959974, ECO:0000269|PubMed:17332249, FT ECO:0000269|PubMed:25808193, ECO:0000269|PubMed:3627975" FT /id="VAR_016029" FT VARIANT 13 FT /note="G -> R (in pylocytic astrocytoma; somatic mutation; FT increase activation of the Ras pathway; dbSNP:rs121913535)" FT /evidence="ECO:0000269|PubMed:16247081" FT /id="VAR_065145" FT VARIANT 14 FT /note="V -> I (in NS3; affects activity and impairs FT responsiveness to GTPase activating proteins; characterized FT by a strong increase of both intrinsic and guanine FT nucleotide exchanged factor-catalyzed nucleotide exchange FT leading to an increased level of the activated state; FT dbSNP:rs104894365)" FT /evidence="ECO:0000269|PubMed:16474405" FT /id="VAR_026109" FT VARIANT 19 FT /note="L -> F (in OES; somatic mutation; FT dbSNP:rs121913538)" FT /evidence="ECO:0000269|PubMed:25808193" FT /id="VAR_083261" FT VARIANT 22 FT /note="Q -> E (in CFC2; exhibits an increase in intrinsic FT and guanine nucleotide exchange factor catalyzed nucleotide FT exchange in combination with an impaired GTPase-activating FT protein-stimulated GTP hydrolysis but functional in FT interaction with effectors; dbSNP:rs121913236)" FT /evidence="ECO:0000269|PubMed:17056636, FT ECO:0000269|PubMed:20949621" FT /id="VAR_064850" FT VARIANT 22 FT /note="Q -> R (in NS3; impairs GTPase-activating protein FT stimulated GTP hydrolysis with unaffected intrinsic FT functions and a virtually functional effector interaction; FT dbSNP:rs727503110)" FT /evidence="ECO:0000269|PubMed:17056636" FT /id="VAR_064851" FT VARIANT 34 FT /note="P -> L (in NS3; characterized by a defective GTPase- FT activating protein sensitivity and a strongly reduced FT interaction with effectors; dbSNP:rs104894366)" FT /evidence="ECO:0000269|PubMed:17056636" FT /id="VAR_064852" FT VARIANT 34 FT /note="P -> Q (in NS3; dbSNP:rs104894366)" FT /evidence="ECO:0000269|PubMed:17056636" FT /id="VAR_064853" FT VARIANT 34 FT /note="P -> R (in CFC2; characterized by a defective FT GTPase-activating protein sensitivity and a strongly FT reduced interaction with effectors; dbSNP:rs104894366)" FT /evidence="ECO:0000269|PubMed:16474405, FT ECO:0000269|PubMed:20949621" FT /id="VAR_026110" FT VARIANT 36 FT /note="I -> M (in NS3; dbSNP:rs727503109)" FT /evidence="ECO:0000269|PubMed:17056636" FT /id="VAR_064854" FT VARIANT 58 FT /note="T -> I (in NS3; affects activity and impairs FT responsiveness to GTPase activating proteins; exhibits only FT minor alterations in its in vitro biochemical behavior FT compared to wild-type protein; dbSNP:rs104894364)" FT /evidence="ECO:0000269|PubMed:16474405, FT ECO:0000269|PubMed:19396835" FT /id="VAR_026111" FT VARIANT 59 FT /note="A -> T (in GASC; also found in bladder cancer; FT somatic mutation; dbSNP:rs121913528)" FT /evidence="ECO:0000269|PubMed:14534542, FT ECO:0000269|PubMed:1553789" FT /id="VAR_016030" FT VARIANT 60 FT /note="G -> R (in CFC2; characterized by a defective FT GTPase-activating protein sensitivity and a strongly FT reduced interaction with effectors; dbSNP:rs104894359)" FT /evidence="ECO:0000269|PubMed:16474404, FT ECO:0000269|PubMed:20949621" FT /id="VAR_026112" FT VARIANT 60 FT /note="G -> S (in NS3; dbSNP:rs104894359)" FT /evidence="ECO:0000269|PubMed:19396835" FT /id="VAR_065146" FT VARIANT 61 FT /note="Q -> H (in lung carcinoma; dbSNP:rs17851045)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:16533793, ECO:0000269|Ref.7" FT /id="VAR_006841" FT VARIANT 61 FT /note="Q -> R (in a colorectal cancer sample; somatic FT mutation; promotes interaction with SHOC2 and PP1C; FT dbSNP:rs121913240)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:35830882, ECO:0000269|PubMed:35831509" FT /id="VAR_036306" FT VARIANT 71 FT /note="Y -> H (in CFC2; dbSNP:rs387907205)" FT /evidence="ECO:0000269|PubMed:21797849" FT /id="VAR_069784" FT VARIANT 117 FT /note="K -> N (in colorectal cancer samples; somatic FT mutation; dbSNP:rs770248150)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:34820593" FT /id="VAR_036307" FT VARIANT 146 FT /note="A -> T (in OES; somatic mutation; also found in FT colorectal cancer samples; dbSNP:rs121913527)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:26970110, ECO:0000269|PubMed:30891959, FT ECO:0000269|PubMed:34820593" FT /id="VAR_036308" FT VARIANT 146 FT /note="A -> V (in OES; somatic mutation; FT dbSNP:rs1057519725)" FT /evidence="ECO:0000269|PubMed:26970110, FT ECO:0000269|PubMed:30891959" FT /id="VAR_083262" FT VARIANT 147 FT /note="K -> E (in CFC2; dbSNP:rs387907206)" FT /evidence="ECO:0000269|PubMed:21797849" FT /id="VAR_069785" FT MUTAGEN 38 FT /note="D->A: Decreased interaction with MAPKAP1/SIN1." FT /evidence="ECO:0000269|PubMed:34380736" FT MUTAGEN 40 FT /note="Y->A: Decreased interaction with MAPKAP1/SIN1." FT /evidence="ECO:0000269|PubMed:34380736" FT MUTAGEN 61 FT /note="Q->L: Promotes GTP binding." FT /evidence="ECO:0000269|PubMed:39809765" FT MUTAGEN 180 FT /note="C->S: Abolished palmitoylation on Cys; reduced FT palmitoylation on Lys residues." FT /evidence="ECO:0000269|PubMed:29239724" FT MUTAGEN 182..185 FT /note="KIKK->RIRR: In K-Ras-3KR; abolished lysine- FT palmitoylation." FT /evidence="ECO:0000269|PubMed:29239724" FT STRAND 3..9 FT /evidence="ECO:0007829|PDB:8ONV" FT STRAND 12..14 FT /evidence="ECO:0007829|PDB:6EPO" FT HELIX 16..25 FT /evidence="ECO:0007829|PDB:8ONV" FT STRAND 28..32 FT /evidence="ECO:0007829|PDB:7F0W" FT TURN 34..36 FT /evidence="ECO:0007829|PDB:6H46" FT STRAND 38..46 FT /evidence="ECO:0007829|PDB:8ONV" FT STRAND 49..57 FT /evidence="ECO:0007829|PDB:8ONV" FT HELIX 60..62 FT /evidence="ECO:0007829|PDB:4Q01" FT HELIX 66..73 FT /evidence="ECO:0007829|PDB:8ONV" FT STRAND 76..83 FT /evidence="ECO:0007829|PDB:8ONV" FT HELIX 87..91 FT /evidence="ECO:0007829|PDB:8ONV" FT HELIX 93..104 FT /evidence="ECO:0007829|PDB:8ONV" FT STRAND 105..107 FT /evidence="ECO:0007829|PDB:5VBM" FT STRAND 111..116 FT /evidence="ECO:0007829|PDB:8ONV" FT STRAND 120..122 FT /evidence="ECO:0007829|PDB:4OBE" FT HELIX 127..137 FT /evidence="ECO:0007829|PDB:8ONV" FT STRAND 141..143 FT /evidence="ECO:0007829|PDB:8ONV" FT TURN 146..148 FT /evidence="ECO:0007829|PDB:8ONV" FT HELIX 152..164 FT /evidence="ECO:0007829|PDB:8ONV" FT HELIX 169..172 FT /evidence="ECO:0007829|PDB:5OCG" FT STRAND 175..177 FT /evidence="ECO:0007829|PDB:4DSN" FT STRAND 182..184 FT /evidence="ECO:0007829|PDB:5TB5" FT VARIANT P01116-2:152 FT /note="V -> G (in NS3; dbSNP:rs104894367)" FT /evidence="ECO:0000305" FT /id="VAR_082908" FT VARIANT P01116-2:153 FT /note="D -> V (in CFC2 and NS3; exhibits only minor FT alterations in its in vitro biochemical behavior compared FT to wild-type protein; dbSNP:rs104894360)" FT /evidence="ECO:0000305" FT /id="VAR_082909" FT VARIANT P01116-2:156 FT /note="F -> I (in NS3; the patient also has features of FT cardiofaciocutaneous syndrome; dbSNP:rs397517042)" FT /evidence="ECO:0000305" FT /id="VAR_082910" FT VARIANT P01116-2:156 FT /note="F -> L (found in a patient with Costello syndrome; FT exhibits an increase in intrinsic and guanine nucleotide FT exchange factor catalyzed nucleotide exchange in FT combination with an impaired GTPase-activating protein- FT stimulated GTP hydrolysis but functional in interaction FT with effectors; dbSNP:rs104894362)" FT /evidence="ECO:0000305" FT /id="VAR_082911" FT MUTAGEN P01116-2:185 FT /note="C->S: Abolished interaction with GPR131." FT /evidence="ECO:0000269|PubMed:28619714" SQ SEQUENCE 189 AA; 21656 MW; 973547B2E11C2C81 CRC64; MTEYKLVVVG AGGVGKSALT IQLIQNHFVD EYDPTIEDSY RKQVVIDGET CLLDILDTAG QEEYSAMRDQ YMRTGEGFLC VFAINNTKSF EDIHHYREQI KRVKDSEDVP MVLVGNKCDL PSRTVDTKQA QDLARSYGIP FIETSAKTRQ RVEDAFYTLV REIRQYRLKK ISKEEKTPGC VKIKKCIIM // ID SMAD4_HUMAN Reviewed; 552 AA. AC Q13485; A8K405; DT 04-MAY-2001, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1996, sequence version 1. DT 28-JAN-2026, entry version 255. DE RecName: Full=SMAD family member 4 {ECO:0000312|HGNC:HGNC:6770}; DE Short=SMAD 4 {ECO:0000305}; DE Short=hSMAD4; DE AltName: Full=Deletion target in pancreatic carcinoma 4; DE AltName: Full=Mothers against decapentaplegic homolog 4; DE Short=MAD homolog 4; DE Short=Mothers against DPP homolog 4; GN Name=SMAD4 {ECO:0000312|HGNC:HGNC:6770}; Synonyms=DPC4, MADH4; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], AND VARIANT PANCREATIC CARCINOMA RP HIS-493. RC TISSUE=Fetal brain; RX PubMed=8553070; DOI=10.1126/science.271.5247.350; RA Hahn S.A., Schutte M., Shamsul Hoque A.T.M., Moskaluk C.A., da Costa L.T., RA Rozenblum E., Weinstein C.L., Fischer A., Yeo C.J., Hruban R.H., Kern S.E.; RT "DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1."; RL Science 271:350-353(1996). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RC TISSUE=Placenta; RX PubMed=8774881; DOI=10.1038/383168a0; RA Zhang Y., Feng X.-H., Wu R.-Y., Derynck R.; RT "Receptor-associated Mad homologues synergize as effectors of the TGF-beta RT response."; RL Nature 383:168-172(1996). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=9098646; DOI=10.1097/00019606-199704000-00003; RA Moskaluk C.A., Hruban R.H., Schutte M., Lietman A.S., Smyrk T., Fusaro L., RA Fusaro R., Lynch J., Yeo C.J., Jackson C.E., Lynch H.T., Kern S.E.; RT "Genomic sequencing of DPC4 in the analysis of familial pancreatic RT carcinoma."; RL Diagn. Mol. Pathol. 6:85-90(1997). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Muscle; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP FUNCTION. RX PubMed=9389648; DOI=10.1101/gad.11.23.3157; RA Liu F., Pouponnot C., Massague J.; RT "Dual role of the Smad4/DPC4 tumor suppressor in TGFbeta-inducible RT transcriptional complexes."; RL Genes Dev. 11:3157-3167(1997). RN [8] RP SUBUNIT. RX PubMed=9670020; DOI=10.1093/emboj/17.14.4056; RA Kawabata M., Inoue H., Hanyu A., Imamura T., Miyazono K.; RT "Smad proteins exist as monomers in vivo and undergo homo- and hetero- RT oligomerization upon activation by serine/threonine kinase receptors."; RL EMBO J. 17:4056-4065(1998). RN [9] RP INTERACTION WITH CITED1. RX PubMed=9707553; DOI=10.1073/pnas.95.17.9785; RA Shioda T., Lechleider R.J., Dunwoodie S.L., Li H., Yahata T., RA de Caestecker M.P., Fenner M.H., Roberts A.B., Isselbacher K.J.; RT "Transcriptional activating activity of Smad4: roles of SMAD hetero- RT oligomerization and enhancement by an associating transactivator."; RL Proc. Natl. Acad. Sci. U.S.A. 95:9785-9790(1998). RN [10] RP INTERACTION WITH ZNF423. RX PubMed=10660046; DOI=10.1016/s0092-8674(00)81561-5; RA Hata A., Seoane J., Lagna G., Montalvo E., Hemmati-Brivanlou A., RA Massague J.; RT "OAZ uses distinct DNA- and protein-binding zinc fingers in separate BMP- RT Smad and Olf signaling pathways."; RL Cell 100:229-240(2000). RN [11] RP CHARACTERIZATION OF SAD DOMAIN. RX PubMed=10636916; DOI=10.1074/jbc.275.3.2115; RA de Caestecker M.P., Yahata T., Wang D., Parks W.T., Huang S., Hill C.S., RA Shioda T., Roberts A.B., Lechleider R.J.; RT "The Smad4 activation domain (SAD) is a proline-rich, p300-dependent RT transcriptional activation domain."; RL J. Biol. Chem. 275:2115-2122(2000). RN [12] RP IDENTIFICATION IN A TERNARY COMPLEX COMPOSED OF STK11/LKB1 AND STK11IP, AND RP INTERACTION WITH STK11/LKB1 AND STK11IP. RX PubMed=11741830; DOI=10.1093/hmg/10.25.2869; RA Smith D.P., Rayter S.I., Niederlander C., Spicer J., Jones C.M., RA Ashworth A.; RT "LIP1, a cytoplasmic protein functionally linked to the Peutz-Jeghers RT syndrome kinase LKB1."; RL Hum. Mol. Genet. 10:2869-2877(2001). RN [13] RP INTERACTION WITH COPS5. RX PubMed=11818334; DOI=10.1093/embo-reports/kvf024; RA Wan M., Cao X., Wu Y., Bai S., Wu L., Shi X., Wang N., Cao X.; RT "Jab1 antagonizes TGF-beta signaling by inducing Smad4 degradation."; RL EMBO Rep. 3:171-176(2002). RN [14] RP INTERACTION WITH ZNF8. RX PubMed=12370310; DOI=10.1128/mcb.22.21.7633-7644.2002; RA Jiao K., Zhou Y., Hogan B.L.M.; RT "Identification of mZnf8, a mouse Kruppel-like transcriptional repressor, RT as a novel nuclear interaction partner of Smad1."; RL Mol. Cell. Biol. 22:7633-7644(2002). RN [15] RP INTERACTION WITH VPS39. RX PubMed=12941698; DOI=10.1093/emboj/cdg428; RA Felici A., Wurthner J.U., Parks W.T., Giam L.R., Reiss M., Karpova T.S., RA McNally J.G., Roberts A.B.; RT "TLP, a novel modulator of TGF-beta signaling, has opposite effects on RT Smad2- and Smad3-dependent signaling."; RL EMBO J. 22:4465-4477(2003). RN [16] RP INTERACTION WITH DACH1. RX PubMed=14525983; DOI=10.1074/jbc.m310021200; RA Wu K., Yang Y., Wang C., Davoli M.A., D'Amico M., Li A., Cveklova K., RA Kozmik Z., Lisanti M.P., Russell R.G., Cvekl A., Pestell R.G.; RT "DACH1 inhibits transforming growth factor-beta signaling through binding RT Smad4."; RL J. Biol. Chem. 278:51673-51684(2003). RN [17] RP INTERACTION WITH DLX1. RX PubMed=14671321; DOI=10.1073/pnas.2536757100; RA Chiba S., Takeshita K., Imai Y., Kumano K., Kurokawa M., Masuda S., RA Shimizu K., Nakamura S., Ruddle F.H., Hirai H.; RT "Homeoprotein DLX-1 interacts with Smad4 and blocks a signaling pathway RT from activin A in hematopoietic cells."; RL Proc. Natl. Acad. Sci. U.S.A. 100:15577-15582(2003). RN [18] RP INTERACTION WITH ZNF521. RX PubMed=14630787; DOI=10.1182/blood-2003-07-2388; RA Bond H.M., Mesuraca M., Carbone E., Bonelli P., Agosti V., Amodio N., RA De Rosa G., Di Nicola M., Gianni A.M., Moore M.A., Hata A., Grieco M., RA Morrone G., Venuta S.; RT "Early hematopoietic zinc finger protein (EHZF), the human homolog to mouse RT Evi3, is highly expressed in primitive human hematopoietic cells."; RL Blood 103:2062-2070(2004). RN [19] RP INTERACTION WITH TRIM33. RX PubMed=15820681; DOI=10.1016/j.cell.2005.01.033; RA Dupont S., Zacchigna L., Cordenonsi M., Soligo S., Adorno M., Rugge M., RA Piccolo S.; RT "Germ-layer specification and control of cell growth by Ectodermin, a Smad4 RT ubiquitin ligase."; RL Cell 121:87-99(2005). RN [20] RP SUBUNIT, AND SUBCELLULAR LOCATION. RX PubMed=15799969; DOI=10.1074/jbc.m500362200; RA Chen H.B., Rud J.G., Lin K., Xu L.; RT "Nuclear targeting of transforming growth factor-beta-activated Smad RT complexes."; RL J. Biol. Chem. 280:21329-21336(2005). RN [21] RP INTERACTION WITH TSC22D1. RX PubMed=15881652; DOI=10.1007/s11010-005-3456-7; RA Choi S.J., Moon J.H., Ahn Y.W., Ahn J.H., Kim D.U., Han T.H.; RT "Tsc-22 enhances TGF-beta signaling by associating with Smad4 and induces RT erythroid cell differentiation."; RL Mol. Cell. Biochem. 271:23-28(2005). RN [22] RP INTERACTION WITH ZMIZ1. RX PubMed=16777850; DOI=10.1074/jbc.m508365200; RA Li X., Thyssen G., Beliakoff J., Sun Z.; RT "The novel PIAS-like protein hZimp10 enhances Smad transcriptional RT activity."; RL J. Biol. Chem. 281:23748-23756(2006). RN [23] RP INTERACTION WITH RBPMS. RX PubMed=17099224; DOI=10.1093/nar/gkl914; RA Sun Y., Ding L., Zhang H., Han J., Yang X., Yan J., Zhu Y., Li J., Song H., RA Ye Q.; RT "Potentiation of Smad-mediated transcriptional activation by the RNA- RT binding protein RBPMS."; RL Nucleic Acids Res. 34:6314-6326(2006). RN [24] RP FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION BY PDPK1, AND INTERACTION RP WITH PDPK1. RX PubMed=17327236; DOI=10.1074/jbc.m609279200; RA Seong H.A., Jung H., Kim K.T., Ha H.; RT "3-Phosphoinositide-dependent PDK1 negatively regulates transforming growth RT factor-beta-induced signaling in a kinase-dependent manner through physical RT interaction with Smad proteins."; RL J. Biol. Chem. 282:12272-12289(2007). RN [25] RP INTERACTION WITH WWTR1. RX PubMed=18568018; DOI=10.1038/ncb1748; RA Varelas X., Sakuma R., Samavarchi-Tehrani P., Peerani R., Rao B.M., RA Dembowy J., Yaffe M.B., Zandstra P.W., Wrana J.L.; RT "TAZ controls Smad nucleocytoplasmic shuttling and regulates human RT embryonic stem-cell self-renewal."; RL Nat. Cell Biol. 10:837-848(2008). RN [26] RP INTERACTION WITH USP9X, UBIQUITINATION, AND MUTAGENESIS OF LYS-519. RX PubMed=19135894; DOI=10.1016/j.cell.2008.10.051; RA Dupont S., Mamidi A., Cordenonsi M., Montagner M., Zacchigna L., Adorno M., RA Martello G., Stinchfield M.J., Soligo S., Morsut L., Inui M., Moro S., RA Modena N., Argenton F., Newfeld S.J., Piccolo S.; RT "FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, RT controls Smad4 monoubiquitination."; RL Cell 136:123-135(2009). RN [27] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-37; LYS-428 AND LYS-507, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [28] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [29] RP POSSIBLE INVOLVEMENT IN PULMONARY HYPERTENSION, AND VARIANT SER-13. RX PubMed=21898662; DOI=10.1002/humu.21605; RA Nasim M.T., Ogo T., Ahmed M., Randall R., Chowdhury H.M., Snape K.M., RA Bradshaw T.Y., Southgate L., Lee G.J., Jackson I., Lord G.M., Gibbs J.S., RA Wilkins M.R., Ohta-Ogo K., Nakamura K., Girerd B., Coulet F., Soubrier F., RA Humbert M., Morrell N.W., Trembath R.C., Machado R.D.; RT "Molecular genetic characterization of SMAD signaling molecules in RT pulmonary arterial hypertension."; RL Hum. Mutat. 32:1385-1389(2011). RN [30] RP INTERACTION WITH ZNF451, IDENTIFICATION IN A COMPLEX WITH ZNF451; SMAD3 AND RP SMAD2, AND SUBUNIT. RX PubMed=24324267; DOI=10.1074/jbc.m113.526905; RA Feng Y., Wu H., Xu Y., Zhang Z., Liu T., Lin X., Feng X.H.; RT "Zinc finger protein 451 is a novel Smad corepressor in transforming growth RT factor-beta signaling."; RL J. Biol. Chem. 289:2072-2083(2014). RN [31] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [32] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-113, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25218447; DOI=10.1038/nsmb.2890; RA Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M., RA Vertegaal A.C.; RT "Uncovering global SUMOylation signaling networks in a site-specific RT manner."; RL Nat. Struct. Mol. Biol. 21:927-936(2014). RN [33] RP INTERACTION WITH CREB3L1. RX PubMed=25310401; DOI=10.1371/journal.pone.0108528; RA Chen Q., Lee C.E., Denard B., Ye J.; RT "Sustained induction of collagen synthesis by TGF-beta requires regulated RT intramembrane proteolysis of CREB3L1."; RL PLoS ONE 9:E108528-E108528(2014). RN [34] RP FUNCTION, INTERACTION WITH CREBBP; EP300; HDAC1 AND ZBTB7A, AND REGION. RX PubMed=25514493; DOI=10.1016/j.bbagrm.2014.12.008; RA Yang Y., Cui J., Xue F., Zhang C., Mei Z., Wang Y., Bi M., Shan D., RA Meredith A., Li H., Xu Z.Q.; RT "Pokemon (FBI-1) interacts with Smad4 to repress TGF-beta-induced RT transcriptional responses."; RL Biochim. Biophys. Acta 1849:270-281(2015). RN [35] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-113, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25755297; DOI=10.1074/mcp.o114.044792; RA Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V., RA Vertegaal A.C.; RT "System-wide analysis of SUMOylation dynamics in response to replication RT stress reveals novel small ubiquitin-like modified target proteins and RT acceptor lysines relevant for genome stability."; RL Mol. Cell. Proteomics 14:1419-1434(2015). RN [36] RP INTERACTION WITH NUP93 AND IPO7. RX PubMed=26878725; DOI=10.1038/ng.3512; RA Braun D.A., Sadowski C.E., Kohl S., Lovric S., Astrinidis S.A., Pabst W.L., RA Gee H.Y., Ashraf S., Lawson J.A., Shril S., Airik M., Tan W., Schapiro D., RA Rao J., Choi W.I., Hermle T., Kemper M.J., Pohl M., Ozaltin F., Konrad M., RA Bogdanovic R., Buescher R., Helmchen U., Serdaroglu E., Lifton R.P., RA Antonin W., Hildebrandt F.; RT "Mutations in nuclear pore genes NUP93, NUP205 and XPO5 cause steroid- RT resistant nephrotic syndrome."; RL Nat. Genet. 48:457-465(2016). RN [37] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-113, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [38] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 319-543. RX PubMed=9214508; DOI=10.1038/40431; RA Shi Y., Hata A., Lo R.S., Massague J., Pavletich N.P.; RT "A structural basis for mutational inactivation of the tumour suppressor RT Smad4."; RL Nature 388:87-93(1997). RN [39] RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 285-552. RX PubMed=10647180; DOI=10.1016/s0969-2126(00)88340-9; RA Qin B., Lam S.S., Lin K.; RT "Crystal structure of a transcriptionally active Smad4 fragment."; RL Structure 7:1493-1503(1999). RN [40] RP X-RAY CRYSTALLOGRAPHY (3 ANGSTROMS) OF 273-552 OF WILD TYPE AND MUTANTS RP ARG-416; ARG-502 AND ARG-515 IN COMPLEX WITH SMAD3, SUBUNIT, AND RP MUTAGENESIS OF ARG-416; ARG-496; ARG-502 AND ARG-515. RX PubMed=11224571; DOI=10.1038/84995; RA Chacko B.M., Qin B., Correia J.J., Lam S.S., de Caestecker M.P., Lin K.; RT "The L3 loop and C-terminal phosphorylation jointly define Smad protein RT trimerization."; RL Nat. Struct. Biol. 8:248-253(2001). RN [41] RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 314-552 IN COMPLEX WITH SMAD2 OR RP SMAD3, AND SUBUNIT. RX PubMed=15350224; DOI=10.1016/j.molcel.2004.07.016; RA Chacko B.M., Qin B.Y., Tiwari A., Shi G., Lam S., Hayward L.J., RA De Caestecker M., Lin K.; RT "Structural basis of heteromeric smad protein assembly in TGF-beta RT signaling."; RL Mol. Cell 15:813-823(2004). RN [42] RP VARIANT JPS CYS-361. RX PubMed=9811934; DOI=10.1093/hmg/7.12.1907; RA Houlston R., Bevan S., Williams A., Young J., Dunlop M., Rozen P., Eng C., RA Markie D., Woodford-Richens K., Rodriguez-Bigas M.A., Leggett B., Neale K., RA Phillips R., Sheridan E., Hodgson S., Iwama T., Eccles D., Bodmer W., RA Tomlinson I.; RT "Mutations in DPC4 (SMAD4) cause juvenile polyposis syndrome, but only RT account for a minority of cases."; RL Hum. Mol. Genet. 7:1907-1912(1998). RN [43] RP VARIANTS JPS GLY-330 AND ARG-352. RX PubMed=12417513; DOI=10.1007/bf02557528; RA Sayed M.G., Ahmed A.F., Ringold J.R., Anderson M.E., Bair J.L., RA Mitros F.A., Lynch H.T., Tinley S.T., Petersen G.M., Giardiello F.M., RA Vogelstein B., Howe J.R.; RT "Germline SMAD4 or BMPR1A mutations and phenotype of juvenile polyposis."; RL Ann. Surg. Oncol. 9:901-906(2002). RN [44] RP VARIANTS JP/HHT ARG-352 AND ASP-386. RX PubMed=15031030; DOI=10.1016/s0140-6736(04)15732-2; RA Gallione C.J., Repetto G.M., Legius E., Rustgi A.K., Schelley S.L., RA Tejpar S., Mitchell G., Drouin E., Westermann C.J.J., Marchuk D.A.; RT "A combined syndrome of juvenile polyposis and hereditary haemorrhagic RT telangiectasia associated with mutations in MADH4 (SMAD4)."; RL Lancet 363:852-859(2004). RN [45] RP VARIANTS [LARGE SCALE ANALYSIS] SER-130; ASN-351 AND HIS-361, AND RP INVOLVEMENT IN COLORECTAL CANCER. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [46] RP VARIANTS MYHRS THR-500 AND VAL-500. RX PubMed=22243968; DOI=10.1016/j.ajhg.2011.12.011; RA Caputo V., Cianetti L., Niceta M., Carta C., Ciolfi A., Bocchinfuso G., RA Carrani E., Dentici M.L., Biamino E., Belligni E., Garavelli L., RA Boccone L., Melis D., Andria G., Gelb B.D., Stella L., Silengo M., RA Dallapiccola B., Tartaglia M.; RT "A restricted spectrum of mutations in the SMAD4 tumor-suppressor gene RT underlies Myhre syndrome."; RL Am. J. Hum. Genet. 90:161-169(2012). RN [47] RP VARIANTS MYHRS MET-500; THR-500 AND VAL-500, AND CHARACTERIZATION OF RP VARIANT MYHRS THR-500. RX PubMed=22158539; DOI=10.1038/ng.1016; RA Le Goff C., Mahaut C., Abhyankar A., Le Goff W., Serre V., Afenjar A., RA Destree A., di Rocco M., Heron D., Jacquemont S., Marlin S., Simon M., RA Tolmie J., Verloes A., Casanova J.L., Munnich A., Cormier-Daire V.; RT "Mutations at a single codon in Mad homology 2 domain of SMAD4 cause Myhre RT syndrome."; RL Nat. Genet. 44:85-88(2012). CC -!- FUNCTION: In muscle physiology, plays a central role in the balance CC between atrophy and hypertrophy. When recruited by MSTN, promotes CC atrophy response via phosphorylated SMAD2/4. MSTN decrease causes SMAD4 CC release and subsequent recruitment by the BMP pathway to promote CC hypertrophy via phosphorylated SMAD1/5/8. Acts synergistically with CC SMAD1 and YY1 in bone morphogenetic protein (BMP)-mediated cardiac- CC specific gene expression. Binds to SMAD binding elements (SBEs) (5'- CC GTCT/AGAC-3') within BMP response element (BMPRE) of cardiac activating CC regions (By similarity). Common SMAD (co-SMAD) is the coactivator and CC mediator of signal transduction by TGF-beta (transforming growth CC factor). Component of the heterotrimeric SMAD2/SMAD3-SMAD4 complex that CC forms in the nucleus and is required for the TGF-mediated signaling CC (PubMed:25514493). Promotes binding of the SMAD2/SMAD4/FAST-1 complex CC to DNA and provides an activation function required for SMAD1 or SMAD2 CC to stimulate transcription. Component of the multimeric CC SMAD3/SMAD4/JUN/FOS complex which forms at the AP1 promoter site; CC required for synergistic transcriptional activity in response to TGF- CC beta. May act as a tumor suppressor. Positively regulates PDPK1 kinase CC activity by stimulating its dissociation from the 14-3-3 protein YWHAQ CC which acts as a negative regulator. {ECO:0000250, CC ECO:0000269|PubMed:17327236, ECO:0000269|PubMed:25514493, CC ECO:0000269|PubMed:9389648}. CC -!- SUBUNIT: Monomer; in the absence of TGF-beta activation CC (PubMed:9670020). Heterotrimer; on TGF-beta activation CC (PubMed:15799969). Heterotrimer composed of two molecules of a C- CC terminally phosphorylated R-SMAD molecule, SMAD2 or SMAD3, and one CC molecule of SMAD4 to form the transcriptional active SMAD2/SMAD3-SMAD4 CC complex (PubMed:15350224, PubMed:15799969). Found in a ternary complex CC composed of SMAD4, STK11/LKB1 and STK11IP. Found in a complex with CC SMAD1 and YY1 (By similarity). Identified in a complex that contains at CC least ZNF451, SMAD2, SMAD3 and SMAD4 (PubMed:24324267). Interacts with CC ATF2, COPS5, DACH1, MSG1, SKI, STK11/LKB1, STK11IP and TRIM33. CC Associates with ZNF423 or ZNF521 in response to BMP2 leading to CC activate transcription of BMP target genes. Interacts with USP9X. CC Interacts (via the MH1 and MH2 domains) with RBPMS. Interacts with CC WWTR1 (via coiled-coil domain). Interacts with CITED1 and CITED2. CC Interacts with PDPK1 (via PH domain) (By similarity). Interacts with CC VPS39; this interaction affects heterodimer formation with SMAD3, but CC not with SMAD2, and leads to inhibition of SMAD3-dependent CC transcription activation. Interactions with VPS39 and SMAD2 may be CC mutually exclusive. Interacts (via MH2 domain) with ZNF451 (via N- CC terminal zinc-finger domains) (PubMed:24324267). Interacts with ZC3H3 CC (By similarity). Interacts weakly with ZNF8 (PubMed:12370310). CC Interacts with NUP93 and IPO7; translocates SMAD4 to the nucleus CC through the NPC upon BMP7 stimulation resulting in activation of SMAD4 CC signaling (PubMed:26878725). Interacts with CREB3L1, the interaction CC takes place upon TGFB1 induction and SMAD4 acts as a CREB3L1 CC coactivator to induce the expression of genes involved in the assembly CC of collagen extracellular matrix (PubMed:25310401). Interacts with DLX1 CC (PubMed:14671321). Interacts with ZBTB7A; the interaction is direct and CC stimulated by TGFB1 (PubMed:25514493). Interacts with CREBBP; the CC recruitment of this transcriptional coactivator is negatively regulated CC by ZBTB7A (PubMed:25514493). Interacts with EP300; the interaction with CC this transcriptional coactivator is negatively regulated by ZBTB7A CC (PubMed:25514493). Interacts with HDAC1 (PubMed:25514493). Interacts CC (via MH2 domain) with ZMIZ1 (via SP-RING-type domain); in the TGF-beta CC signaling pathway increases the activity of the SMAD3/SMAD4 CC transcriptional complex (PubMed:16777850). Interacts (via N-terminus) CC with TSC22D1 (PubMed:15881652). {ECO:0000250|UniProtKB:O70437, CC ECO:0000250|UniProtKB:P97471, ECO:0000269|PubMed:10660046, CC ECO:0000269|PubMed:11224571, ECO:0000269|PubMed:11741830, CC ECO:0000269|PubMed:11818334, ECO:0000269|PubMed:12370310, CC ECO:0000269|PubMed:12941698, ECO:0000269|PubMed:14525983, CC ECO:0000269|PubMed:14630787, ECO:0000269|PubMed:14671321, CC ECO:0000269|PubMed:15350224, ECO:0000269|PubMed:15799969, CC ECO:0000269|PubMed:15820681, ECO:0000269|PubMed:15881652, CC ECO:0000269|PubMed:16777850, ECO:0000269|PubMed:17099224, CC ECO:0000269|PubMed:17327236, ECO:0000269|PubMed:18568018, CC ECO:0000269|PubMed:19135894, ECO:0000269|PubMed:24324267, CC ECO:0000269|PubMed:25310401, ECO:0000269|PubMed:25514493, CC ECO:0000269|PubMed:26878725, ECO:0000269|PubMed:9670020, CC ECO:0000269|PubMed:9707553}. CC -!- INTERACTION: CC Q13485; P36896: ACVR1B; NbExp=4; IntAct=EBI-347263, EBI-1384128; CC Q13485; P31749: AKT1; NbExp=6; IntAct=EBI-347263, EBI-296087; CC Q13485; P05067: APP; NbExp=3; IntAct=EBI-347263, EBI-77613; CC Q13485; P10398: ARAF; NbExp=6; IntAct=EBI-347263, EBI-365961; CC Q13485; Q92747: ARPC1A; NbExp=6; IntAct=EBI-347263, EBI-1020827; CC Q13485; Q9Y2T1: AXIN2; NbExp=4; IntAct=EBI-347263, EBI-4400025; CC Q13485; Q9NXR7: BABAM2; NbExp=5; IntAct=EBI-347263, EBI-949389; CC Q13485; P62324: BTG1; NbExp=4; IntAct=EBI-347263, EBI-742279; CC Q13485; Q9Y297: BTRC; NbExp=2; IntAct=EBI-347263, EBI-307461; CC Q13485; Q96HB5: CCDC120; NbExp=4; IntAct=EBI-347263, EBI-744556; CC Q13485; P24385: CCND1; NbExp=4; IntAct=EBI-347263, EBI-375001; CC Q13485; Q00534: CDK6; NbExp=3; IntAct=EBI-347263, EBI-295663; CC Q13485; P17676: CEBPB; NbExp=2; IntAct=EBI-347263, EBI-969696; CC Q13485; Q969H4: CNKSR1; NbExp=5; IntAct=EBI-347263, EBI-741671; CC Q13485; Q9UI36: DACH1; NbExp=7; IntAct=EBI-347263, EBI-347111; CC Q13485; Q9NPI6: DCP1A; NbExp=5; IntAct=EBI-347263, EBI-374238; CC Q13485; Q92988: DLX4; NbExp=5; IntAct=EBI-347263, EBI-1752755; CC Q13485; P29320: EPHA3; NbExp=6; IntAct=EBI-347263, EBI-1641575; CC Q13485; P21860: ERBB3; NbExp=6; IntAct=EBI-347263, EBI-720706; CC Q13485; P43268-3: ETV4; NbExp=3; IntAct=EBI-347263, EBI-12130722; CC Q13485; Q01844: EWSR1; NbExp=3; IntAct=EBI-347263, EBI-739737; CC Q13485; Q00597: FANCC; NbExp=5; IntAct=EBI-347263, EBI-81625; CC Q13485; Q9NW38: FANCL; NbExp=6; IntAct=EBI-347263, EBI-2339898; CC Q13485; Q9GZV9: FGF23; NbExp=3; IntAct=EBI-347263, EBI-6594125; CC Q13485; Q12778: FOXO1; NbExp=5; IntAct=EBI-347263, EBI-1108782; CC Q13485; O43524: FOXO3; NbExp=12; IntAct=EBI-347263, EBI-1644164; CC Q13485; P98177: FOXO4; NbExp=2; IntAct=EBI-347263, EBI-4481939; CC Q13485; P23769: GATA2; NbExp=10; IntAct=EBI-347263, EBI-2806671; CC Q13485; Q14344: GNA13; NbExp=5; IntAct=EBI-347263, EBI-465387; CC Q13485; P78333: GPC5; NbExp=5; IntAct=EBI-347263, EBI-2558325; CC Q13485; P49841: GSK3B; NbExp=5; IntAct=EBI-347263, EBI-373586; CC Q13485; Q13547: HDAC1; NbExp=7; IntAct=EBI-347263, EBI-301834; CC Q13485; P20823: HNF1A; NbExp=5; IntAct=EBI-347263, EBI-636034; CC Q13485; P01112: HRAS; NbExp=5; IntAct=EBI-347263, EBI-350145; CC Q13485; P23458: JAK1; NbExp=5; IntAct=EBI-347263, EBI-1383438; CC Q13485; P52333: JAK3; NbExp=3; IntAct=EBI-347263, EBI-518246; CC Q13485; Q8WZ60: KLHL6; NbExp=6; IntAct=EBI-347263, EBI-6426464; CC Q13485; Q9P2J3: KLHL9; NbExp=3; IntAct=EBI-347263, EBI-2510152; CC Q13485; O95835: LATS1; NbExp=7; IntAct=EBI-347263, EBI-444209; CC Q13485; P61968: LMO4; NbExp=8; IntAct=EBI-347263, EBI-2798728; CC Q13485; Q8N653: LZTR1; NbExp=5; IntAct=EBI-347263, EBI-2350056; CC Q13485; Q96RN5: MED15; NbExp=2; IntAct=EBI-347263, EBI-394506; CC Q13485; Q8NI38: NFKBID; NbExp=3; IntAct=EBI-347263, EBI-10271199; CC Q13485; Q9UBE8: NLK; NbExp=6; IntAct=EBI-347263, EBI-366978; CC Q13485; P29474: NOS3; NbExp=4; IntAct=EBI-347263, EBI-1391623; CC Q13485; Q04721: NOTCH2; NbExp=5; IntAct=EBI-347263, EBI-2652733; CC Q13485; P24468: NR2F2; NbExp=4; IntAct=EBI-347263, EBI-2795198; CC Q13485; Q16620: NTRK2; NbExp=4; IntAct=EBI-347263, EBI-3904881; CC Q13485; Q8TE49: OTUD7A; NbExp=4; IntAct=EBI-347263, EBI-1049564; CC Q13485; Q9Y6X2: PIAS3; NbExp=3; IntAct=EBI-347263, EBI-2803703; CC Q13485; P42338: PIK3CB; NbExp=3; IntAct=EBI-347263, EBI-2609540; CC Q13485; P28340: POLD1; NbExp=7; IntAct=EBI-347263, EBI-716569; CC Q13485; Q16633: POU2AF1; NbExp=3; IntAct=EBI-347263, EBI-943588; CC Q13485; O00743: PPP6C; NbExp=4; IntAct=EBI-347263, EBI-359751; CC Q13485; P04049: RAF1; NbExp=6; IntAct=EBI-347263, EBI-365996; CC Q13485; Q8WWW0: RASSF5; NbExp=7; IntAct=EBI-347263, EBI-367390; CC Q13485; Q8NHQ8: RASSF8; NbExp=5; IntAct=EBI-347263, EBI-306805; CC Q13485; Q04206: RELA; NbExp=5; IntAct=EBI-347263, EBI-73886; CC Q13485; P21912: SDHB; NbExp=5; IntAct=EBI-347263, EBI-1056481; CC Q13485; O95754: SEMA4F; NbExp=5; IntAct=EBI-347263, EBI-20855345; CC Q13485; P29353: SHC1; NbExp=5; IntAct=EBI-347263, EBI-78835; CC Q13485; P12755: SKI; NbExp=16; IntAct=EBI-347263, EBI-347281; CC Q13485; P12757: SKIL; NbExp=6; IntAct=EBI-347263, EBI-2902468; CC Q13485; Q13309: SKP2; NbExp=5; IntAct=EBI-347263, EBI-456291; CC Q13485; Q15797: SMAD1; NbExp=18; IntAct=EBI-347263, EBI-1567153; CC Q13485; Q15796: SMAD2; NbExp=31; IntAct=EBI-347263, EBI-1040141; CC Q13485; P84022: SMAD3; NbExp=43; IntAct=EBI-347263, EBI-347161; CC Q13485; Q13485: SMAD4; NbExp=7; IntAct=EBI-347263, EBI-347263; CC Q13485; O15198: SMAD9; NbExp=4; IntAct=EBI-347263, EBI-748763; CC Q13485; O15198-2: SMAD9; NbExp=3; IntAct=EBI-347263, EBI-12273450; CC Q13485; O15524: SOCS1; NbExp=4; IntAct=EBI-347263, EBI-968198; CC Q13485; P08047: SP1; NbExp=2; IntAct=EBI-347263, EBI-298336; CC Q13485; Q08117-2: TLE5; NbExp=3; IntAct=EBI-347263, EBI-11741437; CC Q13485; Q9UPN9: TRIM33; NbExp=6; IntAct=EBI-347263, EBI-2214398; CC Q13485; P16473: TSHR; NbExp=6; IntAct=EBI-347263, EBI-13939599; CC Q13485; P63279: UBE2I; NbExp=6; IntAct=EBI-347263, EBI-80168; CC Q13485; Q93008: USP9X; NbExp=2; IntAct=EBI-347263, EBI-302524; CC Q13485; Q9UPY6: WASF3; NbExp=6; IntAct=EBI-347263, EBI-3907133; CC Q13485; Q15915: ZIC1; NbExp=3; IntAct=EBI-347263, EBI-11963196; CC Q13485; P70056: foxh1; Xeno; NbExp=2; IntAct=EBI-347263, EBI-9969973; CC Q13485; P70398: Usp9x; Xeno; NbExp=4; IntAct=EBI-347263, EBI-2214043; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15799969, CC ECO:0000269|PubMed:17327236}. Nucleus {ECO:0000269|PubMed:15799969}. CC Note=Cytoplasmic in the absence of ligand. Migrates to the nucleus when CC complexed with R-SMAD (PubMed:15799969). PDPK1 prevents its nuclear CC translocation in response to TGF-beta (PubMed:17327236). CC {ECO:0000269|PubMed:15799969, ECO:0000269|PubMed:17327236}. CC -!- DOMAIN: The MH1 domain is required for DNA binding. CC -!- DOMAIN: The MH2 domain is required for both homomeric and heteromeric CC interactions and for transcriptional regulation. Sufficient for nuclear CC import. CC -!- PTM: Phosphorylated by PDPK1. {ECO:0000269|PubMed:17327236}. CC -!- PTM: Monoubiquitinated on Lys-519 by E3 ubiquitin-protein ligase CC TRIM33. Monoubiquitination hampers its ability to form a stable complex CC with activated SMAD2/3 resulting in inhibition of TGF-beta/BMP CC signaling cascade. Deubiquitination by USP9X restores its competence to CC mediate TGF-beta signaling. {ECO:0000269|PubMed:19135894}. CC -!- DISEASE: Pancreatic cancer (PNCA) [MIM:260350]: A malignant neoplasm of CC the pancreas. Tumors can arise from both the exocrine and endocrine CC portions of the pancreas, but 95% of them develop from the exocrine CC portion, including the ductal epithelium, acinar cells, connective CC tissue, and lymphatic tissue. {ECO:0000269|PubMed:8553070}. Note=The CC gene represented in this entry may be involved in disease pathogenesis. CC -!- DISEASE: Juvenile polyposis syndrome (JPS) [MIM:174900]: Autosomal CC dominant gastrointestinal hamartomatous polyposis syndrome in which CC patients are at risk for developing gastrointestinal cancers. The CC lesions are typified by a smooth histological appearance, predominant CC stroma, cystic spaces and lack of a smooth muscle core. Multiple CC juvenile polyps usually occur in a number of Mendelian disorders. CC Sometimes, these polyps occur without associated features as in JPS; CC here, polyps tend to occur in the large bowel and are associated with CC an increased risk of colon and other gastrointestinal cancers. CC {ECO:0000269|PubMed:12417513, ECO:0000269|PubMed:9811934}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Juvenile polyposis/hereditary hemorrhagic telangiectasia CC syndrome (JP/HHT) [MIM:175050]: JP/HHT syndrome phenotype consists of CC the coexistence of juvenile polyposis (JIP) and hereditary hemorrhagic CC telangiectasia (HHT) [MIM:187300] in a single individual. JIP and HHT CC are autosomal dominant disorders with distinct and non-overlapping CC clinical features. The former, an inherited gastrointestinal malignancy CC predisposition, is caused by mutations in SMAD4 or BMPR1A, and the CC latter is a vascular malformation disorder caused by mutations in ENG CC or ACVRL1. All four genes encode proteins involved in the transforming- CC growth-factor-signaling pathway. Although there are reports of patients CC and families with phenotypes of both disorders combined, the genetic CC etiology of this association is unknown. {ECO:0000269|PubMed:15031030}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:16959974}. Note=The disease CC may be caused by variants affecting the gene represented in this entry. CC -!- DISEASE: Note=SMAD4 variants may be associated with susceptibility to CC pulmonary hypertension, a disorder characterized by plexiform lesions CC of proliferating endothelial cells in pulmonary arterioles. The lesions CC lead to elevated pulmonary arterial pression, right ventricular CC failure, and death. The disease can occur from infancy throughout life CC and it has a mean age at onset of 36 years. Penetrance is reduced. CC Although familial pulmonary hypertension is rare, cases secondary to CC known etiologies are more common and include those associated with the CC appetite-suppressant drugs. {ECO:0000269|PubMed:21898662}. CC -!- DISEASE: Myhre syndrome (MYHRS) [MIM:139210]: An autosomal dominant CC syndrome characterized by pre- and postnatal growth deficiency, CC intellectual disability, generalized muscle hypertrophy and striking CC muscular build, decreased joint mobility, cryptorchidism, and unusual CC facies. Dysmorphic facial features include microcephaly, midface CC hypoplasia, prognathism, and blepharophimosis. Typical skeletal CC anomalies are short stature, square body shape, broad ribs, iliac CC hypoplasia, brachydactyly, flattened vertebrae, and thickened calvaria. CC Other features, such as congenital heart disease, may also occur. CC {ECO:0000269|PubMed:22158539, ECO:0000269|PubMed:22243968}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the dwarfin/SMAD family. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/371/SMAD4"; CC -!- WEB RESOURCE: Name=Mendelian genes SMAD family member 4 (SMAD4); CC Note=Leiden Open Variation Database (LOVD); CC URL="https://databases.lovd.nl/shared/genes/SMAD4"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF045447; AAC03051.1; -; Genomic_DNA. DR EMBL; AF045438; AAC03051.1; JOINED; Genomic_DNA. DR EMBL; AF045439; AAC03051.1; JOINED; Genomic_DNA. DR EMBL; AF045440; AAC03051.1; JOINED; Genomic_DNA. DR EMBL; AF045441; AAC03051.1; JOINED; Genomic_DNA. DR EMBL; AF045442; AAC03051.1; JOINED; Genomic_DNA. DR EMBL; AF045443; AAC03051.1; JOINED; Genomic_DNA. DR EMBL; AF045444; AAC03051.1; JOINED; Genomic_DNA. DR EMBL; AF045445; AAC03051.1; JOINED; Genomic_DNA. DR EMBL; AF045446; AAC03051.1; JOINED; Genomic_DNA. DR EMBL; U44378; AAA91041.1; -; mRNA. DR EMBL; AK290770; BAF83459.1; -; mRNA. DR EMBL; CH471096; EAW62985.1; -; Genomic_DNA. DR EMBL; BC002379; AAH02379.1; -; mRNA. DR CCDS; CCDS11950.1; -. DR PIR; S71811; S71811. DR RefSeq; NP_001393970.1; NM_001407041.1. DR RefSeq; NP_001393971.1; NM_001407042.1. DR RefSeq; NP_005350.1; NM_005359.6. DR PDB; 1DD1; X-ray; 2.62 A; A/B/C=285-552. DR PDB; 1G88; X-ray; 3.00 A; A/B/C=285-552. DR PDB; 1MR1; X-ray; 2.85 A; A/B=319-552. DR PDB; 1U7F; X-ray; 2.60 A; B=314-552. DR PDB; 1U7V; X-ray; 2.70 A; B=314-549. DR PDB; 1YGS; X-ray; 2.10 A; A=319-552. DR PDB; 5C4V; X-ray; 2.60 A; A/C/E=314-549. DR PDB; 5MEY; X-ray; 2.05 A; A=10-140. DR PDB; 5MEZ; X-ray; 2.98 A; A/B=10-140. DR PDB; 5MF0; X-ray; 3.03 A; A/B=10-140. DR PDB; 5UWU; X-ray; 2.24 A; D=133-149. DR PDB; 6YIC; X-ray; 1.60 A; P=398-406. DR PDBsum; 1DD1; -. DR PDBsum; 1G88; -. DR PDBsum; 1MR1; -. DR PDBsum; 1U7F; -. DR PDBsum; 1U7V; -. DR PDBsum; 1YGS; -. DR PDBsum; 5C4V; -. DR PDBsum; 5MEY; -. DR PDBsum; 5MEZ; -. DR PDBsum; 5MF0; -. DR PDBsum; 5UWU; -. DR PDBsum; 6YIC; -. DR AlphaFoldDB; Q13485; -. DR SASBDB; Q13485; -. DR SMR; Q13485; -. DR BioGRID; 110264; 532. DR ComplexPortal; CPX-1; SMAD2-SMAD3-SMAD4 complex. DR ComplexPortal; CPX-3208; SMAD2-SMAD4 complex. DR ComplexPortal; CPX-3252; SMAD3-SMAD4 complex. DR ComplexPortal; CPX-54; SMAD1-SMAD4 complex. DR CORUM; Q13485; -. DR DIP; DIP-31512N; -. DR FunCoup; Q13485; 4708. DR IntAct; Q13485; 524. DR MINT; Q13485; -. DR STRING; 9606.ENSP00000341551; -. DR GlyCosmos; Q13485; 5 sites, 1 glycan. DR GlyGen; Q13485; 10 sites, 1 O-linked glycan (10 sites). DR iPTMnet; Q13485; -. DR MetOSite; Q13485; -. DR PhosphoSitePlus; Q13485; -. DR SwissPalm; Q13485; -. DR BioMuta; SMAD4; -. DR DMDM; 13959561; -. DR CPTAC; CPTAC-1268; -. DR CPTAC; CPTAC-1269; -. DR jPOST; Q13485; -. DR MassIVE; Q13485; -. DR PaxDb; 9606-ENSP00000341551; -. DR PeptideAtlas; Q13485; -. DR ProteomicsDB; 59479; -. DR Pumba; Q13485; -. DR Antibodypedia; 3711; 1151 antibodies from 45 providers. DR DNASU; 4089; -. DR Ensembl; ENST00000342988.8; ENSP00000341551.3; ENSG00000141646.18. DR Ensembl; ENST00000398417.6; ENSP00000381452.1; ENSG00000141646.18. DR Ensembl; ENST00000588860.6; ENSP00000465878.2; ENSG00000141646.18. DR Ensembl; ENST00000589076.6; ENSP00000466934.2; ENSG00000141646.18. DR Ensembl; ENST00000589941.2; ENSP00000465874.2; ENSG00000141646.18. DR Ensembl; ENST00000590061.2; ENSP00000464772.2; ENSG00000141646.18. DR GeneID; 4089; -. DR KEGG; hsa:4089; -. DR MANE-Select; ENST00000342988.8; ENSP00000341551.3; NM_005359.6; NP_005350.1. DR UCSC; uc010xdp.3; human. DR AGR; HGNC:6770; -. DR CIViC; 4089; 29 evidence items across 22 molecular profiles. DR ClinPGx; PA30527; -. DR CTD; 4089; -. DR DisGeNET; 4089; -. DR GeneCards; SMAD4; -. DR GeneReviews; SMAD4; -. DR HGNC; HGNC:6770; SMAD4. DR HPA; ENSG00000141646; Low tissue specificity. DR MalaCards; SMAD4; -. DR MIM; 114500; phenotype. DR MIM; 139210; phenotype. DR MIM; 174900; phenotype. DR MIM; 175050; phenotype. DR MIM; 260350; phenotype. DR MIM; 600993; gene. DR OpenTargets; ENSG00000141646; -. DR Orphanet; 1333; Familial pancreatic carcinoma. DR Orphanet; 91387; Familial thoracic aortic aneurysm and aortic dissection. DR Orphanet; 329971; Generalized juvenile polyposis/juvenile polyposis coli. DR Orphanet; 774; Hereditary hemorrhagic telangiectasia. DR Orphanet; 2588; Myhre syndrome. DR VEuPathDB; HostDB:ENSG00000141646; -. DR eggNOG; KOG3701; Eukaryota. DR GeneTree; ENSGT00940000157435; -. DR InParanoid; Q13485; -. DR OMA; CWIEVQI; -. DR OrthoDB; 5875866at2759; -. DR PAN-GO; Q13485; 10 GO annotations based on evolutionary models. DR PhylomeDB; Q13485; -. DR PathwayCommons; Q13485; -. DR Reactome; R-HSA-1181150; Signaling by NODAL. DR Reactome; R-HSA-1502540; Signaling by Activin. DR Reactome; R-HSA-201451; Signaling by BMP. DR Reactome; R-HSA-2173789; TGF-beta receptor signaling activates SMADs. DR Reactome; R-HSA-2173795; Downregulation of SMAD2/3:SMAD4 transcriptional activity. DR Reactome; R-HSA-2173796; SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription. DR Reactome; R-HSA-3311021; SMAD4 MH2 Domain Mutants in Cancer. DR Reactome; R-HSA-3315487; SMAD2/3 MH2 Domain Mutants in Cancer. DR Reactome; R-HSA-452723; Transcriptional regulation of pluripotent stem cells. DR Reactome; R-HSA-5689880; Ub-specific processing proteases. DR Reactome; R-HSA-8941326; RUNX2 regulates bone development. DR Reactome; R-HSA-8941855; RUNX3 regulates CDKN1A transcription. DR Reactome; R-HSA-8952158; RUNX3 regulates BCL2L11 (BIM) transcription. DR Reactome; R-HSA-9615017; FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes. DR Reactome; R-HSA-9617828; FOXO-mediated transcription of cell cycle genes. DR Reactome; R-HSA-9733709; Cardiogenesis. DR Reactome; R-HSA-9735871; SARS-CoV-1 targets host intracellular signalling and regulatory pathways. DR Reactome; R-HSA-9754189; Germ layer formation at gastrulation. DR Reactome; R-HSA-9823730; Formation of definitive endoderm. DR Reactome; R-HSA-9839394; TGFBR3 expression. DR Reactome; R-HSA-9844594; Transcriptional regulation of brown and beige adipocyte differentiation by EBF2. DR SignaLink; Q13485; -. DR SIGNOR; Q13485; -. DR Agora; ENSG00000141646; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 4089; 81 hits in 1216 CRISPR screens. DR ChiTaRS; SMAD4; human. DR EvolutionaryTrace; Q13485; -. DR GeneWiki; Mothers_against_decapentaplegic_homolog_4; -. DR GenomeRNAi; 4089; -. DR Pharos; Q13485; Tbio. DR PRO; PR:Q13485; -. DR Proteomes; UP000005640; Chromosome 18. DR RNAct; Q13485; protein. DR Bgee; ENSG00000141646; Expressed in ventricular zone and 198 other cell types or tissues. DR ExpressionAtlas; Q13485; baseline and differential. DR GO; GO:0032444; C:activin responsive factor complex; IDA:BHF-UCL. DR GO; GO:0005813; C:centrosome; IDA:HPA. DR GO; GO:0000785; C:chromatin; IDA:BHF-UCL. DR GO; GO:0036064; C:ciliary basal body; IDA:HPA. DR GO; GO:0097542; C:ciliary tip; IDA:HPA. DR GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0071144; C:heteromeric SMAD protein complex; IPI:ComplexPortal. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:BHF-UCL. DR GO; GO:0071141; C:SMAD protein complex; IDA:UniProtKB. DR GO; GO:0005667; C:transcription regulator complex; IDA:BHF-UCL. DR GO; GO:0003682; F:chromatin binding; IEA:Ensembl. DR GO; GO:0005518; F:collagen binding; IEA:Ensembl. DR GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:GO_Central. DR GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:BHF-UCL. DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB. DR GO; GO:0031005; F:filamin binding; IEA:Ensembl. DR GO; GO:0070411; F:I-SMAD binding; IPI:BHF-UCL. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0042803; F:protein homodimerization activity; IPI:BHF-UCL. DR GO; GO:0070412; F:R-SMAD binding; IPI:BHF-UCL. DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:GO_Central. DR GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IEA:Ensembl. DR GO; GO:0043565; F:sequence-specific DNA binding; IDA:BHF-UCL. DR GO; GO:0043199; F:sulfate binding; IMP:CAFA. DR GO; GO:0000976; F:transcription cis-regulatory region binding; IDA:BHF-UCL. DR GO; GO:0001223; F:transcription coactivator binding; IPI:UniProtKB. DR GO; GO:0001222; F:transcription corepressor binding; IPI:HGNC-UCL. DR GO; GO:0032924; P:activin receptor signaling pathway; NAS:ComplexPortal. DR GO; GO:0030325; P:adrenal gland development; IEA:Ensembl. DR GO; GO:0009653; P:anatomical structure morphogenesis; IBA:GO_Central. DR GO; GO:0036302; P:atrioventricular canal development; ISS:BHF-UCL. DR GO; GO:0003190; P:atrioventricular valve formation; ISS:BHF-UCL. DR GO; GO:0007411; P:axon guidance; IEA:Ensembl. DR GO; GO:0030509; P:BMP signaling pathway; IDA:BHF-UCL. DR GO; GO:0003360; P:brainstem development; IEA:Ensembl. DR GO; GO:0001658; P:branching involved in ureteric bud morphogenesis; IEA:Ensembl. DR GO; GO:0003161; P:cardiac conduction system development; NAS:BHF-UCL. DR GO; GO:0014898; P:cardiac muscle hypertrophy in response to stress; IEA:Ensembl. DR GO; GO:0030154; P:cell differentiation; IBA:GO_Central. DR GO; GO:0008283; P:cell population proliferation; IEA:Ensembl. DR GO; GO:0071773; P:cellular response to BMP stimulus; NAS:BHF-UCL. DR GO; GO:0071333; P:cellular response to glucose stimulus; IEA:Ensembl. DR GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IMP:BHF-UCL. DR GO; GO:0048589; P:developmental growth; IEA:Ensembl. DR GO; GO:0006351; P:DNA-templated transcription; IDA:ComplexPortal. DR GO; GO:0042733; P:embryonic digit morphogenesis; IEA:Ensembl. DR GO; GO:0060956; P:endocardial cell differentiation; ISS:BHF-UCL. DR GO; GO:0042118; P:endothelial cell activation; IEA:Ensembl. DR GO; GO:0010631; P:epithelial cell migration; IMP:BHF-UCL. DR GO; GO:0001837; P:epithelial to mesenchymal transition; IMP:BHF-UCL. DR GO; GO:0003198; P:epithelial to mesenchymal transition involved in endocardial cushion formation; IEA:Ensembl. DR GO; GO:0070371; P:ERK1 and ERK2 cascade; IEA:Ensembl. DR GO; GO:0097191; P:extrinsic apoptotic signaling pathway; IMP:BHF-UCL. DR GO; GO:0061040; P:female gonad morphogenesis; IEA:Ensembl. DR GO; GO:0048859; P:formation of anatomical boundary; IEA:Ensembl. DR GO; GO:0001702; P:gastrulation with mouth forming second; IEA:Ensembl. DR GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl. DR GO; GO:0070102; P:interleukin-6-mediated signaling pathway; ISS:BHF-UCL. DR GO; GO:0006879; P:intracellular iron ion homeostasis; ISS:BHF-UCL. DR GO; GO:0035556; P:intracellular signal transduction; IMP:CACAO. DR GO; GO:0003220; P:left ventricular cardiac muscle tissue morphogenesis; ISS:BHF-UCL. DR GO; GO:0048382; P:mesendoderm development; IEA:Ensembl. DR GO; GO:0072133; P:metanephric mesenchyme morphogenesis; IEA:Ensembl. DR GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IMP:BHF-UCL. DR GO; GO:0010614; P:negative regulation of cardiac muscle hypertrophy; ISS:BHF-UCL. DR GO; GO:1905305; P:negative regulation of cardiac myofibril assembly; ISS:BHF-UCL. DR GO; GO:0030308; P:negative regulation of cell growth; IDA:BHF-UCL. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IEA:Ensembl. DR GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:BHF-UCL. DR GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; ISS:BHF-UCL. DR GO; GO:0042177; P:negative regulation of protein catabolic process; IEA:Ensembl. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; ISS:BHF-UCL. DR GO; GO:0072134; P:nephrogenic mesenchyme morphogenesis; IEA:Ensembl. DR GO; GO:0014033; P:neural crest cell differentiation; IEA:Ensembl. DR GO; GO:0048665; P:neuron fate specification; IMP:BHF-UCL. DR GO; GO:0001649; P:osteoblast differentiation; IEA:Ensembl. DR GO; GO:0003148; P:outflow tract septum morphogenesis; ISS:BHF-UCL. DR GO; GO:0001541; P:ovarian follicle development; IEA:Ensembl. DR GO; GO:0010666; P:positive regulation of cardiac muscle cell apoptotic process; IEA:Ensembl. DR GO; GO:0003251; P:positive regulation of cell proliferation involved in heart valve morphogenesis; ISS:BHF-UCL. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB. DR GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; ISS:BHF-UCL. DR GO; GO:1901203; P:positive regulation of extracellular matrix assembly; IMP:BHF-UCL. DR GO; GO:0046881; P:positive regulation of follicle-stimulating hormone secretion; IEA:Ensembl. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL. DR GO; GO:0033686; P:positive regulation of luteinizing hormone secretion; IEA:Ensembl. DR GO; GO:1902895; P:positive regulation of miRNA transcription; IEA:Ensembl. DR GO; GO:0060391; P:positive regulation of SMAD protein signal transduction; ISS:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:GO_Central. DR GO; GO:0030511; P:positive regulation of transforming growth factor beta receptor signaling pathway; IDA:BHF-UCL. DR GO; GO:0006355; P:regulation of DNA-templated transcription; NAS:ComplexPortal. DR GO; GO:0051797; P:regulation of hair follicle development; IEA:Ensembl. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central. DR GO; GO:0032909; P:regulation of transforming growth factor beta2 production; IMP:BHF-UCL. DR GO; GO:0001666; P:response to hypoxia; IMP:BHF-UCL. DR GO; GO:0071559; P:response to transforming growth factor beta; IDA:UniProtKB. DR GO; GO:0048733; P:sebaceous gland development; IEA:Ensembl. DR GO; GO:0062009; P:secondary palate development; ISS:BHF-UCL. DR GO; GO:0072520; P:seminiferous tubule development; IEA:Ensembl. DR GO; GO:0007338; P:single fertilization; IEA:Ensembl. DR GO; GO:0060395; P:SMAD protein signal transduction; IDA:BHF-UCL. DR GO; GO:0032525; P:somite rostral/caudal axis specification; IEA:Ensembl. DR GO; GO:0007283; P:spermatogenesis; IEA:Ensembl. DR GO; GO:0006366; P:transcription by RNA polymerase II; IEA:Ensembl. DR GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IDA:BHF-UCL. DR GO; GO:0060065; P:uterus development; IEA:Ensembl. DR GO; GO:0060412; P:ventricular septum morphogenesis; ISS:BHF-UCL. DR CDD; cd10492; MH1_SMAD_4; 1. DR CDD; cd10498; MH2_SMAD_4; 1. DR DisProt; DP00464; -. DR FunFam; 2.60.200.10:FF:000002; Mothers against decapentaplegic homolog; 1. DR FunFam; 3.90.520.10:FF:000002; Mothers against decapentaplegic homolog; 1. DR Gene3D; 2.60.200.10; -; 1. DR Gene3D; 3.90.520.10; SMAD MH1 domain; 1. DR IDEAL; IID00132; -. DR InterPro; IPR013790; Dwarfin. DR InterPro; IPR003619; MAD_homology1_Dwarfin-type. DR InterPro; IPR013019; MAD_homology_MH1. DR InterPro; IPR017855; SMAD-like_dom_sf. DR InterPro; IPR001132; SMAD_dom_Dwarfin-type. DR InterPro; IPR008984; SMAD_FHA_dom_sf. DR InterPro; IPR036578; SMAD_MH1_sf. DR PANTHER; PTHR13703:SF63; MOTHERS AGAINST DECAPENTAPLEGIC HOMOLOG 4; 1. DR PANTHER; PTHR13703; SMAD; 1. DR Pfam; PF03165; MH1; 1. DR Pfam; PF03166; MH2; 1. DR SMART; SM00523; DWA; 1. DR SMART; SM00524; DWB; 1. DR SUPFAM; SSF56366; SMAD MH1 domain; 1. DR SUPFAM; SSF49879; SMAD/FHA domain; 1. DR PROSITE; PS51075; MH1; 1. DR PROSITE; PS51076; MH2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Cytoplasm; Disease variant; DNA-binding; KW Isopeptide bond; Metal-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Transcription; KW Transcription regulation; Ubl conjugation; Zinc. FT CHAIN 1..552 FT /note="SMAD family member 4" FT /id="PRO_0000090861" FT DOMAIN 18..142 FT /note="MH1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00438" FT DOMAIN 323..552 FT /note="MH2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00439" FT REGION 1..322 FT /note="Mediates interaction with ZBTB7A" FT /evidence="ECO:0000269|PubMed:25514493" FT REGION 44..69 FT /note="Required for interaction with TSC22D1" FT /evidence="ECO:0000269|PubMed:15881652" FT REGION 168..194 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 236..256 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 275..320 FT /note="SAD" FT COMPBIAS 170..194 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 245..256 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 71 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250" FT BINDING 115 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250" FT BINDING 127 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250" FT BINDING 132 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250" FT SITE 515 FT /note="Necessary for heterotrimerization" FT MOD_RES 37 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 428 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 507 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT CROSSLNK 113 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:25218447, FT ECO:0007744|PubMed:25755297, ECO:0007744|PubMed:28112733" FT CROSSLNK 519 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:19135894" FT VARIANT 13 FT /note="N -> S (rare variant; found in a patient with FT pulmonary hypertension; uncertain significance; FT dbSNP:rs281875323)" FT /evidence="ECO:0000269|PubMed:21898662" FT /id="VAR_066870" FT VARIANT 130 FT /note="P -> S (in a colorectal cancer sample; somatic FT mutation; dbSNP:rs1555685186)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036475" FT VARIANT 330 FT /note="E -> G (in JPS; dbSNP:rs281875324)" FT /evidence="ECO:0000269|PubMed:12417513" FT /id="VAR_022833" FT VARIANT 351 FT /note="D -> N (in a colorectal cancer sample; somatic FT mutation; dbSNP:rs1057519739)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036476" FT VARIANT 352 FT /note="G -> R (in JP/HHT and JPS; dbSNP:rs121912581)" FT /evidence="ECO:0000269|PubMed:12417513, FT ECO:0000269|PubMed:15031030" FT /id="VAR_019571" FT VARIANT 361 FT /note="R -> C (in JPS; dbSNP:rs80338963)" FT /evidence="ECO:0000269|PubMed:9811934" FT /id="VAR_019572" FT VARIANT 361 FT /note="R -> H (in a colorectal cancer sample; somatic FT mutation; dbSNP:rs377767347)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036477" FT VARIANT 386 FT /note="G -> D (in JP/HHT; dbSNP:rs121912580)" FT /evidence="ECO:0000269|PubMed:15031030" FT /id="VAR_019573" FT VARIANT 493 FT /note="D -> H (in pancreatic carcinoma; dbSNP:rs121912578)" FT /evidence="ECO:0000269|PubMed:8553070" FT /id="VAR_011380" FT VARIANT 500 FT /note="I -> M (in MYHRS; dbSNP:rs281875320)" FT /evidence="ECO:0000269|PubMed:22158539" FT /id="VAR_067602" FT VARIANT 500 FT /note="I -> T (in MYHRS; there is an enhanced levels of FT SMAD4 protein with lower levels of ubiquitinated SMAD4 FT fibroblasts compared to controls suggesting stabilization FT of the mutant protein; 8-fold increase in phosphorylated FT SMAD2 and SMAD3; 11-fold increase in phosphorylated SMAD1, FT SMAD5 and SMAD8 in cell nuclei compared to controls; FT dbSNP:rs281875321)" FT /evidence="ECO:0000269|PubMed:22158539, FT ECO:0000269|PubMed:22243968" FT /id="VAR_067603" FT VARIANT 500 FT /note="I -> V (in MYHRS; dbSNP:rs281875322)" FT /evidence="ECO:0000269|PubMed:22158539, FT ECO:0000269|PubMed:22243968" FT /id="VAR_067604" FT MUTAGEN 416 FT /note="R->S: No effect on heterotrimerization. Partially FT diminished transcriptional activation." FT /evidence="ECO:0000269|PubMed:11224571" FT MUTAGEN 496 FT /note="R->S: No effect on heterotrimerization. Partially FT diminished transcriptional activation." FT MUTAGEN 502 FT /note="R->S: No effect on heterotrimerization. Greatly FT reduced transcriptional activation." FT /evidence="ECO:0000269|PubMed:11224571" FT MUTAGEN 515 FT /note="R->S: Reduced heterotrimerization." FT /evidence="ECO:0000269|PubMed:11224571" FT MUTAGEN 519 FT /note="K->R: Abolishes ubiquitination." FT /evidence="ECO:0000269|PubMed:19135894" FT HELIX 16..24 FT /evidence="ECO:0007829|PDB:5MEY" FT STRAND 29..31 FT /evidence="ECO:0007829|PDB:5MEY" FT HELIX 33..47 FT /evidence="ECO:0007829|PDB:5MEY" FT HELIX 51..62 FT /evidence="ECO:0007829|PDB:5MEY" FT TURN 63..65 FT /evidence="ECO:0007829|PDB:5MEY" FT STRAND 73..75 FT /evidence="ECO:0007829|PDB:5MEY" FT STRAND 78..80 FT /evidence="ECO:0007829|PDB:5MEY" FT STRAND 82..84 FT /evidence="ECO:0007829|PDB:5MEY" FT STRAND 87..89 FT /evidence="ECO:0007829|PDB:5MEY" FT HELIX 91..99 FT /evidence="ECO:0007829|PDB:5MEY" FT STRAND 109..111 FT /evidence="ECO:0007829|PDB:5MEY" FT HELIX 119..121 FT /evidence="ECO:0007829|PDB:5MEY" FT STRAND 124..127 FT /evidence="ECO:0007829|PDB:5MEY" FT HELIX 130..132 FT /evidence="ECO:0007829|PDB:5MEY" FT STRAND 133..135 FT /evidence="ECO:0007829|PDB:5MEY" FT HELIX 143..145 FT /evidence="ECO:0007829|PDB:5UWU" FT STRAND 288..291 FT /evidence="ECO:0007829|PDB:1DD1" FT STRAND 321..330 FT /evidence="ECO:0007829|PDB:1YGS" FT STRAND 333..342 FT /evidence="ECO:0007829|PDB:1YGS" FT STRAND 346..353 FT /evidence="ECO:0007829|PDB:1YGS" FT STRAND 359..363 FT /evidence="ECO:0007829|PDB:1YGS" FT HELIX 364..366 FT /evidence="ECO:0007829|PDB:1U7F" FT HELIX 374..380 FT /evidence="ECO:0007829|PDB:1YGS" FT TURN 381..385 FT /evidence="ECO:0007829|PDB:1YGS" FT STRAND 387..392 FT /evidence="ECO:0007829|PDB:1YGS" FT TURN 393..395 FT /evidence="ECO:0007829|PDB:1YGS" FT STRAND 396..401 FT /evidence="ECO:0007829|PDB:1YGS" FT STRAND 403..405 FT /evidence="ECO:0007829|PDB:1YGS" FT STRAND 407..410 FT /evidence="ECO:0007829|PDB:1YGS" FT HELIX 412..416 FT /evidence="ECO:0007829|PDB:1YGS" FT TURN 417..419 FT /evidence="ECO:0007829|PDB:1YGS" FT STRAND 427..429 FT /evidence="ECO:0007829|PDB:1YGS" FT STRAND 434..438 FT /evidence="ECO:0007829|PDB:1YGS" FT HELIX 440..454 FT /evidence="ECO:0007829|PDB:1YGS" FT TURN 455..458 FT /evidence="ECO:0007829|PDB:1DD1" FT HELIX 461..464 FT /evidence="ECO:0007829|PDB:1DD1" FT HELIX 493..497 FT /evidence="ECO:0007829|PDB:1YGS" FT STRAND 500..506 FT /evidence="ECO:0007829|PDB:1YGS" FT HELIX 518..520 FT /evidence="ECO:0007829|PDB:1YGS" FT STRAND 521..529 FT /evidence="ECO:0007829|PDB:1YGS" FT HELIX 530..541 FT /evidence="ECO:0007829|PDB:1YGS" SQ SEQUENCE 552 AA; 60439 MW; 7EE3C4647712DA90 CRC64; MDNMSITNTP TSNDACLSIV HSLMCHRQGG ESETFAKRAI ESLVKKLKEK KDELDSLITA ITTNGAHPSK CVTIQRTLDG RLQVAGRKGF PHVIYARLWR WPDLHKNELK HVKYCQYAFD LKCDSVCVNP YHYERVVSPG IDLSGLTLQS NAPSSMMVKD EYVHDFEGQP SLSTEGHSIQ TIQHPPSNRA STETYSTPAL LAPSESNATS TANFPNIPVA STSQPASILG GSHSEGLLQI ASGPQPGQQQ NGFTGQPATY HHNSTTTWTG SRTAPYTPNL PHHQNGHLQH HPPMPPHPGH YWPVHNELAF QPPISNHPAP EYWCSIAYFE MDVQVGETFK VPSSCPIVTV DGYVDPSGGD RFCLGQLSNV HRTEAIERAR LHIGKGVQLE CKGEGDVWVR CLSDHAVFVQ SYYLDREAGR APGDAVHKIY PSAYIKVFDL RQCHRQMQQQ AATAQAAAAA QAAAVAGNIP GPGSVGGIAP AISLSAAAGI GVDDLRRLCI LRMSFVKGWG PDYPRQSIKE TPCWIEIHLH RALQLLDEVL HTMPIADPQP LD //